---
document_datetime: 2023-09-21 21:40:39
document_pages: 139
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0022-epar-assessment-report-variation_en.pdf
document_name: enhertu-h-c-005124-ii-0022-epar-assessment-report-variation_en.pdf
version: success
processing_time: 275.3981171
conversion_datetime: 2025-12-22 20:32:43.251235
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
15 December 2022 EMA/CHMP/14752/2023

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Enhertu

International non-proprietary name: trastuzumab deruxtecan

Procedure No. EMEA/H/C/005124/II/0022

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................7                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................7  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................8                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................8                       |
| 2.1. Introduction.........................................................................................................8 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................8           |
| 2.1.2. About the product............................................................................................13      |                                                                                                         |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                            | ......13                                                                                                |
| 2.1.4. General comments on compliance with                                                                                  | GCP........................................................13                                           |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................14          |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................14                                             |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................14    |
| 2.3.1. Introduction....................................................................................................14   |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................16      |                                                                                                         |
| 2.3.3. Pharmacodynamics..........................................................................................30         |                                                                                                         |
| 2.3.4. PK/PD modelling..............................................................................................31      |                                                                                                         |
| 2.3.5. Discussion on clinical                                                                                               | pharmacology...................................................................47                       |
| 2.3.6. Conclusions on clinical pharmacology.................................................................48              |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................48    |
| 2.4.1. Main study......................................................................................................48   |                                                                                                         |
| 2.4.2. Discussion on clinical efficacy............................................................................96        |                                                                                                         |
| 2.4.3. Conclusions on the clinical efficacy...................................................................              | 101                                                                                                     |
| 2.5. Clinical safety                                                                                                        | .................................................................................................. 101  |
| 2.5.1. Discussion on clinical safety ............................................................................           | 127                                                                                                     |
| 2.5.2. Conclusions on clinical safety ..........................................................................            | 129                                                                                                     |
| 2.5.3. PSUR cycle                                                                                                           | ................................................................................................... 130 |
| 2.6. Risk management plan......................................................................................             | 130                                                                                                     |
| 2.7. Update of the Product information ......................................................................               | 132                                                                                                     |
| 2.7.1. User consultation...........................................................................................         | 132                                                                                                     |
| 3. Benefit-Risk Balance............................................................................132                      |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                    | ......................................................................................... 132           |
| 3.1.1. Disease or condition.......................................................................................          | 132                                                                                                     |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 132                                                                                                     |
| 3.1.3. Main clinical studies .......................................................................................        | 133                                                                                                     |
| 3.2. Favourable effects ............................................................................................        | 133                                                                                                     |
| 3.3. Uncertainties and limitations about favourable effects...........................................                      | 134                                                                                                     |
| 3.4. Unfavourable effects.........................................................................................          | 134                                                                                                     |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | ....................................... 135                                                             |
| 3.6. Effects Table....................................................................................................      | 135                                                                                                     |
| 3.7. Benefit-risk assessment and discussion...............................................................                  | 136                                                                                                     |
| 3.7.1. Importance of favourable and unfavourable effects............................................                        | 136                                                                                                     |
| 3.7.2. Balance of benefits and risks...........................................................................             | 137                                                                                                     |
| 3.7.3. Additional considerations on the benefit-risk balance                                                                | ......................................... 137                                                           |

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions .....................................................................................................  137 4. Recommendations ...............................................................................  138 5. EPAR changes  ......................................................................................  139

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AC Adjudication Committee ADA anti-drug antibody ADC antibody-drug conjugate ADR adverse drug reaction AE adverse event AESI adverse event of special interest AI aromatase inhibitor ASCO/CAP American Society of Clinical Oncology/College of American Pathologists AST aspartate aminotransferase AUC area under the serum concentration-time curve BC breast cancer BICR blinded independent central review BRCA germline breast cancer susceptibility gene CDK4/6  cyclin-dependent kinase 4 and 6 CDx companion diagnostic CE Conformité Européenne CI confidence interval Cmax maximum serum concentration Cmin minimum serum concentration CNS central nervous system CR complete response CSR clinical study report CT computed tomography CTCAE  Common Terminology Criteria for Adverse Events DAR drug-to-antibody ratio DCO data cut-off DoR duration of response DXd the released payload, a topoisomerase I inhibitor derivative of exatecan EAIR exposure-adjusted incidence rate ECOG PS Eastern Cooperative Oncology Group performance status EDC electronic data capture EORTC  European Organisation for Research and Treatment of Cancer

<div style=\"page-break-after: always\"></div>

| EQ-5D-5L                                            | EuroQoL-5 dimensions-5 levels of severity           |
|-----------------------------------------------------|-----------------------------------------------------|
| ER                                                  | exposure-response                                   |
| ET                                                  | endocrine therapy                                   |
| EU                                                  | European Union                                      |
| FAS                                                 | Full Analysis Set                                   |
| FDA                                                 | Food and Drug Administration                        |
| GI                                                  | gastrointestinal                                    |
| HER2                                                | human epidermal growth factor receptor 2            |
| HR                                                  | hazard ratio                                        |
| HRQoL                                               | health-related quality of life                      |
| IA                                                  | interim analysis                                    |
| ICH                                                 | International Council for Harmonisation             |
| ICR                                                 | independent central review                          |
| IHC                                                 | immunohistochemistry                                |
| ILD                                                 | interstitial lung disease                           |
| INV                                                 | investigator assessment                             |
| IRR                                                 | infusion-related reaction                           |
| ISH                                                 | in situ hybridization                               |
| ITT                                                 | intent-to-treat                                     |
| IUO                                                 | Investigational Use Only                            |
| IV                                                  | intravenous                                         |
| IXRS                                                | interactive web/voice response system               |
| LV                                                  | left ventricular                                    |
| LVEF                                                | left ventricular ejection fraction                  |
| mAb                                                 | monoclonal antibody                                 |
| MedDRA Medical Dictionary for Regulatory Activities | MedDRA Medical Dictionary for Regulatory Activities |
| MRI                                                 | magnetic resonance imaging                          |
| NAb                                                 | neutralizing antibody                               |
| nab                                                 | nanoparticle albumin-bound                          |
| NCA                                                 | noncompartmental analysis                           |
| NCCN                                                | National Comprehensive Cancer Network               |
| NE                                                  | not estimable                                       |
| ORR                                                 | objective response rate                             |

<div style=\"page-break-after: always\"></div>

OS overall survival PARP poly (ADP-ribose) polymerase PBRER  Periodic Benefit Risk Evaluation Report PD progressive disease PD-L1 programmed cell death ligand 1 PFS progression-free survival PIK3CA phosphatidylinositol-4,5-bisphosphate 3 kinase catalytic subunit alpha PK pharmacokinetic(s) PopPK  population pharmacokinetic(s) PPS Per-protocol Analysis Set PR partial response PRO Patient-reported outcome(s) PT preferred term Q3W every 3 weeks QLQ-C30 Quality-of-life C-30 QLQ-BR45/BR323 Quality-of-life BR 45/BR23 RECIST v1.1 Response Evaluation Criteria in Solid Tumors Version 1.1 SAE serious adverse event SAP statistical analysis plan SCE summary of clinical efficacy SCS summary of clinical safety SD stable disease SERM selective estrogen receptor modulator SMQ Standardised MedDRA Query SoC standard of care T-DXd  trastuzumab deruxtecan, Enhertu® TEAE treatment-emergent adverse event TNBC triple-negative breast cancer TPC treatment of physician's choice TTDD time to definitive deterioration US United States v Version vs versus

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Daiichi Sankyo Europe GmbH submitted to the European Medicines Agency on 31 May 2022 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Patients with hormone receptor positive (HR+) breast cancer must additionally have received or be ineligible for endocrine therapy; for ENHERTU, based on final results from study DS8201-A-U303 (DESTINY-Breast04). This is a Phase III, multicentre, randomised, open-label, active-controlled trial of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-antibody Drug Conjugate (ADC), versus treatment of physician's choice for HER2-low, unresectable and/or metastatic breast cancer subjects.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.4 of the RMP has also been submitted.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update section 4.4 of the SmPC to update the dosing recommendation for corticosteroid treatment (e.g. prednisolone) with a daily dose.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision CW/0001/2015 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## Scientific advice

The MAH received Scientific Advice from the CHMP on 20 September 2018 (EMEA/H/SA/3715/3/2018/II). The Scientific Advice pertained to clinical aspects of the dossier.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

| Rapporteur: Aaron Sosa Mejia                  | Co-Rapporteur:   | Paula Boudewina van Hennik   |
|-----------------------------------------------|------------------|------------------------------|
| Timetable                                     |                  | Actual dates                 |
| Submission date                               |                  | 31 May 2022                  |
| Start of procedure:                           |                  | 18 June 2022                 |
| CHMP Rapporteur Assessment Report             |                  | 5 August 2022                |
| PRAC Rapporteur Assessment Report             |                  | 11 August 2022               |
| PRAC members comments                         |                  | 24 August 2022               |
| CHMP Co-Rapporteur Critique                   |                  | 23 August 2022               |
| Updated PRAC Rapporteur Assessment Report     |                  | 25 August 2022               |
| PRAC Outcome                                  |                  | 1 September 2022             |
| CHMP members comments                         |                  | 5 September 2022             |
| Updated CHMP Rapporteur(s) (Joint) Assessment | Report           | 9 September 2022             |
| Request for supplementary information (RSI)   |                  | 15 September 2022            |
| CHMP Rapporteur Assessment Report             |                  | 15 November 2022             |
| PRAC Rapporteur Assessment Report             |                  | 18 November 2022             |
| PRAC members comments                         |                  | 23 November 2022             |
| Updated PRAC Rapporteur Assessment Report     |                  | 24 November 2022             |
| PRAC Outcome                                  |                  | 1 December 2022              |
| CHMP members comments                         |                  | 5 December 2022              |
| Updated CHMP Rapporteur Assessment Report     |                  | 8 December 2022              |
| Opinion                                       |                  | 15 December 2022             |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

The initially applied indication was as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within 6

<div style=\"page-break-after: always\"></div>

months of completing adjuvant chemotherapy. Patients with hormone receptor positive (HR+) breast cancer must additionally have received or be ineligible for endocrine therapy.

## Epidemiology and risk factors

Breast Cancer (BC) is the most commonly diagnosed cancer worldwide (11.7% of all cancer sites) and the leading cause of cancer death in women (15.5% of all cancer sites in 2020). In 2020, there was an estimated 2.26 million new cases of female BC globally, with an estimated 684,996 deaths due to BC (Globocan 2020).

## Biologic features

According to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) recommendations for HER2 testing in BC, HER2 receptor status is classified as 'HER2-positive' (tumors scoring 3+ or 2+ by immunohistochemistry [IHC] and HER2 gene amplification by in situ hybridization [ISH]) or 'HER2 negative' (tumors scoring 2+ by IHC and no evidence of HER2 gene amplification by ISH or tumors scoring 1+ or 0 by IHC). Among patients with HER2-negative BC, approximately 50% have tumors with low HER2 expression (defined as tumors scoring 2+ or 1+ by IHC and no evidence of HER2 gene amplification). HER2-low tumors constitute a heterogeneous population that include both luminal-type hormone receptor-positive BC and hormone receptor-negative BC (triple-negative breast cancer [TNBC]).

## Management

Current therapeutic guidelines for patients with breast cancer exhibiting HER2-low expression are the same as those for patients with HER2 negative breast cancer. In the targeted metastatic setting, treatment recommendations are based on tumor hormone receptor status (positive or negative, i.e., presence or absence of estrogen and/or progesterone receptors), presence or absence of visceral crisis, and menopausal status (Gennari et al. ESMO. 2021).

The recommended treatment in the targeted second- and subsequent-line setting for patients with hormone receptor positive (HR+) disease, previously exposed to endocrine therapy (ET), are fulvestrant in combination with a CDK4/6 inhibitor. If a CDK4/6 inhibitor was not previously used, everolimus with either an AI, tamoxifen or fulvestrant, monotherapy with fulvestrant, a non-steroidal or a steroidal AI, or a selective oestrogen receptor modulator (SERM) is recommended. For patients with PIK3CA-mutated tumours, the preferred option is fulvestrant with alpelisib.  Once metastatic hormone receptor-positive HER2-negative BC is refractory to ET, the standard of care (SoC) is sequential systemic single-agent chemotherapy. Because of the lack of clear superiority, no specific chemotherapy is recommended in clinical practice guidelines but the most commonly used regimens include anthracyclines (doxorubicin and liposomal doxorubicin), anti-metabolites (capecitabine and gemcitabine), microtubule inhibitors (vinorelbine and eribulin), and taxanes (paclitaxel). Combination therapies, although rarely used, may be useful in patients with rapid clinical progression or need for rapid symptom and/or disease control.  Other available systemic therapies include PARP inhibitors for patients with BRCA germline mutations and alpelisib for patients with PIK3CA-mutated tumors.

For patients with HR-negative disease (Triple-negative disease (TNBC)), the available treatment options are as follows.  For patients with PDL1-negative disease, the treatment in the first-line setting is sequential single agent chemotherapy using the same preferred chemotherapeutic options as those for patients with hormone receptor-positive HER2-negative BC refractory to ET.  Regardless of BRCA status, for patients with TNBC previously treated with anthracyclines and taxanes in the adjuvant or

<div style=\"page-break-after: always\"></div>

neoadjuvant setting, platinum agents are the preferred option. For patients with BRCA mutations, the recommendation is to use PARP inhibitors or platinum agents and for patients with PD L1-positive TNBC, the preferred therapeutic option in the first-line setting is an immune-checkpoint inhibitor in combination with chemotherapy. For the later line setting after at least two previous regimens, with at least one of them in the metastatic setting, the antibody-drug conjugate (ADC) sacituzumab govitecan is approved (see Trodelvy SmPC/EPAR).

Table 1 Treatment Options in Metastatic HER2-negative Breast Cancer Refractory to or Ineligible for Endocrine-based Therapy (modified)

| Product Name          | Relevant Indication                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Dosing/ Administration                                                                    | Efficacy Information                                                                                                                                                                                                                                                                                    |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Doxorubicin Docetaxel | Doxorubicin: 2L+ For the treatment of ALL, AML, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic BC, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma Docetaxel: 2L+ Single agent for locally advanced or metastatic BC after chemotherapy failure | Doxorubicin: 60 to 75 mg/m 2 IV infusion Q3W Docetaxel: 60 to 100 mg/m 2 single agent Q3W | Chan et al 1999 Doxorubicin (n = 165): ORR: 33.3% (95% CI: 26.1, 40.5) Median TTP: 21 weeks (95% CI not reported) Median OS: 14 months (95% CI not reported) Docetaxel (n = 161): ORR: 47.8% (95% CI: 40.1, 55.5) Median TTP: 26 weeks (95% CI not reported) Median OS: 15 months (95% CI not reported) |
| Paclitaxel            | 2L+ Treatment of BC after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.                                                                                                                                                                                                                                                             | 175 mg/m 2 IV over 3 hours Q3W or 80 mg/m 2 weekly                                        | Nabholtz et al 1996 High-dose paclitaxel (175 mg/m 2 ; n = 235) ORR: 29% (95% CI: 23, 36) Median DoR: 8.2 months (range: 3.6 to 16.5+) Median TTP: 4.2 months (95% CI not reported) Median OS: 11.7 months (95% CI not reported)                                                                        |
| Liposomal doxorubicin | 2L+ Monotherapy for patients with metastatic BC, where there is an increased cardiac risk associated with conventional doxorubicin                                                                                                                                                                                                                                                                                                                                                           | 50 mg/m 2 Q4W                                                                             | O'Brien et al 2004 Liposomal doxorubicin (n = 254): ORR: 33% (95% CI not reported) Median PFS: 6.9 months (95% CI not reported) (HR: 1.00 [95% CI: 0.82, 1.22]) Median OS: 21 months (95% CI not reported) (HR: 0.94 [95% CI: 0.74, 1.19]) Median DoR: 7.3 months (95% CI not reported)                 |
| Capecitabine          | 2L+ As monotherapy in patients resistant to both                                                                                                                                                                                                                                                                                                                                                                                                                                             | Monotherapy: 1250 mg/m 2                                                                  | Blum et al 1999 (monotherapy) Capecitabine (n = 162):                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Product Name   | Relevant Indication                                                                                                                                                                                                                                                                        | Dosing/ Administration                                                    | Efficacy Information                                                                                                                                                                                                                                                                                                                                                               |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                | paclitaxel and an anthracycline-containing regimen                                                                                                                                                                                                                                         | BID orally for 2 weeks followed by a 1-week reset period in 3-week cycles | ORR: 20% (95% CI: 14, 28) Median DoR: 8.1 months (95% CI not reported) Median TTP: 93 days (95% CI: 84, 106) Median OS: 12.8 months (95% CI not reported)                                                                                                                                                                                                                          |
| Gemcitabine    | 1L+ In combination with paclitaxel, for first-line treatment of metastatic BC after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated                                                                                 | 1250 mg/m 2 for 30 minutes on Day 1 and 8 of each 21-day cycle            | Rha et al 2005 Gemcitabine (n = 41) ORR: 20% (95% CI not reported) Median DoR: 9 months (range: 2 to 25) Median PFS: 4.5 months (95% CI: 3, 5) Median OS: 11 months (95% CI: 4, 18).                                                                                                                                                                                               |
| Nab-paclitaxel | 2L+ Metastatic BC after failure of combination chemotherapy for metastatic disease or relapse with 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated                                                                | 260 mg/m 2 IV Q3W                                                         | Gradishar et al 2005 Nab-paclitaxel (n = 229): ORR: 33.0% (95% CI: 27.1, 39.3) Median TTP: 23.0 weeks (95% CI not reported) Median OS: 65.0 weeks (95% CI not reported) Standard paclitaxel (n = 225): ORR: 19.0% (95% CI: 13.6, 23.8) Median TTP: 16.9 weeks (95% CI not reported) Median OS: 55.7 weeks (95% CI not reported)                                                    |
| Ixabepilone    | 2L+ Monotherapy: treatment of metastatic or locally advanced BC in patients after failure of an anthracycline, a taxane, and capecitabine 2L+: In combination with capecitabine: treatment of metastatic or locally advanced BC in patients after failure of an anthracycline and a taxane | 40 mg/m 2 IV infusion over 3 hours Q3W                                    | Thomas et al. 2007 Ixabepilone plus capecitabine (n = 375): ORR: 34.7% (95% CI: 29.9, 39.7) Median DoR: 6.4 months (95% CI: 5.6, 7.1) Median PFS: 5.8 months (95% CI: 5.45, 6.97) (HR: 0.75 [95% CI: 0.64, 0.88]; P -value = 0.0003) Capecitabine (n = 377): ORR: 14.3% (95% CI: 10.9, 18.3) Median DoR: 5.6 months (95% CI: 4.2, 7.5) Median PFS: 4.2 months (95% CI: 3.81, 4.50) |
| Eribulin       | 2L+ : Treatment of patients with metastatic BC who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in                                                              | 1.4 mg/m 2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.      | EMBRACE Eribulin (n = 508): ORR: 12% (95% CI: 9.4, 15.5) Median DoR: 4.2 months (95% CI: 3.8, 5.0)                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Product Name                                                      | Relevant Indication                                                                                                                                                                                                                               | Dosing/ Administration                                                     | Efficacy Information                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                   | either the adjuvant or metastatic setting.                                                                                                                                                                                                        |                                                                            | Median PFS: 3.7 months (95% CI: 3.3, 3.9) (HR: 0.87 [95% CI: 0.71, 1.05]; P -value = 0.137) Median OS: 13.1 months (95% CI: 11.8, 14.3) (HR: 0.81 [95% CI: 0.66, 0.99]; P -value = 0.041) Eribulin (n = 554): ORR: 11.0% (95% CI: 8.5, 13.9) Median PFS: 4.1 months (95% CI: 3.5, 4.3) (HR: 1.08 [95% CI: 0.93, 1.25]; P -value = 0.30) Median OS: 15.9 months (95% CI: 15.2, 17.6) (HR: 0.88 [95% CI: 0.77, 1.00]; P -value = 0.056) |
| Abemaciclib                                                       | 2L+ As monotherapy for the treatment of adult patients with hormone receptor- positive, HER2-negative advanced or metastatic BC with disease progression following ET and prior chemotherapy in the metastatic setting.                           | As monotherapy, 200 mg BID orally                                          | MONARCH 1 Abemaciclib (n = 132) ORR: 19.7% (95% CI: 13.3, 27.5) Median DoR: 8.6 months (95% CI: 5.8, 10.2) Median PFS: 6.0 months (95% CI: 4.2, 7.5) Median OS: 17.7 months (95% CI: 16.0, not reached)                                                                                                                                                                                                                               |
| Hormone Receptor-negative Disease (Triple-negative Breast Cancer) | Hormone Receptor-negative Disease (Triple-negative Breast Cancer)                                                                                                                                                                                 | Hormone Receptor-negative Disease (Triple-negative Breast Cancer)          | Hormone Receptor-negative Disease (Triple-negative Breast Cancer)                                                                                                                                                                                                                                                                                                                                                                     |
| Sacituzumab govitecan                                             | 2L+ Unresectable locally advanced or metastatic TNBC who have received 2 or more prior systemic therapies, at least 1 of them for metastatic disease                                                                                              | 10 mg/kg once weekly on Days 1 and 8 of continuous 21-day treatment cycles | ASCENT Sacituzumab govitecan (n = 235): ORR: 31% (95% CI not reported) Median DoR: 6.3 months (95% CI: 5.5, 9.0) Median PFS: 4.8 months (95% CI: 4.1, 5.8) (HR 0.43 [95% CI: 0.35, 0.54]; P -value <0.0001) Median OS: 11.8 months (95% CI: 10.5, 13.8) (HR 0.51 [95% CI: 0.41, 0.62]; P -value <0.0001)                                                                                                                              |
| Pembrolizumab                                                     | In combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (Combined Positive Score ≥10) (who have not received prior chemotherapy for metastatic disease) | 200 mg Q3W or 400 mg Q6W as an IV infusion over 30 minutes                 | KEYNOTE-355 Pembrolizumab + chemotherapy (n = 220) ORR: 53% (95% CI: 46, 60) Median DoR: 19.3 months (95% CI: 9.9, 29.8) Median PFS: 9.7 months (95% CI: 7.6, 11.3) (HR: 0.65 [95% CI: 0.49, 0.86]; P- value = 0.012)                                                                                                                                                                                                                 |

1L+ = first-line and subsequent lines; 2L+ = second-line and subsequent lines; ALL = acute lymphocytic leukemia; AML = acute myeloid leukemia; BC = breast cancer; BID = twice daily; CI = confidence interval; DoR = duration of response; ET = endocrine therapy; HER2 = human epidermal growth factor receptor 2; HR = hazard ratio; IV = intravenous; NE = not estimable; ORR = objective response rate; OS = overall survival; PD-L1 = programmed cell death ligand 1; PFS = progression-free survival; Q3W = every 3 weeks; Q4W = every 4 weeks; Q6W = every

<div style=\"page-break-after: always\"></div>

6 weeks; TNBC = triple-negative breast cancer; TPC = treatment of physician's choice; TTF = time to treatment failure; TTP = time to progression

Treatment outcomes with currently approved therapies in patients with metastatic HER2-negative breast cancer, who progressed on ET and at least 1 line of chemotherapy illustrate the high unmet medical need for new treatment options (Table 1).  No targeted therapy is specifically approved for patients with HER2-low BC. The most recently approved single agents for patients with metastatic hormone receptor-positive HER2-low BC, who progressed on or are not eligible for ET are abemaciclib and eribulin. Abemaciclib has since been approved in earlier lines of therapy and is rarely used in the proposed setting where the cornerstone of treatment remains conventional chemotherapy.

## 2.1.2. About the product

Enhertu, trastuzumab deruxtecan, is a HER2-targeted antibody-drug conjugate. The antibody is a humanised anti-HER2 IgG1 attached to deruxtecan, a topoisomerase I inhibitor (DXd) bound by a tetrapeptide-based cleavable linker. The antibody-drug conjugate is stable in plasma. The function of the antibody portion is to bind to HER2 expressed on the surface of certain tumour cells. After binding, the trastuzumab deruxtecan complex then undergoes internalisation and intracellular linker cleavage by lysosomal enzymes that are upregulated in cancer cells. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic cell death. DXd, an exatecan derivative, is approximately 10 times more potent than SN-38, the active metabolite of irinotecan.

Enhertu is currently approved as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. In November 2022, the CHMP gave a positive opinion for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

Enhertu is currently conditionally approved and the confirmatory study for the CMA is Study U301, a phase 3, multicentre, randomised, open-label, active-controlled study of T-DXd versus treatment of investigator's choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1. The due date for submission is estimated to 4Q 2022.

The recommended dose of Enhertu is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. The same posology is proposed for the applied indication.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The focus of this application is the randomized, active controlled Phase 3 Study DS8201-A-U303 (DESTINY-Breast04; hereinafter referred to as Study U303) in which the target population are patients with unresectable or metastatic HER2-low BC, who received T-DXd at the target dose of 5.4 mg/kg or treatment per physician's choice (TPC) in the second-line metastatic setting. It is agreed that the scientific advice given from the CHMP regarding the pivotal study U303 was generally followed.

## 2.1.4. General comments on compliance with GCP

The Applicant stated that all studies of trastuzumab deruxtecan were conducted in accordance with the ethical principles of Good Clinical Practice (GCP), according to International Council for Harmonisation (ICH) Harmonised Tripartite Guideline E6 and that all trials conformed to the Declaration of Helsinki

<div style=\"page-break-after: always\"></div>

and informed, written consent was obtained from all patients as per GCP requirement.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

The default PECSURFACEWATER was above the PEC action limit for triggering a full ERA (see EPAR from initial MA). The PEC based on maximum daily dose was approximately 21-fold higher than if based on the actual dose regime recommended (once every 3 weeks). A PEC accounting for the actual dosing regimen would clearly be below the trigger ( ≤ 0.01 μ g/L); however, the PEC was subsequently refined by utilising prevalence data on the newly claimed indication. In order to estimate refined PECSURFACEWATER, calculation of refined Fpen was based on breast cancer prevalence data as provided in the Globocan database. The prevalence data were not specifying the type of HER-2 status, hence, the new indication of HER-2 low status can be assumed included in the general prevalence of breast cancer. Therefore, no increase in consumption for calculation of refined Fpen is expected with this extension of indication.

## Summary of main study results

| Substance (INN/Invented Name): trastuzumab deruxtecan               | Substance (INN/Invented Name): trastuzumab deruxtecan   | Substance (INN/Invented Name): trastuzumab deruxtecan                   | Substance (INN/Invented Name): trastuzumab deruxtecan   |
|---------------------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------------------|---------------------------------------------------------|
| CAS-number (if available):                                          | CAS-number (if available):                              | CAS-number (if available):                                              | CAS-number (if available):                              |
| PBT screening                                                       |                                                         | Result                                                                  | Conclusion                                              |
| Bioaccumulation potential- log K ow                                 | OECD107                                                 | Log D OW = 1.924 @ pH 5 Log D OW = 1.799 @ pH 7 Log D OW = 1.280 @ pH 9 | Potential PBT No                                        |
| PBT-assessment                                                      | PBT-assessment                                          | PBT-assessment                                                          | PBT-assessment                                          |
| Parameter                                                           | Result relevant for conclusion                          |                                                                         | Conclusion                                              |
| Bioaccumulation                                                     | log K ow                                                | <4.5                                                                    | not B                                                   |
| Bioaccumulation                                                     | BCF                                                     | Not required                                                            | not B                                                   |
| Persistence                                                         | DT50 or ready biodegradability                          | Not required                                                            | not P                                                   |
| Toxicity                                                            | NOEC or CMR                                             | Not required                                                            | not T                                                   |
| PBT-statement:                                                      | The compound is not considered as PBT nor vPvB          | The compound is not considered as PBT nor vPvB                          | The compound is not considered as PBT nor vPvB          |
| Phase I                                                             | Phase I                                                 | Phase I                                                                 | Phase I                                                 |
| Calculation                                                         | Value                                                   | Unit                                                                    | Conclusion                                              |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0.00565                                                 | µ g/L                                                                   | > 0.01 threshold No                                     |
| Other concerns (e.g. chemical class)                                |                                                         |                                                                         | None                                                    |

## 2.3. Clinical aspects

## 2.3.1. Introduction

The clinical package included in the current application is based on data from a Phase 3 study in subjects with HER2-low BC (Study U303) and data from nine prior studies. See below table.

<div style=\"page-break-after: always\"></div>

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Table 2 Tabular overview of clinical studies

| Study Number Module   | Dev. Phase   | Study Objectives                                                                                                                                                                                                                                                                 |   N | Dose                                   | Sampling TimePoints                                                                                                                                                             |
|-----------------------|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| J101 Module 5.3.3.2   |              | Determination oftheMTDor theRP2D of trastuzumab deruxtecan, assessment of the PK profiles of trastuzumab deruxtecan, DXd, and total anti-HER2 antibody, evaluation of efficacy, and assessment of safety and tolerability in subjects with advancedsolid malignant tumors        | 292 | 0.8, 1.6, 3.2, 5.4, 6.4, and 8.0 mg/kg | Cycle 1: Predose, EO1, 2,4, and 7 hours, and 1,3,7,14 and 21a days after SOA Cycle 3: Predose, EO1, 4 hours, and 7 and 14 days after SOA. Cycles 2, 4, 6 and 8: Predose and EOI |
| J2022                 | 2            | Comparison ofthe efficacy and safety of trastuzumab deruxtecan and TPC in HER2-overexpressing advanced gastric or GEJ adenocarcinoma subjects who have progressed on two prior regimens including fluoropyrimidine agent, platinum agent and trastuzumab(brand,                  | 231 | 6.4 mg/kg                              | Cycle 1, 3: Predose, EOI, 4 and 7 hours, and 7,14 and 21a days after SOA Cycles 2, 4, 6 and 8: Predose and EOI                                                                  |
| J1023                 |              | Assessment of thePK of trastuzumab deruxtecan after multiple dosing, assessment ofthe effect of T-DXd on the QTc interval, and evaluation of efficacy and safety in subjects with HER2-expressing metastatic and/or unresectable BC                                              |  51 | 6.4 mg/kg                              | Cycles 1 and 3: Predose, EOI, 2, 4,and 7hours,and 1,3,7,14 and 21° days after SOA Cycles 2, 4, 6 and 8: Predose and EOI                                                         |
| A1034                 |              | Assessment of the PK profiles of trastuzumab deruxtecan,DXd, and total anti-HER2 antibody, assessment of safety and tolerability of T-DXd, and investigation of anti-tumor activity in subjects with HER2-positive advanced and/or refractory gastric, GEJ adenocarcinoma, or BC |  12 | 6.4 mg/kg                              | Cycles 1 and 3: Predose, EOI, 2, 4, and 7hours, and 1,3,7,14, and 21a days after SOA Cycles 2, 4, 6 and 8: Predose and EOI                                                      |
| A1045                 |              | Evaluation of the effects of ritonavir and itraconazoleonthePKoftrastuzumab deruxtecan and DXd, assessment of safety, and evaluation of efficacy in subjects with HER2-expressing advanced solid malignant tumors                                                                |  40 | 5.4 mg/kg                              | Cycles 1,4,6 and 8: Predose and EOI Cycles 2 and 3: Predose, EOI, 2, 4, and 7hours, and 1,3,7, 11, and 16 days after SOA                                                        |

<div style=\"page-break-after: always\"></div>

| Study Number Module   | Dev. Phase   | Study Objectives                                                                                                                                                                                                                                                                                                 |   N | Dose                    | Sampling Time Points                                                                                                                                                                                                                                                                                                                                        |
|-----------------------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| U201 Module 5.3.5.2   |              | Determination of thePK and RP2D of trastuzumabderuxtecan,evaluationof E-R relationships for efficacy and safety, and evaluation of efficacy andsafety in HER2-positive, unresectable and/or metastatic BC subjects previously treated with T-DM1                                                                 | 253 | 5.4, 6.4, and 7.4 mg/kg | Part 1 PK: Cycle 1:Predose,EO1, 2,4,and 7hours,and1,3,7,14and 21° days after SOA Cycle 2,4,6,and 8: Predose and EOI Cycle 3: Predose, EO1, and 4 and 7hours afterSOA Dose-finding/RP2DEvaluation: Cycle 1: Predose,EO1,4 and 7 hours, and 7,14 and 21° days afler SOA Cycles 2,4,6,and 8: Predose and EOI Cycle 3: Predose, EO1, and 4 and 7 hours afterSOA |
| U2046                 | 2            | EvaluationoftheORRoftrastuzumab deruxtecan in HER2-overexpressing .../or HER2-mutated advanced NSCLC subjects                                                                                                                                                                                                    | 181 | 6.4 mg/kg               | Cycle 1:Predose,EO1,5hours and 7,14, and 21a days after SOA Cycles 2, 3,4,and 6: Predose and EOI                                                                                                                                                                                                                                                            |
| U2057                 |              | Investigationoftheefficacyof trastuzumabderuxtecanbasedon confirmed ORR, as assessed by an independent central imagingfacility review using RECIST v1.1, in subjects with HER2-positive unresectable or metastatic gastric or GEJ adenocarcinoma that hasprogressed on or after a trastuzumab-containing regimen |  79 | 6.4 mg/kg               | Cycle 1: Predose, EO1, 5 ±2 hours and 8, 15 and 21# days afler SOA Cycles 2. 3.4,6 and 8: Predose and EOI                                                                                                                                                                                                                                                   |
| U3028                 |              | Comparison of the efficacy of trastuzumab deruxtecan vs T-DM1 as measured byPFS for HER2-positive, unresectable and/or metastatic BC subjects previously treated with trastuzumabandtaxane                                                                                                                       | 524 | 5.4 mg/kg               | Cycle 1: Predose,EO1, 5 hours and 21a days after SOA Cycles 2,3,4,6, and 8: Predose and EOI                                                                                                                                                                                                                                                                 |
| U303 Module 5.3.5.1   | 3            | Comparison ofPFSbenefit ofT-DXd to physician's choice in HER2-low, HR-positive BC, based on BICR                                                                                                                                                                                                                 | 557 | 5.4 mg/kg               | Cycle 1: Predose, EO1, 5 hours and 21a days after SOA Cycles 2.3.4 and subsequent: Predose and EOI                                                                                                                                                                                                                                                          |

T-DM1 = trastuzumab emtansine; T-DXd = trastuzumab deruxtecan.

BC = breast cancer; BICR = blinded independent central review; Dev. = development; DXd =released payload (MAAA-118la); EOI = end ofinfusion; E-R = exposure-response; GEJ = gastroesophageal junction; HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; N = number of subjects; MTD = maximum tolerated dose; NSCLC = non-small cell lung cancer; ORR = objective response rate; PFS = progression-free survival; PK = pharmacokinetic(s); RECIST v1.1 = Response Evaluation Criteria in Solid Tumors Version 1.1; RP2D = recommended Phase 2 dose; SOA = start of administration;

aIfthe schedule on Day 1 of the next cycle was delayed for 3 days or more,including ifthe subject could not continue onto the next cycle, blood sample was collected 21 days after the start of drug administration (±2 days). If the next schedule was not delayed, sampling at that point was not necessary.

## 2.3.2. Pharmacokinetics

## Bioanalysis

For characterization of T-DXd PK, concentrations of T-DXd (the intact antibody-drug conjugate [ADC]), total anti-HER2 antibody, and DXd were measured by validated bioanalytical methods. Immunogenicity assessment for anti-T-DXd antibodies in serum was conducted using a validated bioanalytical method. The ADA positive samples were further analysed for detection of NAb against T-DXd.

## Pop PK analyses

Data handling was performed using R (version 4.0.5 or higher) or SAS (version 9.4 or higher). NONMEM (version 7.4.3 or higher) was used for PK analyses. FOCE INTER was used for PopPK model development. Xpose and PsN (version 4.8.1) were used for model diagnostics and covariate testing. R

<div style=\"page-break-after: always\"></div>

(version 4.0.5) in RStudio (version 1.1.383 or higher) was used for data exploration, post-processing of results and simulations based on the final models for T-DXd and DXd.

The Pop PK analysis was performed using PK data from four Phase 1 studies (Studies J101, J102, A103 and A104), four Phase 2 studies (Studies U201, J202, U204 and U205), and two Phase 3 studies (Studies U302 and U303) (see table 2). After inclusion of Study U303, the analysis dataset had 1128 (67%), 293 (18%), 199 (12%), and 55 (3%) subjects with BC, GC, NSCLC, and other cancers (including colorectal), respectively. Of these, 919 (55%) were HER2-positive, and 468 (28%) were HER2-low, with the remaining subjects (17%) having HER2-negative, mutant, overexpressing, or missing status. A summary of included PK data is shown in below table.

Table 3 Summary of PK data

| Category                                | Previous data   | Previous data   | U303            | U303            | Overall         | Overall         |
|-----------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                                         | T-DXd           | DXd             | T-DXd           | DXd             | T-DXd           | DXd             |
| Subjects                                | Subjects        | Subjects        | Subjects        | Subjects        | Subjects        | Subjects        |
| Total Subjects                          | 1327            | 1327            | 371             | 371             | 1698            | 1698            |
| Subjects with evaluable observations    | 1313            | 1313            | 362             | 361             | 1675            | 1674            |
| PK Observations                         | PK Observations | PK Observations | PK Observations | PK Observations | PK Observations | PK Observations |
| Evaluable non-BQL observations included | 19551 (92.0%)   | 19681 (92.7%)   | 3770 (89.0%)    | 3572 (85.0%)    | 23321 (91.5%)   | 23253 (91.4%)   |
| Co-medication inhibitor excluded        | 105 (0.5%)      | 104 (0.5%)      | 76 (1.8%)       | 75 (1.8%)       | 181 (0.7%)      | 179 (0.7%)      |
| Other excluded                          | 201 (0.9%)      | 201 (0.9%)      | 18 (0.4%)       | 17 (0.4%)       | 219 (0.9%)      | 218 (0.9%)      |
| Outlier excluded                        | 105 (0.5%)      | 23 (0.1%)       | 0 (0%)          | 0 (0%)          | 105 (0.4%)      | 23 (0.1%)       |
| Post-doseBQL excluded                   | 101 (0.5%)      | 34 (0.2%)       | 11 (0.3%)       | 3 (0.1%)        | 112 (0.4%)      | 37 (0.1%)       |
| Pre-dose BQL excluded                   | 1195 (5.6%)     | 1199 (5.6%)     | 359 (8.5%)      | 354 (8.4%)      | 1554 (6.1%)     | 1553 (6.1%)     |
| Re-analyzed PK observations (non-BQL)   | 0 (0%)          | 0 (0%)          | 0 (0%)          | 181 (4.3%)      | 0 (0%)          | 181 (0.7%)      |
| Totalobservations                       | 21258           | 21242           | 4234            | 4202            | 25492           | 25444           |

Abbreviations: BQL = below the limit of quantitation; PK = pharmacokinetic.

Source: DS8201\\_303-subject\\_count.csv, DS8201\\_303-observation\\_count.csv, 2022-02-22-ds8201\\_303\\_eda.r.

The previous PopPK analysis that included data from all studies, except for Study U303, was used for model development. The T-DXd data was described by a two-compartment model with linear elimination, and DXd was described by a one-compartment model, with time-varying release of drug from T-DXd (figure below).

Figure 1 Structural model schematic

<!-- image -->

Abbreviations: CLDxd = clearance of DXd; CLr-Dxd = clearance of T-DXd; IV = intravenous; Krel = release rate constant; Q = distributional clearance for T-DXd; V1,r-Dxa = central volume of T-DXd; V2.r-Dxa = peripheral volume of T-DXd; VDxd = volume of DXd.

<div style=\"page-break-after: always\"></div>

A sequential modelling approach was used to re-estimate model parameters with the updated analysis dataset. First the T-DXd parameter estimates and corresponding covariate effects were re-estimated using only the PK data for T-DXd. The effects of Asian from Japan on V2,T-DXd changed by &gt;20% relative to the prior estimates. This effect was retained in the T-DXd model as removal increased the OFV by 34 units. Region was correlated with race-country. No new covariate correlations were identified. The final T-DXd model (run010) suggested that CL,T-DXd increased with increasing body weight, baseline tumour size, and for GC, NSCLC or other cancers; CL,T-DXd decreased with increasing albumin and being Asian from Japan; V1,T-DXd increased with increasing body weight, in males and for GC; and V2,T-DXd decreased in Asian subjects from Japan. The final Pop PK parameters for T-DXd is shown in below table.

Table 4 Final Pop PK parameters for T-DXd

| Variable                                          | Estimate      | Estimate   | Between-SubjectVariability   | Between-SubjectVariability   | Between-SubjectVariability   |
|---------------------------------------------------|---------------|------------|------------------------------|------------------------------|------------------------------|
|                                                   | Typical Value | RSE (%)    | Magnitude (%CV)              | RSE (%)                      | Shrinkage (%)                |
| Clearance (CLT-Dxd, L/day)                        | 0.410         | 0.933      | 23.8                         | 2.13                         | 11.1                         |
| Central Volume of Distribution (V1,T-Dxd, L)      | 2.68          | 0.478      | 15.1                         | 1.86                         | 8.63                         |
| Distributional Clearance (Qr-Dxd, L/day)          | 0.198         | 1.25       | 29.0                         | 4.26                         | 40.0                         |
| Peripheral Volume of Distribution (V2,T-Dxd, L)   | 6.64          | 3.08       | 79.7                         | 3.07                         | 24.0                         |
| Albumin (g/L) on CLr.Dxd                          | -0.480        | 10.0       |                              |                              |                              |
| Race-country (Japan) on CLr-Dxd                   | -0.0928       | 13.6       |                              |                              |                              |
| Tumor Size (mm) on CLr.Dxd                        | 0.0533        | 16.1       |                              |                              |                              |
| Body Weight (kg) on CLr-Dxd                       | 0.385         | 8.14       |                              |                              |                              |
| GC on CLT-DXd                                     | 0.175         | 12.4       |                              |                              |                              |
| NSCLC and Other Cancers (not BC or GC) on CLT-DXd | 0.0968        | 19.0       |                              |                              |                              |
| Body Weight (kg) on V1,T-Dxd                      | 0.430         | 4.65       |                              |                              |                              |
| Sex (Male) on V1,T-Dxd                            | 0.136         | 10.3       |                              |                              |                              |
| GC on V1,T-DXd                                    | 0.0976        | 15.2       |                              |                              |                              |
| Race-country (Japan) on V2,T-Dxd                  | -0.269        | 9.43       |                              |                              |                              |
| Residual Variability                              |               |            |                              |                              |                              |
| Proportional Residual ErrorStd Dev                | 0.167         | 0.216      |                              |                              |                              |
| Additive Residual Error Std Dev (ng/mL)           | 1059          | 1.72       |                              |                              |                              |
| Covariance of CLT-Dxd and V1,T-Dxd                | 0.0179        | 3.42       |                              |                              |                              |

BC = breast cancer; CLr-Dxd = elimination clearance of T-DXd; CV = coefficient of variation; ETA = random between-subject effect; GC = gastric cancer; NSCLC = non-small cell lung cancer; Qr-Dxd = distributional clearance; RSE = relative standard error; Std Dev = standard deviation; SE = standard error; sqrt = square root; T-DXd = trastuzumab deruxtecan; V1,T-Dxd = T-DXd central volume of distribution; V2,T-Dxd = T-DXd peripheral

volumeofdistribution

Note: RSE of parameter estimates were calculated as 100× (SE/typical value); RSE of between-subject variability magnitude was calculated as 100 × (SE/variance estimate)/2. CV (%) for between-subject variability estimates were based on the estimated variances.Shrinkage(%)was calculated as 100x(1-Std Dev[ETA]/sqrt[variance]).Overall residual unexplained variability shrinkage was estimated to be 9.08%. The correlation coefficient between CLr-Dxd and V1,r-Dxa was estimated as 0.505.

-: not applicable

Source: Module 5.3.3.5 Population PK Analysis Report PMx019,Table 4-6

The DXd parameters and corresponding covariate effects were then re-estimated based on the whole updated dataset with parameters for T-DXd fixed. With the addition of Study U303, the covariate effects of GC and NSCLC on CL,DXd and FL-DP1 formulation, NSCLC and race-country (non-Asian) on the V,DXd changed by &gt;20% compared to the same parameters in the previous DXd PopPK model. The effects of GC and NSCLC on CL,DXd and FL-DP1 formulation on V,DXd were no longer significant following backward deletion (p&gt;0.001) and were removed. Removal of NSCLC and race-country (nonAsian) effects on V,DXd resulted in a significant increase in OFV of 26 and 93 units and therefore they were retained. Covariate correlations were identified between race-country, region, weight and BSA. Thus, race-country was not tested. Parameter estimates for the final DXd model (run034) are presented in Table 5. Residual variability was modelled with a proportional error structure and estimated to be 30% with 7.51% shrinkage.

<div style=\"page-break-after: always\"></div>

Table 5 Parameter estimates for the final DXd model

| Variable                               | Estimate      | Estimate   | Between-SubjectVariability   | Between-SubjectVariability   | Between-SubjectVariability   |
|----------------------------------------|---------------|------------|------------------------------|------------------------------|------------------------------|
|                                        | Typical Value | RSE (%)    | Magnitude (%CV)              | RSE (%)                      | Shrinkage (%)                |
| DXd Clearance (CLDxa, L/h)             | 19.6          | 2.20       | 30.1                         | 3.59                         | 33.0                         |
| DXd Volume of Distribution (Vpxd, L)   | Fixed 17*BSA  |            | 47.0                         | 2.59                         | 21.1                         |
| Release Rate (Krel, 1/h)               | 0.0196        | 2.16       | 32.9                         | 3.55                         | 25.4                         |
| Fraction of Krel at Cycle >1 (FPC1)    | 0.741         | 0.969      | 26.7                         | 2.70                         | 26.2                         |
| Exponent of Cycle effect onKrel (FPC2) | -0.158        | 2.60       |                              |                              |                              |
| Ritonavir on CLpxd                     | -0.121        | 14.2       |                              |                              |                              |
| Itraconazole on CLDxd                  | -0.111        | 19.4       |                              |                              |                              |
| AST (U/L) on CLDxd                     | -0.195        | 10.3       |                              |                              |                              |
| Total Bilirubin (μumol/L) on CLDxd     | -0.147        | 14.2       |                              |                              |                              |
| Body Weight (kg) on CLDxd              | 0.316         | 16.3       |                              |                              |                              |
| Age (years) on Vpxd                    | 0.630         | 10.1       |                              |                              |                              |
| FL-DP2 Formulation on Vpxd             | 0.583         | 12.1       |                              |                              |                              |
| NSCLC on VDxd                          | -0.204        | 21.6       |                              |                              |                              |
| Race-Country (Non-Asian) on Vpxd       | -0.244        | 8.91       |                              |                              |                              |
| Residual UnexplainedVariability        |               |            |                              |                              |                              |
| Proportional Residual ErrorStd Dev     | 0.304         | 0.351      |                              |                              |                              |

AST = aspartate aminotransferase; BSA =body surface area; CLpxd = elimination clearance of DXd; CV = coefficient of variation;DXd=released payload (MAAA-1181a);ETA =random between-subjecteffect; FL-DP2 = frozen liquid drug product 2; FPC1 = fraction of Krel after Cycle 1; FPC2 = exponent of Cycle effect on Krer; Krel = release rate constant; NSCLC = non-small cell lung cancer; RSE = relative standard error; Std Dev = standard deviation; SE = standard error; sqrt = square root;Vpxd =volume of distribution. Note:RSE of parameter estimate was calculated as 100×(SE/typical value); RSE of between-subject variability magnitude was calculated as 100× (SE/variance estimate)/2. CV% for the between-subject variability estimates were based on the estimated variances.Shrinkage(%)was calculated as 100×(1-Std Dev[ETA]/sqrt[variance]). Overall residual unexplained variability shrinkage was estimated to be 7.51%. -:not applicable

Source:Module 5.3.3.5PopulationPKAnalysis Report PMx019,Table 4-8

Prediction-corrected VPCs are presented in the below figures.

<div style=\"page-break-after: always\"></div>

Figure 2 Prediction-corrected VPC for the T-DXd and DXd PopPK model (run034)

All DatabyTime SinceFirst Dose

Abbreviations: PopPK = population pharmacokinetics; pred = prediction; VPC = visual predictive check. Note: Left plot is the prediction-corrected VPC for T-DXd and the right plot is the prediction-corrected VPC for DXd. Blue dots are prediction-corrected observed concentrations; blue lines are 50th (solid), 5th (dashed), and 95th (dashed) percentiles of observed concentrations; and black lines are 50th (solid), 5th (dashed), and 95th (dashed)percentiles of simulations. Gray bands are 95%prediction interval for corresponding black lines based on 5o0 simulations. Short yellow lines indicate bin intervals.

<!-- image -->

Source:VPC-TIME-both-all-data034.pdf,VPC-TAD-both-all-data-034.pdf, 2022-02-23-ds8201-303-gof.r.

<div style=\"page-break-after: always\"></div>

Figure 3 Prediction-corrected VPC for the final T-DXd PopPK model (run034), stratified by HER2 status

<!-- image -->

Abbreviations: HER2 = human epidermal growth factor receptor 2; PopPK = population pharmacokinetics; predcorr = prediction-corrected; VPC =visual predictive check.

Note: Blue dots are prediction-corrected observed concentrations; blue lines are 50th (solid), 5th (dashed), and 95th (dashed) percentiles of observed concentrations; and black lines are 50th (solid), 5th (dashed), and 95th (dashed) percentiles of simulations. Gray bands are 95% prediction interval for corresponding black lines based on 5o0 simulations. Short yellow lines indicate bin intervals.

Source:VPC-TIME-both-HER2-034.pdf VPC-TAD-both-HER2-034.pdf, 2022-02-23-ds8201-303-gofR

<div style=\"page-break-after: always\"></div>

Figure 4 Prediction-corrected VPC for the final DXd PopPK model (run034), stratified by HER2 status

<!-- image -->

Abbreviations:HER2=human epidermal growth factor receptor 2;PopPK =population pharmacokinetics; predcorr = prediction-corrected; VPC = visual predictive check.

Note: Blue dots are prediction-corrected observed concentrations; blue lines are 50th (solid), 5th (dashed), and 95th (dashed) percentiles of observed concentrations; and black lines are 50th (solid), 5th (dashed), and 95th (dashed)percentiles of simulations. Gray bands are 95%prediction interval for corresponding black lines based on 500 simulations. Short yellow lines indicate bin intervals.

Source:VPC-TIME-both-HER2-034.pdfVPC-TAD-both-HER2-034.pdf,2022-02-23-ds8201-303-gofR

A sensitivity analysis of the final DXd PopPK model showed no impact of removing CWRES≥5 T -DXd and DXd outliers from Study U303 (run034s). A second sensitivity analysis showed no impact of including additional 211 (of which 30 were BLQ) DXd samples (run034ss), that were re-analysed after primary DCO.

## ADME characteristics

The absorption, distribution, metabolism, and excretion of T-DXd, total anti-HER2 antibody and DXd was well-characterised and described in the initial BC application (see initial EPAR).

Mean observed exposure profiles of T-DXd, Total Anti-HER2 Antibody and DXd following 5.4 mg/kg Q3W are shown in Figure 5.

<div style=\"page-break-after: always\"></div>

Figure 5 Time Course of Mean (+/- SD) Serum Concentrations of T-DXd, Total Anti-HER2 Antibody and DXd Concentrations- Semi-logarithmic Scale (PK Analysis Set)

<!-- image -->

DXd= released dug; HER2 =human epidermal growth factor receptor2; PK =pha macokinetic; Std Dev = standarddeviation; T-DXd=tra stuzumab deruxtecan

Data cut-off:11Jan2022

Source: Figure 14.4.1.2

Exposure parameters for HER2-low subjects in Study U303 were predicted using the final Pop PK model for DXd (run 0034). T-DXd and DXd exposure were comparable between HER2-positive and HER2-low BC at the same dose. PK parameters for T-DXd and DXd based on the non-compartmental analysis of Cycle 1 PK data for HER2-positive or HER2-low patients following 5.4 or 6.4 mg/kg doses are displayed in Tables 6 and 7, respectively.

<div style=\"page-break-after: always\"></div>

Table 6 Summary of T-DXd PK Parameters: Integrated Analysis of Cycle 1 PK Data in Subjects with Breast Cancer

|                              | PK Parameter (Unit)          | PK Parameter (Unit)          | PK Parameter (Unit)          | PK Parameter (Unit)               | PK Parameter (Unit)          |
|------------------------------|------------------------------|------------------------------|------------------------------|-----------------------------------|------------------------------|
| Dose                         | Cmax (μg/mL)                 | Tmax (b)a                    | AUClast (μg*d/mL)            | AUC21d (μg*d/mL)                  | Ctrough (μg/mL)              |
| 5.4 mg/kg (BC HER2-Positive) | 5.4 mg/kg (BC HER2-Positive) | 5.4 mg/kg (BC HER2-Positive) | 5.4 mg/kg (BC HER2-Positive) | 5.4 mg/kg (BC HER2-Positive)      | 5.4 mg/kg (BC HER2-Positive) |
| N Mean a Std Dev Min/Max     | 232 124.15 32.608            | 232 2.167 0.02/166.73        | 232 544.68 163.415           | 190 572.6 167.08 115 756.5 205.10 | 215 5.5 5.13                 |
| 6.4mg/kg (BC HER2-Positive)  | 6.4mg/kg (BC HER2-Positive)  |                              |                              |                                   |                              |
| N Mean a Std Dev Min/Max     | 122 165.23 50.955            | 122 2.073                    | 122 740.9                    |                                   | 116 9.2455                   |
| N Mean a                     | 21                           | 0.02/7.05                    | 212.27                       |                                   | 20.02356                     |
| 5.4mg/kg(BCHER2-Low)         | 5.4mg/kg(BCHER2-Low)         | 5.4mg/kg(BCHER2-Low)         | 5.4mg/kg(BCHER2-Low)         | 5.4mg/kg(BCHER2-Low)              | 5.4mg/kg(BCHER2-Low)         |
| Std Dev Min/Max              | 133.37 17.886                | 21 2.117 1.50/7.07           | 21 581.6 175.73              | 20 555.1 122.10                   | 21 9.7 26.07                 |
| 6.4 mg/kg (BC HER2-Low)      | 6.4 mg/kg (BC HER2-Low)      | 6.4 mg/kg (BC HER2-Low)      | 6.4 mg/kg (BC HER2-Low)      | 6.4 mg/kg (BC HER2-Low)           | 6.4 mg/kg (BC HER2-Low)      |
| N Mean a                     | 79 171.73                    | 79 2.067 1.50, 7.23          | 79                           | 79 680.9                          | 78 7.3                       |
| Std Dev Min/Max              |                              |                              | 680.1                        |                                   |                              |
|                              | 91.525                       |                              |                              | 147.49                            |                              |
|                              |                              |                              | 149.38                       |                                   | 10.44                        |

AUC21d = area under the concentration-time curve from time zero to Day 21; AUClast = area under the serum concentration-time curve from time zero to the time of the last quantifiable serum concentration; BC = breast cancer; Cmax = maximum observed serum concentration; Ctrough = trough serum concentration; HER2 = human epidermal growth factor receptor 2; max = maximum; min = minimum; N = number of subjects; PK = pharmacokinetic; Std Dev = standard deviation; T-DXd = trastuzumab deruxtecan; Tmax = time of Cmax.

a Mean (Std Dev) values are presented for all parameters except Tmax, for which median (range) is presented. Source: Module 5.3.5.3 Integrated PK Analysis,Table 14.2.3.1

Table 7 Summary of DXd PK Parameters: Integrated Analysis of Cycle 1 in Subjects with Breast Cancer

|                                                       | PK Parameter (Unit)                                   | PK Parameter (Unit)                                   | PK Parameter (Unit)                                   | PK Parameter (Unit)                                   | PK Parameter (Unit)                                   |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| Dose                                                  | Cmax (μg/mL)                                          | Tmax (h)a                                             | AUClast (μg*d/mL)                                     | AUC21d (μg*d/mL)                                      | Ctrough (μg/mL)                                       |
| 5.4 mg/kg (BC HER2-Positive)                          | 5.4 mg/kg (BC HER2-Positive)                          | 5.4 mg/kg (BC HER2-Positive)                          | 5.4 mg/kg (BC HER2-Positive)                          | 5.4 mg/kg (BC HER2-Positive)                          | 5.4 mg/kg (BC HER2-Positive)                          |
| N Mean a Std Dev Min/Max                              | 232 8.1871 5.72156                                    | 232 6.792 0.24/166.51                                 | 232 31.729 17.6583                                    | 109 33.334 16.5512 103                                | 226 0.26349 0.249939                                  |
| 6.4mg/kg (BC HER2-Positive)                           | 6.4mg/kg (BC HER2-Positive)                           | 6.4mg/kg (BC HER2-Positive)                           | 6.4mg/kg (BC HER2-Positive)                           | 6.4mg/kg (BC HER2-Positive)                           | 6.4mg/kg (BC HER2-Positive)                           |
| N Mean a Std Dev Min/Max                              | 122 10.453 9.3428                                     | 122 6.840 0.34/191.47                                 | 122 43.69 32.364                                      | 43.61 31.395                                          | 115 0.35105 0.244394                                  |
| 5.4 mg/kg (BC HER2-Low)                               | 5.4 mg/kg (BC HER2-Low)                               | 5.4 mg/kg (BC HER2-Low)                               | 5.4 mg/kg (BC HER2-Low)                               | 5.4 mg/kg (BC HER2-Low)                               | 5.4 mg/kg (BC HER2-Low)                               |
| Mean a Std Dev                                        | 10.689 5.2101                                         | 4.100                                                 | 41.57                                                 | 20 41.41 18.107                                       | 21                                                    |
| N 21 21 21 0.39816 17.830 0.448617 Min/Max 2.05/23.48 | N 21 21 21 0.39816 17.830 0.448617 Min/Max 2.05/23.48 | N 21 21 21 0.39816 17.830 0.448617 Min/Max 2.05/23.48 | N 21 21 21 0.39816 17.830 0.448617 Min/Max 2.05/23.48 | N 21 21 21 0.39816 17.830 0.448617 Min/Max 2.05/23.48 | N 21 21 21 0.39816 17.830 0.448617 Min/Max 2.05/23.48 |
| N Mean a                                              | 79                                                    | 79                                                    | 79 40.82                                              | 76 40.64                                              | 78                                                    |
| 6.4 mg/kg (BC HER2-Low)                               | 6.4 mg/kg (BC HER2-Low)                               | 6.4 mg/kg (BC HER2-Low)                               | 6.4 mg/kg (BC HER2-Low)                               | 6.4 mg/kg (BC HER2-Low)                               | 6.4 mg/kg (BC HER2-Low)                               |
| Min/Max                                               | 13.399 4.3519                                         | 6.767 3.83/7.25                                       | 11.787                                                |                                                       | 0.32806                                               |
|                                                       |                                                       |                                                       |                                                       | 11.938                                                |                                                       |
| Std Dev                                               |                                                       |                                                       |                                                       |                                                       | 0.201258                                              |

AUC21d = area under the concentration-time curve from time zero to Day 21; AUClast = area under the serum concentration-time curve from time zero to the time ofthe last quantifiable serum concentration; BC =breast cancer; Cmax = maximum observed serum concentration; Ctrough = trough serum concentration; DXd = released payload (MAAA-1181a); HER2 = human epidermal growth factor receptor 2; max = maximum; min = minimum; N = number of subjects; PK = pharmacokinetic; Std Dev = standard deviation; Tmax = time of Cmax.

a Mean (Std Dev) values are presented for all parameters except Tmax, for which median (range) is presented. Source: Module 5.3.5.3 Integrated PK Analysis Table 14.2.3.3

<div style=\"page-break-after: always\"></div>

## Special populations

In the Pop PK population, there were 571 Asian subjects from Japan, 337 Asian subjects not from Japan, and 767 non-Asian subjects. Subjects were aged 20 to 96 years, weighing 27.3 to 125 kg, with BSA ranging 1.06 to 2.45 m 2 , albumin ranging 22 to 55 g/L, total bilirubin ranging 1 to 57.1 U/L, ALT ranging 2.00 to 202 U/L, LDH ranging 99.0 to 6850 U/L, ALP ranging 24.0 to 2650 U/L and CrCL ranging 25.3 to 264 mL/min. Of the 1675 subjects, 962 (58%) subjects received prior HER2 therapy.

The clinical relevance of covariate effects included in the final Pop PK model was evaluated using Forest plots (Figures 6 and 7). For TDXd, subjects with low albumin (31 g/L; 5th percentile) had an approximately 21% lower steady state Cmin when compared to a typical BC subject with an albumin of 40 g/L. Subjects with extreme values of body weight (90kg; 95th percentile) had an approximately 27% higher Cmax and a 30% higher AUC relative to a typical BC subject of body weight 59 kg.

Figure 6 Forest plot of covariate effects on T-DXd exposure

<!-- image -->

For DXd, subjects with extreme values of body weight (90 kg; 95th percentile) had an approximately 28% higher steady state Cmin, 34% higher Cmax, and a 36% higher AUC relative to a typical BC subject with body weight of 59 kg.

<div style=\"page-break-after: always\"></div>

| Covariate               | Percentile   | anieA     | Ratio[90%CI]         |
|-------------------------|--------------|-----------|----------------------|
| Body weight (kg)        | 5th 25th     | 44        | 0.841[0.822,0.861]   |
|                         |              | 52        | 0.93[0.923,0.939]    |
|                         | 50th         | 60        | 1.01[1.01,1.01]      |
|                         | 75th         | 69        | 1.1 [1.08, 1.11]     |
|                         | 95th         | 90        | 1.28[1.23,1.32]      |
| AST(U/L)                | 5th          | 15        | 0.874[0.853.0.8921   |
|                         | 25th         | 20        | 0.924 [0.911, 0.935] |
|                         | 50th         | 27        | 0.96[0.976,0.963]    |
|                         | 75th         | 41        | 1.06 [1.05,1.07]     |
|                         | 95th         | 86        | 1.23[1.19,1.27]      |
| Total bilirubin(umol/L) | 5th          | 3         | 0.88[0.849,0.903]    |
|                         | 25th         | 5         | 0.938[0.921,0.951]   |
|                         | 50th         | 8         | 0.994[0.992,0.996]   |
|                         | 75th         | 10        | 1.04[1.03.1.05]      |
|                         | 95th         | 17        | 1.12[1.09,1.15]      |
| Race-country            |              | Non-Asian | 1[0.998,1]           |
| Cancertype              |              | NSCLC     | 0.841[0.84,0.843]    |

Figure 7 Forest plot of covariate effects on DXd exposure

<!-- image -->

Boxplots of exposure metrics by hepatic function and by renal function are displayed in Figures 8, 9, 10 and 11.

<div style=\"page-break-after: always\"></div>

Figure 8 Boxplots of post hoc steady state T-DXd exposures in HER2-low BC subjects receiving 5.4 mg/kg Q3W by hepatic function

<!-- image -->

Abbreviations: AUC = area under the concentration-time curve; BC = breast cancer; Cmax = maximum concentration; Cmin = minimum concentration; HER2 = human epidermal growth factor receptor 2; n = number of subjects; Q3 W = every 3 weeks; ss = steady state.

Notes: Boxes show the median and interquartile range of data. Whiskers represent the extent of data within 1.5 times the interquartile range. Points represent data outside the whiskers. Hepatic function was categorized using the NCI ODWG criteria [12].

Source:ds8201-intact-boxplots.docx, 2022-03-ds8201a-303-intact.r.

Figure 9 Boxplots of post hoc steady state DXd exposures in HER2-low BC subjects receiving 5.4 mg/kg Q3W by hepatic function

<!-- image -->

Abbreviations: AUC = area under the concentration-time curve; BC = breast cancer; Cmax = maximum concentration; Cmin =minimum concentration; HER2 =human epidermal growth factor receptor 2; n =number of subjects; Q3W = every 3 weeks; ss = steady state.

Notes: Boxes show the median and interquartile range of data. Whiskers represent the extent of data within 1.5 times the interquartile range. Points represent data outside the whiskers. Hepatic function was categorized using the NCI ODWG criteria [12].

Source: ds8201-payload-boxplots.docx, 2022-03-ds8201a-303-payload.r.

<div style=\"page-break-after: always\"></div>

Figure 10 Boxplots of post hoc steady state T-DXd exposures in HER2-low BC subjects receiving 5.4 mg/kg Q3W by renal function

<!-- image -->

Abbreviations: AUC = area under the concentration-time curve; BC = breast cancer; Cmax = maximum concentration; Cmin = minimum concentration; CrCL = creatinine clearance; FDA = Food and Drug Administration; HER2 = human epidermal growth factor receptor 2; n = number of subjects; Q3W = every 3 weeks; ss = steady state.

Notes: Boxes show the median and interquartile range of data. Whiskers represent the extent of data within 1.5 times the interquartile range. Points represent data outside the whiskers. Renal function was categorized using the 2010 FDA Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function [13]. Normal function, mild impairment, moderate impairment, and severe impairment were defined as CrCL (using Cockcroft and Gault equation) of≥90, 60 to 89, 30 to 59, and 15 to 29 mL/min, respectively. One (1) subject with severe renal impairment is not displayed.

Source: ds8201-intact-boxplots.docx, 2022-03-ds8201a-303-intact.r.

Figure 11 Boxplots of post hoc steady state DXd exposures in HER2-low BC subjects receiving 5.4 mg/kg Q3W by renal function

<!-- image -->

Abbreviations: AUC = area under the concentration-time curve; BC = breast cancer; Cmax = maximum concentration; Cmin =minimum concentration; CrCL = creatinine clearance; CrCL = creatinine clearance; FDA =Food and Drug Administration; HER2 =human epidermal growth factor receptor 2; n = number of subjects; Q3W = every 3 weeks; ss = steady state.

Notes: Boxes show the median and interquartile range of data. Whiskers represent the extent of data within 1.5 times the interquartile range. Points represent data outside the whiskers. Renal function was categorized using the 2010 FDA Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function [13]. Normal function, mild impairment, moderate impairment, and severe impairment were defined as CrCL (using

Forest plots updated with effects of body weight at the 1 st  and 2.5 th  percentiles are shown in Figure 12 below for DXd exposure metrics.

<div style=\"page-break-after: always\"></div>

| Covariate                | Percentile   |           | Ratio [90% CI]       |
|--------------------------|--------------|-----------|----------------------|
| Body weight (kg)         | 1st          | 39        | 0.787 [0.762, 0.814] |
|                          | 2.5th        | 41        | 0.814 [0.793, 0.838] |
|                          | 5th          |           | 0.841 [0.822, 0.861] |
|                          | 25th         | 52        | 0.93 [0.923, 0.939]  |
|                          | 50th         | 60        | 1.01 [1.01, 1.01]    |
|                          | 75th         | 69        | 1.1 [1.08, 1.11]     |
|                          | 95th         | 90        | 1.28 [1.23, 1.32]    |
| AST (UL)                 | 5th          | 15        | 0.874 [0.853, 0.892] |
|                          | 25th         | 20        | 0.924 [0.911, 0.935] |
|                          | 50th         |           | 0.98 [0.976, 0.983]  |
|                          | 75th         | 41        | 1.06 [1.05, 1.07]    |
|                          | 95th         | 86        | 1.23 [1.19, 1.27]    |
| Total bilirubin (umol/L) | 5th          | 3         | 0.88 [0.849, 0.903]  |
|                          | 25th         | 5         | 0.938 [0.921, 0.951] |
|                          | 50th         | 8         | 0.994 [0.992, 0.996] |
|                          | 75th         | 10        | 1.04 [1.03, 1.05]    |
|                          | 95th         | 17        | 1.12 [1.09, 1.15]    |
| Race-country Cancer type |              | Non-Aslan | 1 [0.998, 1]         |
|                          |              | NSCLC     | 0.841 [0.84, 0.843]  |

| Covariate                | Percontile   | Valuo     | Ratio [90% CI]       |
|--------------------------|--------------|-----------|----------------------|
| Body weight (kg)         | 1st          | 39        | 0.748 [0.726, 0.772] |
|                          | 2.5th        | 41        | 0.78 [0.76, 0.802]   |
|                          | 5th          | 44        | 0.811 [0.794, 0.83]  |
|                          | 25th         | 52        | 0.917 [0.909, 0.925] |
|                          | 50th         | 60        | 1.01 [1.01, 1.01]    |
|                          | 75th         | 69        | 1.12 [1.1, 1.13]     |
|                          | 95th         | 90        | 1.34 [1.29, 1.38]    |
| AST (U/L)                | 5th          | 15        | 0.879 [0.859, 0.897] |
|                          | 25th         | 20        | 0.927 [0.915, 0.939] |
|                          | 50th         | 27        | 0.981 [0.977, 0.984] |
|                          | 75th         | 41        | 1.06 [1.05, 1.07]    |
|                          | 95th         | 86        | 1.22 [1.18, 1.26]    |
| Total bllirubin (umol/L) | Sth          | 3         | 0.885 [0.855, 0.908] |
|                          | 25th         | 5         | 0.941 [0.925, 0.953] |
|                          | 50th         | 8         | 0.995 [0.992, 0.997] |
|                          | 75th         | 10        | 1.03 [1.03, 1.04]    |
|                          | 95th         | 17        | 1.11 [1.09, 1.14]    |
| Race=country Cancer type |              | Non=Asian | 1.01 [1.01, 1.01]    |
|                          |              | NSCLC     | 0.991 [0.988, 0.996] |

Figure 12 Forest plots of covariate effects of body weight at the 1 st  and 2.5 th percentiles

<!-- image -->

Rato relie to o typical BC cubject WT=STkg, AST=30uL BI=SumolL, Aeam, non Jepan

<div style=\"page-break-after: always\"></div>

| Covariate                | Percentile   | Value     | Ratio [90% CI]       |
|--------------------------|--------------|-----------|----------------------|
| Body weight (kg)         | 1st          | 39        | 0.734 [0.711, 0.759] |
|                          | 2.5th        | 41        | 0.768 [0.747, 0.79]  |
|                          | 5th          | 44        | 0.8 [0.783, 0.82]    |
|                          | 25th         | 52        | 0.912 [0.904, 0.92]  |
|                          | 50th         | 60        | 1.01 [1.01, 1.02]    |
|                          | 75th         | 69        | 1.12 [1.11, 1.14]    |
|                          | 95th         | 90        | 1.36 [1.31, 1.41]    |
| AST (U/L)                | 5th          | 15        | 0.874 [0.853, 0.892] |
|                          | 25th         | 20        | 0.924 [0.911,0.936]  |
|                          | 50th         | 27        | 0.98 [0.976, 0.983]  |
|                          | 75th         | 41        | 1.06 [1.05, 1.07]    |
|                          | 95th         | 86        | 1.23 [1.19, 1.27]    |
| Total bilirubin (umol/L) | 5th          | 3         | 0.88 [0.849, 0.904]  |
|                          | 25th         | 5         | 0.938 [0.921, 0.951] |
|                          | 50th         | 8         | 0.994 [0.992, 0.996] |
|                          | 75th         | 10        | 1.04 [1.03, 1.05]    |
|                          | 95th         | 17        | 1.12 [1.09, 1.15]    |
| Race-country             |              | Non-Asian | 1 [0.998, 1]         |
| Cancer type              |              | NSCLC     | 0.913 [0.912, 0.915] |

## 2.3.3. Pharmacodynamics

Primary and secondary pharmacology is described in the initial BC application (see initial EPAR).

## Immunogenicity

In Study U303, the treatment-emergent incidence of ADAs against T-DXd was 2.0% (7 of 357 subjects). The data available indicated no association between ADA status and allergic-type reactions. The incidence of NAbs against T-DXd was 0.1% across all studies (1 of 1668 subjects). The timepoints of immunogenicity samples in Study U303 are shown in Table 8. A summary of the available immunogenicity data is shown in Table 9.

Table 8 Immunogenicity sampling strategy for Study U303

| Protocol   | Anti-DrugAntibodySamplingPoints   | Anti-DrugAntibodySamplingPoints   | Anti-DrugAntibodySamplingPoints   | Anti-DrugAntibodySamplingPoints   | Anti-DrugAntibodySamplingPoints   | Anti-DrugAntibodySamplingPoints   | Anti-DrugAntibodySamplingPoints   |
|------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|            | C1D1 BI                           | C1D8                              | C2D1 BI                           | Cycle 4 and Later Cycles BI       | EOT                               | Follow-UpVisits                   |                                   |
| U303       | X                                 |                                   | X                                 | X                                 |                                   | D40andlong-term survivalfollow-up |                                   |

ADA=anti-drugantibody;BI=beforeinfusion;C=Cycle;D=Day;EOT=endoftreatment.

Note:ADAsamplesweretakenwithin8hoursBIonDay1inCycles1,2,and 4,and thenevery4cycles(Cycles8, 12,16, etc); from Cycle 2 onward, samples were taken on Day 1 ±2 days. If positive ADA at the 40-day (+7 days) Follow-upVisit,sampleswerecollected every3months(±1 month)up to1year afterthelast dose,oruntil the ADA became negative, or until the ADA titer became less than baseline (applicable when pre-existing ADA was observed),orstartofnewanticancertherapy,orsubjectwithdrewconsentfromthestudy(whicheveroccurredfirst). Source:Module5.3.5.1DS8201-A-U303CSR,Table6.4

<!-- image -->

Ratiorelative to a typical BC subject:WT=59kg,AST=30U/L Bil=8umol/L,Asian,nonJapan

<div style=\"page-break-after: always\"></div>

Table 9 Summary of clinical immunogenicity data

| Statistic                                          | Prior Clinical Studies (N =1130)   | U303 (N = 371)   | Overall (N = 1701)   |
|----------------------------------------------------|------------------------------------|------------------|----------------------|
| Baseline assessment                                |                                    |                  |                      |
| Subjects with Baseline Data, n (%)                 | 1310 (98.5)                        | 352 (94.9)       | 1662 (97.7)          |
| ADA Positive at Baseline, n (%) a                  | 70 (5.3)                           | 20 (5.7)         | 90 (5.4)             |
| NAb Positive at Baseline, n (%) a                  | 2 (0.2)                            | 1 (0.3)          | 3 (0.2)              |
| Post-baselineassessment                            |                                    |                  |                      |
| Subjects with Post-Baseline Data, n (%)            | 1311 (98.6)                        | 357 (96.2)       | 1668 (98.1)          |
| ADA Positive Post-Baseline, n (%) b                | 36 (2.7)                           | 13 (3.6)         | 49 (2.9)             |
| NAb Positive Post-Baseline, n (%) b                | 1 (0.1)                            | 1 (0.3)          | 2 (0.1)              |
| ADA Positive atBaseline andPost-Baseline, n (%) c  | 12 (0.9)                           | 6 (1.8)          | 18 (1.1)             |
| NAbPositive at Baseline and Post-Baseline, n (%) c | 0                                  | 0                | 0                    |
| Treatment-Emergent ADA Positive, n (%) b, d        | 27 (2.1)                           | 7 (2.0)          | 34 (2.0)             |
| Treatment-Induced ADA Positive, n (%) b,e          | 24 (1.8)                           | 7 (2.0)          | 31 (1.9)             |
| Treatment-Boosted ADA Positive, n (%) b,f          | 3 (0.2)                            | 0                | 3 (0.2)              |
| Treatment-Emergent NAb Positive, n (%) b, g        | 1 (0.1)                            | 0                | 1 (0.1)              |

ADA = anti-drug antibody; n = number of subjects; N = total number subjects; NAb = neutralizing antibody; T-DXd = trastuzumab deruxtecan.

Note: The \"prior clinical studies\" were the following nine studies: J101, J102, A103, A104, U201, J202, U204, U205, and U302.

a Denominator for percentages is the number of subjects with baseline immunogenicity data.

c Denominator for percentages is the number of subjects with baseline and post-baseline immunogenicity data.

b Denominator for percentages is the number of subjects with post-baseline immunogenicity data.

d Treatment-emergent ADA positive: positive post-baseline after negative or missing baseline result, or titer increased after positivebaseline result.

f Treatment-boosted ADA positive: ADA titer increased following positive baseline result.

e Treatment-induced ADA positive: positive post-baseline result where baseline result was negative or missing.

g Treatment-emergent NAb positive: NAb-positive subjects among treatment-emergent ADA-positive subjects. Source: Module 5.3.5.3 SCP TFLs,Table 2.1.1.

## 2.3.4. PK/PD modelling

## Exposure-response (ER) analyses

R (version 4.0.5) was used for exposure-efficacy modelling, data explorations prior to and/or after modelling, and simulations based on exposure-efficacy models.

Exposure metrics were generated from the final PopPK model using individual post hoc Bayes estimates. Binary variables were explored using boxplots, logistic regression plots or exposure-event tables. For time-to-event variables, Kaplan-Meier survival curves were plotted by exposure quartile. Cox regression models were fit to the endpoints. Covariates were tested on the intercept and the slope of logistic ER relationships or on the intercept of Cox regression models. Covariates were tested using a forward search at p&lt;0.05 followed by a backward search at p&lt;0.01 using the likelihood ratio test. Exposure was included in the backward search process, except for logistic regression safety endpoints.

## Exposure-efficacy relations

All subjects with HER2-positive BC from Study U303 who were treated with T-DXd and had individual estimated exposures were included in the exposure-efficacy population. Efficacy data from Study U303 and Study J101 were not pooled due to the differences in subject population and study design. Thus, a total of 362 HER2-low subjects were included in the exposure-efficacy analyses of PFS, OS and ORR, of which 324 were HR-positive.

<div style=\"page-break-after: always\"></div>

For PFS , Cox-regression showed a significant correlation (using a z-test) to T-DXd AUC in Cycle 1 for all subjects (p=0.038), but not in HR-positive (p=0.112) subjects. Because exposure was not present in the final model for PFS in all subjects or for PFS in HR positive subjects, no PFS simulations were performed. PFS final model parameters are shown in Table 10.

Table 10 PFS final model parameters in all subjects

| Exposure-Response Model   | Exposure-Response Model   | Parameter   | Estimate   | Standard Error   | RSE (%)   |
|---------------------------|---------------------------|-------------|------------|------------------|-----------|
| Exposure Metric           | Endpoint                  | Parameter   | Estimate   | Standard Error   | RSE (%)   |
| None                      | PFSin all subjects        | AST         | 0.00565    | 0.00207          | 37        |

Abbreviations: AST = aspartate aminotransferase; PFS = progression free survival; RSE = relative standard error. Source: ee.analysis.1

For OS , T-DXd Cmin in Cycle 1 (Cmin1) were selected for all subjects and for HR-positive subjects because it had the smallest p-value (p&lt;0.001) by log-rank test and a negative effect on the OS hazard ratio in the univariate Cox-regression analysis. T-DXd AUC1, T-DXd AUCSS, and T-DXd CminSS had also significant effect on OS for all subjects. A significant ER relationship was detected for OS in all subjects which was confirmed by model-based analysis using multivariate Cox-regression that showed significant effect of T-DXd Cmin1. Other covariates that were detected included ECOG, AST, prior chemotherapy lines in the metastatic setting and race-country. See figure 13 and Table 11.

<div style=\"page-break-after: always\"></div>

Figure 13 Kaplan-Meier curves for OS by exposure quartiles

(A) HR-positive subjects (N=324)

<!-- image -->

## (B) All subjects (N=362)

<!-- image -->

Abbreviations: HR = hormone-receptor; OS = overall survival; CI = confidence interval; N = number of subjects; Q = exposure quartile.

Note: Curves are Kaplan Meier curves stratified by exposure quartiles. Points are censor times. P-value is for the log-rank test.

Source: ee.analysis.r

10

<div style=\"page-break-after: always\"></div>

Table 11 OS final model parameters in all subjects

| Exposure-ResponseModel     | Exposure-ResponseModel   | Parameter                            | Estimate   | Standard   | RSE   |
|----------------------------|--------------------------|--------------------------------------|------------|------------|-------|
| Exposure Metric            | Endpoint                 |                                      |            | Error      | (%)   |
| T-DXd Cmin Cycle 1 (μg/mL) | OS in all subjects       | Slope                                | -0.154     | 0.0441     | 29    |
| T-DXd Cmin Cycle 1 (μg/mL) | OS in all subjects       | ECOG≥1                               | 0.607      | 0.173      | 29    |
| T-DXd Cmin Cycle 1 (μg/mL) | OS in all subjects       | AST (U/L)                            | 0.00976    | 0.00256    | 26    |
| T-DXd Cmin Cycle 1 (μg/mL) | OS in all subjects       | Prior chemotherapylines metastatic>2 | 0.451      | 0.17       | 38    |
| T-DXd Cmin Cycle 1 (μg/mL) | OS in all subjects       | Asian from Japan                     | 0.0851     | 0.235      | 276   |
| T-DXd Cmin Cycle 1 (μg/mL) | OS in all subjects       | AsiannotfromJapan                    | -0.682     | 0.227      | 33    |

Abbreviations: ECOG = Eastein Cooperative Oncology Group performance status; OS = overall survival; RSE = relativestandardeiror.

Source: ee.analysis.r

The exposure-response of OS showed a shallow relationship across all covariates. Day 360 OS probabilities at the 5th, 50th and 95th percentiles of exposure were 0.815, 0.877, and 0.929 respectively. The difference between Day 360 OS probability at the extremes of exposure in U303 were within 6% of the Day 360 OS probability at the median exposure.

For ORR in all subjects and in HR-positive subjects, CminSS was selected because it had the smallest p-values (p=0.004 and p=0.009) by Kruskal-Wallis test. ORR in HR-positive subjects was not modelled. See Figures 14, 15 and Table 12 for ORR.

Figure 14 Boxplot of T-DXd CminSS grouped by ORR status

(A) HR-positive subjects (N=324)

<!-- image -->

(B) All subjects (N=362)

<!-- image -->

Abbreviations: Cminss = trough concentration at steady state; ORR = confirmed objective response rate by blinded independent centralreview.

Note: Thick horizontal line represents median, box ends show the upper and lower quartiles of the data, whiskers show the range of points within 1.5 times the interquartile range, and points are data that lie outside the whiskers (circles). The p-value is for a Kruskal-Wallis test of difference between distributions. Source: ee.analysis.r

<div style=\"page-break-after: always\"></div>

Figure 15 ORR in all subjects versus T-DXd CminSS

<!-- image -->

Abbreviations: Cminss = T-DXd trough concentration at steady-state; CI = confidence interval; N =number of subjects; ORR = confirmed objective response rate by blinded independent central review. stratified into exposure quartiles. Red points are ORR per exposure quartile plotted at the median exposure per quartile. Vertical red bars are 90% CIs of the confirmed ORR. Gray band represents the 5th to 95t percentile CI of a linear logistic regression fit. The p-value is the significance level of the slope of the logistic regression fit using a z-test. Horizontal boxplot below shows the exposure distribution for the 5.4 mg/kg dose group; the box shows the interquartile range and whiskers show points within 1.5 times the interquartile range.

Source: ee.analysis.r

Table 12 Summary of ORR final model parameters

| Exposure-Response Model   | Exposure-Response Model   |           |          |       |         |
|---------------------------|---------------------------|-----------|----------|-------|---------|
| ExposureMetric            | Efficacy Endpoint         | Parameter | Estimate | Error | RSE (%) |
| T-DXd Cminss              | ORR in all                | Intercept | -0.636   | 0.293 |         |
| (μg/mL)                   | subjects                  | Slope     | 0.060    | 0.022 | 36      |

Abbreviations: Cminss = trough concentration at steady-state; ORR = confirmed objective response rate by independentcentralreview;RSE=relativestandarderror. Note:RSEvalue notreported for theintercept term, because not relevant for logistic regression. Source:ee.analysis.1

There was a significant ER relationship between T-DXd CminSS and increasing ORR in all subjects. No other covariates were detected in the multivariate logistic regression analysis.

Kaplan-Meier Plots for PFS and OS data stratified for weight quartiles in Study U303 are shown in Figure 16.

<div style=\"page-break-after: always\"></div>

Figure 16 Kaplan-Meier Plots for PFS and OS data stratified by baseline body weight for weight quartiles in Study U303

<!-- image -->

## Exposure-safety relations

The previous exposure-safety analyses were based on data from Studies J101, J102, A103, A104, U201, J202, U204, U205, U302 and updated with data from Study U303. A total of 1675 subjects were included, of whom 1328 (79%) were female and 347 (21%) were male, 569 (34%) were Asians from Japan, 337 (20%) were Asians from countries other than Japan, and 769 (46%) were non-Asians. The median age was 58 years, and the median body weight was 60.0 kg. Most subjects had BC (67%) and were HER2-positive (55%) and 22% were HER2-low.

The evaluated endpoints were: Grade 3 TEAEs, Grade 3 anaemia, Grade 3 neutrophil count decreased, Grade 3 platelet count decreased, Any Grade drug-related adjudicated interstitial lung disease (ILD), Grade 3 adjudicated ILD, and Grade 2 laboratory defined left-ventricular ejection fraction (LVEF)

<div style=\"page-break-after: always\"></div>

decreased by echocardiogram/multigated acquisition scan (ECHO/MUGA). Additional safety endpoints were included in explorative analyses.

Per modeled safety endpoint, the prior model was fit to the updated exposure-safety analysis set and model parameters and covariate effects were re-estimated. Any covariates that were not significant (p&gt;0.05 using z-test) were removed and re-evaluated using forward and backward covariate analysis. See Figure 5-12 and Table 5-20 for Grade ≥3 TEAEs, Figure 5-18 and Table 5-25 for Grade ≥ 3 anemia; Figure 5-24 and Table 5-30 for Grade ≥ 3 neutropenia; Figure 5-30 and Table 5-35 for Grade ≥ 3 thrombocytopenia; Figure 5-36 and Table 5-40 for Grade ≥ 2 LVEF decrease and Figures 5-42, 5-43 and Table 5-46, 5-47 for Any Grade ILD.

Figure 17 Probability of Grade ≥ 3 TEAEs versus exposure

Figure 5-12: Probability of Grade ≥3 TEAEs versus exposure

<!-- image -->

Abbreviations: Cavg = average concentration; CI = confidence interval; N = number of subjects; TEAE = treatment emergent adverseevent.

Note: Plot shows probability of AE versus exposure. Yes and No refer to if subjects experienced or did not experience Grade ≥3 TEAEs. Subjects are stratified into exposure quartiles. Red points are AE rates per exposure quartile plotted at the median exposure of the quartile. Vertical red bars are 90% CIs of the AE rate. Blue line is the linear logistic regression fit. Gray band represents the 5th to 95th percentile CI of the fit. The pvalue is the significance level of the slope of the logistic regression fit using a z-test. The plot shows data for all dose groups. Horizontal boxplot below shows the exposure distribution for the 5.4 mg/kg dose group; the box shows the interquartile range and whiskers show points within 1.5 times the interquartile range.

Source:es.analysis.r

<div style=\"page-break-after: always\"></div>

Table 13 Grade ≥ 3 TEAE final model parameters

| Exposure-ResponseModel            | Exposure-ResponseModel   |                                      |          |                |         |
|-----------------------------------|--------------------------|--------------------------------------|----------|----------------|---------|
| Exposure Metric                   | Endpoint                 | Parameter                            | Estimate | Standard Error | RSE (%) |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | Intercept                            | -1.23    | 0.209          |         |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | Slope                                | 0.999    | 0.117          | 12      |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | Albumin (g/L)                        | -0.0668  | 0.0132         | 20      |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | Gastric cancer                       | -1.26    | 0.479          | 38      |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | NSCLC (HER2 mutant)                  | -1.51    | 0.792          | 52      |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | NSCLC (HER2 overexpressing)          | -1.92    | 0.827          | 43      |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | Other tumor type                     | -0.37    | 0.857          | 232     |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | Prior CDK46Inhibitor                 | -0.249   | 0.182          | 73      |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | CDK46 Missing                        | 0.238    | 0.141          | 59      |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | Gastric cancer on slope              | 0.801    | 0.299          | 37      |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | NSCLC (HER2 mutant) on slope         | 1.56     | 0.621          | 40      |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | NSCLC (HER2 overexpressing) on slope | 1.18     | 0.524          | 44      |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | Other tumor type on slope            | 0.0806   | 0.489          | 607     |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 TEAE            | Weight (kg) on slope                 | -0.00876 | 0.00233        | 27      |

Abbreviations: AE = adverse event; Cavg= average concentration; CDK46 = cyclin-dependent kinase 4 or 6; HER2 = human epidermal growth factor receptor 2; NSCLC = non-small cell lung cancer; RSE = relative standard error; TEAE = treatment-emergent adverse event.

Note: RSE value not reported for the intercept term, because not relevant for logistic regression. The large RSE for or it may reflect a small sample size. Overall, tumor type is still significant as a categorical variable. Source: es.analysis.r

<div style=\"page-break-after: always\"></div>

Figure 18 Probability of Grade ≥3 anemia versus exposure

<!-- image -->

DXd Cavg to time ofevent(ng/mL)

Abbreviations: AE = adverse event; Cavg = average concentration; CI = confidence interval; N = number of subjects.

Note: Plot shows probability of AE versus exposure. Yes and No refer to if subjects experienced or did not experience anemia (laboratory-based). Subjects are stratified into exposure quartiles. Red points are AE rates per exposure quartile plotted at the median exposure of the quartile. Vertical red bars are 9o% CIs of the AE rate. Blue line is the linear logistic regression fit. Gray band represents the 5th to 95th percentile CI of the fit. The p-value is the significance level of the slope of the logistic regression fit using a z-test. The plot shows data for all dose groups. Horizontal boxplot below the graph shows the exposure distribution for the 5.4 mg/kg dose group; the box shows the interquartile range and whiskers show points within 1.5 times the interquartile range. Source: es.analysis.r

<div style=\"page-break-after: always\"></div>

Table 14 Grade ≥3 lab-based anemia final model parameters

| Exposure-Response Model           | Exposure-Response Model   |                                        |          |                | RSE   |
|-----------------------------------|---------------------------|----------------------------------------|----------|----------------|-------|
| Exposure Metric                   | Safety Endpoint           | Parameter                              | Estimate | Standard Error | (%)   |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | Intercept                              | -3.67    | 0.283          |       |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | Slope                                  | 1.54     | 0.169          | 11    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | Hemoglobin (g/L)                       | -0.0663  | 0.00650        | 10    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | Weight (kg)                            | 0.0232   | 0.00837        | 36    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | Prior CDK46Inhibitor                   | -1.10    | 0.350          | 32    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | CDK46 Missing                          | -0.574   | 0.206          | 36    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | Gastric cancer type on slope           | 0.122    | 0.125          | 102   |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | NSCLC (HER2 mutant) on slope           | -0.0467  | 0.274          | 587   |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | NSCLC (HER2 overexpressing) on slope   | -1.15    | 0.442          | 38    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | Other tumor type on slope              | -0.382   | 0.217          | 57    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | Creatinine clearance (mL/min) on slope | -0.00794 | 0.0019         | 24    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | Total bilirubin (μmol/L) on slope      | -0.0293  | 0.0105         | 36    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | Non-Asian on slope                     | -0.754   | 0.140          | 19    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 lab-based anemia | Asian not from Japan on slope          | -0.238   | 0.134          | 56    |

Abbreviations: Cavg = average concentration; CDK46 = cyclin-dependent kinase 4 or 6; HER2 = human epidermal growth factor receptor 2; NSCLC = non-small cell lung cancer; RSE = relative standard error.

Note:RSEvalue notreported for theintercept term,becausenotrelevantforlogisticregression.ThelargeRSEfor Asian not from Japan indicates that this race-country category is not significantly different from Asian from Japan for Grade ≥3 anemia. Overall race-country category was still significant as a categorical variable. The large RSE for gastric cancer and NSCLC HER2 mutant indicates that these tumor types are not significantly different from BC for Grade &gt;3 anemia. Overall, tumor type was still significant as a categorical variable.

Source: es.analysis.r

<div style=\"page-break-after: always\"></div>

Figure 19 Probability of Grade ≥3 neutropenia versus Dxd exposure

<!-- image -->

Abbreviations: AE = adverse event; Cavg = average concentration; CI = confidence interval; N = number of subjects.

Note: Plot shows probability of AE versus exposure. Yes and No refer to if subjects experienced or did not experience neutropenia (laboratory-based). Subjects are stratified into exposure quartiles. Red points are AE rates per exposure quartile plotted at the median exposure of the quartile. Vertical red bars are 90% CIs of the AE rate. Blue line is the linear logistic regression fit. Gray band represents the 5th to 95th percentile CI of the fit. The p-value is the significance level of the slope of the logistic regression fit using a z-test. The plot shows data for all dose groups. Horizontal boxplot below the graph shows the exposure distribution for the 5.4 mg/kg dose group. The box shows the interquartile range and whiskers show points within 1.5 times the interquartile range.

Source: es.analysis.r

<div style=\"page-break-after: always\"></div>

Table 15 Grade ≥3 neutropenia final model parameters

| Exposure-Response Model           | Exposure-Response Model   | Parameter                           | Estimate   | Standard   | RSE (%)   |
|-----------------------------------|---------------------------|-------------------------------------|------------|------------|-----------|
| Exposure Metric                   | Safety Endpoint           | Parameter                           | Estimate   | Error      | RSE (%)   |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 neutropenia      | Intercept                           | -3.36      | 0.293      |           |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 neutropenia      | Slope                               | 1.40       | 0.163      | 12        |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 neutropenia      | Neutrophils (10^9/L)                | -0.785     | 0.105      | 13        |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 neutropenia      | Non-Asian                           | 0.558      | 0.377      | 68        |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 neutropenia      | Asian not from Japan                | 1.57       | 0.416      | 26        |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 neutropenia      | Prior checkpoint inhibitor on slope | 0.460      | 0.169      | 37        |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 neutropenia      | Albumin (g/L) on slope              | -0.0339    | 0.00914    | 27        |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 neutropenia      | Non-Asian on slope                  | -1.02      | 0.211      | 21        |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 neutropenia      | Asian not from Japan on slope       | -1.11      | 0.243      | 22        |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 neutropenia      | Neutrophils (10^9/L) on slope       | 0.228      | 0.0434     | 19        |

Abbreviations: Cavg = average concentration; RSE = relative standard error.

Note: RSE value not reported for the intercept term, because not relevant for logistic regression.

Source: es.analysis.r

Figure 20 Probability of Grade ≥3 thrombocytopenia versus exposure

<!-- image -->

Abbreviations: AE = adverse event; Cavg = average concentration; CI = confidence interval; N = number of subjects.

Note: Plot shows probability of AE versus exposure. Yes and No refer to if subjects experienced or did not experience thrombocytopenia (laboratory-based). Subjects are stratified into exposure quartiles. Red points are AE rates per exposure quartile plotted at the median exposure of the quartile. Vertical red bars are 90% CIs of the AE rate. Blue line is the linear logistic regression fit. Gray band represents the 5th to 95th percentile CI of the fit. The p-value is the significance level of the slope of the logistic regression fit using a z-test. The plot shows data for all dose groups. Horizontal boxplot below shows the exposure distribution for the 5.4 mg/kg dose group; the box shows the interquartile range and whiskers show points within 1.5 times the interquartile range.

Source: es.analysis.r

<div style=\"page-break-after: always\"></div>

Table 16 Grade ≥3 thrombocytopenia final model parameters

| Exposure-Response Model           | Exposure-Response Model   | Parameter                     | Estimate   | Standard   | RSE   |
|-----------------------------------|---------------------------|-------------------------------|------------|------------|-------|
| Exposure Metric                   | Safety Endpoint           |                               |            | Error      | (%)   |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 thrombocytopenia | Intercept                     | -4.26      | 0.226      |       |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 thrombocytopenia | Slope                         | 1.21       | 0.119      | 10    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 thrombocytopenia | Creatinineclearance(mL/min)   | 0.00941    | 0.0034     | 36    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 thrombocytopenia | Platelets (10^9/L) on slope   | -0.00331   | 0.000543   | 16    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 thrombocytopenia | Non-Asian on slope            | -0.788     | 0.13       | 16    |
| DXd Cavg to time of event (ng/mL) | Grade ≥3 thrombocytopenia | Asian not from Japan on slope | 0.0486     | 0.131      | 270   |

Abbreviations: Cavg = average concentration; RSE = relative standard error.

Note: RSE value not reported for the intercept term, because not relevant for logistic regression. The large RSE for Asian not from Japan indicates this race-country category is similar to the Asian from Japan reference group.

Overall,race-countrywasstillsignificantasacategoricalvariable.

Source: es.analysis.r

Figure 21 Probability of Grade ≥ 2 LVEF decreases (ECHO/MUGA) versus exposure

<!-- image -->

Abbreviations:AE=adverse event;CI=confidence interval; conc =concentration;ECHO=echocardiogrambased; LVEF = left ventricular ejection fraction; MUGA = multigated acquisition scan; N = number of subjects. Note: Plot shows probability of AE versus exposure. Yes and No refer to if subjects experienced or did not experience LVEF decrease (ECHO/MUGA). Subjects are stratified into exposure quartiles. Red points are AE rates per exposure quartile plotted at the median exposure of the quartile. Vertical red bars are 9o% CIs of the AE rate. Blue line is the linear logistic regression fit. Gray band represents the 5th to 95th percentile CI of the fit. The p-value is the significance level of the slope of the logistic regression fit using a z-test. The plot shows data for all dose groups. Horizontal boxplot below the graph shows the exposure distribution for the 5.4 mg/kg dose group; the box shows the interquartile range and whiskers show points within 1.5 times the interquartile range. Source:es.analysis.r

<div style=\"page-break-after: always\"></div>

Table 17 Grade ≥ 2 LVEF decreases (ECHO/MUGA) final model parameters

| Exposure-ResponseModel            | Exposure-ResponseModel           | Parameter         | Estimate   | Standard   | RSE   |
|-----------------------------------|----------------------------------|-------------------|------------|------------|-------|
| Exposure Metric                   | Safety Endpoint                  |                   |            | Error      | (%)   |
| T-DXdpeakconc steadystate (μg/mL) | Grade>2LVEF decrease (ECHO/MUGA) | Intercept         | -2.62      | 0.353      |       |
| T-DXdpeakconc steadystate (μg/mL) | Grade>2LVEF decrease (ECHO/MUGA) | Slope             | 0.00896    | 0.00235    | 26    |
| T-DXdpeakconc steadystate (μg/mL) | Grade>2LVEF decrease (ECHO/MUGA) | Sex Male          | -0.799     | 0.209      | 26    |
| T-DXdpeakconc steadystate (μg/mL) | Grade>2LVEF decrease (ECHO/MUGA) | Non-Asian         | -0.381     | 0.157      | 41    |
| T-DXdpeakconc steadystate (μg/mL) | Grade>2LVEF decrease (ECHO/MUGA) | AsiannotfromJapan | -0.778     | 0.221      | 28    |

Abbreviations: conc =concentration;ECHO=echocardiogram-based;LVEF=left ventricular ejectionfraction; MUGA=multigated acquisition scan;RSE=relativestandard error.

Note:RSEvaluenotreportedfor theinterceptterm,becausenotrelevantforlogisticregression. Source:es.analysis.r

Figure 22 Rate of Any Grade and Grade ≥3 ILD versus exposure

<!-- image -->

T-DXd AUCsteady state(μg/mLxday)

T-DXd peakconc steady state(μg/mL)

Abbreviations: AE = adverse event; AUC = area under the concentration-time curve; CI = confidence interval; conc = concentration; ILD = interstitial lung disease; N = number of subjects.

Note: Yes and No refer to if subjects experienced or did not experience ILD. Subjects are stratified into exposure quartiles. Red points are AE rates per exposure quartile plotted at the median exposure of the quartile. Vertical red bars are 90% CIs of the AE rate. Blue line is the linear logistic regression fit. Gray band represents the 5th to 95th percentile CI of the fit. The p-value is the significance level of the slope of the logistic regression fit using a z-test. The plot shows data for all dose groups. Horizontal boxplot below shows the exposure distribution for the 5.4 mg/kg dose group; the box shows the interquartile range and whiskers show points within 1.5 times the interquartile range.

Source: es.analysis.r

<div style=\"page-break-after: always\"></div>

Figure 23 Kaplan-Meier curves with univariate Cox regression fit for Any Grade ILD for AUC exposure quartiles

<!-- image -->

Table 18 Any Grade ILD final model parameters

| Exposure-Response Model            | Exposure-Response Model   |                               |          |                |         |
|------------------------------------|---------------------------|-------------------------------|----------|----------------|---------|
| Exposure Metric                    | Safety Endpoint           | Parameter                     | Estimate | Standard Error | RSE (%) |
| T-DXd AUC steady state (μg/mLxday) | Any Grade ILD             | Slope                         | 0.00148  | 0.000264       | 18      |
| T-DXd AUC steady state (μg/mLxday) | Any Grade ILD             | Creatinine clearance (mL/min) | -0.00989 | 0.00241        | 24      |
| T-DXd AUC steady state (μg/mLxday) | Any Grade ILD             | Non-Asian                     | -0.609   | 0.14           | 23      |
| T-DXd AUC steady state (μg/mLxday) | Any Grade ILD             | Asian not from Japan          | -1.12    | 0.227          | 20      |
| T-DXd AUC steady state (μg/mLxday) | Any Grade ILD             | Oxygen saturation (%)         | -0.0971  | 0.0398         | 41      |

Abbreviations: AUC = area under the concentration-time curve; ILD = interstitial lung disease; RSE = relative standard error.

Source: es.analysis.r

Table 5-47: Grade ≥3 ILD final model parameter's

| Exposure-Response Model              | Exposure-Response Model   | Parameter             | Estimate   | Standard   | RSE   |
|--------------------------------------|---------------------------|-----------------------|------------|------------|-------|
| Exposure Metric                      | Safety Endpoint           |                       |            | Error      | (%)   |
| T-DXd peak conc steady state (μg/mL) | Grade≥3 ILD               | Slope                 | 0.0192     | 0.00448    | 23    |
| T-DXd peak conc steady state (μg/mL) | Grade≥3 ILD               | ECOG≥1                | 0.96       | 0.319      | 33    |
| T-DXd peak conc steady state (μg/mL) | Grade≥3 ILD               | Oxygen saturation (%) | -0.17      | 0.051      | 30    |
| T-DXd peak conc steady state (μg/mL) | Grade≥3 ILD               | Albumin (g/L)         | -0.079     | 0.0317     | 40    |

Abbreviations: conc = concentration; ECOG = Eastern Cooperative Oncology Group Performance Status; ILD = interstitial lung disease; RSE = relative standard error.

Source: es.analysis.r

Predicted incidence rate for all safety end-points are summarised in Table 19 and 20.

<div style=\"page-break-after: always\"></div>

Table 19 Incidence Rate of Adverse Events in Subjects with Breast Cancer (at 5.4 mg/kg Q3W T-DXd), Predicted in the Final Model (by HER2 Status, Region, and Race-Country)

|                 |              | Model-PredictedRate,% Estimate (90% CI)   | Model-PredictedRate,% Estimate (90% CI)   | Model-PredictedRate,% Estimate (90% CI)   | Model-PredictedRate,% Estimate (90% CI)   | Model-PredictedRate,% Estimate (90% CI)   |
|-----------------|--------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
|                 | N            | Grade ≥3 TEAE                             | Grade ≥3 Anemia                           | Grade ≥3 Neutropenia                      | Grade ≥3 Thrombocyt                       | Grade ≥2 LVEFDecrease                     |
| HER2 Status     | HER2 Status  | HER2 Status                               | HER2 Status                               | HER2 Status                               | HER2 Status                               | HER2 Status                               |
| HER2-Positive   | 645          | 56.5 (51.8, 61.1)                         | 9.8 (7.2, 13.2)                           | 17.5 (13.9, 21.9)                         | 6.3 (4.6, 8.5)                            | 14.4 (12.0, 17.4)                         |
| HER2-Low        | 362          | 51.5 (45.4, 57.3)                         | 7.3 (4.8, 11.3)                           | 15.7 (12.2, 19.9)                         | 6.1 (4.3, 8.4)                            | 14.5 (12.1, 17.4)                         |
| Region          | Region       | Region                                    | Region                                    | Region                                    | Region                                    | Region                                    |
| Asia            | 560          | 57.6 (52.6, 62.3)                         | 11.7 (8.5, 15.5)                          | 23.7 (19.4, 29.0)                         | 8.9 (6.6, 11.5)                           | 14.6 (11.9, 18.1)                         |
| Europe          | 284          | 53.1 (47.5, 58.2)                         | 4.8 (3.0, 7.6)                            | 10.6 (8.0, 14.0)                          | 3.0 (2.0, 4.5)                            | 14.8 (12.6, 17.8)                         |
| North America   | 234          | 54.2 (48.4, 59.6)                         | 10.7 (7.2, 15.0)                          | 12.0 (9.1, 16.0)                          | 4.6 (3.1, 6.5)                            | 14.5 (12.1, 17.4)                         |
| ROW             | 50           | 52.4 (46.0, 58.3)                         | 5.2 (3.2, 8.4)                            | 11.8 (8.6, 16.1)                          | 3.7 (2.2, 6.1)                            | 16.5 (13.5, 20.2)                         |
| Race-Country    | Race-Country | Race-Country                              | Race-Country                              | Race-Country                              | Race-Country                              | Race-Country                              |
| Non-Asian       | 542          | 53.3 (47.8, 58.7)                         | 6.8 (4.6, 9.8)                            | 10.9 (8.4, 14.1)                          | 3.4 (2.2, 5.0)                            | 15.1 (12.7, 18.1)                         |
| Asian-Japan     | 303          | 60.1 (54.9, 65.1)                         | 13.5 (10.0, 17.7)                         | 25.4 (21.3, 30.3)                         | 8.7 (6.5, 11.0)                           | 18.6 (15.8, 22.4)                         |
| Asian Non-Japan | 283          | 55.4 (50.3, 60.3)                         | 10.7 (7.3, 14.9)                          | 22.5 (17.9, 28.4)                         | 10.0 (7.2, 13.4)                          | 9.8 (7.4, 13.1)                           |

BC = breast cancer; CI = confidence interval; HER2 = human epidermal growth factor receptor 2; LVEF = left ventricular ejection fraction; N = number of subjects; T-DXd = trastuzumab deruxtecan;

Thrombocyt = thrombocytopenia; ROW = rest of the world; TEAE = treatment-emergent adverse event; Q3w=every3weeks.

Note: Modeled safety endpoint rates use BC subjects from all dose groups in indicated group. Exposures are dose-normalized to a 5.4 mg/kg T-DXd dose.

Source: Module 5.3.3.5 Exposure-Response Analysis Report PMx020, Table 5-60, Table 5-61, and Table 5-62

Table 20 Incidence Rate of Interstitial Lung Disease in Subjects with Breast Cancer (at 5.4 mg/kg Q3W T-DXd), Predicted in the Final Model (by HER2 Status, Region, and Race-Country)

|                 | N   | Model-Predicted Rate, % Estimate (90%C1)   | Model-Predicted Rate, % Estimate (90%C1)   | Model-Predicted Rate, % Estimate (90%C1)   | Model-Predicted Rate, % Estimate (90%C1)   |
|-----------------|-----|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
|                 |     | ILDAny Grade                               | ILDAny Grade                               | ILD Grade ≥3                               | ILD Grade ≥3                               |
|                 |     | Day 180                                    | Day 360                                    | Day 180                                    | Day 360                                    |
| HER2Status      |     |                                            |                                            |                                            |                                            |
| HER2-Positive   | 645 | 7.4 (6.2, 8.7)                             | 15.6 (13.5, 17.6)                          | 1.6 (1.1, 2.2)                             | 3.2 (2.3,4.1)                              |
| HER2-Low        | 362 | 6.9 (5.8, 8.2)                             | 14.5 (12.6, 16.7)                          | 2.0 (1.4, 2.8)                             | 3.8 (2.7, 5.0)                             |
| Region          |     |                                            |                                            |                                            |                                            |
| Asia            | 560 | 8.4 (7.1, 9.9)                             | 17.4 (15.0, 20.0)                          | 1.4 (0.9, 1.9)                             | 2.7 (1.9, 3.7)                             |
| Europe          | 284 | 6.9 (5.5, 8.5)                             | 14.4 (12.0, 17.0)                          | 2.0 (1.3, 3.0)                             | 3.7 (2.7, 5.1)                             |
| North America   | 234 | 6.6 (5.4, 8.0)                             | 14.0 (11.8, 16.5)                          | 1.9 (1.3, 2.7)                             | 3.8 (2.7, 5.0)                             |
| ROW             | 50  | 6.6 (5.2, 8.1)                             | 14.0 (11.3, 16.8)                          | 2.6 (1.6, 4.1)                             | 5.1 (3.4, 7.6)                             |
| Race-Country    |     |                                            |                                            |                                            |                                            |
| Non-Asian       | 542 | 6.8 (5.5, 8.4)                             | 14.5 (12.0, 16.9)                          | 2.1 (1.5, 2.9)                             | 4.0 (3.0, 5.2)                             |
| Asian-Japan     | 303 | 12.1 (10.1, 14.2)                          | 24.8 (21.4, 28.6)                          | 1.3 (0.9, 1.9)                             | 2.6 (1.8, 3.5)                             |
| Asian Non-Japan | 283 | 3.9 (2.5, 5.3)                             | 8.4 (5.7, 11.4)                            | 1.5 (1.0, 2.1)                             | 2.9 (2.0, 4.1)                             |

BC = breast cancer; CI = confidence interval; HER2 = human epidermal growth factor receptor 2; N = number of subjects; Q3 W = every 3 weeks; T-DXd = trastuzumab deruxtecan; ROW = rest of the world;

TEAE = treatment-emergent adverse event.

Note: Simulations were based on subjects in the specified population and race-country category using subject-specific exposures and covariates. Simulated number of subjects includes all BC subjects in the indicated category. The 90% CI was based on model uncertainty and covariate variability.

Source: Module 5.3.3.5 Exposure-Response Analysis Report PMx020, Tables 5-50 and 5-51

<div style=\"page-break-after: always\"></div>

## 2.3.5. Discussion on clinical pharmacology

The clinical pharmacology package included in the current application is based on data from a Phase 3 study in subjects with HER2-low BC (Study U303) plus data from nine prior studies. The T-DXd PK was described by a two-compartment model with linear elimination, and DXd PK was described by a onecompartment model, with time-varying release of drug from T-DXd. The previous Pop PK model for BC was updated with data from Study U303 in a sequential way with T-DXd data first. In the Pop PK population, 919 subjects (55%) were HER2-positive, and 468 subjects (28%) were HER2-low. No new covariates were identified. The final Pop PK model (run034) could adequately describe the data from BC patients independent of HER2 status (positive or low).

The absorption, distribution, metabolism, and excretion of T-DXd, total anti-HER2 antibody and DXd is considered well-characterised and described in the initial BC application. The recommended 5.4 mg/kg Q3W dose regimen for HER2-low BC patients applied in Study U303 resulted in comparable exposures to the approved regimen of T -DXd for subjects with unresectable or metastatic HER2-positive BC. The recommended dose regimen is weight-based and resulted in increased Cmax and AUC with increasing body weight. Extended Forest plots indicated that subjects of lower body weight (&lt;41 kg, corresponding to the 2.5 th  body weight percentile) experienced T-Dxd and Dxd exposures at steadystate, below the 0.8 exposure ratio relative to a typical Asian female BC subject of 59 kg. The impact was largest on Cmax,ss and AUC,ss and less pronounced on Cmin,ss. For subjects with body weights above 90 kg, the steady-state exposure for T-Dxd and Dxd were predicted to be above the upper 1.25 exposure ratio.

Steady-state exposures of T-DXd and DXd were comparable between HER2-low subjects with normal hepatic function (n=179) and mild hepatic impairment (n=203) and between HER2-low subjects with normal renal function (n=209), mild (n=130) or moderate renal impairment (n=45). The incidence of post-baseline ADAs and NAbs in Study U303 was low, 3.6% and 0.3%, respectively.

The exposure-efficacy relationship was evaluated in Study U303 HER2-low subjects (n=362) for PFS, OS and ORR. For OS and ORR, a significant ER relationship was detected in all subjects, however, the effect was not deemed clinically relevant for ORR. As weight had great impact on exposure, a subgroup analysis of efficacy measures per weight quartiles displayed by Kaplan Meier plots was requested and indicated some effect on OS for the lowest weight quartile which included weights up to 54 kg.

The previous exposure-safety analyses were updated with the data from Study U303 (total n=1675). The E-R relationships were consistent with those detected previously. T-DXd steady-state Cmax was correlated with Grade ≥ 2 LVEF and Grade ≥ 3 ILD. T-DXd steady-state AUC was correlated with Any Grade ILD. DXd CavgTOE was correlated with Grade ≥ 3 TEAE and laboratory-based Grade ≥ 3 anemia, neutropenia and thrombocytopenia. Across all evaluated safety endpoints, the model-predicted incidence rates were comparable between HER2-positive and HER2-low BC subjects.

The magnitude of effect on ORR at the extremes of exposure in Study U303 is not deemed clinically meaningful relative to ORR at the median exposure. No relationships between increasing DXd exposures and decreasing PFS/OS hazard or increasing ORR probability were detected in the exposureefficacy analysis. Also, no effect of HER2 status (positive versus low) was detected in this analysis.

Treatment benefit of HER2-low BC patients with very low body weight was further discussed. In the HER2-low BC population in Study U303, 13 subjects had a body weight below 44 kg (cut-off close to the 5th percentile of body weight in the 'all BC population'). Of these, 8 subjects discontinued due to progressive disease. This subgroup of patients seemed to have worse prognosis in terms of ECOG

<div style=\"page-break-after: always\"></div>

status, renal function, old age, prior lines of treatment and disease burden. Comparison of simulated T-DXd and DXd exposures at T-DXd doses of 5.4 and 6.4 mg/kg in subjects with a body weight ≤ 44 kg, indicated the higher dose would result in approximate 20% exposure increase at Cycle 1 and at steady-state. A multi-variate E-R analysis indicated that the predicted OS probability at Day 360 for subjects with a body weight ≤ 44 kg would be similar at both T-DXd doses. Comparing the safety profiles stratified for body weight in the 'all BC population', the 6.4 mg/kg dose seemed to result in a worse safety profile compared to 5.4 mg/kg in the ≤ 44 kg subgroup of patients. Thus, the recommendation for the 5.4 mg/kg dose independent of body weight is supported.

## 2.3.6. Conclusions on clinical pharmacology

Overall, the clinical pharmacology is considered adequately described for treatment of HER2-low BC subjects with T-DXd at the recommended dose 5.4 mg/kg Q3W. The final bioanalytical reports for Study U303 will be submitted within 6 months of study closure (PAM-REC).

## 2.4. Clinical efficacy

## 2.4.1. Main study

Destiny Breast04 - Study U303: A randomized, Phase III, open-label, multi-centre study to compare the safety and efficacy of trastuzumab deruxtecan versus the physician's choice in HER2-low, unresectable and/or metastatic breast cancer

Figure 24 Study U303 (DESTINY-Breast04) Design

<!-- image -->

BICR = blinded independent central review; CDK = cyclin-dependent kinase; DoR = duration of response; FAS = Full Analysis Set; HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; IHC = immunohistochemistry; INV = investigator; ISH = in situ hybridization; max = maximum; min = minimum; ORR = objective response rate; OS = overall survival; PFS = progressionfree survival; R = randomization; T-DXd = trastuzumab deruxtecan; vs = versus

<div style=\"page-break-after: always\"></div>

## Methods

## Study participants

## Inclusion Criteria

Subjects had to satisfy all of the criteria shown below to be included in the study. For subjects randomized to the TPC arm, the investigator followed the label approved in the country of drug administration for eligibility criteria for the individual treatment options (capecitabine, eribulin, gemcitabine, paclitaxel, or nab-paclitaxel).

1. Competent and able to comprehend, sign, and date an IRB- or IEC-approved ICF before performance of any study-specific procedures or tests.

2. Men or women ≥18 years of age.
3. Pathologically documented BC that:
- a. Was unresectable or metastatic.

b. Had a history of low HER2 expression, defined as IHC 2+/ISH-negative or IHC 1+ (ISH-negative or untested).

c. Was assessed as low HER2 expression, defined as IHC 2+/ISH-negative or IHC 1+ according to ASCO-CAP 2018 HER2 testing guidelines, adapted by Daiichi Sankyo Inc. and Ventana Medical Systems, Inc., evaluated at a central laboratory.

d. Was hormone receptor-positive or hormone receptor-negative. Approximately 60 subjects with hormone receptor-negative BC were to be enrolled; the remaining subjects were to be hormone receptorpositive (positive for estrogen receptor or progesterone receptor if finding of ≥1% immunoreactive tumor cell nuclei).

e. If the BC was hormone receptor-positive, it was documented as refractory to ET, defined as having progressed on at least 1 endocrine therapy and determined by the investigator that the subject would no longer benefit from further treatment with ET.

f. If the BC was hormone receptor-positive, had or had not been treated with a CDK4/6 inhibitor. No more than 240 subjects with hormone receptor-positive BC who had no prior therapy with a CDK4/6 inhibitor and at least 240 subjects with hormone receptor-positive BC who had prior therapy with a CDK4/6 inhibitor were to be enrolled.

g. Had been treated with at least 1 and no more than 2 prior lines of chemotherapy in the recurrent or metastatic setting.

· If recurrence occurred within 6 months of (neo)adjuvant chemotherapy, (neo)adjuvant therapy would count as 1 line of chemotherapy.

· Targeted agents (such as mammalian target of rapamycin [mTOR] inhibitors, poly adenosine diphosphate ribose polymerase [PARP] inhibitors, programmed cell death ligand [PD-L] inhibitors, programmed cell death ligand 1 [PD-L1] inhibitors, histone deacetylase inhibitors, or CDK4/6 inhibitors) and endocrine therapies on their own did not contribute to the count of prior lines of chemotherapy, although regimens with such agents in combination with chemotherapy still counted as 1 line of chemotherapy.

h. Was never previously HER2-positive (IHC 3+ or IHC 2+/ISH-positive) on prior pathology testing (per ASCO-CAP guidelines) or was historically HER2 IHC 0 only.

<div style=\"page-break-after: always\"></div>

i. Was never previously treated with anti-HER2 therapy.

4. Had documented radiologic progression (during or after most recent treatment).

5. An adequate archival tumor tissue sample was available for assessment of HER2 status by central laboratory (based on most recent available tumor tissue sample obtained either prior to or after the last treatment regimen). If archival tumor tissue was not available, a fresh tumor tissue biopsy was required.

6. Had a recent tumor tissue sample after the most recent treatment regimen or subject agreed to undergo a tissue biopsy prior to randomization for exploratory biomarker analysis.

7. Presence of at least 1 measurable lesion based on CT or MRI per modified Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).26

• Brain lesions were considered as non-target lesions only.

8. Had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

9. Had left ventricular ejection fraction (LVEF) ≥50% within 28 days prior to randomization.

10. Had adequate bone marrow function within 14 days before randomization, defined as:

a. Platelet count ≥100,000/mm3 (platelet transfusion was not allowed within 1 week prior to Screening assessment).

b. Hemoglobin level ≥9.0 g/dL (red blood cell transfusion was not allowed within 1 week prior to Screening assessment).

c. Absolute neutrophil count ≥1500/mm3 (granulocyte colony -stimulating factor [G-CSF] administration was not allowed within 1 week prior to Screening assessment).

11. Had adequate renal function within 14 days before randomization, defined as:

· Creatinine clearance ≥30 mL/min, as calculated using the Cockcroft -Gault equation: CrCl (mL/min) = [140 - age (years)] × weight (kg) 72 × serum creatinine (mg/dL) {× 0.85 for females}.

12. Had adequate hepatic function within 14 days before randomization, defined as:

• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤5 × upper limit of normal (ULN).

· Total bilirubin ≤1.5 × ULN if no liver metastases or &lt;3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline.

13. Had adequate blood clotting function within 14 days before randomization, defined as:

· International normalized ratio/prothrombin time ≤1.5 × ULN and either partial thromboplastin or activated partial thromboplastin time.

14. Male and female subjects of reproductive/childbearing potential were required to agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and after the last dose of T-DXd for at least 7 months for females or 4.5 months for males or according to the label approved in the country of drug administration for the TPCs. Male subjects were required to agree to inform all female partners that they were participating in a clinical study that could cause birth defects.

15. Male subjects were not allowed to freeze or donate sperm starting at Screening and throughout the study period, and at least 4.5 months after the final study drug administration or according to the label

<div style=\"page-break-after: always\"></div>

approved in the country of drug administration for the TPCs. Preservation of sperm was to be considered prior to enrollment in this study.

16. Female subjects were not allowed to donate ova, or retrieve for their own use, from the time of Screening and throughout the study drug period, and for at least 7 months after the final study drug administration or according to the label approved in the country of drug administration for the TPCs.

17. Had adequate treatment washout period before randomization/enrollment, defined as chloroquine /hydroxychloroquine &gt;14 days.

## Exclusion Criteria

The investigator was instructed to follow the label approved in the country of drug administration for the individual treatment options for eligibility criteria if the subject was randomized to the TPC arm.

Subjects with any of the following were disqualified from entering the study:

1. Ineligibility for the declared TPC comparator because of previous treatment with the same comparator in the metastatic setting or the comparator was contraindicated. Subjects were eligible to be treated with a comparator with which they had not previously been treated.

2. Prior treatment with an ADC consisting of an exatecan derivative that is a topoisomerase I inhibitor, including prior participation in a study involving an ADC produced by Daiichi Sankyo Inc. and/or AstraZeneca.

3. Uncontrolled or significant cardiovascular disease, including any of the following:

a. History of myocardial infarction within 6 months before randomization, or troponin levels consistent with myocardial infarction (as defined according to the manufacturer) 28 days prior to randomization.

b. History of symptomatic congestive heart failure (New York Heart Association Class II to IV).

c. Corrected QT interval (QTc) prolongation to &gt;470 ms (females) or &gt;450 ms (males) based on average of Screening triplicate 12-lead electrocardiograms (ECGs).

4. History of (noninfectious) ILD/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that could not be ruled out by imaging at Screening.

5. Spinal cord compression or clinically active central nervous system metastases, defined as untreated or symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.

· Subjects with treated brain metastases that were no longer symptomatic and who required no treatment with corticosteroids or anticonvulsants could be included in the study if they had recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment.

6. Multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or contralateral BC.

7. History of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product.

8. History of severe hypersensitivity reactions to other monoclonal antibodies.

9. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.

<div style=\"page-break-after: always\"></div>

10. Substance abuse or medical conditions such as clinically significant cardiac or pulmonary diseases or psychological conditions, that could, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results.

11. Social, familial, or geographical factors that could interfere with study participation or follow-up.

12. Known human immunodeficiency virus (HIV) infection or active hepatitis B or C infection. Subjects positive for hepatitis C antibody were eligible only if polymerase chain reaction was negative for hepatitis C ribonucleic acid (RNA). Subjects were to be tested for HIV prior to randomization if required by local regulations or IRB/IEC.

13. Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline. Subjects with chronic Grade 2 toxicities could be eligible at the discretion of the investigator after consultation with the Sponsor Medical Monitor or designee (e.g., Grade 2 chemotherapy-induced neuropathy).

14. Therapeutic radiation therapy or major surgery within 4 weeks before study drug or palliative stereotactic radiation therapy within 2 weeks before study drug.

15. Systemic treatment with anticancer therapy (immunotherapy [non-antibody-based therapy], retinoid therapy) or hormonal therapy within 3 weeks before study drug; antibody-based-anticancertherapy within 4 weeks before randomization; or treatment with nitrosoureas or mitomycin C within 6 weeks before study drug; or treatment with small-molecule targeted agents within 2 weeks, or 5 halflives, whichever was longer.

16. Participation in a therapeutic clinical study within 3 weeks before study drug (for small-molecule targeted agents, this nonparticipation period was 2 weeks or 5 half-lives, whichever was longer), current participation in other therapeutic investigational procedures, or prior participation in this investigational study.

17. Pregnancy, breastfeeding, or a plan to become pregnant.

18. Subject could not be study site personnel or Sponsor employee directly involved in the clinical study, or an immediate family member of someone directly involved.

19. Otherwise considered inappropriate for the study by the investigator.

20. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within 3 months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, pleural effusion, etc.), and any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (i.e., rheumatoid arthritis, Sjögren's, sarcoidosis, etc.), or prior pneumonectomy.

## Treatments

T-DXd was given intravenously (IV) at a dose of 5.4 mg/kg every 3 weeks (Q3W) (21-day cycle) until disease progression or unacceptable toxicity.

<div style=\"page-break-after: always\"></div>

Table 21 Treatment per Physician's choice in the control arm

| Comparator     | Dosing Regimen                                                                                                                           |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Capecitabine   | 1000-1250 mg/m2 PO twice daily on Days 1-14; cycled every 21 days                                                                        |
| Eribulin       | 1.4 mga/m2 IV on Days 1 and 8; cycled every 21 days                                                                                      |
| Gemcitabine    | Option 1: 800-1200 mg/m2 IV on Days 1 and 8; cycled every 21 days Option 2: 800-1200 mg/m2 IV on Days 1, 8, and 15; cycled every 28 days |
| Paclitaxel     | Option 1: 175 mg/m2 IV on Day 1; cycled every 21 days Option 2: 80 mg/m2 IV on Day 1 weekly                                              |
| Nab-paclitaxel | Option 1: 260 mg/m2 IV; cycled every 21 days Option 2: 100 mg/m2 or 125 mg/m2 IV on Days 1, 8, and 15; cycled every 28 days              |

NCCN= NationalComprehensive Cancer Network; IV = intra venously; PO =orally

a Refers to eribulin mesylate (1.23 mgeribulin base = 1.4 mgeribulin mesylate)

In both treatment arms, the study drug was continued according until discontinuation criteria were met, which included progressive disease, unacceptable toxicity, or withdrawal of consent by subject.

## Objectives

## Primary Objective

The primary objective was to compare the PFS benefit of T-DXd to TPC in the cohort of subjects with HER2-low, hormone receptor-positive BC (i.e., the hormone receptor-positive cohort of the Full Analysis Set [FAS]), based on BICR.

## Key Secondary Objectives

The key secondary objectives were as follows:

- To compare the PFS benefit of T-DXd to TPC in all randomized subjects regardless of hormonereceptor status (i.e., the FAS), based on BICR
- To compare the OS benefit of T-DXd to TPC in subjects with HER2-low hormone receptor-positive BC
- To compare the OS benefit of T-DXd to TPC in the FAS.

## Other Secondary Objectives

Other secondary objectives were as follows:

- To investigate the efficacy of T-DXd compared to TPC on the following parameters:
- -PFS in subjects with HER2-low hormone receptor-positive BC, based on investigator assessment
- -Confirmed ORR, based on BICR and investigator assessment in subjects with HER2-low hormone receptor-positive BC
- -DoR, based on BICR in subjects with HER2-low hormone receptor-positive BC
- -Confirmed ORR and DoR in the FAS
- To determine pharmacokinetics (PK) of T-DXd
- To evaluate the safety of T-DXd compared to TPC

<div style=\"page-break-after: always\"></div>

· To evaluate Health Economics and Outcomes Research (HEOR) endpoints for T-DXd compared to TPC.

## Exploratory Objectives

The exploratory objectives were to evaluate the following:

· Clinical benefit rate (CBR; the proportion of complete response [CR], partial response [PR], and ≥6 months' stable disease [SD]), based on BICR in subjects with hormone receptor-positive BC and in the FAS

- Disease control rate (DCR), based on BICR in subjects with hormone receptor positive BC and in the FAS
- Time to response (TTR) based on BICR in subjects with hormone receptor-positive BC and in the FAS
- PFS on the next line of therapy (PFS2)
- Potential biomarkers of response/resistance
- Exposure-response relationships for efficacy and safety endpoints
- PFS, OS, confirmed ORR, and DoR in subjects with HER2-low hormone receptor negative BC.

## Outcomes/endpoints

## Primary Efficacy Endpoint

The primary efficacy endpoint was PFS based on BICR in the hormone receptor-positive cohort. PFS was defined as the time from the date of randomization to the earliest date of first objective documentation of radiographic disease progression according to RECIST v1.1 or death due to any cause. If a subject had not progressed or died at the analysis DCO date, PFS was censored at the last adequate tumor evaluation date before the DCO date. Discontinuation associated with disease progression without supporting objective evidence satisfying progression criteria per RECIST v1.1 was not considered to be a PFS event.

## Key Secondary Efficacy Endpoints

- PFS based on BICR in all randomized subjects (i.e., regardless of hormone receptor status)
- OS in the hormone receptor-positive cohort
- OS in all randomized subjects

OS was defined as the time from the date of randomization to the date of death from any cause.  If there was no death reported for a subject before the DCO for OS analysis, OS was censored at the last contact date at which the subject was known to be alive.

## Other Secondary Efficacy Endpoints

- PFS based on investigator assessment (INV).
- Confirmed ORR based on BICR and INV.  Confirmed ORR was defined as the proportion of subjects with best overall response of complete response (CR) or partial response (PR) that was confirmed by a second assessment.
- DoR based on BICR.  DoR was defined as the time from the date of the first documentation of objective response (confirmed CR or PR) to the date of the first documentation of disease progression

<div style=\"page-break-after: always\"></div>

or death.  Subjects who were progression-free at the time of the DCO were censored at the date of the last evaluable tumor assessment.

## Exploratory Efficacy Endpoints

- Clinical benefit rate (CBR) based on BICR:  CBR was defined as the sum of CR rate, PR rate, and the rate of stable disease (SD) lasting more than 6 months.
- Disease control rate (DCR) based on BICR and INV:  DCR was defined as the sum of CR rate, PR rate, and SD rate.
- Time to response (TTR) based on BICR:  TTR was defined as the time from the date of randomization to the date of first documentation of objective response (confirmed CR or PR) for responding subjects.
- PFS on next-line therapy (PFS2) based on INV:  PFS2 was defined as the time from the date of randomization to the first documented progression on next-line therapy or death due to any cause, whichever came first.
- PFS, OS, confirmed ORR, and DoR based on BICR in the hormone receptor-negative cohort.
- Best percent change in the sum of diameters (SoD) of measurable tumors based on BICR.

## Health Economics and Outcome Research Endpoints

Health Economics and Outcome Research (HEOR) endpoints derived using the QLQ-C30, QLQ-BR45 (BR23), and EQ-5D-5L questionnaires, and hospitalization-related endpoints. The primary patient reported outcome (PRO) variable of interest was the global health status/global quality-of-life (QoL) scale score of the QLQ C30.  Secondary PRO variables of interest were physical functioning, emotional functioning, and social functioning subscale scores of the QLQ C30, the BC symptom scale of the QLQBR45, and the index score of the EQ 5D-5L. Because the QLQ-BR45 was still undergoing validation at the time of the analysis, these analyses were performed using the QLQ-BR23 scoring guidelines and are presented in the results as QLQ-BR45/BR23.

## Sample size

Approximately 480 subjects with hormone receptor-positive BC were planned to be randomized (approximately 320 T-DXd and 160 TPC). In addition, approximately 60 subjects with hormone receptor-negative BC (approximately 40 T-DXd and 20 TPC) were planned to be enrolled for exploratory purposes.

Assuming a true hazard ratio of 0.68 (corresponding an improvement in median PFS from the physician's choice arm of 4.2 months [NCT00337103] to a median PFS in T-DXd arm of 6.2 months), a total of 318 PFS events per BICR in HR-positive cohort was needed to ensure at least 90% power of log-rank test to reject the null hypothesis of no difference in PFS distributions at 2-sided alpha of 0.05 in HR-positive cohort (primary analysis). A total of ~480 HR-positive subjects (~320 T-DXd and ~160 physician's choice) and ~60 HR-negative subjects (~40 T-DXd and ~20 physician's choice) would be randomized, for a total enrollment of ~540 subjects (~360 T-DXd and ~180 physician's choice).

The primary efficacy analyses was to be event driven, and the primary analyses for PFS was to be performed when approximately 318 PFS events per BICR have been observed in the HR-positive population. The expected data cut-off dates for the final analyses of PFS was to be approximately 28.3 months after the first subject is randomized, based on updated enrolment rates.

<div style=\"page-break-after: always\"></div>

The key secondary endpoint of OS was to be compared between the 2 treatment groups, provided that the log-rank tests for comparison of PFS in both the HR-positive cohort and the FAS demonstrate statistical significance. Assuming a median OS of 15 months in the control arm and a hazard ratio of 0.72, a total of 333 OS events was needed to ensure 80% power of a log-rank test to reject a null hypothesis of no difference in OS distributions at an overall 2-sided significance level of 0.05 under a 3-look group sequential design using Lan-DeMets alpha spending function with O'Brien-Fleming type superiority stopping boundary provided PFS is statistically significant. Final OS analysis was projected approximately 49.3 months from the date of first subject randomized when 333 OS events were documented in the HR-positive cohort. Approximately 162 (49%) and 233 (70%) out of the target total OS events were projected at the first and the second OS interim analyses in the HR positive cohort.

The sample size computation was performed using the EAST 6.4.

## Randomisation

Subjects will be randomized into 1 of the 2 treatment arms (T-DXd versus physician's choice) in a 2:1 ratio. The randomization was to be stratified by:

- HER2 IHC status of tissue samples assessed by a central laboratory: HER2 IHC 1+ vs. HER2 IHC 2+/ISH-

- Number of prior lines of chemotherapy: 1 vs. 2

- HR/CDK status: HR-positive with prior CDK4/6 inhibitor treatment vs.HR-positive without prior CDK4/6 inhibitor treatment vs.HR-negative.

Randomization was to be managed through an Interactive Web/Voice Response System (IXRS) for subjects meeting all eligibility criteria.

All subjects were to have physician's choice treatment declared and recorded in the IXRS prior to randomization.

## Blinding (masking)

The study was open-label.

## Statistical methods

Full Analysis Set (FAS)

The FAS included all subjects randomized into the study, including those who did not receive a dose of study treatment. Subjects were to be analysed according to the treatments and strata assigned at randomization.

The hormone receptor positive cohort of FAS, according to baseline hormone receptor status per IXRS, was to be the primary analysis set for efficacy analyses.

## Per-Protocol Analysis Set (PPS)

The PPS included all subjects in the hormone receptor positive cohort who complied sufficiently with the protocol with respect to exposure to study treatment, availability of tumor assessment, and absence of major protocol violations likely to impact efficacy outcome.

<div style=\"page-break-after: always\"></div>

## Primary efficacy endpoint: PFS based on BICR

The primary efficacy analysis was to be the comparison of the distribution of PFS per BICR in hormone receptor positive cohort between the two treatment groups using stratified log-rank test, with stratification factors from IXRS, at two-sided significance level of 0.05.

The distribution of PFS was to be estimated using the Kaplan-Meier (K-M) method for each treatment arm, and the results were to be presented graphically by treatment group.

The median PFS and the two-sided 95% confidence intervals (CIs) using Brookmeyer and Crowley method was to be provided for each treatment group. In addition, PFS rates at fixed time points (e.g., 3, 6, 9, 12 months) and the two-sided 95% CIs will be provided for each treatment group.

The hazard ratio of PFS and its two-sided 95% CI were estimated using stratified Cox proportional hazards regression model with treatment group as model factor and the stratification factors from IXRS as strata.

Table 22 Censoring rules for PFS

| Case Scenario                                                                                                                                           | Event/Censor (Event or' Censoring Description)                                                                      | Event or Censoring Date                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| Nobaselineevaluabletumor assessment                                                                                                                     | Censored (no baseline tumor assessment)                                                                             | Date of randomization                                                                                           |
| No post-baseline tumor assessment                                                                                                                       | Censored (no post- baseline assessment)                                                                             | Dateofrandomization                                                                                             |
| Early death (within 14 weeks of randomization) without baseline or postbaseline tumor assessment                                                        | Event (death)                                                                                                       | Date of death                                                                                                   |
| Radiographic disease progression or death without missing two or more consecutive tumor assessments immediately preceding the event                     | Event (progression or death)                                                                                        | Date of progressive disease assessment or date of death                                                         |
| Disease progression or death after missing ≥ 2 consecutive scheduled tumor assessments (i.e., more than 14 weeks)                                       | Censor (event after missing 2 or more consecutive tumor assessments)                                                | Date of last evaluable tumor assessment (prior to earliest of death/progression date and analysis cut-off date) |
| At least one post-baseline response assessment, subject with no death or objective documentation of radiographic disease progression (progression-free) | Censor (lost to follow-up; withdraw consent; ongoing without event; adequate tumor assessment no longer available*) | Date of last evaluable tumor assessment (prior to analysis cut-off date, NOT coded as “inevaluable\")            |
| Anti-cancer therapy started prior to disease progression, death or analysis cut-off date (**)                                                           | Censor (anti-cancer therapy)                                                                                        | Date of last evaluable tumor assessment prior to anti-cancer therapy (other than study drug)                    |

** This censoringrule will be used forsensitivityanalysis

* Censoringreason willbe lost to follow-up if dateof lost to follow-up from end oftreatment page orpost-treatment follow-up page is within 2 consecutivetumor assessments from la st adequate tumor assessment; Censoring rea son willbe withdrewconsentif date ofwithdrawofconsent fromstudyiswithin 2consecutivetumorassessments from la st adequatetumora ssessment; Censoringreason willbe ongoing without progressionif cutoff date is within 2 consecutive tumor a ssessments from la st adequate tumora ssessment; Otherwise censoringreason willbe a dequate assessmentno longer available.

Source SAP v 2.0, page 57/152

Supportive and Sensitivity Analyses

As a sensitivity analysis to assess the impact of stratification on primary efficacy analysis, the two treatment groups were to be compared using an unstratified log-rank test. The same censoring rules used for the primary efficacy analysis were to be applied.

<div style=\"page-break-after: always\"></div>

The primary efficacy analyses were to be repeated for FAS and PPS if the PPS and the full analysis sets differed.

A stratified Cox regression model with strata collected through IXRS as stratification factor was to be fitted to evaluate the effect of other baseline demographic or disease characteristics on the estimated hazard ratio. This model included the following key prognostic factors as covariates: ECOG performance status (0, 1), lines of endocrine therapy received in the metastatic setting (0, 1, &gt;=1), history CNS metastases (yes, no), and age (&lt;65, ≥ 65 years old).

In addition to the above, the sensitivity analyses of the primary efficacy endpoint were to be performed to assess the impact of censoring rules used for the primary efficacy analysis. Sensitivity analyses included the following:

· Using the BICR-assessed PFS data on the hormone receptor positive cohort, and including PFS events whenever they occurred, i.e. not censoring for missing 2 consecutive tumor assessments

· Using the BICR PFS data on the hormone receptor positive cohort, but censoring for new anticancer therapy

· Backdating PFS analysis: repeat BICR PFS analysis not censoring for missing tumor assessment, but backdate PFS event time in the case that PFS event occurred after missing one or more tumor assessments. In such cases, the PFS event date would be considered to be 6 weeks after last evaluable tumor assessment occurring prior to progression/death.

Additional supportive analyses included:

· Number of subjects and number of events by treatment arm within each stratum to be presented along with hazard ratio obtained using unstratified cox regression model, provided enough events are observed within each stratum. No formal statistical comparison to be carried out within stratum.

If there is ≥ 10% discrepancy between strata constructed through the eCRF data and those obtained through IXRS, a sensitivity analysis may be performed where the stratum is based on the eCRF data.

If the number of BICR PFS events by the data cutoff date is more than 328 (3% over the target number of PFS events), a sensitivity analysis using the data up to the target 318 BICR PFS events was to be carried out following the primary analysis approach.

Sensitivity analyses due to COVID-19

Sensitivity analysis of primary analysis of PFS may have been performed if there was a considerable number of subjects who may have been impacted by COVID-19 and had delayed or missing tumor scan assessments by either excluding data from these subjects or not applying the censoring rule of missing 2 or more consecutive tumor assessments due to COVID-19 for PFS. No P-value was to be presented for these sensitivity analyses.

## Key Secondary endpoint: OS

Overall survival was to be compared between the 2 treatment groups, using a stratified log-rank test stratified by the randomization stratification factors as recorded by IXRS, at 2-sided significance level adjusting for alpha spending, provided superiority in PFS per BICR is demonstrated in both hormone receptor positive cohort and FAS. The survival distribution of OS was to be estimated by Kaplan-Meier method and results will be presented graphically. The median survival time and the 2-sided 95% CI for the median were to be provided using Brookmeyer and Crowley method for each treatment group.

The treatment effect hazard ratio and its 95% CI were estimated, using stratified Cox proportional hazards regression model stratified by the randomization stratification factors as recorded by the IXRS.

<div style=\"page-break-after: always\"></div>

## Censoring rules for OS

If there was no death reported for a subject before the data cutoff for OS analysis, OS was to be censored at the last contact date at which the subject was known to be alive.

## Supportive Analyses for OS

If the analysis of OS was significant, a Cox regression model stratified by the IXRS stratification factors was to fitted to evaluate the effect of the same prognostic factors as specified earlier for the Cox regression analysis for PFS.

## Other secondary efficacy endpoint: Confirmed Objective Response Rate

ORR was summarized by treatment group along with the two-sided 95% CIs using the ClopperPearson method. The difference of ORR between the two treatment groups was summarized and the 95% CI calculated using continuity correction. The Cochran-Mantel-Haenszel test stratified by the randomization stratification factors per IXRS was used to compare ORR at two-sided significance level of 0.05.

Subjects with only non-measurable disease at baseline were included in the numerator only if a complete response was observed.

## Interim Analyses and Data Monitoring

No formal interim analysis was planned for PFS.

Up to three analyses of OS were planned:

· First interim analysis at the time of the final analysis for PFS (provided PFS is significant in both hormone receptor positive cohort and FAS), at which point a total of 162 OS events (49% information fraction) in hormone receptor positive cohort are expected.

· If the first OS interim analysis was not significant, a second interim analysis for OS was planned when approximately 233 OS events (70% information fraction) in hormone receptor positive cohort had been documented.

· If the second OS interim analysis was not significant, a final analysis for OS after approximately 333 OS events in hormone receptor positive cohort had been documented.

OS was to be compared between the 2 treatment groups at either interim or final analysis, provided superiority in PFS was demonstrated for both the hormone receptor positive cohort and the FAS. A hierarchical testing procedure was adopted as described below.

A group sequential design, utilizing 3-look Lan-DeMets alpha spending function with O'Brien-Fleming type stop boundary was used to construct the efficacy stopping boundaries with an overall 2-sided significance level of 0.05. The trial allowed for the early stopping of the study for a superior OS, provided the log-rank test for PFS had demonstrated statistical significance in both hormone receptor positive cohort and FAS. The same interim efficacy stopping boundaries was used for OS hypotheses testing with hormone receptor positive cohort and FAS. If the study continues to final analysis, the efficacy stopping boundaries at the final OS analysis to control the 2-sided significance level of the repeated testing at 0.05 was to derived separately for hormone receptor positive cohort and FAS based on the actual number of OS events documented at the cut-off date, and the actual information fractions and the alpha already spent at the interim analyses. This was to ensure the overall significance level at 0.05 (2-sided) across the 2 OS hypotheses testing with hormone receptor positive cohort and FAS, and the repeated testing of the OS hypotheses at the interim and the final analyses,

<div style=\"page-break-after: always\"></div>

provided the log-rank test for PFS had demonstrated statistical significance in both hormone receptor positive cohort and FAS.

It was recognized that the information fractions at the interim analyses may not be as planned. The stopping boundary was to be updated based on the actual information fraction at the interim analyses.

## Multiple Comparisons/Multiplicity

The primary efficacy endpoint, and the key secondary efficacy endpoints were to be tested hierarchically to maintain the overall two-sided type-I error rate to 0.05 or less, in the order below:

1. PFS based on BICR in the hormone receptor positive cohort
2. PFS based on BICR in the FAS
3. OS in the hormone receptor positive cohort (up to 3 analyses)
4. OS in the FAS (up to 3 analyses)

The statistical testing for a key secondary endpoint was to be performed only when the analyses in the hierarchy above the current endpoint had demonstrated statistical significance.

Table 23 Changes to the SAP and to the planned analyses specified in protocol

|   Protocol Version | Approval Date   | Salient Changes, if any                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                1   | Nov 11,2020     | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                1.1 | Oct 10,2021     | Refine the safety analyses Add summary for ORR and DoR for HR- negative cohort (exploratory objective, but no analyses were specified in SAP v1.0) Provide algorithm for TPC duration of exposure Specify algorithm for prior lines of chemotherapy and lines of endocrine therapy UpdatePROsection Adddeath dateimputationrule Refine the algorithm for time windows for ECOGandPRO Clarify HR positive cohorts and HR negative cohort ofFAS,is based onbaselineHR status Add censoring rules for PFS2 |

Source SAP v2.0 page 74/152

Four changes made to the analytic conventions after the finalization of SAP v2.0 on 04 Jan 2022 (before database lock date of 08 Feb 2022) were implemented without a SAP addendum: as summarized below.

1. Added subject disposition for HR-positive cohort and HR-negative cohort.
2. Added summary of major protocol deviation for HR-positive cohort.
3. PFS follow-up (time from the PFS end date to DCO in weeks) and OS follow-up (time from the OS end date to DCO in months) were to be summarized for total patients, instead of 'by treatment arm'.
4. Added subgroup analysis for selected TEAE and grouped terms.

<div style=\"page-break-after: always\"></div>

## Results

Figure 25 Participant flow in Study U303

<!-- image -->

DCO = data cut-off; N= numberofsubjects; PK = phamacokinetic; T-DXd =tra stuzumab deruxtecan; TPC = treatment ofphysician's choice

Data cut-off: 11 Jan 2022

Source: Table 14.1.1.1.1

Table 24 Main Reasons for Screen Failures in Study U303

| Reason for Screen Failure                                                                                                                 |   Number of Subjects |
|-------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Subject did not satisfy inclusion/exclusion criteria a                                                                                    |                  135 |
| Inclusion 3: pathologically documented breast cancer                                                                                      |                   26 |
| Inclusion 6: have a recent tumour tissue sample after the most recent treatment regimen or agree to undergo biopsy prior to randomisation |                   19 |
| Inclusion 8: ECOG PS 0 or 1                                                                                                               |                   11 |

<div style=\"page-break-after: always\"></div>

| Reason for Screen Failure                                                       |   Number of Subjects |
|---------------------------------------------------------------------------------|----------------------|
| Inclusion 10: adequate bone marrow function within 14 days before randomisation |                   10 |
| Inclusion 12: adequate hepatic function within 14 days before randomisation     |                   19 |
| Exclusion 3: uncontrolled or significant cardiovascular disease                 |                   11 |
| Exclusion 5: has spinal cord compression or clinically active CNS metastases    |                   52 |
| Other b                                                                         |                   43 |
| Physician decision                                                              |                    8 |
| Withdrawal by subject                                                           |                    7 |
| Other:                                                                          |                    5 |
| Study closed to enrolment before subject completed screening                    |                    1 |
| Death                                                                           |                    2 |
| Subject admitted to hospice due to worsening condition                          |                    1 |
| Screening for the impact of new crown pneumonia failed                          |                    1 |
| Adverse event                                                                   |                    1 |

CNS = central nervous system; EC = exclusion criteria; ECOG PS = Eastern Cooperative Group Performance Score; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus IC = inclusion criteria.

a Refer to section 4.1 and Section 4.2 of the protocol for full details of inclusion and exclusion criteria, respectively.  Subjects may be counted more than once (ie, Did not meet multiple exclusion and/or inclusion criteria).

b IC 1 (n=2), IC 2 (n=1), IC 4 (n=4), IC 5 (n=2), IC 7 (n=9), IC 9 (n=4), IC 11 (n=2), EC 4 (n=3), EC 6 (n=1), EC 7 (n=1), EC 9 (n=1), EC 10 (n=1), EC 12 (n=3), EC 14 (n=1), EC 15 (n=4), EC 16 (n=1), EC 20 (n=5), EC 21 (n=2)

Source: Module 5.3.5.1 DS-8201-A-U303 CSR Listing 16.2.1.1 and 16.2.2.1.

## Recruitment

From 21 Dec 2018 to the DCO of 11 Jan 2022, 557 patients were enrolled from study sites in the United States (27), Japan (18), France (16), China (15), Italy (13), Spain (12), Greece (8), Portugal (8), Republic of Korea (8), Israel (6), Switzerland (6), Austria (4), Belgium (4), Russia (3), Sweden (3), Taiwan (3), United Kingdom (3), Canada (2), and Hungary (2). Median duration of follow (study duration) as of DCO: 16.1 months in the T-DXd arm and 13.5 months in the TPC arm.

## Conduct of the study

After the initial release (Version 1.0, 23 Aug 2018), the study protocol was amended 4 times. Key changes in each amendment were as follows:

## Amendment 1 (Version 2.0) - 23 Nov 2018, Before the First Subject Signed an ICF

The primary changes made by Amendment 1 were as follows:

- Added information on T-DXd dosing (starting dose, infusion time for initial dose, and dose modifications)
- Updated text regarding Screening to be within 14 days of randomization
- Clarified prohibited medications and treatments for T-DXd and TPC
- Updated CBR to include at least 6 months' SD
- Clarified inclusion/exclusion criteria

<div style=\"page-break-after: always\"></div>

- Added HEOR questionnaires at Cycle 2 Day 1
- Updated AESI wording to reflect the latest T-DXd safety profile
- Clarified the EOT visit timing and updated the 40-day Follow-up and Long-term/Survival Follow-up visits to allow for a window of ±7 days.

## Amendment 2 (Protocol Version 3.0) - 24 Apr 2019, During the Course of the Study

The primary changes made by Amendment 2 were as follows:

- Clarified tissue biopsy text regarding archival and fresh sample requirements
- Increased the number of study centers to approximately 255 sites
- Clarified the number of hormone receptor-positive and hormone receptor-negative subjects with and without prior therapy with a CDK4/6 inhibitor to be enrolled in the study
- Added statement that the investigator should follow the locally approved label for the individual treatment options for subjects randomized to the TPC arm
- Updated the inclusion criterion related to hormone receptor-positive subjects
- Updated the criterion for recalculating a subject's dose based on a change in body weight
- Updated the inclusion criterion related to male and female subjects of reproductive/childbearing potential
- Amended the ILD monitoring/management instructions.

## Amendment 3 (Protocol Version 4.0) - 23 Apr 2020, During the Course of the Study

The primary changes made by Amendment 3 were the clarification that tumor assessments were to be conducted every 6 weeks from randomization and clarification regarding the TPC dose regimens.

## Amendment 4 (Version 5.0) - 12 Oct 2020, During the Course of the Study

The primary changes made by Amendment 4 were as follows:

· Added new timepoints for OS analyses. The study was originally designed to perform OS analysis at the same time as the final PFS analysis. This early analysis would not have provided adequate followup and statistical power to detect a statistically significant difference in OS. Therefore, the protocol was amended to include OS as a key secondary endpoint with adequate follow-up to provide statistical power to detect meaningful improvement in OS between the 2 treatment arms.

- Added PFS2 as an exploratory objective and endpoint.

· To evaluate the impact of the global pandemic caused by COVID-19, added an analysis to identify subjects affected by COVID-19, and updated the analysis plan to identify the impact of COVID-19 on study conduct, efficacy, and safety.

## Contingency Measures Implemented to the Conduct of the Study as a Result of the COVID19 Pandemic

## Changes in Collection of Data

Because of site closures and travel restrictions, 4 subjects were transferred to another existing study site or satellite site that was different from the site at which the subject originally enrolled. In such cases, the transfer was initiated by the investigator. Study activities, including drug dispensing and

<div style=\"page-break-after: always\"></div>

dosing for each subject, were performed per protocol at the transfer site. Modification of study procedures as a result of the COVID-19 pandemic was not necessary.

## Changes in Monitoring/Oversight

Risk-based/remote monitoring activities were initiated at the beginning of the study. During the COVID-19 pandemic, based on site and/or country policy, on-site monitoring visits were not conducted if sites could not accept visitors. During this time, on-site monitoring visits were replaced with remote visits/more frequent remote monitoring and telephone contacts were made where permissible by local regulations. Monitors used virtual monitoring visits to reinforce AE reporting and timely data entry.

Targeted source data verification was the primary task during these on-site visits, focusing on primary efficacy and key safety data points. At the time of the primary analysis database lock, targeted source data verification could not be completed for some sites due to site access limitations as a result of the COVID-19 pandemic. The risk to data quality was considered minimal, as alternative methods of riskbased monitoring/central monitoring of data review and data cleaning activities were conducted over the course of the study.

Table 25 Major Protocol Deviations in the Hormone Receptor-positive Cohort and the Full Analysis Set

| Deviation Category                                          | Number (%) of Subjects           | Number (%) of Subjects           | Number (%) of Subjects   | Number (%) of Subjects   |
|-------------------------------------------------------------|----------------------------------|----------------------------------|--------------------------|--------------------------|
| Deviation Category                                          | Hormone Receptor-positive Cohort | Hormone Receptor-positive Cohort | Full Analysis Set        | Full Analysis Set        |
| Deviation Category                                          | T-DXd (N= 331)                   | TPC (N= 163)                     | T-DXd (N= 373)           | TPC (N =184)             |
| Subjects with anymajor protocol deviation                   | 36 (10.9)                        | 30 (18.4)                        | 42 (11.3)                | 35 (19.0)                |
| Relatedto COVID-19                                          | 3 (0.9)                          | 0                                | 3 (0.8)                  | 0                        |
| Serious adverse eventreporting                              | 8 (2.4)                          | 6 (3.7)                          | 9 (2.4)                  | 7 (3.8)                  |
| Informed consent                                            | 8 (2.4)                          | 2 (1.2)                          | 8 (2.1)                  | 2 (1.1)                  |
| Eligibility criteria                                        | 8 (2.4)                          | 10 (6.1)                         | 11 (2.9)                 | 10 (5.4)                 |
| Study procedures                                            | 8 (2.4)                          | 1 (0.6)                          | 8 (2.1)                  | 3 (1.6)                  |
| Relatedto COVID-19                                          | 2 (0.6)                          | 0                                | 2 (0.5)                  | 0                        |
| Investigationalproduct                                      | 6 (1.8)                          | 12 (7.4)                         | 7 (1.9)                  | 13 (7.1)                 |
| Relatedto COVID-19                                          | 1 (0.3)                          | 0                                | 1 (0.3)                  | 0                        |
| Concomitant and prohibited  medications or non-drug therapy | 4 (1.2)                          | 0                                | 4 (1.1)                  | 0                        |
| Laboratory assessmentcriteria                               | 1 (0.3)                          | 2 (1.2)                          | 3 (0.8)                  | 3 (1.6)                  |

COVID-19 =coronavirus disease 2019; T-DXd =tra stuzumab deruxtecan; TPC =treatment of physician's choice

For each category and deviation, subjects who experiencedmultiple events in that category or deviation were counted only once.

Percentages were calculatedusing the numberofsubjects in the column heading as the denominator.

Data cut-off: 11 Jan 2022

Source: Table 14.1.1.2.1,14.1.1.2.2

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 26 Demographic and Baseline Disease Characteristics in the Hormone Receptorpositive Cohort and the Full Analysis Set (Study U303)

| Parameter                                    | Hormone Receptor-positive Cohort             | Hormone Receptor-positive Cohort   | Full Analysis Set   | Full Analysis Set   |
|----------------------------------------------|----------------------------------------------|------------------------------------|---------------------|---------------------|
|                                              | T-DXd (N = 331)                              | TPC (N = 163)                      | T-DXd (N = 373)     | TPC (N = 184)       |
| Age (years)                                  |                                              |                                    |                     |                     |
| Mean (Std Dev)                               | 56.3 (10.57)                                 | 56.3 (11.39)                       | 56.5 (10.58)        | 56.5 (11.51)        |
| Median                                       | 56.8                                         | 55.7                               | 57.5                | 55.9                |
| Min, Max                                     | 31.5, 80.2                                   | 28.4, 80.0                         | 31.5, 80.2          | 28.4, 80.5          |
| Age group (years), n (%)                     |                                              |                                    |                     |                     |
| <65                                          | 260 (78.5)                                   | 120 (73.6)                         | 290 (77.7)          | 136 (73.9)          |
| ≥65                                          | 71 (21.5)                                    | 43 (26.4)                          | 83 (22.3)           | 48 (26.1)           |
| <75                                          | 320 (96.7)                                   | 157 (96.3)                         | 359 (96.2)          | 175 (95.1)          |
| ≥75                                          | 11 (3.3)                                     | 6 (3.7)                            | 14 (3.8)            | 9 (4.9)             |
| Sex, n (%)                                   |                                              |                                    |                     |                     |
| Female                                       | 329 (99.4)                                   | 163 (100.0)                        | 371 (99.5)          | 184 (100.0)         |
| Male                                         | 2 (0.6)                                      | 0                                  | 2 (0.5)             | 0                   |
| Region, a n (%)                              |                                              |                                    |                     |                     |
| Asia                                         | 128 (38.7)                                   | 60 (36.8)                          | 147 (39.4)          | 66 (35.9)           |
| North America                                | 54 (16.3)                                    | 30 (18.4)                          | 60 (16.1)           | 33 (17.9)           |
| Europe + Israel                              | 149 (45.0)                                   | 73 (44.8)                          | 166 (44.5)          | 85 (46.2)           |
| Race, n (%)                                  |                                              |                                    |                     |                     |
| White                                        | 156 (47.1)                                   | 78 (47.9)                          | 176 (47.2)          | 91 (49.5)           |
| Black or African American                    | 7 (2.1)                                      | 2 (1.2)                            | 7 (1.9)             | 3 (1.6)             |
| Asian                                        | 131 (39.6)                                   | 66 (40.5)                          | 151 (40.5)          | 72 (39.1)           |
| American Indian or Alaska Native             | 0                                            | 0                                  | 0                   | 0                   |
| Native Hawaiian or Other Pacific Islander    | 0                                            | 0                                  | 1 (0.3)             | 0                   |
| Other                                        | 37 (11.2)                                    | 16 (9.8)                           | 38 (10.2)           | 17 (9.2)            |
| Missing                                      | 0                                            | 1 (0.6)                            | 0                   | 1 (0.5)             |
| Stratification factors per IXRS              |                                              |                                    |                     |                     |
| HER2 status, n (%)                           |                                              |                                    |                     |                     |
| IHC 1+                                       | 193 (58.3)                                   | 95 (58.3)                          | 215 (57.6)          | 106 (57.6)          |
| IHC 2+/ISH-negative                          | 138 (41.7)                                   | 68 (41.7)                          | 158 (42.4)          | 78 (42.4)           |
| Number of prior lines of chemotherapy, n (%) | Number of prior lines of chemotherapy, n (%) |                                    |                     |                     |
| 1                                            | 197 (59.5)                                   | 96 (58.9)                          | 212 (56.8)          | 103 (56.0)          |

<div style=\"page-break-after: always\"></div>

| Parameter                                                | Hormone Receptor-positive   | Hormone Receptor-positive   | Full Analysis Set   | Full Analysis Set   |
|----------------------------------------------------------|-----------------------------|-----------------------------|---------------------|---------------------|
| Parameter                                                | T-DXd (N = 331)             | TPC (N = 163)               | T-DXd (N = 373)     | TPC (N = 184)       |
| 2                                                        | 134 (40.5)                  | 67 (41.1)                   | 161 (43.2)          | 81 (44.0)           |
| Hormone receptor/CDK status, n (%)                       |                             |                             |                     |                     |
| Hormone receptor-positive with prior CDK4/6 inhibitor    | 233 (70.4)                  | 115 (70.6)                  | 233 (62.5)          | 115 (62.5)          |
| Hormone receptor-positive without prior CDK4/6 inhibitor | 98 (29.6)                   | 48 (29.4)                   | 98 (26.3)           | 48 (26.1)           |
| Hormone receptor-negative                                | -                           | -                           | 42 (11.3)           | 21 (11.4)           |
| Subgroups                                                |                             |                             |                     |                     |
| Lines of prior ET in any setting, n (%)                  |                             |                             |                     |                     |
| 0                                                        | 1 (0.3)                     | 3 (1.8)                     | 26 (7.0)            | 19 (10.3)           |
| 1                                                        | 65 (19.6)                   | 34 (20.9)                   | 74 (19.8)           | 35 (19.0)           |
| 2                                                        | 112 (33.8)                  | 46 (28.2)                   | 117 (31.4)          | 49 (26.6)           |
| ≥3                                                       | 153 (46.2)                  | 80 (49.1)                   | 156 (41.8)          | 81 (44.0)           |
| Lines of prior ET in the metastatic setting - derived, n | (%)                         |                             |                     |                     |
| 0                                                        | 28 (8.5)                    | 17 (10.4)                   | 60 (16.1)           | 34 (18.5)           |
| 1                                                        | 105 (31.7)                  | 49 (30.1)                   | 108 (29.0)          | 51 (27.7)           |
| 2                                                        | 110 (33.2)                  | 53 (32.5)                   | 115 (30.8)          | 54 (29.3)           |
| ≥3                                                       | 88 (26.6)                   | 44 (27.0)                   | 90 (24.1)           | 45 (24.5)           |
| Reported history of CNS metastases at baseline, n        | (%)                         |                             |                     |                     |
| Yes                                                      | 30 (9.1)                    | 13 (8.0)                    | 37 (9.9)            | 15 (8.2)            |
| No                                                       | 301 (90.9)                  | 150 (92.0)                  | 336 (90.1)          | 169 (91.8)          |
| Renal function at baseline, b n (%)                      |                             |                             |                     |                     |
| Within normal range                                      | 185 (55.9)                  | 79 (48.5)                   | 202 (54.2)          | 87 (47.3)           |
| Mild impairment                                          | 104 (31.4)                  | 61 (37.4)                   | 123 (33.0)          | 69 (37.5)           |
| Moderate impairment                                      | 37 (11.2)                   | 18 (11.0)                   | 41 (11.0)           | 23 (12.5)           |
| Severe impairment                                        | 0                           | 0                           | 1 (0.3)             | 0                   |
| End-stage renal disease                                  | 0                           | 0                           | 0                   | 0                   |
| Missing                                                  | 5 (1.5)                     | 5 (3.1)                     | 6 (1.6)             | 5 (2.7)             |
| Hepatic function at baseline, b n (%)                    |                             |                             |                     |                     |
| Normal hepatic function                                  | 149 (45.0)                  | 83 (50.9)                   | 170 (45.6)          | 98 (53.3)           |
| Mild impairment                                          | 176 (53.2)                  | 78 (47.9)                   | 195 (52.3)          | 84 (45.7)           |
| Moderate impairment                                      | 2 (0.6)                     | 0                           | 3 (0.8)             | 0                   |
| Severe impairment                                        | 0                           | 0                           | 0                   | 0                   |
| Missing                                                  | 4 (1.2)                     | 2 (1.2)                     | 5 (1.3)             | 2 (1.1)             |
| Baseline visceral disease, c n (%)                       |                             |                             |                     |                     |

<div style=\"page-break-after: always\"></div>

| Parameter                      | Hormone Receptor-positive Cohort   | Hormone Receptor-positive Cohort   | Full Analysis Set   | Full Analysis Set   |
|--------------------------------|------------------------------------|------------------------------------|---------------------|---------------------|
|                                | T-DXd (N = 331)                    | TPC (N = 163)                      | T-DXd (N = 373)     | TPC (N = 184)       |
| Yes                            | 298 (90.0)                         | 146 (89.6)                         | 332 (89.0)          | 157 (85.3)          |
| No                             | 33 (10.0)                          | 17 (10.4)                          | 41 (11.0)           | 27 (14.7)           |
| Baseline CNS metastases, n (%) |                                    |                                    |                     |                     |
| Yes                            | 18 (5.4)                           | 7 (4.3)                            | 24 (6.4)            | 8 (4.3)             |
| No                             | 313 (94.6)                         | 156 (95.7)                         | 349 (93.6)          | 176 (95.7)          |
| ECOG PS, n (%)                 |                                    |                                    |                     |                     |
| 0                              | 187 (56.5)                         | 95 (58.3)                          | 200 (53.6)          | 105 (57.1)          |
| 1                              | 144 (43.5)                         | 68 (41.7)                          | 173 (46.4)          | 79 (42.9)           |
| 2                              | 0                                  | 0                                  | 0                   | 0                   |
| >2                             | 0                                  | 0                                  | 0                   | 0                   |

CDK = cyclin-dependent kinase; CNS = central nervous system; CSR = clinical study report; ECOG PS = Eastern Cooperative Oncology Group performance status; ET = endocrine therapy; HER2 = human epidermal growth factor receptor 2;

IHC = immunohistochemistry; IXRS = interactive web/voice response system; ISH = in situ hybridization; Max = maximum; Min = minimum; SAP = statistical analysis plan; Std Dev = standard deviation; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice a   Asia = China, Japan, Republic of Korea, Taiwan; Europe + Israel = Austria, Belgium, France, Greece, Hungary, Israel, Italy, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom; North America = US, Canada. In this study, Israel was combined with Europe geographic subgroup.

b   Definitions for hepatic and renal function at baseline are specified in DS8201-A-U303 CSR Appendix 16.1.9.1 SAP Version 2.0 Section 7.2.1.5.

c   Visceral disease is defined in SAP Appendix 11.3 see (DS8201-A-U303 CSR Appendix 16.1.9.1 SAP Version 2.0 Section 7.2.1.5).

Source: DS8201-A-U303 CSR Tables 14.1.2.1.1.1, 14.1.2.1.4.1, 14.1.3.2.1, and 14.1.3.2.2

<div style=\"page-break-after: always\"></div>

Table 27 Baseline Disease Characteristics in the Hormone Receptor-positive Cohort and the Full Analysis Set (Study U303)

| Parameter                                                            | Nunber (%) of Subjects                                               | Nunber (%) of Subjects                                               | Nunber (%) of Subjects                                               | Nunber (%) of Subjects                                               |
|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
|                                                                      | HormoneReceptor-positive Cohort                                      | HormoneReceptor-positive Cohort                                      | Full Analysis Set                                                    | Full Analysis Set                                                    |
|                                                                      | T-DXd (N=331)                                                        | TPC (N= 163)                                                         | T-DXd (N=373)                                                        | TPC (N= 184)                                                         |
| Stra tification factor: HER2 IHC status perIXRS                      | Stra tification factor: HER2 IHC status perIXRS                      | Stra tification factor: HER2 IHC status perIXRS                      | Stra tification factor: HER2 IHC status perIXRS                      | Stra tification factor: HER2 IHC status perIXRS                      |
| HER2IHC1+                                                            | 193 (58.3)                                                           | 95 (58.3)                                                            | 215 (57.6)                                                           | 106 (57.6)                                                           |
| HER2 IHC2+/ISHnegative                                               | 138 (41.7)                                                           | 68 (41.7)                                                            | 158 (42.4)                                                           | 78 (42.4)                                                            |
| Stra tificationfactor: Numberof prior lines of chemotherapy per IXRS | Stra tificationfactor: Numberof prior lines of chemotherapy per IXRS | Stra tificationfactor: Numberof prior lines of chemotherapy per IXRS | Stra tificationfactor: Numberof prior lines of chemotherapy per IXRS | Stra tificationfactor: Numberof prior lines of chemotherapy per IXRS |
| 1                                                                    | 197 (59.5)                                                           | 96(58.9)                                                             | 212 (56.8)                                                           | 103 (56.0)                                                           |
| 2                                                                    | 134 (40.5)                                                           | 67 (41.1)                                                            | 161 (43.2)                                                           | 81 (44.0)                                                            |
| Stratificationfactor:Hormonereceptor/CDK status perIXRS              | Stratificationfactor:Hormonereceptor/CDK status perIXRS              | Stratificationfactor:Hormonereceptor/CDK status perIXRS              | Stratificationfactor:Hormonereceptor/CDK status perIXRS              | Stratificationfactor:Hormonereceptor/CDK status perIXRS              |
| Hormonereceptor-positive with prior CDK4/6                           | 233 (70.4)                                                           | 115 (70.6)                                                           | 233 (62.5)                                                           | 115 (62.5)                                                           |
| Hormonereceptor-positive withoutprio1 CDK4/6                         | 98 (29.6)                                                            | 48 (29.4)                                                            | 98 (26.3)                                                            | 48 (26.1)                                                            |
| Hormonereceptor-negative                                             | 0                                                                    | 0                                                                    | 42 (11.3)                                                            | 21 (11.4)                                                            |
| Hormonereceptor - deriveda                                           | Hormonereceptor - deriveda                                           | Hormonereceptor - deriveda                                           | Hormonereceptor - deriveda                                           | Hormonereceptor - deriveda                                           |
| Positive                                                             | 328 (99.1)                                                           | 162 (99.4)                                                           | 333 (89.3)                                                           | 166 (90.2)                                                           |
| Negative                                                             | 3 (0.9)                                                              | 1 (0.6)                                                              | 40 (10.7)                                                            | 18 (9.8)                                                             |
| Reportedhistory ofCNS metastases                                     | 30 (9.1)                                                             | 13 (8.0)                                                             | 37 (9.9)                                                             | 15 (8.2)                                                             |
| Baseline CNS metastases                                              | 18 (5.4)                                                             | 7 (4.3)                                                              | 24(6.4)                                                              | 8 (4.3)                                                              |
| Renalfunctionb                                                       | Renalfunctionb                                                       | Renalfunctionb                                                       | Renalfunctionb                                                       | Renalfunctionb                                                       |
| Within normalrange                                                   | 185 (55.9)                                                           | 79 (48.5)                                                            | 202 (54.2)                                                           | 87 (47.3)                                                            |
| Mild impa iment                                                      | 104 (31.4)                                                           | 61(37.4)                                                             | 123 (33.0)                                                           | 69 (37.5)                                                            |

<!-- image -->

| Parameter                            | Number(%) of Subjects            | Number(%) of Subjects            | Number(%) of Subjects   | Number(%) of Subjects   |
|--------------------------------------|----------------------------------|----------------------------------|-------------------------|-------------------------|
|                                      | Hormone Receptor-positive Cohort | Hormone Receptor-positive Cohort | Full Analysis Set       | Full Analysis Set       |
|                                      | T-DXd (N=331)                    | TPC (N= 163)                     | T-DXd (N=373)           | TPC (N=184)             |
| Moderate impairment                  | 37(11.2)                         | 18 (11.0)                        | 41 (11.0)               | 23 (12.5)               |
| Severe impairment                    | 0                                | 0                                | 1(0.3)c                 | 0                       |
| Missingd                             | 5 (1.5)                          | 5 (3.1)                          | 6 (1.6)                 | 5 (2.7)                 |
| Hepatic function e                   |                                  |                                  |                         |                         |
| Within normalrange                   | 149 (45.0)                       | 83 (50.9)                        | 170 (45.6)              | 98 (53.3)               |
| Mild impaiment                       | 176 (53.2)                       | 78 (47.9)                        | 195 (52.3)              | 84 (45.7)               |
| Moderate impaiment                   | 2 (0.6)                          | 0                                | 3 (0.8)                 | 0                       |
| Missingd                             | 4(1.2)                           | 2 (1.2)                          | 5 (1.3)                 | 2 (1.1)                 |
| Presence ofbaselinelungmetastases    | 98 (29.6)                        | 58 (35.6)                        | 120 (32.2)              | 63 (34.2)               |
| Presence ofbaseline livermetastases  | 247 (74.6)                       | 116 (71.2)                       | 266 (71.3)              | 123 (66.8)              |
| Presence ofbaseline visceraldiseasef | 298 (90.0)                       | 146 (89.6)                       | 332 (89.0)              | 157 (85.3)              |
| ECOGperformancestatus                |                                  |                                  |                         |                         |
| 0                                    | 187 (56.5)                       | 95 (58.3)                        | 200 (53.6)              | 105 (57.1)              |
| 1                                    | 144 (43.5)                       | 68 (41.7)                        | 173 (46.4)              | 79 (42.9)               |

<div style=\"page-break-after: always\"></div>

- AST = aspartateaminotransfeiase; CDK =cyclin-dependentkinase; CNS =centralnervous system; ECOG= Easten Coopeiative Oncology Group; EDC = electronic data capture; HER2 =human epidermal growth factorreceptor 2; IHC = immunochemistry; ISH= in situ hybridization; IXRS = intera ctive web/voiceresponse system; T-DXd =tra stuzumab deruxtecan; TBL =totalbilirubin; TPC =trea tment ofphysician's choice; ULN = upper limit of normal

Positive = estro gen receptors negativeand progesteronereceptors positive; estro genreceptors positive and progesterone receptors negative; estro genreceptors positive and progesterone receptors positive; estrogen receptorspositive andprogesteronereceptors indeterminate; estrogenreceptors indeterminate andprogesterone receptorspositive

Percentages were calculatedusing the number ofsubjects in the column heading as the denominator. a Hormonereceptor (basedon factors from EDC):

Negative = estrogen receptors negativeandprogesterone receptors negative

Indeterminate = estro genreceptors negative and progesteronereceptors indeterminate; estrogenreceptors indeterminate andpro gesterone receptors negative; estro genreceptors indeteiminate andprogesterone-receptors indeterminate

Data presented here are basedon EDC. Data from IXRS could not be modified. The derived data in EDC captured the correctstatus. Further details are provided in Table 14.1.2.2.

- b Renalfunction:
- noimalfunction=creatinine clearance≥90 mL/min
- mild impairment =creatinineclearance ≥60,&lt;90 mL/min
- modeiate impaiment=creatinine clearance≥30,&lt;60 mL/min
- severe impairment =creatinineclearance≥15,&lt;30 mL/min
- end stage renaldisease=creatinine clearance&lt;15 mL/min
- c A protocoldeviation was capturedforthis subject. The site mistakenly used themale paiameters to calculate the creatininecleaiance and theinvestigatoroverlooked this while reviewingeligibility criteria.
- d Sites switched from usinga centrallaboratory to locallaboratory on 17 Apr 2019 (ie, after enrollmenthad started). Sites were instructedto obtainlocallaboratory data (includingbaseline) forallsubjects. There were somesites that collectedcentralbaseline data andthe data were notcaptured into the EDC; as aresult, the centraldata appearedas missing data for these subjects. Forall subjects denotedas \"missing\"' exceptthe 3 subjects detailed below, thebaseline data are captured in the centrallaboiatory database andthesubject's values were within normalrange. Forthe other 3 subjects,1 subjectwasrandomized andnevertreatedandthe other 2 subjects were confirmedto have met thecriteria via site query; noprotocoldeviations were capturedforthese 3 subjects.
- Hepatic function:
- normalfunction= TBL ≤ULN and (AST≤ULN) without Gilbert's syndrome, TBL ≤3.0 x ULN and (AST ULN) with Gilbert's syndrome
- mild impairment =TBL &gt;ULN,≤1.5 x ULN and any AST without Gilbert's syndrome, TBL &gt;ULN,≤3.0 x ULN and (AST &gt;ULN) with Gilbert's syndrome, TBL ≤ULN and(AST &gt;ULN)regardless ofGilbert's syndrome
- modeiate impaiment=TBL &gt;1.5 x ULN,≤3.0 x ULN and anyAST withoutGilbert's syndrome
- severe impaiment = TBL &gt;3.0 x ULN and any AST regardless of Gilbert's syndrome.
- f Baseline visceraidisease was determined with any target ornon-target tumor in the lesion locations specified in Section 7.2.1.5 of the StatisticalAnalysis Plan (Appendix 16.1.9)

Data cut-off: 11 Jan 2022

Source: Tables 14.1.2.1.1.1, 14.1.2.1.4.1

In most patients, HER2 status was determined based on archival tissue (about 86%) and about 14% had a fresh biopsy taken.

<div style=\"page-break-after: always\"></div>

Table 28 Breast Cancer History in the Hormone Receptor-positive Cohort and the Full Analysis Set

| Parameter                                                 | Number (%) of Subjects                                    | Number (%) of Subjects                                    | Number (%) of Subjects                                    | Number (%) of Subjects                                    |
|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
|                                                           | Hormone Receptor-positive Cohort                          | Hormone Receptor-positive Cohort                          | Full Analysis Set                                         | Full Analysis Set                                         |
|                                                           | T-DXd (N=331)                                             | TPC (N =163)                                              | T-DXd (N =373)                                            | TPC (N=184)                                               |
| Timefrom initialhistologicaldiagnosisto studydiug(months) | Timefrom initialhistologicaldiagnosisto studydiug(months) | Timefrom initialhistologicaldiagnosisto studydiug(months) | Timefrom initialhistologicaldiagnosisto studydiug(months) | Timefrom initialhistologicaldiagnosisto studydiug(months) |
| 1n                                                        | 329                                                       | 152                                                       | 371                                                       | 172                                                       |
| Mean (Std Dev)                                            | 103.8 (79.62)                                             | 95.4 (81.70)                                              | 100.5 (78.36)                                             | 88.7 (79.44)                                              |
| Median                                                    | 80.1                                                      | 71.4                                                      | 75.4                                                      | 64.0                                                      |
| Minimum, maximum                                          | 5,445                                                     | 4,358                                                     | 5,445                                                     | 4,358                                                     |
| Histology                                                 |                                                           |                                                           |                                                           |                                                           |
| Adenocarcinoma                                            | 217 (65.6)                                                | 107 (65.6)                                                | 243 (65.1)                                                | 123 (66.8)                                                |
| Inflammatory                                              | 4(1.2)                                                    | 1 (0.6)                                                   | 5 (1.3)                                                   | 1(0.5)                                                    |
| Other                                                     | 110 (33.2)                                                | 55 (33.7)                                                 | 125 (33.5)                                                | 60 (32.6)                                                 |
| Grade                                                     |                                                           |                                                           |                                                           |                                                           |
| Well differentiated                                       | 20 (6.0)                                                  | 9 (5.5)                                                   | 25 (6.7)                                                  | 11 (6.0)                                                  |
| Moderately differentiated                                 | 81 (24.5)                                                 | 48 (29.4)                                                 | 90 (24.1)                                                 | 52 (28.3)                                                 |
| Poorly differentiated                                     | 83 (25.1)                                                 | 35 (21.5)                                                 | 99 (26.5)                                                 | 42 (22.8)                                                 |
| Undifferentiated                                          | 1 (0.3)                                                   | 1 (0.6)                                                   | 1(0.3)                                                    | 1 (0.5)                                                   |
| Unknown                                                   | 146 (44.1)                                                | 70 (42.9)                                                 | 158 (42.4)                                                | 78 (42.4)                                                 |
| HER2 expression(IHC)locala                                |                                                           |                                                           |                                                           |                                                           |
| 0                                                         | 2 (0.6)                                                   | 0                                                         | 2 (0.5)                                                   | 0                                                         |
| 1+                                                        | 171 (51.7)                                                | 93 (57.1)                                                 | 194 (52.0)                                                | 102 (55.4)                                                |
| 2+                                                        | 155 (46.8)                                                | 70 (42.9)                                                 | 174 (46.6)                                                | 81 (44.0)                                                 |
| Not evaluable                                             | 1 (0.3)                                                   | 0                                                         | 1 (0.3)                                                   | 0                                                         |
| Not examined                                              | 2 (0.6)                                                   | 0                                                         | 2 (0.5)                                                   | 1 (0.5)                                                   |
| HER2 gene amplification (ISH) local                       | HER2 gene amplification (ISH) local                       | HER2 gene amplification (ISH) local                       | HER2 gene amplification (ISH) local                       | HER2 gene amplification (ISH) local                       |
| Amplified (positive)                                      | 0                                                         | 0                                                         | 0                                                         | 0                                                         |
| Equivocal                                                 | 13 (3.9)                                                  | 7 (4.3)                                                   | 16 (4.3)                                                  | 7(3.8)                                                    |
| Non-amplified (negative)                                  | 173 (52.3)                                                | 84(51.5)                                                  | 196 (52.5)                                                | 97 (52.7)                                                 |
| Examined but not evaluable                                | 9 (2.7)                                                   | 3 (1.8)                                                   | 9 (2.4)                                                   | 3 (1.6)                                                   |
| Missing                                                   | 136 (41.1)                                                | 69 (42.3)                                                 | 152 (40.8)                                                | 77 (41.8)                                                 |
| BRCA1                                                     |                                                           |                                                           |                                                           |                                                           |
| Positive (mutated)                                        | 3 (0.9)                                                   | 2 (1.2)                                                   | 3 (0.8)                                                   | 2 (1.1)                                                   |
| Nega tive (wild type)                                     | 93 (28.1)                                                 | 56 (34.4)                                                 | 112 (30.0)                                                | 65 (35.3)                                                 |
| Indeteminate                                              | 3 (0.9)                                                   | 1 (0.6)                                                   | 3 (0.8)                                                   | 1 (0.5)                                                   |
| Invalid                                                   | 0                                                         | 1 (0.6)                                                   | 0                                                         | 1 (0.5)                                                   |
| Missing                                                   | 232 (70.1)                                                | 103 (63.2)                                                | 255 (68.4)                                                | 115 (62.5)                                                |
| BRCA2                                                     |                                                           |                                                           |                                                           |                                                           |
| Positive (mutated)                                        | 11 (3.3)                                                  | 8 (4.9)                                                   | 15 (4.0)                                                  | 8 (4.3)                                                   |
| Nega tive (wild type)                                     | 87 (26.3)                                                 | 50 (30.7)                                                 | 103 (27.6)                                                | 59 (32.1)                                                 |
| Indeteminate                                              | 3 (0.9)                                                   | 2 (1.2)                                                   | 3 (0.8)                                                   | 2 (1.1)                                                   |
| Invalid                                                   | 0                                                         | 1 (0.6)                                                   | 0                                                         | 1 (0.5)                                                   |
| Missing                                                   | 230 (69.5)                                                | 102 (62.6)                                                | 252 (67.6)                                                | 114 (62.0)                                                |

IHC =immunochemisty; ISH =in situ hybridization; Std Dev = standard deviation; T-DXd =tra stuzumab deruxtecan; TPC =treatment ofphysician's choice

BRCA1 =breast cancer gene 1; BRCA2=breastcancergene 2; HER2=humanepidemmalgrowth factorreceptor2;

Percentages were calculatedusingthe numberof subjects in the column headingas the denominator.

Data cut-off:11 Jan 2022

Source: Tables 14.1.3.1.1,14.1.3.1.2

α From most recenttissue sample

<div style=\"page-break-after: always\"></div>

## Prior anticancer therapies

## Table 29 Prior Lines of Breast Cancer Systemic Therapy in the Hormone Receptor positive Cohort and the Full Analysis Set

| Parameter                                                       | Number (%) of Subjects                                          | Number (%) of Subjects                                          | Number (%) of Subjects                                          | Number (%) of Subjects                                          |
|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
|                                                                 | Hormone Receptor- positive Cohort                               | Hormone Receptor- positive Cohort                               | Full Analysis Set                                               | Full Analysis Set                                               |
|                                                                 | T-DXd (N=331)                                                   | TPC (N =163)                                                    | T-DXd (N=373)                                                   | TPC (N =184)                                                    |
| Lines of prior systemic therapy in any setting                  |                                                                 |                                                                 |                                                                 |                                                                 |
| 1                                                               | 2 (0.6)                                                         | 3 (1.8)                                                         | 5 (1.3)                                                         | 4 (2.2)                                                         |
| 2                                                               | 37 (11.2)                                                       | 24 (14.7)                                                       | 48 (12.9)                                                       | 33 (17.9)                                                       |
| V3                                                              | 292 (88.2)                                                      | 136 (83.4)                                                      | 320 (85.8)                                                      | 147 (79.9)                                                      |
| 1n                                                              | 331                                                             | 163                                                             | 373                                                             | 184                                                             |
| Mean (Std Dev)                                                  | 4.3 (1.70)                                                      | 4.4 (1.97)                                                      | 4.2 (1.71)                                                      | 4.2 (1.95)                                                      |
| Median                                                          | 4.0                                                             | 4.0                                                             | 4.0                                                             | 4.0                                                             |
| Minimum, Maximum                                                | 1, 13                                                           | 1,12                                                            | 1, 13                                                           | 1, 12                                                           |
| Lines of prior systemic therapy in metastatic setting - derived | Lines of prior systemic therapy in metastatic setting - derived | Lines of prior systemic therapy in metastatic setting - derived | Lines of prior systemic therapy in metastatic setting - derived | Lines of prior systemic therapy in metastatic setting - derived |
| 1                                                               | 23 (6.9)                                                        | 14 (8.6)                                                        | 39 (10.5)                                                       | 19 (10.3)                                                       |
| 2                                                               | 85 (25.7)                                                       | 41 (25.2)                                                       | 100 (26.8)                                                      | 53 (28.8)                                                       |
| V3                                                              | 223 (67.4)                                                      | 108 (66.3)                                                      | 234 (62.7)                                                      | 112 (60.9)                                                      |
| 11                                                              | 331                                                             | 163                                                             | 373                                                             | 184                                                             |
| Mean (Std Dev)                                                  | 3.3 (1.49)                                                      | 3.3 (1.45)                                                      | 3.2 (1.52)                                                      | 3.1 (1.45)                                                      |
| Median                                                          | 3.0                                                             | 3.0                                                             | 3.0                                                             | 3.0                                                             |
| Minimum, Maximum                                                | 1,9                                                             | 1,8                                                             | 1,9                                                             | 1,8                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Lines of prior endocrine therapy 0                               | 1 (0.3)                                                          | 3 (1.8)                                                          | 26 (7.0)                                                         | 19 (10.3)                                                        |
|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| 1                                                                | 65 (19.6)                                                        | 34 (20.9)                                                        | 74 (19.8)                                                        | 35 (19.0)                                                        |
| 2                                                                | 112 (33.8)                                                       | 46 (28.2)                                                        | 117 (31.4)                                                       | 49 (26.6)                                                        |
| 23                                                               | 153 (46.2)                                                       | 80 (49.1)                                                        | 156 (41.8)                                                       | 81(44.0)                                                         |
| n                                                                | 331                                                              | 163                                                              | 373                                                              | 184                                                              |
| Mean (Std Dev)                                                   | 2.6 (1.26)                                                       | 2.6 (1.37)                                                       | 2.4 (1.37)                                                       | 2.3 (1.48)                                                       |
| Median                                                           | 2.0                                                              | 2.0                                                              | 2.0                                                              | 2.0                                                              |
| Minimum, Maximum                                                 | 0,9                                                              | 0,8                                                              | 0, 9                                                             | 0,8                                                              |
| Lines of prior endocrine therapy in metastatic setting - derived | Lines of prior endocrine therapy in metastatic setting - derived | Lines of prior endocrine therapy in metastatic setting - derived | Lines of prior endocrine therapy in metastatic setting - derived | Lines of prior endocrine therapy in metastatic setting - derived |
| 0                                                                | 28 (8.5)                                                         | 17 (10.4)                                                        | 60 (16.1)                                                        | 34 (18.5)                                                        |
| 1                                                                | 105 (31.7)                                                       | 49 (30.1)                                                        | 108 (29.0)                                                       | 51 (27.7)                                                        |
| 2                                                                | 110 (33.2)                                                       | 53 (32.5)                                                        | 115 (30.8)                                                       | 54 (29.3)                                                        |
| 23                                                               | 88 (26.6)                                                        | 44 (27.0)                                                        | 90 (24.1)                                                        | 45 (24.5)                                                        |
| n                                                                | 331                                                              | 163                                                              | 373                                                              | 184                                                              |
| Mean (Std Dev)                                                   | 1.9 (1.20)                                                       | 1.9 (1.17)                                                       | 1.8 (1.27)                                                       | 1.7 (1.23)                                                       |
| Median                                                           | 2.0                                                              | 2.0                                                              | 2.0                                                              | 2.0                                                              |
| Minimum, Maximum                                                 | 0,7                                                              | 0,6                                                              | 0,7                                                              | 0,6                                                              |
| Lines of prior chemotherapy                                      | Lines of prior chemotherapy                                      | Lines of prior chemotherapy                                      | Lines of prior chemotherapy                                      | Lines of prior chemotherapy                                      |
| 0                                                                | 0                                                                | 1(0.6) a                                                         | 0                                                                | 1 (0.5)*                                                         |
| 1                                                                | 89 (26.9)                                                        | 49 (30.1)                                                        | 93 (24.9)                                                        | 52 (28.3)                                                        |
| 2                                                                | 155 (46.8)                                                       | 61 (37.4)                                                        | 176 (47.2)                                                       | 71 (38.6)                                                        |
| 23                                                               | 87 (26.3)                                                        | 52 (31.9)                                                        | 104 (27.9)                                                       | 60 (32.6)                                                        |
| n                                                                | 331                                                              | 163                                                              | 373                                                              | 184                                                              |
| Mean (Std Dev)                                                   | 2.0 (0.81)                                                       | 2.1 (0.93)                                                       | 2.1 (0.81)                                                       | 2.1 (0.95)                                                       |
| Median                                                           | 2.0                                                              | 2.0                                                              | 2.0                                                              | 2.0                                                              |
| Minimum, Maximum                                                 | 1,5                                                              | 0,5                                                              | 1,5                                                              | 0,5                                                              |
| Lines of prior chemotherapy in metastatic setting-derived b      | Lines of prior chemotherapy in metastatic setting-derived b      | Lines of prior chemotherapy in metastatic setting-derived b      | Lines of prior chemotherapy in metastatic setting-derived b      | Lines of prior chemotherapy in metastatic setting-derived b      |
| 0                                                                | 1 (0.3)                                                          | 1 (0.6)                                                          | 1 (0.3)                                                          | 1 (0.5)                                                          |

<div style=\"page-break-after: always\"></div>

| 1                                           | 203 (61.3)                                  | 93 (57.1)                                   | 221 (59.2)                                  | 100 (54.3)                                  |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| 2                                           | 124 (37.5)                                  | 69 (42.3)                                   | 145 (38.9)                                  | 83 (45.1)                                   |
| V3                                          | 3 (0.9)                                     | 0                                           | 6 (1.6)                                     | 0                                           |
| n                                           | 331                                         | 163                                         | 373                                         | 184                                         |
| Mean (Std Dev)                              | 1.4 (0.51)                                  | 1.4 (0.51)                                  | 1.4 (0.53)                                  | 1.4 (0.51)                                  |
| Median                                      | 1.0                                         | 1.0                                         | 1.0                                         | 1.0                                         |
| Minimum, Maximum                            | 0,3                                         | 0,2                                         | 0,3                                         | 0,2                                         |
| Intent of any prior breast cancer therapy c | Intent of any prior breast cancer therapy c | Intent of any prior breast cancer therapy c | Intent of any prior breast cancer therapy c | Intent of any prior breast cancer therapy c |
| Metastatic                                  | 330 (99.7)                                  | 162 (99.4)                                  | 371 (99.5)                                  | 182 (98.9)                                  |
| Adjuvant                                    | 212 (64.0)                                  | 99 (60.7)                                   | 229 (61.4)                                  | 109 (59.2)                                  |
| Neo-adjuvant                                | 61 (18.4)                                   | 38 (23.3)                                   | 75 (20.1)                                   | 45 (24.5)                                   |
| Maintenance                                 | 23 (6.9)                                    | 10 (6.1)                                    | 24 (6.4)                                    | 11 (6.0)                                    |
| Locally advanced                            | 11 (3.3)                                    | 4 (2.5)                                     | 13 (3.5)                                    | 5 (2.7)                                     |
| Preventive                                  | 2 (0.6)                                     | 1 (0.6)                                     | 2 (0.5)                                     | 2 (1.1)                                     |
| Other                                       | 2 (0.6)                                     | 2 (1.2)                                     | 2 (0.5)                                     | 2(1.1)                                      |

Std Dev= standarddeviation; T-DXd =trastuzumab deruxtecan; TPC =trea tmentof physician’s choice

Percentageswere calculatedusingthe numberofsubjects in the column headingasthe denominator.

Results are presentedin descendingorderof subjects within theT-DXd armof StudyU303 within thehormone receptor-positive cohort.

b Ifrecurenceoccured within 6 months of (neo)adjuvant chemotherapy, (neo)adjuvanttherapy was countedas 1 line of chemotherapy in the advanced diseasesetting. Subjects with O and 3 prior lines of chemotherapy representprotocoldeviations.

a A protocol deviation was capturedforthis subject.

Subjects mayhave been treated with more than 1 type oftherapy.

Data cut-off: 11 Jan 2022

Source:Tables14.1.3.2.1,14.1.3.2.2

<div style=\"page-break-after: always\"></div>

## Table 30 Most Common Prior Breast Cancer Systemic Therapy Administered in the Hormone Receptor-positive Cohort and the Full Analysis Set

<!-- image -->

| Parameter                            | Number (%) of Subjects             | Number (%) of Subjects             | Number (%) of Subjects   | Number (%) of Subjects   |
|--------------------------------------|------------------------------------|------------------------------------|--------------------------|--------------------------|
|                                      | Horinone Receptor- positive Cohort | Horinone Receptor- positive Cohort | Full Analysis Set        | Full Analysis Set        |
|                                      | T-DXd (N=331)                      | TPC (N=163)                        | T-DXd (N=373)            | TPC (N=184)              |
| Any prior systemic cancer therapy    |                                    |                                    |                          |                          |
| Targeted Therapy                     | 259 (78.2)                         | 132 (81.0)                         | 279 (74.8)               | 140 (76.1)               |
| CDK4/6 inhibitor                     | 233 (70.4)                         | 115 (70.6)                         | 239 (64.1)               | 119 (64.7)               |
| Palbociclib                          | 197 (59.5)                         | 100 (61.3)                         | 203 (54.4)               | 104 (56.5)               |
| Abemaciclib                          | 29 (8.8)                           | 10 (6.1)                           | 30 (8.0)                 | 10 (5.4)                 |
| Ribociclib                           | 16 (4.8)                           | 13 (8.0)                           | 16 (4.3)                 | 13 (7.1)                 |
| Investigational antineoplastic drugs | 3 (0.9)                            | 2 (1.2)                            | 3 (0.8)                  | 2 (1.1)                  |
| Ribociclib succinate                 | 1 (0.3)                            | 0                                  | 1 (0.3)                  | 0                        |
| Immunotherapy                        | 10 (3.0)                           | 8 (4.9)                            | 20 (5.4)                 | 12 (6.5)                 |
| Pembrolizumab                        | 3 (0.9)                            | 1(0.6)                             | 3 (0.8)                  | 2 (1.1)                  |
| Durvalumab                           | 3 (0.9)                            | 0                                  | 3 (0.8)                  | 0                        |
| Atezolizumab                         | 2 (0.6)                            | 2 (1.2)                            | 12 (3.2)                 | 5 (2.7)                  |
| Avelumab                             | 1(0.3)                             | 1 (0.6)                            | 1 (0.3)                  | 1 (0.5)                  |
| Durvalumab; tremelimumab             | 1 (0.3)                            | 0                                  | 1 (0.3)                  | 0                        |
| Others                               | 128 (38.7)                         | 70 (42.9)                          | 140 (37.5)               | 76 (41.3)                |
| Everolimus                           | 79 (23.9)                          | 44 (27.0)                          | 84 (22.5)                | 45 (24.5)                |
| Bevacizumab                          | 29 (8.8)                           | 16 (9.8)                           | 31 (8.3)                 | 19 (10.3)                |
| Alpelisib                            | 11 (3.3)                           | 8 (4.9)                            | 12 (3.2)                 | 8 (4.3)                  |
| Talazoparib                          | 5 (1.5)                            | 3 (1.8)                            | 5 (1.3)                  | 3 (1.6)                  |
| Olaparib                             | 3 (0.9)                            | 2(1.2)                             | 5 (1.3)                  | 3 (1.6)                  |
| Endocrine therapy                    | 330 (99.7)                         | 160 (98.2)                         | 347 (93.0)               | 165 (89.7)               |
| Letrozole                            | 212 (64.0)                         | 108 (66.3)                         | 222 (59.5)               | 113 (61.4)               |
| Fulvestrant                          | 211 (63.7)                         | 107 (65.6)                         | 217 (58.2)               | 110 (59.8)               |
| Tamoxifen                            | 160 (48.3)                         | 81 (49.7)                          | 166 (44.5)               | 82 (44.6)                |
| Exemestane                           | 133 (40.2)                         | 64 (39.3)                          | 138 (37.0)               | 65 (35.3)                |
| Anastrozole                          | 103 (31.1)                         | 46 (28.2)                          | 106 (28.4)               | 46 (25.0)                |
| Chemotherapy                         | 331 (100.0)                        | 162 (99.4)                         | 373 (100.0)              | 183 (99.5)               |

<div style=\"page-break-after: always\"></div>

| Cyclophosphamide                     | 182 (55.0)   | 85 (52.1)   | 207 (55.5)   | 93 (50.5)   |
|--------------------------------------|--------------|-------------|--------------|-------------|
| Capecitabine                         | 177 (53.5)   | 83 (50.9)   | 191 (51.2)   | 95 (51.6)   |
| Paclitaxel                           | 161 (48.6)   | 82 (50.3)   | 187 (50.1)   | 93 (50.5)   |
| Docetaxel                            | 109 (32.9)   | 62 (38.0)   | 126 (33.8)   | 68 (37.0)   |
| Epinubicin                           | 68 (20.5)    | 38 (23.3)   | 81 (21.7)    | 42 (22.8)   |
| Supportive Therapy                   | 79 (23.9)    | 37 (22.7)   | 85 (22.8)    | 39 (21.2)   |
| Goserelin acetate                    | 32 (9.7)     | 13 (8.0)    | 35 (9.4)     | 13 (7.1)    |
| Leuprorelin acetate                  | 19 (5.7)     | 8 (4.9)     | 21 (5.6)     | 9 (4.9)     |
| Goserelin                            | 18 (5.4)     | 8 (4.9)     | 18 (4.8)     | 8 (4.3)     |
| Leuprorelin                          | 4(1.2)       | 1 (0.6)     | 4 (1.1)      | 1 (0.5)     |
| Triptorelin                          | 4(1.2)       | 0           | 4 (1.1)      | 0           |
| Other                                | 8 (2.4)      | 3 (1.8)     | 8 (2.1)      | 4 (2.2)     |
| Investigational antineoplastic drugs | 6 (1.8)      | 1 (0.6)     | 6 (1.6)      | 1(0.5)      |
| Placebo                              | 1 (0.3)      | 1 (0.6)     | 1 (0.3)      | 1 (0.5)     |
| Ipatasertib                          | 1 (0.3)      | 0           | 1 (0.3)      | 1 (0.5)     |
| Investigational drug                 | 0            | 1(0.6)      | 0            | 1 (0.5)     |

* Results were presentedin descendingorderof subjects withintheT-DXd anmof Study U303 within thehomone receptor-posifivecohort.

CDK = cyclin-dependent kinase; T-DXd=trastuzmab deruxtecan; TPC =treatment ofphysician'schoice Percentages were calculatedusingthe numberofsubjects m the cohmn headingas thedenominator.

Data cut-off 11 Jan 2022

Source: Tables 14.1.3.2.1, 14.1.3.2.2

Table 31 Proportion of anthracycline pretreated subjects HR+ and FAS

|                               | HR+           | HR+         | FAS           | FAS         |
|-------------------------------|---------------|-------------|---------------|-------------|
|                               | T-DXd (N=331) | TPC (N=163) | T-DXd (N=373) | TPC (N=184) |
| Prior anthracyclines use a,b  | 210 (63.4)    | 102 (62.6)  | 239 (64.1)    | 113 (61.4)  |
| Adjuvant/neoadjuvant c        | 155 (46.8)    | 72 (44.2)   | 178 (47.7)    | 80 (43.5)   |
| Locally advanced/metastatic d | 63 (19.0)     | 34 (20.9)   | 71 (19.0)     | 37 (20.1)   |

FAS = full analysis set; HR+ = hormone receptor positive; IXRS = Interactive Web/Voice Response System; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice.

a A subject may receive multiple therapies intended for different purposes.

b Prior anthracyclines is defined as prior anticancer therapy of 'anthracyclines', 'doxorubicin', 'epirubicin', 'daunorubicin', or

'idarubicin' in CMDECOD and CMTRT in ADCM.

c  Adjuvant/neoadjuvant: subject with prior anthracycline therapy intended for adjuvant and/or neoadjuvant.

d Locally advanced/metastatic: subject with prior anthracycline therapy intended for locally advanced and/or metastatic. HR+ status based on IXRS.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Table 32 Data sets analysed (Study U303)

| Analysis Set               | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects   |
|----------------------------|--------------------------|--------------------------|--------------------------|
|                            | T-DXd (N=373)            | TPC (N = 184)            | Total (N=557)            |
| Full AnalysisSet           | 373 (100.0)              | 184 (100.0)              | 557 (100.0)              |
| Safety Analysis Set        | 371 (99.5)               | 172 (93.5)               | 543 (97.5)               |
| Per-protocol Analysis Set  | 361 (96.8)               | 164 (89.1)               | 525 (94.3)               |
| PharmacokineticAnalysisSet | 370 (99.2)               | 0                        | 370 (66.4)               |

T-DXd=trastuzumab deruxtecan; TPC=treatmentofphysician’s choice

Datacut-off:11Jan2022

Source:Table14.1.1.1.1

## Outcomes and estimation

The data cut-off for the presented results was 11 January 2022.

Primary endpoint - PFS by BIRC

Table 33 Progression-free Survival per Blinded Independent Central Review in the Hormone Receptor-positive Cohort and Full Analysis Set (Study U303)

| Parameter                                     | Hormone Receptor-positive Cohort            | Hormone Receptor-positive Cohort            | Full Analysis Set                           | Full Analysis Set                           |
|-----------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                               | T-DXd (N = 331)                             | TPC (N = 163)                               | T-DXd (N = 373)                             | TPC (N = 184)                               |
| Subjects (%) with events                      | 211 (63.7)                                  | 110 (67.5)                                  | 243 (65.1)                                  | 127 (69.0)                                  |
| Progressive disease                           | 180 (54.4)                                  | 101 (62.0)                                  | 208 (55.8)                                  | 117 (63.6)                                  |
| Death                                         | 31 (9.4)                                    | 9 (5.5)                                     | 35 (9.4)                                    | 10 (5.4)                                    |
| Subjects (%) without events (censored)        | 120 (36.3)                                  | 53 (32.5)                                   | 130 (34.9)                                  | 57 (31.0)                                   |
| No baseline evaluable tumor assessment        | 0                                           | 0                                           | 0                                           | 0                                           |
| No post-baseline tumor assessment             | 3 (0.9)                                     | 14 (8.6)                                    | 3 (0.8)                                     | 15 (8.2)                                    |
| Event after missing 2 consecutive assessments | 28 (8.5)                                    | 15 (9.2)                                    | 31 (8.3)                                    | 17 (9.2)                                    |
| Lost to follow-up                             | 0                                           | 1 (0.6)                                     | 0                                           | 1 (0.5)                                     |
| Withdrew consent                              | 4 (1.2)                                     | 7 (4.3)                                     | 4 (1.1)                                     | 7 (3.8)                                     |
| Ongoing without event                         | 67 (20.2)                                   | 8 (4.9)                                     | 69 (18.5)                                   | 8 (4.3)                                     |
| Adequate tumor assessment no longer available | 18 (5.4)                                    | 8 (4.9)                                     | 23 (6.2)                                    | 9 (4.9)                                     |
| Median PFS, months a                          | 10.1                                        | 5.4                                         | 9.9                                         | 5.1                                         |
| 95% CI                                        | 9.5, 11.5                                   | 4.4, 7.1                                    | 9.0, 11.3                                   | 4.2, 6.8                                    |
| Stratified log-rank test P -value (2-sided) b | <0.0001                                     | <0.0001                                     | <0.0001                                     | <0.0001                                     |
| Stratified Cox proportional hazards model b   | Stratified Cox proportional hazards model b | Stratified Cox proportional hazards model b | Stratified Cox proportional hazards model b | Stratified Cox proportional hazards model b |
| Hazard ratio                                  | 0.5085                                      | 0.5085                                      | 0.5014                                      | 0.5014                                      |

<div style=\"page-break-after: always\"></div>

| Parameter   | Hormone Receptor-positive Cohort   | Hormone Receptor-positive Cohort   | Full Analysis Set   | Full Analysis Set   |
|-------------|------------------------------------|------------------------------------|---------------------|---------------------|
|             | T-DXd (N = 331)                    | TPC (N = 163)                      | T-DXd (N = 373)     | TPC (N = 184)       |
| 95% CI      | 0.4012, 0.6444                     | 0.4012, 0.6444                     | 0.4013, 0.6265      | 0.4013, 0.6265      |

CDK = cyclin-dependent kinase; CI = confidence interval; CSR = clinical study report; HER2 = human epidermal growth factor receptor 2; IXRS = interactive web/voice response system; PFS = progression-free survival; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

a Median PFS was from Kaplan-Meier analysis. CI for median was computed using the Brookmeyer-Crowley method.

b Two-sided P -value from stratified log-rank test and stratified Cox proportional hazards model with stratification factors: HER2 status, number of prior lines of chemotherapy, and hormone receptor/CDK status as defined by the IXRS. Data cut-off: 11 Jan 2022 Source: DS8201-A-U303 CSR Tables 14.2.1.1.1 and 14.2.1.1.2

Figure 26 Kaplan-Meier Plot of Progression-free Survival by Blinded Independent Central Review in Hormone Receptor-positive Cohort (Study U303)

<!-- image -->

CI = confidence interval; HR = hazard ratio; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice Stratified Cox proportional hazards model for hazard ratio and stratified log-rank test for the P -value. Data cut-off: 11 Jan 2022 Source: DS8201-A-U303 CSR Figure 14.2.1.1.1

<div style=\"page-break-after: always\"></div>

Figure 27 Kaplan-Meier Plot of Progression-free Survival by Blinded Independent Central Review in the Full Analysis Set (Study U303)

<!-- image -->

CI = confidence interval; HR= hazard ratio; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice Stratified Cox proportional hazards model for hazard ratio and stratified log-rank test for the P -value. Data cut-off: 11 Jan 2022 Source: DS8201-A-U303 CSR Figure 14.2.1.1.2

Secondary endpoint - OS (analysis at the time of the final analysis for PFS)

Table 34 Overall Survival in the Hormone Receptor-positive Cohort and Full Analysis Set (Study U303)

| Parameter                                 | Hormone Receptor- positive Cohort   | Hormone Receptor- positive Cohort   | Full Analysis Set   | Full Analysis Set   |
|-------------------------------------------|-------------------------------------|-------------------------------------|---------------------|---------------------|
|                                           | T-DXd (N = 331)                     | TPC (N = 163)                       | T-DXd (N = 373)     | TPC (N = 184)       |
| Subjects with events (deaths), n (%)      | 126 (38.1)                          | 73 (44.8)                           | 149 (39.9)          | 90 (48.9)           |
| Subjects without event (censored), n (%)  | 205 (61.9)                          | 90 (55.2)                           | 224 (60.1)          | 94 (51.1)           |
| Alive                                     | 183 (55.3)                          | 67 (41.1)                           | 201 (53.9)          | 70 (38.0)           |
| Lost to follow-up                         | 5 (1.5)                             | 1 (0.6)                             | 6 (1.6)             | 1 (0.5)             |
| Withdrawal by Subject                     | 16 (4.8)                            | 22 (13.5)                           | 16 (4.3)            | 23 (12.5)           |
| Other                                     | 1 (0.3)                             | 0                                   | 1 (0.3)             | 0                   |
| Median OS (months) a                      | 23.9                                | 17.5                                | 23.4                | 16.8                |
| 95% CI                                    | 20.8, 24.8                          | 15.2, 22.4                          | 20.0, 24.8          | 14.5, 20.0          |
| Stratified log-rank P -value b            | 0.0028                              | 0.0028                              | 0.0010              | 0.0010              |
| Stratified Cox regression hazards ratio b | 0.6432                              | 0.6432                              | 0.6408              | 0.6408              |
| 95% CI                                    | 0.4804, 0.8610                      | 0.4804, 0.8610                      | 0.4903, 0.8375      | 0.4903, 0.8375      |

<div style=\"page-break-after: always\"></div>

| Parameter                       | Hormone Receptor- positive Cohort   | Hormone Receptor- positive Cohort   | Full Analysis Set   | Full Analysis Set   |
|---------------------------------|-------------------------------------|-------------------------------------|---------------------|---------------------|
|                                 | T-DXd (N = 331)                     | TPC (N = 163)                       | T-DXd (N = 373)     | TPC (N = 184)       |
| OS rate at 3 months c (95% CI)  | 97.0 (94.4, 98.4)                   | 96.1 (91.5, 98.2)                   | 96.2 (93.7, 97.8)   | 95.3 (90.9, 97.6)   |
| OS rate at 6 months c (95% CI)  | 93.6 (90.3, 95.8)                   | 89.2 (83.0, 93.3)                   | 92.4 (89.2, 94.7)   | 88.1 (82.2, 92.2)   |
| OS rate at 9 months c (95% CI)  | 87.4 (83.3, 90.6)                   | 76.7 (68.9, 82.8)                   | 85.3 (81.3, 88.5)   | 74.0 (66.6, 80.0)   |
| OS rate at 12 months c (95% CI) | 80.7 (76.0, 84.6)                   | 69.6 (61.3, 76.4)                   | 78.8 (74.3, 82.7)   | 66.5 (58.8, 73.2)   |
| OS rate at 18 months c (95% CI) | 63.5 (57.4, 69.0)                   | 48.8 (39.5, 57.5)                   | 61.7 (55.9, 66.9)   | 45.9 (37.5, 54.0)   |
| OS rate at 24 months c (95% CI) | 48.9 (40.9, 56.5)                   | 37.4 (26.8, 48.0)                   | 48.1 (40.8, 54.9)   | 32.0 (21.9, 42.4)   |

CDK = cyclin-dependent kinase; CI = confidence interval; HER2 = human epidermal growth factor receptor 2; IXRS = interactive web/voice response system; OS = overall survival; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

OS was defined as the time from the date of randomization to the date of death from any cause.  If there was no death reported for a subject before the data cutoff for the OS analysis, OS was censored at the last contact date at which the subject was known to be alive. a Median OS is from Kaplan-Meier analysis. CI for median was computed using the Brookmeyer-Crowley method. b Two-sided P -value from stratified log-rank test and stratified Cox proportional hazards model adjusted for IXRS stratification factors: HER2 status, number of prior lines of chemotherapy, hormone receptor/CDK status as defined by the IXRS. c Estimate and CI for OS rate at the specified time point are from Kaplan-Meier analysis. Data cutoff: 11 Jan 2022 Source: DS8201-A-U303 CSR Tables 14.2.2.1 and 14.2.2.2

Figure 28 Kaplan-Meier Plot of Overall Survival in Hormone Receptor-positive Cohort (Study U303)

<!-- image -->

T-DXd(331)331325323319314309303293285280268260250228199190168144 1169581 70 51 40 26 1498662

Data cut-off: 11 Jan 2022 Source: DS8201-A-U303 CSR Figure 14.2.2.1.1

<div style=\"page-break-after: always\"></div>

Figure 29 Kaplan-Meier Plot of Overall Survival in Full Analysis Set

<!-- image -->

Data cut-off: 11 Jan 2022 Source: DS8201-A-U303 CSR Figure 14.2.2.1.2

Other secondary endpoints - ORR and DOR

Table 35 Objective Response Rate and Clinical Benefit Rate Based on Blinded Independent Central Review in the Hormone Receptor-positive Cohort and Full Analysis Set (Study U303)

| Parameter                        | Hormone Receptor-positive Cohort   | Hormone Receptor-positive Cohort   | Full Analysis Set   | Full Analysis Set   |
|----------------------------------|------------------------------------|------------------------------------|---------------------|---------------------|
|                                  | T-DXd (N = 331)                    | TPC (N = 163)                      | T-DXd (N = 373)     | TPC (N = 184)       |
| Best overall response, n (%)     |                                    |                                    |                     |                     |
| Complete response                | 12 (3.6)                           | 1 (0.6)                            | 13 (3.5)            | 2 (1.1)             |
| Partial response                 | 164 (49.5)                         | 26 (16.0)                          | 183 (49.1)          | 28 (15.2)           |
| Stable disease                   | 115 (34.7)                         | 81 (49.7)                          | 129 (34.6)          | 91 (49.5)           |
| Progressive disease              | 26 (7.9)                           | 34 (20.9)                          | 31 (8.3)            | 41 (22.3)           |
| Not evaluable                    | 14 (4.2)                           | 21 (12.9)                          | 17 (4.6)            | 22 (12.0)           |
| Confirmed ORR a                  |                                    |                                    |                     |                     |
| n (%)                            | 175 (52.9) b                       | 27 (16.6)                          | 195 (52.3)          | 30 (16.3)           |
| 95% CI c                         | 47.3, 58.4                         | 11.2, 23.2                         | 47.1, 57.4          | 11.3, 22.5          |
| P -value (stratified analysis) d | <0.0001                            | <0.0001                            | <0.0001             | <0.0001             |
| Clinical benefit rate e          |                                    |                                    |                     |                     |
| n (%)                            | 238 (71.9)                         | 57 (35.0)                          | 262 (70.2)          | 62 (33.7)           |

<div style=\"page-break-after: always\"></div>

| Parameter                        | Hormone Receptor-positive Cohort   | Hormone Receptor-positive Cohort   | Full Analysis Set   | Full Analysis Set   |
|----------------------------------|------------------------------------|------------------------------------|---------------------|---------------------|
|                                  | T-DXd (N = 331)                    | TPC (N = 163)                      | T-DXd (N = 373)     | TPC (N = 184)       |
| 95% CI c                         | 66.7, 76.7                         | 27.7, 42.8                         | 65.3, 74.8          | 26.9, 41.0          |
| P -value (stratified analysis) d | <0.0001                            | <0.0001                            | <0.0001             | <0.0001             |

CI = confidence interval; CR = complete response; IXRS = interactive web/voice response system; ORR = objective response rate; PR = partial response; SD = stable disease; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

a   ORR = CR + PR; all responses are confirmed responses.

b   One subject in the T-DXd arm who had a confirmed best overall response of complete or partial response had baseline scan done after randomization but before the first dose and thus was considered a non-responder in the calculation of confirmed ORR.

c   Based on Clopper-Pearson method for single proportion and for the difference of 2 proportions with continuity correction

d   Two-sided P -value based on the Cochran-Mantel-Haenszel test adjusted for stratification factors (hormone receptor status, prior treatment with pertuzumab, history of visceral disease) as defined by the IXRS

e   defined as CR + PR + SD &gt;6 months Data cut-off date: 11 Jan 2022 Source: DS8201-A-U303 CSR Tables 14.2.3.1.1 and 14.2.3.1.2

Table 36 Duration of Response Based on Blinded Independent Central Review in Hormone Receptor-positive Cohort and Full Analysis Set (Study U303)

| Parameter                                            | Hormone Receptor-positive Cohort   | Hormone Receptor-positive Cohort   | Full Analysis Set   | Full Analysis Set   |
|------------------------------------------------------|------------------------------------|------------------------------------|---------------------|---------------------|
|                                                      | T-DXd (N = 331)                    | TPC (N = 163)                      | T-DXd (N = 373)     | TPC (N = 184)       |
| Subjects with CR or PR, n                            | 176                                | 27                                 | 196                 | 30                  |
| Subjects with subsequent events, n (%)               | 100 (56.8)                         | 18 (66.7)                          | 113 (57.7)          | 20 (66.7)           |
| Progressive disease                                  | 87 (49.4)                          | 16 (59.3)                          | 99 (50.5)           | 18 (60.0)           |
| Death                                                | 13 (7.4)                           | 2 (7.4)                            | 14 (7.1)            | 2 (6.7)             |
| Subjects without subsequent events (censored), n (%) | 76 (43.2)                          | 9 (33.3)                           | 83 (42.3)           | 10 (33.3)           |
| Event after missing 2 consecutive assessments        | 13 (7.4)                           | 2 (7.4)                            | 15 (7.7)            | 3 (10.0)            |
| Lost to follow-up                                    | 0                                  | 0                                  | 0                   | 0                   |
| Withdrew consent                                     | 3 (1.7)                            | 1 (3.7)                            | 3 (1.5)             | 1 (3.3)             |
| Ongoing without event                                | 49 (27.8)                          | 4 (14.8)                           | 51 (26.0)           | 4 (13.3)            |
| Adequate tumor assessment no longer available        | 11 (6.3)                           | 2 (7.4)                            | 14 (7.1)            | 2 (6.7)             |
| Median confirmed DoR, a months                       | 10.7                               | 6.8                                | 10.7                | 6.8                 |
| 95% CI                                               | 8.5, 13.7                          | 6.5, 9.9                           | 8.5, 13.2           | 6.0, 9.9            |

CI = confidence interval; CR = complete response; DoR = duration of response; PR = partial response; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

Responses were confirmed responses.

Percentage was calculated using number of subjects with CR/PR

a   Median is from Kaplan-Meier estimate. Confidence interval for median is computed using the Brookmeyer-Crowley method. Data cut-off date: 11 Jan 2022 Source: DS8201-A-U303 CSR Tables 14.2.3.2.1 and 14.2.3.2.2

<div style=\"page-break-after: always\"></div>

## Exploratory endpoint - PFS 2 (Progression-free Survival on Next Line of Treatment)

Table 37 Progression-free Survival on Next Line Therapy in the Hormone Receptor-positive Cohort and the Full Analysis Set Based on Investigator Assessment (Study U303)

| Parameter                                    | Hormone Receptor-positive Cohort            | Hormone Receptor-positive Cohort            | Full Analysis Set                           | Full Analysis Set                           |
|----------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                              | T-DXd (N = 331)                             | TPC (N = 163)                               | T-DXd (N = 373)                             | TPC (N = 184)                               |
| Subjects with events, n (%)                  | 172 (52.0)                                  | 96 (58.9)                                   | 199 (53.4)                                  | 112 (60.9)                                  |
| Progression on next line of therapy          | 108 (32.6)                                  | 65 (39.9)                                   | 125 (33.5)                                  | 73 (39.7)                                   |
| Death                                        | 64 (19.3)                                   | 31 (19.0)                                   | 74 (19.8)                                   | 39 (21.2)                                   |
| Subjects (%) without events (censored)       | 159 (48.0)                                  | 67 (41.1)                                   | 174 (46.6)                                  | 72 (39.1)                                   |
| No new anti-cancer therapy                   | 86 (26.0)                                   | 25 (15.3)                                   | 89 (23.9)                                   | 26 (14.1)                                   |
| No progression/death on next line of therapy | 38 (11.5)                                   | 23 (14.1)                                   | 43 (11.5)                                   | 24 (13.0)                                   |
| Second new anti-cancer therapy               | 35 (10.6)                                   | 19 (11.7)                                   | 42 (11.3)                                   | 22 (12.0)                                   |
| Stratified Cox proportional hazards model a  | Stratified Cox proportional hazards model a | Stratified Cox proportional hazards model a | Stratified Cox proportional hazards model a | Stratified Cox proportional hazards model a |
| Hazard ratio                                 | 0.5424                                      | 0.5424                                      | 0.5513                                      | 0.5513                                      |
| 95% CI                                       | 0.4206, 0.6995                              | 0.4206, 0.6995                              | 0.4344, 0.6996                              | 0.4344, 0.6996                              |
| Median PFS2 (months) b                       | 15.5                                        | 10.5                                        | 15.4                                        | 10.5                                        |
| 95% CI                                       | 13.8, 17.5                                  | 8.4, 11.9                                   | 13.6, 17.3                                  | 8.3, 11.4                                   |

CDK = cyclin-dependent kinase: CI = confidence interval; HER2 = human epidermal growth factor receptor 2; IXRS = interactive web/voice response system; KM = Kaplan-Meier; PFS2 = progression-free survival on next line of treatment; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

a Stratified Cox proportional hazards model with stratification factors:  HER2 status, number of prior lines of chemotherapy, and hormone receptor/CDK status as defined by the IXRS.

b   Median PFS2 was from Kaplan-Meier analysis; CI for median was computed using Brookmeyer-Crowley method. Data cut-off: 11 Jan 2022 Source: DS8201-A-U303 CSR Tables 14.2.3.7 and 14.2.3.8

Table 38 Progression-free survival on subsequent line of therapy based on investigator assessment (HR- cohort of FAS)

| T-DXd (N=40)   | T-DXd (N=40)     | T-DXd (N=40)                    | TPC (N=18)   | TPC (N=18)       | TPC (N=18)                      |                                       |
|----------------|------------------|---------------------------------|--------------|------------------|---------------------------------|---------------------------------------|
| n              | No of Events (%) | Median PFS2 (95% CI) a (months) | n            | No of Events (%) | Median PFS2 (95% CI) a (months) | T-DXd vs. TPC Hazard Ratio (95% CI) b |
| 40             | 25 (62.5)        | 12.9 (9.6, 18.2)                | 18           | 14 (77.8)        | 8.9 (5.0, 14.1)                 | 0.7236 (0.3399, 1.5405)               |

CDK = cyclin-dependent kinase; CI = confidence interval; EDC = electronic data capture system; FAS = full analysis set; HER2 = human epidermal growth factor receptor 2; HR+/= hormone receptor positive/negative; IHC = immunohistochemistry; ISH = in situ hybridisation; IXRS = Interactive Web/Voice Response System; PFS2 = progression-free survival on next-line treatment; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice.

a   Median PFS2 is from Kaplan-Meier analysis.  CI for median is computed using the Brookmeyer-Crowley method.

<div style=\"page-break-after: always\"></div>

b   Hazard ratio and 95% CI from stratified Cox proportional hazards model with stratification factors: HER2 IHC status (1+ vs. 2+/ISH-), HR/CDK status (HR+ with prior CDK4/6 vs. HR+ without CDK4/6 vs. HR-), and number of prior lines of chemotherapy (1 vs. 2) as defined by the IXRS.

HR-: estrogen receptors negative and progesterone receptors negative based on factors reported from EDC.

PFS2 is defined as the time from the date of randomisation to the date of the first documented progression on next-line therapy based on investigator assessment or death due to any cause, whichever comes first. Source: Appendix 1 Table 8.

## Exploratory endpoints - PFS and OS in the Hormone Receptor-negative Cohort

## Figure 30 Kaplan-Meier Plot of Progression-free Survival by Blinded Independent Central Review in the Hormone Receptor-negative Cohort Based on IXRS (Study U303)

<!-- image -->

CI = confidence interval; HR = hazard ratio; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice Stratified Cox proportional hazards model for HR and stratified log-rank test for the P -value.

Data in this figure are based on the 63 subjects with hormone receptor-negative disease per IXRS.

Data cut-off: 11 Jan 2022 Source: DS8201-A-U303 CSR Figure14.2.1.1.3

<div style=\"page-break-after: always\"></div>

Figure 31 Kaplan-Meier Plot of Overall Survival in Hormone Receptor-negative Cohort Based on IXRS (Study U303)

<!-- image -->

Data cut-off: 11 Jan 2022 Source: DS8201-A-U303 CSR Figure 14.2.2.1.3

## Exploratory endpoint - Patient-related outcomes (PRO)

In both arms, compliance for questionnaires was &gt;92% at baseline and &gt;80% for Cycle 2 through Cycle 27. Data from the QLQ-C30 questionnaire showed that all scales either remained stable or improved up to Cycle 33, after which the number of subjects became too small to allow for meaningful interpretation. The global health status/global QoL score of the QLQ-C30 (the primary PRO variable of interest) remained stable over time for subjects in both treatment arms up to and including Cycle 21, indicating that HRQoL was maintained throughout treatment.

There was a delay in TTDD by at least 10 points in the T-DXd arm compared with the TPC arm for the following:

- QLQ-C30 global health status scale: the median TTDD by at least 10 points in global health status/global QoL scale score was 7.6 months (95%CI: 5.8, 9.2) in the T-DXd arm vs 5.1 months (95% CI: 3.1, 6.9) in the TPC arm (stratified HR: 0.71 [95%CI: 0.56, 0.92]).
- QLQ-C30 pain symptom sub-scale: the median TTDD by at least 10 points in pain symptoms was 9.7 months (95%CI: 8.5, 11.1) in the T-DXd arm vs 4.4 months (95% CI: 2.8, 6.2) in the TPC arm (stratified HR: 0.51 [95%CI: 0.39, 0.65]).
- QLQ-C30 physical  functioning  sub-scale:  the  median  TTDD  by  at  least  10 points  in  physical functioning was 9.2 months (95%CI: 7.6, 11.3) in the T-DXd arm vs 4.9 months (95% CI: 4.0, 6.1) in the TPC arm (stratified HR: 0.54 [95%CI: 0.42, 0.70]).
- QLQ-C30 emotional functioning sub-scale: the median TTDD by at least 10 points in emotional functioning was 11.3 months (95%CI: 9.9, 13.8) in the T-DXd arm vs 6.3 months (95%CI: 5.7, 7.9) in the TPC arm (stratified HR: 0.64 [95%CI: 0.48, 0.85]).
- QLQ-C30 social functioning subscale: the median TTDD by at least 10 points in social functioning was 7.7 months (95% CI: 5.9, 9.2) in the T-DXd arm vs 4.4 months (95%CI: 2.8, 5.8) in the TPC arm (stratified HR: 0.67 [95%CI: 0.53, 0.86]).

<div style=\"page-break-after: always\"></div>

- QLQ-BR45 (BR23) breast symptoms sub-scale: the median TTDD by at least 10 points in breast symptoms was 20.3 months (95%CI: 15.3, NE) in the T-DXd arm vs NE (95% CI: 10.5, NE) in the TPC arm (stratified HR: 0.71 [95%CI: 0.50, 1.01]).
- QLQ-BR45 (BR23) arm symptoms sub-scale: the median TTDD by at least 10 points in arm symptoms was 9.8 months (95%CI: 7.4, 11.2) in the T-DXd arm vs 5.4 months (95% CI: 3.3, 7.1) in the TPC arm (stratified HR: 0.67 [95%CI: 0.50, 0.88]).

VAS of the EQ-5D-5L: the median TTDD by at least 10 points in VAS was 8.8 months (95% CI: 7.1, 10.9) in the T-DXd arm vs 4.7 months (95%CI: 3.9, 6.1) in the TPC arm (stratified HR: 0.70 [95%CI: 0.54, 0.91]).

## Ancillary analyses

## Concordance analyses between Investigator and BICR

Table 39 Concordance Analysis of Progression-free Survival Between Investigator and Blinded Independent Central Review Assessments for the Full Analysis Set (Study U303)

|                 |                | BICR PFS Result n (%)   | BICR PFS Result n (%)   | BICR PFS Result n (%)   |       |                  |
|-----------------|----------------|-------------------------|-------------------------|-------------------------|-------|------------------|
| Treatment Group | INV PFS Result | Death                   | PD                      | Censored                | Total | Concordance Rate |
| T-DXd (N = 373) | Death          | 20 (87.0)               | 3 (13.0)                | 0                       | 23    | 79.36%           |
| T-DXd (N = 373) | PD             | 15 (6.1)                | 180 (72.9)              | 52 (21.1)               | 247   | 79.36%           |
| T-DXd (N = 373) | Censored       | 0                       | 25 (24.3)               | 78 (75.7)               | 103   | 79.36%           |
| T-DXd (N = 373) | Total          | 35                      | 208                     | 130                     | 373   | 79.36%           |
| TPC (N = 184)   | Death          | 2 (40.0)                | 3 (60.0)                | 0                       | 5     | 80.43%           |
| TPC (N = 184)   | PD             | 7 (4.8)                 | 109 (74.7)              | 30 (20.5)               | 146   | 80.43%           |
| TPC (N = 184)   | Censored       | 1 (3.0)                 | 5 (15.2)                | 27 (81.8)               | 33    | 80.43%           |
| TPC (N = 184)   | Total          | 10                      | 117                     | 57                      | 184   | 80.43%           |

BICR = blinded independent central review; INV = investigator; PD = progressive disease; PFS = progression-free survival;

T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

Percentages are based on row total.

Data cut-off: 11 Jan 2022 Source: DS8201-A-U303 CSR Table 14.2.5.1.2

## Subgroup analyses

<div style=\"page-break-after: always\"></div>

Figure 32 Forest Plot of Treatment Comparison for Progression-free Survival by Blinded Independent Central Review in Subgroups in Full Analysis Set Based on Electronic Data Capture (Study U303)

<!-- image -->

| Subgroup                                  | Number of Event s T-DXd   | TPC     | Medlian PFS [Months, 95% CI] T-DXd TPC   |                                 | Hazard Ratio [95% Cl]           |
|-------------------------------------------|---------------------------|---------|------------------------------------------|---------------------------------|---------------------------------|
| HER2 Satus                                |                           |         |                                          |                                 |                                 |
| HER2 IHC 1+ (n=321)                       | 134/214                   | 75/107  | 10.0 [8.6, 12.3] 4.8 [3.0, 7.0]          |                                 | 0.4748 [0.3558, 0.6336]         |
| HER2 IHC 2+/ SH Negative (n=236)          | 109/159                   | 52/77   | 9.9 [8.0, 11.5]5.1[2.9, 7.1]             | 亚                               | 0.5459 [0.3901, 0.7639]         |
| Number of prior lines of chemot herapy in |                           |         |                                          |                                 |                                 |
| 1 (n=321)                                 | 14 1/221                  | 68/100  | 10.1 [8.4, 12.2] 6.4 [4.3, 7.8]          |                                 | 0.5222 [0.3891, 0.7007]         |
| >=2(n=234)                                | 101/151                   | 59/83   | 9.7 [8.1, 11.4]4.2[3.0, 5.4]             |                                 | 0.4896 [0.3527, 0.6795]         |
| Prior CDK 4/6 - derived besed on beseline |                           |         |                                          |                                 |                                 |
| valuefrom EDC                             |                           |         |                                          |                                 |                                 |
| Yes(n=353)                                | 151/235                   | 77/118  | 10.0 [8.1, 11.3]5.4 [3.0, 7.0]           | 亚                               | 0.5453 [0.4123, 0.7212]         |
| No (n=146)                                | 62/98                     | 36/48   | 11.5 [9.5, 16.4]5.4 [4.3, 8.1]           | 亚                               | 0.4211 [0.2769, 0.6404]         |
| Age                                       |                           |         |                                          |                                 |                                 |
| <65 (n=426)                               | 191/290                   | 93/136  | 9.8 [8.4, 11.1]4.6 [2.9, 5.9]            |                                 | 0.4740 [0.3681, 0.6102]         |
| >=65 (n=131)                              | 52/83                     | 34/48   | 11.4 [8.3, 13.3] 6.2 [4.3, 10.8]         |                                 | 0.5683 [0.3647, 0.8854]         |
| Age                                       |                           |         |                                          |                                 |                                 |
| <75 (n=534)                               | 236/359                   | 121/175 | 9.9 [8.6, 11.3]4.6 [4.0, 6.2]            | e                               | 0.4797 [0.3835, 0.6001]         |
| >=75 (n=23)                               | 7/14                      | 6/9     | 11.5 [2.9, NE] 12.6 [2.5, NE]            |                                 | 1.0737 [0.3544, 3.2525]         |
| Race                                      |                           |         |                                          |                                 |                                 |
| White (n=267)                             | 116/176                   | 54/91   | 9.7[8.4, 11.5]5.6 [3.1, 8.3]             |                                 | 0.6300 [0.4541, 0.8739]         |
| Asian (n=223)                             | 97/151                    | 59/72   | 10.9 [9.0, 13.8]4.6 [2.9, 5.8]           |                                 | 0.3770 [0.2701, 0.5261]         |
| Other (n=55)                              | 26/38                     | 12/17   | 6.3 [5.4, 11.7] 7.0 [1.4, 11.0]          |                                 | 0.7828 [0.3946, 1.5528]         |
|                                           |                           |         |                                          | 2 Hazard Ratio (T-DXd vs TPC)   |                                 |
| Region                                    |                           |         |                                          |                                 |                                 |
| Asia(n=213)                               | 94/147                    | 53/66   | 10.9 [9.0, 13.8] 4.6[2.8, 6.4]           |                                 | 0.3778 [0.2672, 0.5341]         |
| North America(n=93)                       | 46/60                     | 20/33   | 8.0 [4.2, 10.0] 4.5 [2.9, 7.2]           | H                               | 0.6207 [0.3599, 1.0704]         |
| Europe+Isreel (n=251)                     | 103/166                   | 54/85   | 10.3 [8.5, 12.3]6.9[2.9, 8.4]            | T                               | 0.6027 [0.4321, 0.8407]         |
| Lines of prior endocrine therapy received |                           |         |                                          |                                 |                                 |
| in the metast atic seting-derived         |                           |         |                                          |                                 |                                 |
| 0 (n=94)                                  | 41/60                     | 27/34   | 9.5 [5.7, 12.2]4.0[1.4, 5.1]             |                                 | 0.3990 [0.2427,0.6559]          |
| 1 (n=159)                                 | 77/108                    | 32/51   | 8.5 [6.9, 9.9]7.8[4.2, 10.7]             | T                               | 0.7962 [0.5257, 1.2058]         |
| 2(n=169)                                  | 64/115                    | 39/54   | 12.0[9.9, 15.1] 4.5 [2.9, 5.9]           |                                 | 0.3125 [0.2056, 0.4750]         |
| >=3 (n=135)                               | 61/90                     | 29/45   | 10.3 [7.5, 13.3] 5.4[2.7, 11.0]          |                                 | 0.5964 [0.3795, 0.9371]         |
| Bes Response to the Last Prior Cancer     |                           |         |                                          |                                 |                                 |
| Syst emic Therapy                         |                           |         |                                          |                                 |                                 |
| Part ial Response (n=70)                  | 33/48                     | 17/22   | 11.4 [7.1, 13.8]2.8[1.4, 4.8]            | 亚                               | 0.2775 [0.1511, 0.5096]         |
| Sable Disease (n=137)                     | 47/82                     | 40/55   | 12.0 [8.4, 19.2] 8.1[4.4, 10.7]          | T⊥                              | 0.5021 [0.3253, 0.7751]         |
| Progressive Disse (n=259)                 | 123/174                   | 57/85   | 99]99                                    | 亚                               | 0.5381 [0.3912, 0.7402]         |
| Unknown(n=72)                             | 34/53                     | 11/19   | 10.0 [7.5, 16.6] 4.5[2.3, 8.5]           |                                 | 0.5209 [0.2579, 1.0522]         |
| Report ed History of CNS M et ast ases    |                           |         |                                          |                                 |                                 |
| Yes (n=52)                                | 30/37                     | 10/15   | 8.1 [5.4, 10.0]:2.0[1.2, 11.0]           |                                 | 0.5777 [0.2791, 1.1956]         |
| (SOg=u)ON                                 | 213/336                   | 117/169 | 910.3 [9.5, 11.7] 5.3[4.2,6.]            |                                 | 0.4915 [0.3906, 0.6186]         |
|                                           |                           |         |                                          | 2 3 Hezard Ratio (T-DXd vs TPC) | 2 3 Hezard Ratio (T-DXd vs TPC) |

<div style=\"page-break-after: always\"></div>

<!-- image -->

CDK4/6=cyclin-dependent kinase 4/6;CI=confidence interval;CNS=central nervous system;ECOG PS=Eastern Cooperative Oncology Group perforrmance status; EDC = electronic data capture; HER2 =human epidermal growth factor receptor 2; IHC =immunohistochemistry; ISH =in situ hybridization; NE = not estimable;PFS=progression-free survival;T-DXd=trastuzumab deruxtecan;TPC=treatment of physician's choice

Analyses were performed only for the category of the subgroup if there were at least 10 PFS events in the treatment arms combined.

Data presented in this figure are based on EDC instead of IXRS.Any data entry in IXRS could not be modified; the derived data in EDC captured the correct statusforthestratificationfactors.

Data cut-off: 11 Jan 2022

Source:DS8201-A-U303CSRFigure14.2.1.3.2

Table 40 Progression-free Survival by Pretreated Status of Anthracyclines Based on BICR (FAS)

|                          | T-DXd (N=373)            | T-DXd (N=373)            | T-DXd (N=373)              | TPC (N=184)              | TPC (N=184)              | TPC (N=184)                |                                       |
|--------------------------|--------------------------|--------------------------|----------------------------|--------------------------|--------------------------|----------------------------|---------------------------------------|
|                          | n                        | Number of Events (%)     | Median (95% CI) a (months) | n                        | Number of Events (%)     | Median (95% CI) a (months) | T-DXd vs. TPC Hazard Ratio (95% CI) b |
| Anthracycline Pretreated | Anthracycline Pretreated | Anthracycline Pretreated | Anthracycline Pretreated   | Anthracycline Pretreated | Anthracycline Pretreated | Anthracycline Pretreated   | Anthracycline Pretreated              |
| Yes c                    | 239                      | 155 (64.9)               | 9.8 (8.5, 11.7)            | 113                      | 81 (71.7)                | 5.3 (3.0, 7.9)             | 0.5298 (0.4034,0.6957)                |
| No                       | 134                      | 88 (65.7)                | 10.0 (7.2, 12.5)           | 71                       | 46 (64.8)                | 4.6 (3.0, 6.8)             | 0.4588 (0.3179,0.6622)                |

BICR = Blinded Independent Central Review; CI = confidence interval; FAS = full analysis set; HR+ = hormone receptor positive; IXRS = Interactive Web/Voice Response System; PFS = progression-free survival;

SAP = statistical analysis plan; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice.

a   Median PFS is from Kaplan-Meier analysis.  CI for median is computed using the Brookmeyer-Crowley method.

b Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only covariate.

c Pretreated anthracyclines use is defined as prior anticancer therapy of 'anthracyclines,' 'doxorubicin,' 'epirubicin,' 'daunorubicin,' or 'idarubicin' in CMDECOD and CMTRT in ADCM.

PFS is defined as the time from the date of randomisation to the date of the first radiographic disease progression or death due to any cause, whichever comes first.  See SAP for the handling of censored cases.

HR+ status based on IXRS.

Source: Appendix 1 Table 11.

Table 41 Overall Survival by Pretreated Status of Anthracyclines (FAS)

|                          | T-DXd (N=373)            | T-DXd (N=373)            | T-DXd (N=373)              | TPC (N=184)              | TPC (N=184)              | TPC (N=184)                |                                       |
|--------------------------|--------------------------|--------------------------|----------------------------|--------------------------|--------------------------|----------------------------|---------------------------------------|
|                          | n                        | Number of Events (%)     | Median (95% CI) a (months) | n                        | Number of Events (%)     | Median (95% CI) a (months) | T-DXd vs. TPC Hazard Ratio (95% CI) b |
| Anthracycline Pretreated | Anthracycline Pretreated | Anthracycline Pretreated | Anthracycline Pretreated   | Anthracycline Pretreated | Anthracycline Pretreated | Anthracycline Pretreated   | Anthracycline Pretreated              |

<div style=\"page-break-after: always\"></div>

|       | T-DXd (N=373)   | T-DXd (N=373)        | T-DXd (N=373)              | TPC (N=184)   | TPC (N=184)          | TPC (N=184)                |                                       |
|-------|-----------------|----------------------|----------------------------|---------------|----------------------|----------------------------|---------------------------------------|
|       | n               | Number of Events (%) | Median (95% CI) a (months) | n             | Number of Events (%) | Median (95% CI) a (months) | T-DXd vs. TPC Hazard Ratio (95% CI) b |
| Yes c | 239             | 97 (40.6)            | 24.5 (18.5, NE)            | 113           | 54 (47.8)            | 17.0 (14.1, 20.2)          | 0.6587 (0.4717,0.9200)                |
| No    | 134             | 52 (38.8)            | 23.4 (19.8, NE)            | 71            | 36 (50.7)            | 16.0 (12.6, 23.6)          | 0.5822 (0.3803,0.8912)                |

CI = confidence interval; FAS = full analysis set; HR+ = hormone receptor positive; IXRS = Interactive Web/Voice Response System; NE = not estimable; OS = overall survival; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice.

a   Median OS is from Kaplan-Meier analysis.  CI for median was computed using the Brookmeyer-Crowley method.

b Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only covariate.

c

Pretreated anthracyclines use is defined as prior anticancer therapy of 'anthracyclines,' 'doxorubicin,'

'epirubicin,' 'daunorubicin,' or 'idarubicin' in CMDECOD and CMTRT in ADCM.

OS is defined as the time from the date of randomisation to the date of death due to any cause, whichever comes first.  If there is no death reported for a subject before the data cutoff for OS analysis, OS will be censored at the last contact date at which the subject is known to be alive.

HR+ status based on IXRS.

Source: Appendix 1 Table 12.

Table 42 Summary of Subjects with De Novo Metastatic Status

|                           | Full Analysis Set   | Full Analysis Set   | HR+ Cohort of Full Analysis Set   | HR+ Cohort of Full Analysis Set   | HR- Cohort of Full Analysis Set   | HR- Cohort of Full Analysis Set   |
|---------------------------|---------------------|---------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| De Novo Metastatic Status | T-DXd (N=373) n(%)  | TPC (N=184) n(%)    | T-DXd (N=331) n(%)                | TPC (N=163) n(%)                  | T-DXd (N=42) n(%)                 | TPC (N=21) n(%)                   |
| Yes                       | 122 (32.7)          | 64 (34.8)           | 108 (32.6)                        | 56 (34.4)                         | 14 (33.3)                         | 8 (38.1)                          |
| No                        | 251 (67.3)          | 120 (65.2)          | 223 (67.4)                        | 107 (65.6)                        | 28 (66.7)                         | 13 (61.9)                         |

HR+/ -= hormone receptor positive/negative; IXRS = Interactive Web/Voice Response System; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice.

De novo metastatic is defined as subjects with the very first reported prior breast cancer therapy was intended for metastatic.

HR+ / -status is based on IXRS.

Source: Appendix 1 Table 13.

<div style=\"page-break-after: always\"></div>

Figure 33 Forest Plot of Treatment Comparison for Overall Survival by Subgroup in the Hormone Receptor-positive Cohort Based on Electronic Data Capture

| Subgaup                                                                  | Nunber of Events T-DXd   | TFC    | Medan OS 6[Months,95%Cl] T-DXd TPC   | Hazad Ratio [95% Cl]    |
|--------------------------------------------------------------------------|--------------------------|--------|--------------------------------------|-------------------------|
| HER2 Status                                                              |                          |        |                                      |                         |
| HER2 IHC 1+ [n=288]                                                      | 70/192                   | 44/96  | 24.7 [20.8, NE] 17.0 [14.1, 22.4]    | 0.6310 [0.4326, 0.9204] |
| HER2 IHC 2+A SH Negative [n=206)                                         | 56/139                   | 29.67  | 21.7 [19.0, 24.5 17.5 [15.1, NE]     | 0.6693 [0.4263, 1.0507] |
| Nurnber of prior lines of chernother apy in metastatic setting - derived |                          |        |                                      |                         |
| 1 (n=296)                                                                | 65/203                   | 39/93  | 24.5 [21.7, NE] 19.5 [16.7, NE]      | 0.6406 [0.4304, 0.9534] |
| >=2 (n=196]                                                              | 61/127                   | 34.69  | 18.5 [16.9, NE] 14.5 [10.8, 20.2]    | 0.6638 [0.4354, 1.0119] |
| Prior CDK 4/6 - derived based on baseline value from EDC                 |                          |        |                                      |                         |
| Yes [n=348]                                                              | 99/233                   | 52/115 | 20.8 [18.5, 24.5 17.0 [14.1, 20.2]   | 0.7115 [0.5083, 0.9958] |
| No (n=143]                                                               | 26/96                    | 20/47  | NE [NE, NE]  19.9 [15.6, NE]         | 0.5138 [0.2863, 0.9219] |
| Age                                                                      |                          |        |                                      |                         |
| <65 (n=380)                                                              | 101/260                  | 53/120 | 24.5 [19.8, NE] 17.5 [14.9, 22.4]    | 0.6801 [0.4874, 0.9490] |
| >=65 [n=114]                                                             | 25/71                    | 20/43  | 23.9 [17.9, NE] 17.1 [9.2, NE]       | 0.5719 [0.3170, 1.0318] |
| Age                                                                      |                          |        |                                      |                         |
| <75 (n=477)                                                              | 123/320                  | 70/157 | 23.4 [20.0, NE] 17.5 [15.2, 22.4]    | 0.6563 [0.4891, 0.8806] |
| Race                                                                     |                          |        |                                      |                         |
| w/hite [n=234]                                                           | 65/156                   | 37/78  | 23.9 [18.5, 24.7, 15.1 [12.3, 20.0]  | 0.5975 [0.3983, 0.8962] |
| Asian (n=197]                                                            | 45/131                   | 28.66  | NE [20.8, NE] 19.9 [16.7, NE]        | 0.7012 [0.4371, 1.1248] |
| Other (n=53)                                                             | 15/37                    | 7/16   | 21.5 [15.0, NE] 15.2 [6.2, NE]       | 0.6768 [0.2745, 1.6688] |

| Subgoup                                    | Number of Events T-DXd   | TFC    | Medan OS [Months, 95% CI] T-DXd TFC   |                              | Hazad Ratio [95% Cl]    |
|--------------------------------------------|--------------------------|--------|---------------------------------------|------------------------------|-------------------------|
| Regjon                                     |                          |        |                                       |                              |                         |
| Asia[n=188)                                | 45/128                   | 26.60  | NE [20.8, NE] 19.9 [16.7, NE]         |                              | 0.6854 [0.4225, 1.1119] |
| North America [n=84]                       | 22/54                    | 16/30  | 19.8 [15.6, 24.8 14.9 [8.8, 19.4]     |                              | 0.5204 [0.2666, 1.0157] |
| Europe + Israel [n=222)                    | 59/149                   | 31/73  | 21.7 [18.8, NE]  20.0 [12.3, NE]      |                              | 0.6789 [0.4390, 1.0498] |
| Lines of prior endocrine ther apy received |                          |        |                                       |                              |                         |
| in the met ast atic setting - derived      |                          |        |                                       |                              |                         |
| 0 (n=45]                                   | 7/28                     | 8/17   | NE [17.4, NE] 14.5 [4.8, NE]          |                              | 0.4103 [0.1484, 1.1344] |
| 1 (n=154)                                  | 41/105                   | 17/49  | 23.4 [17.2, NE]  20.2 [16.7, NE]      |                              | 1.0237 [0.5812, 1.8032] |
| 2 [n=163]                                  | 39/110                   | 26.53  | 21.7 [20.0, NE] 16.0 [12.3, 19.5]     |                              | 0.4596 [0.2772, 0.7620] |
| >=3 [n=132)                                | 39.88                    | 22/44  | 21.7 [18.1, NE] 16.8 [12.7, NE]       |                              | 0.6338 [0.3747, 1.0720] |
| Best Response to the Last Prior Cancer     |                          |        |                                       |                              |                         |
| Systemic Ther apy                          |                          |        |                                       |                              |                         |
| Partia Response [n=61]                     | 15/41                    | 11/20  | 24.7 [18.2, NE] 15.1 [4.8, NE]        |                              | 0.4311 [0.1967, 0.9448] |
| S able Disease [n=122]                     | 28/74                    | 25/48  | 23.9 [19.7, NE] 17.0 [13.5, 22.4]     |                              | 0.5783 [0.3362, 0.9949] |
| Prog essive Disease [n=225]                | 65/150                   | 29/75  | 20.0 [17.2, 24.5 19.4 [12.6, NE]      |                              | 0.8816 [0.5689, 1.3661] |
| Unknown [n=68)                             | 16/51                    | 7/17   | NE [18.5, NE] 19.5 [12.7, NE]         |                              | 0.5155 [0.2082, 1.2762] |
| Reported History of CNS M et ast ases      |                          |        |                                       |                              |                         |
| Yes[n=43]                                  | 15/30                    | 6/13   | 21.7 [13.6, 24.8 NE [5.7, NE]         |                              | 0.6653 [0.2473, 1.7898] |
| No (n=451)                                 | 111/301                  | 67/150 | 23.9 [20.8, NE] 17.5 [15.2, 22.4]     |                              | 0.6396 [0.4720, 0.8665] |
|                                            |                          |        |                                       | Hazar d Ratio (T-DXd vs TPC) |                         |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Subgoup                      | Number of Events T-DXd   | T PC   | Medan OS [Months, 95% CI] T-DXd TPC   | Hazard Ratio [95% CI]   |
|------------------------------|--------------------------|--------|---------------------------------------|-------------------------|
| Baseline CNS M et ast ases   |                          |        |                                       |                         |
| Yes [n=25]                   | 11/18                    | 4/7    | 19.0 [13.4, 24.5 7.5 [0.6,NE]         | 0.6163 [0.1838, 2.0660] |
| No (n=469)                   | 115/313                  | 69/156 | 24.5 [20.8, NE] 17.5 [15.6, 22.4]     | 0.6447 [0.4781, 0.8694] |
| Renal Function at Baseline   |                          |        |                                       |                         |
| Normal Function (n=264)      | 68/185                   | 36/79  | 23.4 [20.0, 24.7, 16.7 [12.6, NE]     | 0.6025 [0.4017, 0.9037] |
| Mildlmpairment (n=165]       | 38/104                   | 28.61  | NE [18.2, NE]  16.8 [12.7, NE]        | 0.5711 [0.3493, 0.9339] |
| Moder ate Impairment [n=55]  | 17/37                    | 5/18   | 18.2 [13.3, NE] NE [17.5, NE]         | 2.2489 [0.8269, 6.1160] |
| Hepatic Function at Baseline |                          |        |                                       |                         |
| Normal Function (n=232]      | 44/149                   | 28/83  | 24.8 [21.7, NE] NE [19.4, NE]         | 0.7745 [0.4820, 1.2445] |
| MildImpairment [n=254]       | 78/176                   | 43/78  | 21.7 [18.2, 24.5 13.6 [8.4, 16.8]     | 0.4944 [0.3395, 0.7200] |
| Baseline Viscer al Disease   |                          |        |                                       |                         |
| Yes[n=444]                   | 122/298                  | 65/146 | 21.7 [19.7. 24.7. 17.5 [15.2, 22.4]   | 0.6967 [0.5153, 0.9419] |
| No (n=50)                    | 4/33                     | 8/17   | NE [NE, NE] 15.7 [13.5, NE]           | 0.2159 [0.0645, 0.7224] |
| ECOG PS                      |                          |        |                                       |                         |
| 0 (n=282)                    | 63/187                   | 35/95  | 24.5 [21.7, NE]  20.2 [16.7, NE]      | 0.6840 [0.4523, 1.0344] |
| 1 (n=212)                    | 63/144                   | 38.68  | 20.8 [17.2, 24.8 15.6 [12.6, 19.5]    | 0.6081 [0.4049, 0.9134] |

CDK = cyclin-dependent kinase; CI =confidence interval; CNS = centralnervous system; ECOG PS =Ea stein Cooperative Oncology Group performance status; EDC = electronic data capture; HER2 = human epidermal growth factorreceptor 2; IXRS = intera ctiveweb/voice response system;

IHC = immunohistochemistry; ISH =in situ hybridization; NE =not estimable; OS =overa llsurvival; T-DXd =trastuzumab deruxtecan; TPC =treatment of physician's choice

HazardratioisfromunstratifiedCoxproportionalhazardsmodelwithtreatmentastheonlycovariate.

## Sensitivity analyses

Table 43 Sensitivity Analysis of Progression-Free Survival per Blinded Independent Central Review Analyses in Hormone Receptorpositive Cohort of the Per-protocol Analysis Set (Study U303)

| Type of Analysis                         | Number (%) of Subjects with Events       | Median PFS (95% CI) a months             | Hazard Ratio (95% CI) b                  |
|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| Analysis using Per-protocol Analysis Set | Analysis using Per-protocol Analysis Set | Analysis using Per-protocol Analysis Set | Analysis using Per-protocol Analysis Set |
| T-DXd                                    | 207 (64.5)                               | 10.1 (9.5, 11.5)                         | 0.5273 (0.4147, 0.6707)                  |
| TPC                                      | 106 (73.1)                               | 5.6 (4.4, 7.3)                           | 0.5273 (0.4147, 0.6707)                  |

CI = confidence interval; PFS = progression-free survival; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

a   Median PFS is from Kaplan-Meier analysis. Confidence interval for median is computed using the Brookmeyer-Crowley method.

b Based on stratified Cox proportional hazards model.

Data cut-off: 11 Jan 2022

Source: DS8201-A-U303 CSR Table 14.2.1.2.1.1

Table 44 Sensitivity Analyses of Progression-Free Survival per Blinded Independent Central Review in Hormone Receptor-positive Cohort (Study U303)

| Type of Analysis                                 | Number (%) of Subjects with Events               | Median PFS (95% CI) a Months                     | Hazard Ratio (95% CI) b                          |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Impact of stratification - Unstratified analysis | Impact of stratification - Unstratified analysis | Impact of stratification - Unstratified analysis | Impact of stratification - Unstratified analysis |
| T-DXd                                            | 211 (63.7)                                       | 10.1 (9.5, 11.5)                                 |                                                  |

<div style=\"page-break-after: always\"></div>

| Type of Analysis                                                               | Number (%) of Subjects with Events                                             | Median PFS (95% CI) a Months                                                   | Hazard Ratio (95% CI) b                                                        |
|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| TPC                                                                            | 110 (67.5)                                                                     | 5.4 (4.4, 7.1)                                                                 | 0.5093 (0.4028, 0.6439)                                                        |
| Impact of censoring rule - Not censoring for missing 2 consecutive assessments | Impact of censoring rule - Not censoring for missing 2 consecutive assessments | Impact of censoring rule - Not censoring for missing 2 consecutive assessments | Impact of censoring rule - Not censoring for missing 2 consecutive assessments |
| T-DXd                                                                          | 239 (72.2)                                                                     | 10.3 (9.5, 11.5)                                                               | 0.5099 (0.4083, 0.6367)                                                        |
| TPC                                                                            | 126 (77.3)                                                                     | 5.8 (4.5, 7.1)                                                                 | 0.5099 (0.4083, 0.6367)                                                        |
| Impact of censoring rule - Censoring for new anti-cancer therapy c             | Impact of censoring rule - Censoring for new anti-cancer therapy c             | Impact of censoring rule - Censoring for new anti-cancer therapy c             | Impact of censoring rule - Censoring for new anti-cancer therapy c             |
| T-DXd                                                                          | 175 (52.9)                                                                     | 10.9 (9.6, 13.8)                                                               | 0.4359 (0.3307, 0.5746)                                                        |
| TPC                                                                            | 84 (51.5)                                                                      | 5.4 (4.3, 6.9)                                                                 | 0.4359 (0.3307, 0.5746)                                                        |
| Impact of censoring rule - Back-dating PFS d                                   | Impact of censoring rule - Back-dating PFS d                                   | Impact of censoring rule - Back-dating PFS d                                   | Impact of censoring rule - Back-dating PFS d                                   |
| T-DXd                                                                          | 239 (72.2)                                                                     | 9.6 (8.3, 10.5)                                                                | 0.5012 (0.4015, 0.6257)                                                        |
| TPC                                                                            | 126 (77.3)                                                                     | 5.3 (4.0, 6.2)                                                                 | 0.5012 (0.4015, 0.6257)                                                        |

CI = confidence interval; PFS = progression-free survival; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice a   Median PFS is from Kaplan-Meier analysis. Confidence interval for median is computed using the Brookmeyer-Crowley method.

b Based on stratified (or unstratified for impact on stratification) Cox proportional hazards model.

c Subjects were censored at the last tumor assessment date before starting the new anti-cancer therapy.

d   Primary PFS analysis was repeated not censoring for missing 1 or more tumor assessments. In such cases, the PFS event date was considered to be 6 weeks after the last evaluable tumor assessment occurring prior to progression or death.

Data cut-off: 11 Jan 2022

Source: DS8201-A-U303 CSR Tables 14.2.1.2.2.1, 14.2.1.2.3.1, 14.2.1.2.4.1, and 14.2.1.2.8

The results of a post-hoc sensitivity analysis including both BICR-assessed and investigator-assessed progressive disease (and/or clinical progression) as events (with the earliest of the two being the event) is shown below.

Table 45 Sensitivity analysis of Progression-Free Survival per both BICR and Investigator Assessment FAS

| T-DXd (N=373)   | T-DXd (N=373)        | T-DXd (N=373)              | TPC (N=184)   | TPC (N=184)          | TPC (N=184)                |                                       |
|-----------------|----------------------|----------------------------|---------------|----------------------|----------------------------|---------------------------------------|
| n               | Number of Events (%) | Median (95% CI) a (months) | n             | Number of Events (%) | Median (95% CI) a (months) | T-DXd vs. TPC Hazard Ratio (95% CI) b |
| 373             | 297 (79.6)           | 8.1 (6.9, 8.4)             | 184           | 158 (85.9)           | 3.0 (2.8, 4.2)             | 0.3951 (0.3211, 0.4861)               |

BICR = blinded independent central review; CDK = cyclin-dependent kinase; CI = confidence interval; FAS = full analysis set; HER2 = human epidermal growth factor receptor 2; HR+/ -= hormone receptor positive/negative; IHC = immunohistochemistry; ISH = in situ hybridisation; IXRS = Interactive Web/Voice Response System; PFS = progression-free survival; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice.

a   Median PFS is from Kaplan-Meier analysis.  CI for median is computed using the Brookmeyer-Crowley method.

b Hazard ratio and 95% CI from stratified Cox proportional hazards model with stratification factors: HER2 IHC status (1+ vs. 2+/ISH-), HR/CDK status (HR+ with prior CDK4/6 vs. HR+ without CDK4/6 vs. HR -), and number of prior lines of chemotherapy (1 vs. 2) as defined by the IXRS.

PFS is defined as the time from the date of randomisation to the date of the first radiographic disease progression, clinical progression, or death due to any cause, whichever comes first.  The earliest event from BICR-assessed and investigator-assessed progressive disease will be used to compute PFS. Source: Appendix 1 Table 7.

<div style=\"page-break-after: always\"></div>

## Biomarker analysis

The eligibility criteria for Study U303 required pathologically documented BC that was centrally assessed as having low HER2 protein expression using an Investigational Use Only (IUO) version of the PATHWAY/VENTANA HER2 (4B5) with a revised HER2-low scoring algorithm. The reagent formulation remained the same as the commercially available PATHWAY/VENTANA HER2 (4B5). Of note, the only difference between the IUO version of the assay used in this study and the approved assay will be the investigational scoring algorithm for the lower cut point bound on the HER2 IHC 1+ category. HER2 ISH testing will follow the scoring criteria specified in the package insert of Ventana INFORM Dual ISH kit.

To define low HER2 expression, it is necessary to clarify the boundary between IHC 0 and IHC 1+. The ASCO-CAP suggests a definition for IHC 1+ as incomplete membrane staining that is faint/barely perceptible and within &gt;10% of the invasive tumour cells. The IHC 0 is defined as no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within ≤ 10% of the invasive tumour cells. Because there is no difference in treatment algorithm for subjects with IHC 0 and IHC 1+ readings, several commercial HER2 tests use alternative cutoffs. To standardize this boundary, the Sponsor used the adapted ASCO-CAP cutoffs to provide the lower boundary for low HER2 expression. The scoring algorithm was revised to define the upper and lower boundary of low HER2 expression by using standard ASCO/CAP IHC definitions. The upper boundary for HER2-low (IHC 2+) remained the same as the lower boundary for HER2-positive BC. The lower boundary of HER2-low expression was defined as IHC 1+.

Analytical validation of the HER2-low cutoff was performed by Ventana Medical Systems, Inc. Analytical sensitivity, specificity, repeatability, reproducibility, immunoreactivity, cut-slide stability, intermediate precision, reader precision, and reagent stability were evaluated. All analytical performance studies conducted for HER2-low on the PATHWAY/VENTANA HER2 (4B5) assay met their prespecified acceptance criteria. The clinical validity of the assay was studied in Study U303 by its use for patient eligibility determination.

Reflex HER2 ISH testing of IHC 2+ cases was performed by using the INFORM HER2 Dual ISH Assay. The ISH assay reagent formulation remained unchanged and the assay was used according to the manufacturer's instructions.

Both local and central results were available for 1201 tumour samples submitted for central testing for determination of HER2 expression. The overall percent agreement between local and central HER2-low assessment was 0.75 (95% CI 0.73, 0.78).

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 46 Summary of Efficacy for trial U303 (DestinyBreast04)

| Title: A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Trial of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-antibody Drug Conjugate (ADC), versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects   | Title: A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Trial of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-antibody Drug Conjugate (ADC), versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                           | DS8201-A-U303                                                                                                                                                                                                                                                              |
| Design                                                                                                                                                                                                                                                                     | Randomised, 2-arm, Phase 3, open-label, multicenter study                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

Hypothesis

Treatments groups

Endpoints and definitions

Duration of main phase:

Duration of Run-in phase:

Treatment until progressive disease, unacceptable toxicity, or withdrawal of

consent not applicable

Duration of Extension phase:

not applicable

Superiority: Significant benefit of PFS

T-DXd

TPC

Primary endpoint

Secondary endpoint

Other secondary

PFS by

BIRC

OS

PFS by INV,

ORR, DoR

endpoints

Database lock

DCO 11 January 2022

## Results and Analysis

| Analysis description                            | Primary Analysis                                                                                   | Primary Analysis                                                                                   | Primary Analysis                                                                                   | Primary Analysis                                                                                   |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | Intent to treat: Primary analysis (for the HR+ population and the FAS*)                            | Intent to treat: Primary analysis (for the HR+ population and the FAS*)                            | Intent to treat: Primary analysis (for the HR+ population and the FAS*)                            | Intent to treat: Primary analysis (for the HR+ population and the FAS*)                            |
| Descriptive statistics and estimate variability | Treatment group                                                                                    | Treatment group                                                                                    | T-DXd (N=373) TPC (N=184)                                                                          | T-DXd (N=373) TPC (N=184)                                                                          |
| Descriptive statistics and estimate variability | Patients with events                                                                               | Patients with events                                                                               | 243 (65.1%) 127 (69%)                                                                              | 243 (65.1%) 127 (69%)                                                                              |
| Descriptive statistics and estimate variability | PFS by BIRC (months)                                                                               | PFS by BIRC (months)                                                                               | 9.9 5.1                                                                                            | 9.9 5.1                                                                                            |
| Descriptive statistics and estimate variability | 95%CI 9.0;                                                                                         | 95%CI 9.0;                                                                                         | 11.3 4.2; 6.8                                                                                      | 11.3 4.2; 6.8                                                                                      |
| Descriptive statistics and estimate variability | OS (months)                                                                                        | OS (months)                                                                                        | 23.4 16.8                                                                                          | 23.4 16.8                                                                                          |
| Descriptive statistics and estimate variability | 95%CI 20.0;                                                                                        | 95%CI 20.0;                                                                                        | 24.8 14.5; 20.0                                                                                    | 24.8 14.5; 20.0                                                                                    |
| Descriptive statistics and estimate variability | Confirmed ORR                                                                                      | Confirmed ORR                                                                                      | 52.3% 16.3%                                                                                        | 52.3% 16.3%                                                                                        |
| Descriptive statistics and estimate variability | 95%CI                                                                                              | 95%CI                                                                                              | 47.1; 57.4 11.3; 22.5                                                                              | 47.1; 57.4 11.3; 22.5                                                                              |
| Descriptive statistics and estimate variability | DoR                                                                                                | DoR                                                                                                | 10.7 6.8                                                                                           | 10.7 6.8                                                                                           |
| Descriptive statistics and estimate variability | 95%CI                                                                                              | 95%CI                                                                                              | 8.5; 13.2 6.0; 9.9                                                                                 | 8.5; 13.2 6.0; 9.9                                                                                 |
| Effect estimate per comparison                  | Primary endpoint                                                                                   | Comparison groups                                                                                  | Comparison groups                                                                                  | T-DXd vs TPC                                                                                       |
| Effect estimate per comparison                  | Primary endpoint                                                                                   | Hazard ratio                                                                                       | Hazard ratio                                                                                       | 0.5014                                                                                             |
| Effect estimate per comparison                  | Primary endpoint                                                                                   | 95%CI                                                                                              | 95%CI                                                                                              | 0.4013; 0.6265                                                                                     |
| Effect estimate per comparison                  | Primary endpoint                                                                                   | P-value                                                                                            | P-value                                                                                            | <0.0001                                                                                            |
| Effect estimate per comparison                  | Secondary endpoint: OS                                                                             | Comparison groups                                                                                  | Comparison groups                                                                                  | T-DXd vs TPC                                                                                       |
| Effect estimate per comparison                  | Secondary endpoint: OS                                                                             | Hazard ratio                                                                                       | Hazard ratio                                                                                       | 0.64                                                                                               |
| Effect estimate per comparison                  | Secondary endpoint: OS                                                                             | 95%CI                                                                                              | 95%CI                                                                                              | 0.49; 0.84                                                                                         |
| Effect estimate per comparison                  | Secondary endpoint: OS                                                                             | P-value                                                                                            | P-value                                                                                            | 0.0010                                                                                             |
| Notes                                           | *Results are only shown for the FAS, since this is the target population for the sought indication | *Results are only shown for the FAS, since this is the target population for the sought indication | *Results are only shown for the FAS, since this is the target population for the sought indication | *Results are only shown for the FAS, since this is the target population for the sought indication |

Trastuzumab deruxtecan iv 5.4 mg/kg every 3 weeks (Q3W), number randomized:

373

Treatment per Physician's choice (single agent chemotherapy) options: capecitabine,

eribulin, gemcitabine, paclitaxel, or nab- paclitaxel, number randomized: 184

Progression-free survival by blinded independent review

Overall survival

Progression-free survival by investigator, confirmed overall response rate, duration of

response free text

<div style=\"page-break-after: always\"></div>

## Supportive study

Study J101 was a Phase 1 first-in-human, multicenter, 2-part (dose escalation followed by dose expansion), open-label, nonrandomized, multiple-dose study of T-DXd in subjects with advanced solid tumors.  The study was conducted in the US and Japan in several types of solid tumors at various doses of T-DXd ranging from 0.8 mg/kg to 8.0 mg/kg.

Results from patients with HER2-low breast cancer (n=54) from the phase I study J101 serve as supportive evidence. Of note, only 21 patients received the proposed dose of 5.4 mg/kg Q3W.

Table 47 Demographics and Baseline Characteristics of the HER2-low Breast Cancer Population Enrolled (Intent-to-Treat Analysis Set; Study J101)

| Parameter                                                                     | HER2-low BC 5.4 mg/kg (N = 21)                                                | HER2-low BC 6.4 mg/kg (N = 33)                                                | Overall HER2-low BC (N = 54)                                                  |
|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Age at Informed Consent                                                       |                                                                               |                                                                               |                                                                               |
| Median (Min-Max)                                                              | 57.0 (37-74)                                                                  | 55.0 (33-75)                                                                  | 56.5 (33-75)                                                                  |
| Age Group (Years), n (%)                                                      |                                                                               |                                                                               |                                                                               |
| <65 Years                                                                     | 15 (71.4)                                                                     | 25 (75.8)                                                                     | 40 (74.1)                                                                     |
| ≥65 Years                                                                     | 6 (28.6)                                                                      | 8 (24.2)                                                                      | 14 (25.9)                                                                     |
| <75 Years                                                                     | 21 (100.0)                                                                    | 32 (97.0)                                                                     | 53 (98.1)                                                                     |
| ≥75 Years                                                                     | 0 (0.0)                                                                       | 1 (3.0)                                                                       | 1 (1.9)                                                                       |
| Sex, n (%)                                                                    |                                                                               |                                                                               |                                                                               |
| Female                                                                        | 21 (100.0)                                                                    | 33 (100.0)                                                                    | 54 (100.0)                                                                    |
| Race, n (%)                                                                   |                                                                               |                                                                               |                                                                               |
| White                                                                         | 12 (57.1)                                                                     | 7 (21.2)                                                                      | 19 (35.2)                                                                     |
| Black or African American                                                     | 1 (4.8)                                                                       | 1 (3.0)                                                                       | 2 (3.7)                                                                       |
| Asian                                                                         | 7 (33.3)                                                                      | 23 (69.7)                                                                     | 30 (55.6)                                                                     |
| Other                                                                         | 1 (4.8)                                                                       | 2 (6.1)                                                                       | 3 (5.6)                                                                       |
| Country, n (%)                                                                |                                                                               |                                                                               |                                                                               |
| Japan                                                                         | 5 (23.8)                                                                      | 22 (66.7)                                                                     | 27 (50.0)                                                                     |
| United States                                                                 | 16 (76.2)                                                                     | 11 (33.3)                                                                     | 27 (50.0)                                                                     |
| ECOG PS, n (%)                                                                |                                                                               |                                                                               |                                                                               |
| 0                                                                             | 16 (76.2)                                                                     | 20 (60.6)                                                                     | 36 (66.7)                                                                     |
| 1                                                                             | 5 (23.8)                                                                      | 13 (39.4)                                                                     | 18 (33.3)                                                                     |
| Hormone receptor status, n (%)                                                |                                                                               |                                                                               |                                                                               |
| Positive                                                                      | 19 (90.5)                                                                     | 28 (84.8)                                                                     | 47 (87.0)                                                                     |
| Negative                                                                      | 2 (9.5)                                                                       | 5 (15.2)                                                                      | 7 (13.0)                                                                      |
| HER2 IHC status (study site testing), n (%)                                   |                                                                               |                                                                               |                                                                               |
| 1+                                                                            | 14 (66.7)                                                                     | 14 (42.4)                                                                     | 28 (51.9)                                                                     |
| 2+/ISH Negative                                                               | 7 (33.3)                                                                      | 19 (57.6)                                                                     | 26 (48.1)                                                                     |
| Number of prior anti-cancer regimens for locally advanced/metastatic, a n (%) | Number of prior anti-cancer regimens for locally advanced/metastatic, a n (%) | Number of prior anti-cancer regimens for locally advanced/metastatic, a n (%) | Number of prior anti-cancer regimens for locally advanced/metastatic, a n (%) |

<div style=\"page-break-after: always\"></div>

| Parameter                                                                                                    | HER2-low BC 5.4 mg/kg (N = 21)                                                                               | HER2-low BC 6.4 mg/kg (N = 33)                                                                               | Overall HER2-low BC (N = 54)                                                                                 |
|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| Median (Min, Max)                                                                                            | 7.0 (2-14)                                                                                                   | 7.0 (3-16)                                                                                                   | 7.0 (2-16)                                                                                                   |
| Number of prior anti-cancer regimens for locally advanced/metastatic, a not including hormone therapy, n (%) | Number of prior anti-cancer regimens for locally advanced/metastatic, a not including hormone therapy, n (%) | Number of prior anti-cancer regimens for locally advanced/metastatic, a not including hormone therapy, n (%) | Number of prior anti-cancer regimens for locally advanced/metastatic, a not including hormone therapy, n (%) |
| Median (Min, Max)                                                                                            | 3.0 (1-10)                                                                                                   | 4.0 (0-10)                                                                                                   | 4.0 (0-10)                                                                                                   |
| Prior CDK4/6 inhibitor, n (%)                                                                                | Prior CDK4/6 inhibitor, n (%)                                                                                | Prior CDK4/6 inhibitor, n (%)                                                                                | Prior CDK4/6 inhibitor, n (%)                                                                                |
| Yes                                                                                                          | 10 (47.6)                                                                                                    | 6 (18.2)                                                                                                     | 16 (29.6)                                                                                                    |
| No                                                                                                           | 11 (52.4)                                                                                                    | 27 (81.8)                                                                                                    | 38 (70.4)                                                                                                    |

BC = breast cancer; CDK4/6 = cyclin-dependent kinase 4/6; ECOG PS = Eastern Cooperative Oncology Group performance status; HER2 =

human epidermal growth factor receptor 2: IHC = immunohistochemistry; ISH = in situ hybridization; Max = maximum; Min = minimum a Therapies intended for 'locally advanced/metastatic' or intended for 'neo-adjuvant', 'adjuvant', or 'maintenance' if progressive disease within 6 months since the end of the therapy.

Data cut-off: 01 Aug 2019 Source: Module 5.3.5.3 SCE J101 HER2-low BC Tables 14.1.3.4.2.2 and 14.1.3.4.2.3

Table 48 Objective Response Rate in HER2-low Breast Cancer Population of Study J101 (Intent-to-Treat Analysis Set; Study J101)

| Parameter                                                          | HER2-low BC 5.4 mg/kg (N = 21)   | HER2-low BC 6.4 mg/kg (N = 33)   | Overall HER2-low BC (N = 54)   |
|--------------------------------------------------------------------|----------------------------------|----------------------------------|--------------------------------|
| Best overall response per ICR with confirmation of response, n (%) |                                  |                                  |                                |
| Complete Response                                                  | 1 (4.8)                          | 0 (0.0)                          | 1 (1.9)                        |
| Partial response                                                   | 6 (28.6)                         | 13 (39.4)                        | 19 (35.2)                      |
| Stable disease                                                     | 11 (52.4)                        | 16 (48.5)                        | 27 (50.0)                      |
| Progressive disease                                                | 3 (14.3)                         | 3 (9.1)                          | 6 (11.1)                       |
| Not evaluable                                                      | 0 (0.0)                          | 1 (3.0)                          | 1 (1.9)                        |
| Confirmed ORR a by ICR                                             |                                  |                                  |                                |
| n (%)                                                              | 7 (33.3)                         | 13 (39.4)                        | 20 (37.0)                      |
| 95% CI b                                                           | 14.6, 57.0                       | 22.9, 57.9                       | 24.3, 51.3                     |
| Confirmed ORR a by investigator assessment                         |                                  |                                  |                                |
| n (%)                                                              | 8 (38.1)                         | 17 (51.5)                        | 25 (46.3)                      |
| 95% CI b                                                           | 18.1, 61.6                       | 33.5, 69.2                       | 32.6, 60.4                     |
| Subgroups                                                          |                                  |                                  |                                |
| Confirmed ORR a by ICR by HER2 status                              |                                  |                                  |                                |
| IHC 1+                                                             |                                  |                                  |                                |
| n                                                                  | 14                               | 14                               | 28                             |
| Confirmed ORR, n (%)                                               | 6 (42.9)                         | 4 (28.6)                         | 10 (35.7)                      |
| 95% CI b                                                           | 17.7, 71.1                       | 8.4, 58.1                        | 18.6, 55.9                     |
| IHC 2+/ISH-negative                                                |                                  |                                  |                                |
| n                                                                  | 7                                | 19                               | 26                             |
| Confirmed ORR, n (%)                                               | 1 (14.3)                         | 9 (47.4)                         | 10 (38.5)                      |
| 95% CI b                                                           | 0.4, 57.9                        | 24.4, 71.1                       | 20.2, 59.4                     |
| Confirmed ORR a by ICR by hormone receptor status                  |                                  |                                  |                                |
| Hormone receptor-positive                                          |                                  |                                  |                                |
| n                                                                  | 19                               | 28                               | 47                             |

<div style=\"page-break-after: always\"></div>

| Parameter                 | HER2-low BC 5.4 mg/kg (N = 21)   | HER2-low BC 6.4 mg/kg (N = 33)   | Overall HER2-low BC (N = 54)   |
|---------------------------|----------------------------------|----------------------------------|--------------------------------|
| Confirmed ORR, n (%)      | 7 (36.8)                         | 12 (42.9)                        | 19 (40.4)                      |
| 95% CI b                  | 16.3, 61.6                       | 24.5, 62.8                       | 26.4, 55.7                     |
| Hormone receptor-negative |                                  |                                  |                                |
| n                         | 2                                | 5                                | 7                              |
| Confirmed ORR, n (%)      | 0 (0.0)                          | 1 (20.0)                         | 1 (14.3)                       |
| 95% CI b                  | 0.0, 84.2                        | 0.5, 71.6                        | 0.4, 57.9                      |

BC = breast cancer; CI = confidence interval; CR = complete response; HER2 = human epidermal growth factor receptor 2; ICR = independent central review; IHC = immunohistochemistry; ISH = in situ hybridization; ORR = objective response rate;

PR = partial response

a   CR+PR

b   95% exact binomial confidence interval

Data cut-off: 01 Aug 2019 Source: Module 5.3.5.3 SCE J101 HER2-low BC Tables 14.2.2.2, 14.2.2.2.1, 14.2.2.2.9, 14.2.2.3, 14.2.2.3.1, and 14.2.2.3.9

The median DoR (01 Aug 2019 DCO) for confirmed responses based on ICR was 10.4 months (95%CI: 8.5, NE) for the overall HER2-low population: 9.6 months (95%CI: 5.7, NE) for the 5.4 mg/kg group and 10.4 months (95%CI: 3.4, NE) for the 6.4 mg/kg group, respectively.

As of 01 Aug 2019 DCO, the median duration of survival follow-up was 12.4 months (range: 1.6 to 34.8) for the overall HER2-low BC population: 11.9 months (range: 2.5 to 33.6) in the 5.4 mg/kg group and 12.9 months (range: 1.6 to 34.8) in the 6.4 mg/kg group. Median OS was 29.4 months (95%CI: 12.9, NE) for the overall HER2-low population: NE (95% CI: 11.1, NE) in the 5.4 mg/kg group and 19.7 months (95% CI: 12.5, NE) in the 6.4 mg/kg group, respectively.

## 2.4.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

The data from Study U303, PopPK analysis and ER analyses support the chosen dose of 5.4 mg/kg.

The efficacy assessment of the applied extension of indication is based on the pivotal study Destiny Breast04 (Study U303), which is a phase 3, randomised, open-label two-arm study comparing trastuzumab deruxtecan (T-DXd) head-to-head with single-agent chemotherapy per Physician's choice (TPC) for the treatment of HER2-low unresectable or metastatic breast cancer. TPC included the currently recommended SOC in the proposed settings, which is single-agent chemotherapy using either capecitabine, eribulin, gemcitabine, paclitaxel or nab-paclitaxel. As pointed out by the Scientific Advice given in 2018, the use of gemcitabine monotherapy is not endorsed in the proposed setting; however, it is considered acceptable and among the standard options used in the EU for the treatment of metastatic breast cancer. The SA also pointed out that prior anthracycline therapy ought to have been given prior to inclusion to the pivotal study, and while this is not specifically mentioned in the in- or exclusion criteria, it was a requirement that included patients must have had received chemotherapy in the metastatic setting or have developed disease recurrence during or within 6 months of completing adjuvant chemotherapy, which would probably have included an anthracycline-based chemotherapy. Single-agent chemotherapy according to physician's choice was to be determined prior to randomisation which is endorsed. The MAH did not consider anthracyclines as comparator as these are commonly given in the neoadjuvant/adjuvant setting, rendering patients ineligible for further anthracycline therapy in the metastatic setting. Furthermore, the risk for cardiotoxicity with cumulating

<div style=\"page-break-after: always\"></div>

dose limits long term treatment. This appears reasonable; however, as about two-thirds of patients received prior anthracycline treatment, anthracyclines might have been a suitable comparator for part of the patients. A post-hoc sensitivity analysis showed that the beneficial effect of T-DXd was observed independent of prior anthracycline use, which is reassuring. Information on prior anthracycline use has been added to section 5.1 of the SmPC.

This extension of indication is for treatment of patients with HER2-low unresectable or metastatic breast cancer, who have received one prior systemic therapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy, i.e. both the 1L and the 2L setting. The percentage of patients who had prior anthracycline use in the (neo)adjuvant setting was 46.3% and 19.4% in the locally advanced and/or metastatic setting. In the metastatic setting, patients had a median of 3 prior lines of systemic therapy (range: 1 to 9) with 57.6% having 1 and 40.9% having 2 prior chemotherapy regimens; 3.9% were early progressors (progression in the neo/adjuvant setting). In HR+ patients, the median number of prior lines of endocrine therapy was 2 (range: 0 to 9) and 70% had prior CDK4/6 inhibitor treatment. The newly proposed indication does not totally reflect the included study population in the pivotal trial in terms of endocrine therapy. For example, a third of the patients included have had 2 prior lines of endocrine therapy in the metastatic setting. In addition, 22.4% of subjects received subsequent endocrine therapy either as single agent or in combination after completion of T-DXd treatment (data not shown). It is also acknowledged that the treating physician may have reasons to treat with chemotherapy, e.g., when there is rapid progression and imminent organ failure (typically due to liver metastases), because a rapid response is needed and the response from endocrine therapy occurs more slowly (Gennari et al. ESMO. 2021). Moreover, there is no reason to doubt effectiveness of T-DXd in patients who did not receive any prior lines of endocrine therapy, so it is considered acceptable to extrapolate the efficacy to patients, who are not previously treated with endocrine therapy.

Low HER2 expression was defined as IHC2+/ISH- or IHC1+ (ISH- or not tested) according to ASCO/CAP guidelines per central assessment using the most recent tumour tissue sample available, which is endorsed. Although there was a slight difference in the wording of the HER2 1+ definition between the ASCO/CAP guidelines, the protocol for the pivotal study, and the pathologist training material used to train DB-04 central pathologist, it is considered that the definitions are similar. This is agreed since the slight difference is only in the wording, not in the interpretation of the staining. In both definitions, the % of cells presenting such staining intensity needs to be &gt;10%.

All patients had to have a history of low HER2 expression; however, the concordance rate between central and local testing was only 75%.  According to the Applicant, differences in testing methodologies and/or local scoring criteria, lack of local pathologist training for determination of HER2low scores, and intrasubject tumour heterogeneity are some of the factors that would likely have contributed to the observed differences between local and central assessment of HER2 expression. Although this is acknowledged, the data indicate that there could be a risk that patients may be selected erroneously for treatment with T-DXd based on unvalidated local tests. As no information was available for patients with discordant results on timing of local test compared to central test and prior therapies, the reasons for the discordant results remain unknown. As most patients had an archival tissue sample for HER2 determination, there is no need to request for fresh tissue samples in the SmPC. In the pivotal study, there were two reasons for tumour tissue collection (HER2 and exploratory biomarker analysis) with different timings of collection. Tumour samples for HER2 testing per inclusion criterion 5 allowed archival tissue prior to last treatment whereas samples for biomarker analysis per inclusion criterion 6 were mandatory after most recent treatment.

Patients were recruited from 19 countries and the median follow-up was 16.1 months in the T-DXd arm vs 13.5 months in the TPC arm at the DCO of 11 January 2022. A total of 713 patients were

<div style=\"page-break-after: always\"></div>

screened and 557 were randomised 2:1 to the two treatment arms and this is an acceptable sample size.  Most patients randomised to the TPC arm received eribulin (51%) followed by capecitabine (20%). Each of the other products made up 8-10% of the TPC arm.

Randomisation was stratified by HER2 IHC status (1+ or 2+), number of prior chemotherapies (1 or 2), and hormone receptor/CDK status (HR+ with CDK4/6 (min 240), HR+ without CDK4/6 (max 240), HR- (about 60)). The stratification factors are endorsed as these might influence efficacy.

Main exclusion criteria were prior treatment with an antibody drug conjugate (ADC) consisting of a topoisomerase I inhibitor, uncontrolled or significant cardiovascular disease, history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current or suspected ILD/pneumonitis, clinically severe pulmonary compromised resulting from intercurrent pulmonary illnesses, and spinal cord compression or clinically active central nervous system (CNS) metastases. These are in line with previous Enhertu studies and adequately described in section 5.1 of the SmPC.

The pivotal study was fully recruited in approximately 4 years and a relevant fraction of the patients has been recruited from an EU like population (~60%). The presented data are from the primary analysis of the primary efficacy endpoint of blinded independent central review (BICR)-assessed progression-free survival (PFS).

The scientific advice given from CHMP in 2018 recommended to consider OS as a primary endpoint and to power the study to obtain robust OS data. The MAH designed the study to achieve at least 80% to test OS, which is endorsed. Of note, 60 subjects with hormone receptor-negative BC were enrolled for exploratory purposes, which is in line with the CHMP recommendations given during the scientific advice. The inclusion of HR-negative patients is endorsed; however, a larger sample size would have been preferred for a more accurate estimation of the effect size in this subgroup.

The primary efficacy endpoint of PFS was assessed by BIRC using RECIST v1.1 in the hormone receptor-positive cohort (HR+) and the key secondary endpoint was PFS by BIRC in all randomised patients (FAS) and OS in both populations. Other secondary endpoints were PFS as assessed by the investigator, confirmed objective response rate (ORR), and duration of response (DOR) and PFS on next-line treatment by the investigator (PFS2). The primary and secondary endpoints are acceptable and established in the current setting. The primary efficacy endpoint and the key secondary efficacy endpoints were tested hierarchically to maintain the overall 2-sided Type I error rate of 0.05 or less and the statistical methods used are acceptable.

After the initial release (v1.0, 23 Aug 2018), the study protocol was amended 4 times. Most changes related to clarifications and updates to the inclusion criteria. The main change was with amendment 4 (v5.0, 12 Oct 2020) adding two interim analyses for OS (originally OS analysis at time of final PFS analysis) to ensure adequate follow-up and statistical power. The Applicant clarified that no information from Study U303 was used or available at the time of protocol amendment 4. Furthermore, the rationale for the amendment was to provide adequate follow-up and statistical power to detect a statistically significant difference in OS with a clinically meaningful improvement of 6 months over the expected SoC survival of 15 months and the revision of the OS assumptions was based on updated OS analysis from Study DS8201-A-J101. Moreover, the timing of the first IA for OS was dependent on the final analysis for PFS, which was unchanged during the study conduct. The timing of the planned second IA of OS was based on the assumed hazard ratio=0.72 and the median OS for the TPC arm of 15 months. The second IA for OS was planned with 70% IF relative to the target number of PFS events at the final analysis. This is acceptable.

Because the Applicant is seeking an indication regardless of HR status, the FAS is the main focus of the assessment. Baseline characteristics in the FAS (T-DXd vs TPC) showed that the median age was ~57

<div style=\"page-break-after: always\"></div>

and 56 years with ~78% and 74% of the patients being less than 65 years old and ~22% and 26% of the patients were ≥65 years, which is considered reflective of the targeted patient population. Two male patients were included, both in the T-DXd treatment arm, which is acceptable since breast cancer is rare in men. Moreover, the results from the pivotal trial are considered extrapolatable to men with HER2-low breast cancer based on the common biological and pharmacological rationale in line with previous EMA decisions. There is limited data in patients older than 75 years as already reflected in section 4.2 of the SmPC.

Most patients were from Europe or Israel (44.5% vs 46.2%) or Asia (39.4% and 35.9%, respectively), so the majority of the patients were White or Asian. Hence, the fraction of European patients is acceptable for interpretation of the study results in an EU context.

More than half of the included patients had received 1 prior line of chemotherapy, while 43.2% and 44% of the patients had 2 prior lines of chemotherapy. Regarding endocrine therapy, many patients had already received two (~30%) or ≥ 3 (~24%) prior lines of endocrine therapy. The number of patients who had received 2 prior lines of chemotherapy and/or ≥ 3 lines of endocrine therapy may be slightly more than what could be expected; however, the study population is considered reflective of the overall targeted patient population. Approximately two-thirds (~62%) of the patients had hormone receptor (HR)-positive tumours and had received a CDK4/6 inhibitor, which is the current SoC, while 26% had HR+ tumors but did not receive a CDK4/6 inhibitor in addition to their endocrine therapy. The latter is considered higher than what would be expected in a European population based on current treatment guidelines. Approximately 11% of the FAS had HR-negative disease, since the number of included patients with HR- tumors was capped, a higher number would have been preferred for a more robust estimation of the effect size. Information on baseline characteristics is, in general, adequately reflected in the SmPC.

The majority of the patients had a history of visceral metastases (89.0% and 85.3%), with presence of liver (71.3% vs 66.8) or lung metastases (32.2% vs 34.2%) at baseline. BRCA status was missing in more than 60% of the patients, so the efficacy of T-DXd in the low number of patients with a BRCA1/2 mutation at baseline cannot be firmly concluded. Relatively few patients had CNS metastases at baseline (5.7%), which is considered reflective of the study population, who had mostly HR+ disease.

Baseline characteristics in the HR- cohort were in general comparable to the overall study population, although the proportion of patients receiving 1 prior line was lower and more patients had ECOG 1 in the HR- population. Also, baseline characteristics were largely comparable between treatment arms, although numbers were small in each arm. It is noted that there were four patients in each treatment arm who had an HR+ status for the electronic data capture (EDC) but not for interactive web/voice response system (IXRS; these were all HR-).

## Efficacy data and additional analyses

The primary endpoint was met and the primary analysis of PFS by BIRC in the HR+ population showed a statistically significant and clinically relevant improvement from 5.4 months (95%CI: 4.4; 7.1) with TPC to 10.1 months (95%CI: 9.5; 11.5) with T-DXd, HR 0.51 (95%CI: 0.40; 0.64). The data is mature with 63.7% events in the active T-DXd arm and 67.5% events in the control arm. The KM curves for PFS by BIRC separate early and remain separated. The performance of the control arm is considered within the expected range for the 2L+ setting as the study population in Destiny Breast04 was heavily pre-treated. In context, the median PFS was 6 months in the 2L setting after one line of chemotherapy (MONARCH1) and only a median PFS of 3.7 months was shown for a pooled analysis from two phase 3 studies (Eribulin vs TPC or capecitabine in a 2L+ setting of HER2-negative MBC).

<div style=\"page-break-after: always\"></div>

Sensitivity analyses conducted on the PFS and those assessing the impact of stratification and censoring rules were consistent with the primary analysis (HR ranging from 0.44 to 0.53), showing PFS benefit for T-DXd over TPC. A post-hoc sensitivity analysis of PFS by BICR in the hormone receptorpositive cohort to assess the impact of censoring due to withdrawal of consent showed no impact on the outcome of the PFS analysis.

Median PFS based on investigator was 9.6 months (95% CI: 8.4, 10.0) in the T-DXd arm compared with 4.2 months (95% CI: 3.4, 4.9) in the TPC arm (HR: 0.37; 95% CI: 0.30, 0.47). The overall concordance rates of PFS between investigator and BICR assessment were about 80% in both arms. A post-hoc sensitivity analysis including both BICR-assessed and investigator-assessed PD (whichever occurred first) confirmed robustness of results.

The secondary endpoint of PFS by BIRC in the FAS also showed a statistically significant and clinically relevant improvement from 5.1 months (95%CI: 4.2; 6.8) with TPC to 9.9 months (95%CI: 9.0; 11.3) with T-DXd, HR 0.50 (95%CI: 0.40, 0.63). These results were similar to those from the HR+ population, which can be expected as the HR+ subgroup constitutes 90% of the FAS. The data from the FAS were also mature with 65.1% events in the active T-DXd arm and 69% events in the control arm and the KM curves also separated early and remained separated .

PFS in the HR- population was 6.6 months (95%CI: 4.1, 11.7) in the T-DXd arm vs 2.9 months (95%CI: 1.4, 4.0) in the TPC arm, HR 0.45 (95%CI: 0.23, 0.87). Hence, the PFS was shorter in both arms, which is considered to be due the generally poorer prognosis of the HR- population. Nevertheless, the difference in PFS between the two arms is considered clinically relevant and these results are considered supportive of the primary endpoint and the claimed hormone-receptor-agnostic indication.

The key secondary endpoint of overall survival in the HR+ population and the FAS was statistically and clinically significantly improved at the time of the first IA with only 38.1% events with T-DXd and 44.8% events in the control arm after 18.4 months of follow up. Hence, the median OS for the HR+ populations was 23.9 months (95%CI: 20.8, 24.8) in the T-DXd arm vs 17.5 months (95%CI: 15.2, 22.4) in the TPC arm, HR 0.64 (95%CI: 0.48, 0.86), while the median OS for the FAS was 23.4 months (95%CI: 20.0, 24.8) in the T-DXd arm vs 16.8 months (95%CI: 14.5, 20.0) in the TPC arm, which is consistent with the results in the HR+ population. A difference in OS of more than 6 months between the treatment arms is considered clinically meaningful. The MAH is recommended to submit the final OS analysis from Study U303, projected to occur in Q4 2024, post-authorisation when available (PAM-REC).

In the HR- subgroup, the median OS was 16.6 months (95%CI: 11.3, NE) in the T-DXd arm vs. 10.3 months (95%CI: 6.1, 15.2) in the TPC arm (HR: 0.63; 95%CI: 0.32, 1.23). Some uncertainty remains on the true effect size in the HR- subgroup due to the small sample size. Nevertheless, given the magnitude of the effect observed, the poor prognosis of the HR- patients and the mechanism of action of T-DXd, it is reasonable to assume that HR- patients will benefit from treatment and inclusion in the indication is sufficiently supported. Additional observational studies will be performed by the Applicant providing further data on effectiveness in the HR- subgroup.

ORR by IRC for the FAS is also clinically and statistically significantly improved from 16.3% in the control arm to 52.3% with T-DXd, and the results were in line with those from the HR+ population. The induced responses were durable: median DoR was 10.7 months in the T DXd arm vs 6.8 months in the TPC arm, and since data was mature with ~57% and ~67 events in each arm, respectively, no updated data has been requested. ORR and median DoR also support a beneficial effect of T-DXd in the HR- subgroup.

<div style=\"page-break-after: always\"></div>

A post-hoc sensitivity analyses in the HR- subgroup based on EDC confirmed a beneficial effect in this subgroup.

The Applicant was advised to provide PFS 2 data. Approximately a third of the patients treated with TDXd in both populations had a second progression of disease on their next line therapy, while ~20% have died. There were slightly more patients who had a PFS2 event in the control arm compared to TDXd in both populations (~40%), but a similar fraction of deaths across the treatment arms, so there is no sign of a detriment for the patients treated with T-DXd. The PFS2 was 15.4 months for the T-DXd treated in the FAS compared to 10.5 months in the control arm, which is reassuring. PFS2 analysis for the HR- subgroup showed a gain in 4 months, supporting a beneficial effect.

Subgroup analyses of PFS by BIRC in the FAS supported a benefit of T-DXd compared with TPC for important pre-specified subgroups including HR status, prior CDK4/6i treatment, number of prior chemotherapies, and IHC 1+ and IHC 2+/ISH- status.

In addition, the OS benefit was observed across the majority of prespecified subgroups with point estimates of HR&lt;1, except for the subgroup who received 1 prior line of ET (HR: 1.02, 95%CI: 0.58, 1.80) and the subgroup with moderate renal impairment (HR: 1.91, 95%CI: 0.84, 4.36). Most patients on T-DXd in the moderate renal impairment subgroup died due to PD and only two patients had an AE as primary cause of death which is reassuring. Further, it is noted that the median PFS (23.6 months) in the TPC arm appears somewhat better than seen in other subgroups (mostly &lt;20 months). Overall, there are no signs of a safety issue and results may be chance finding in this small subgroup (n=64). Information on somewhat worse safety profile in this subgroup, and especially occurrence of ILD, is already included in the SmPC.

Patient-reported outcomes: There seems to be no detriment on QoL in patients treated with T-DXd compared to TPC and numerical increases in QoL may support the beneficial effect of T-DXd; however, the open-label study design precludes firm conclusions. Hence, the PRO results are not presented in the SmPC.

## 2.4.3. Conclusions on the clinical efficacy

The results from the pivotal Study U303 showed a statistically significant and clinically relevant improvement of both progression-free survival and overall survival in the HR+ population and the ITT population (FAS) for treatment with T-DXd compared to treatment per Physician's choice (TPC) in patients with HER2-low, unresectable or metastatic breast cancer treated with a prior chemotherapy. Supportive data are available in the HR- population, though some uncertainty remains on the true effect size in the HR- subgroup due to the small sample size. Nevertheless, given the magnitude of efficacy observed, the poor prognosis of the HR- patients and the mechanism of action of T-DXd, it is reasonable to assume that HR- patients will benefit from treatment and inclusion in the indication is sufficiently supported. The Applicant was recommended to provide the final efficacy data from the pivotal U303 study post-approval.

## 2.5. Clinical safety

## Introduction

Safety data were summarised from the pooled safety population, who had received at least one dose of Enhertu 5.4 mg/kg (n=944) across multiple tumour types in clinical studies. Moreover, safety data from the pivotal study (n=543) was provided (Safety Analyses Set).

<div style=\"page-break-after: always\"></div>

Table 49: Summary of Groups Included in Safety Data Presentations

| Evaluation                                                                                                                        | Drug / Dose         | Number of Subjects Treated                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------|---------------------|-----------------------------------------------------------------------------------|
| Data for Primary Analysis Subjects with HER2-low BC from Study U303                                                               | T-DXd 5.4 mg/kg TPC | T-DXd: 371 TPC: 172                                                               |
| All BC T-DXd 5.4 mg/kg Pool Multi-study pool of subjects with HER2-positive or HER2-low BC who received T-DXd 5.4 mg/kg (N = 883) | T-DXd 5.4 mg/kg     | 883 Study U303: 371 Study U302: 257 Study U201: 184 Study J101: 71                |
| All Tumor Types T- DXd ≥5.4 mg/kg Pool Multi-study pool of subjects with any tumor type who received T- DXd ≥5.4 mg/kg (N = 1590) | T-DXd 5.4 mg/kg     | 944 Study U303: 371 Study U302: 257 Study U201: 184 Study J101: 91 Study U204: 41 |
| All Tumor Types T- DXd ≥5.4 mg/kg Pool Multi-study pool of subjects with any tumor type who received T- DXd ≥5.4 mg/kg (N = 1590) | T-DXd 6.4 mg/kg     | 619 Study J101: 183 Study J202: 169 Study U201: 48 Study U204: 140 Study U205: 79 |
| All Tumor Types T- DXd ≥5.4 mg/kg Pool Multi-study pool of subjects with any tumor type who received T- DXd ≥5.4 mg/kg (N = 1590) | T-DXd 7.4 mg/kg     | Study U201: 21                                                                    |
| All Tumor Types T- DXd ≥5.4 mg/kg Pool Multi-study pool of subjects with any tumor type who received T- DXd ≥5.4 mg/kg (N = 1590) | T-DXd 8.0 mg/kg     | Study J101: 6                                                                     |

BC = breast cancer; HER2 = human epidermal growth factor receptor 2; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice Source:, Module 5.3.5.3 SCS SAP v1.0

<div style=\"page-break-after: always\"></div>

## Patient exposure

## Table 50: Summary of Exposure in Study U303 (Safety Analysis Set)

| Parameter                                       | T-DXd (N =371)                                  | Overall TPC (N =172)                            | Eribulin (N =89)                                | Capecitabine (N =36)                            | Nab- paclitaxel (N =17)                         | Gemcitabine (N =16)                             | Paclitaxel (N =14)                              | AIlBC T-DXd 5.4 mg/kg Pool (N=883)              |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Treatment duration(months)a                     | Treatment duration(months)a                     | Treatment duration(months)a                     | Treatment duration(months)a                     | Treatment duration(months)a                     | Treatment duration(months)a                     | Treatment duration(months)a                     | Treatment duration(months)a                     | Treatment duration(months)a                     |
| Mean                                            | 9.17                                            | 4.44                                            | 4.32                                            | 5.82                                            | 3.91                                            | 2.61                                            | 4.33                                            | 11.68                                           |
| Std Dev                                         | 6.428                                           | 3.722                                           | 3.360                                           | 5.064                                           | 3.747                                           | 1.809                                           | 2.406                                           | 7.641                                           |
| Median                                          | 8.21                                            | 3.47                                            | 3.65                                            | 4.11                                            | 2.76                                            | 1.63                                            | 4.29                                            | 9.89                                            |
| Minimum, Maximum                                | 0.2,33.3                                        | 0.3, 17.6                                       | 0.3, 17.5                                       | 0.3,17.6                                        | 0.7,16.8                                        | 1.1, 6.9                                        | 0.4, 9.0                                        | 0.2, 37.1                                       |
| Duration of treatment as of data cut-offa n (%) | Duration of treatment as of data cut-offa n (%) | Duration of treatment as of data cut-offa n (%) | Duration of treatment as of data cut-offa n (%) | Duration of treatment as of data cut-offa n (%) | Duration of treatment as of data cut-offa n (%) | Duration of treatment as of data cut-offa n (%) | Duration of treatment as of data cut-offa n (%) | Duration of treatment as of data cut-offa n (%) |
| ≤3 months                                       | 71 (19.1)                                       | 79 (45.9)                                       | 36 (40.4)                                       | 15 (41.7)                                       | 10 (58.8)                                       | 13 (81.3)                                       | 5 (35.7)                                        | 120 (13.6)                                      |
| >3to≤6months                                    | 71 (19.1)                                       | 57 (33.1)                                       | 38 (42.7)                                       | 7 (19.4)                                        | 4 (23.5)                                        | 2 (12.5)                                        | 6 (42.9)                                        | 142 (16.1)                                      |
| >6 to ≤9 months                                 | 73 (19.7)                                       | 20 (11.6)                                       | 9 (10.1)                                        | 5 (13.9)                                        | 2 (11.8)                                        | 1 (6.3)                                         | 3 (21.4)                                        | 139 (15.7)                                      |
| >9 to ≤12 months                                | 47 (12.7)                                       | 6 (3.5)                                         | 3 (3.4)                                         | 3 (8.3)                                         | 0                                               | 0                                               | 0                                               | 100 (11.3)                                      |
| >12 to≤18 months                                | 66 (17.8)                                       | 10 (5.8)                                        | 3 (3.4)                                         | 6 (16.7)                                        | 1 (5.9)                                         | 0                                               | 0                                               | 163 (18.5)                                      |
| >18 to ≤24 months                               | 33 (8.9)                                        | 0                                               | 0                                               | 0                                               | 0                                               | 0                                               | 0                                               | 163 (18.5)                                      |
| >24months                                       | 10 (2.7)                                        | 0                                               | 0                                               | 0                                               | 0                                               | 0                                               | 0                                               | 56 (6.3)                                        |
| Total patient-years of exposure b               | 283.5                                           | 63.6                                            | 32.1                                            | 17.5                                            | 5.5                                             | 3.5                                             | 5.1                                             | 859.6                                           |
| Cumulative dose level c                         | Cumulative dose level c                         | Cumulative dose level c                         | Cumulative dose level c                         | Cumulative dose level c                         | Cumulative dose level c                         | Cumulative dose level c                         | Cumulative dose level c                         | Cumulative dose level c                         |
| Mean (Std Dev)                                  | 65.57 (45.261)                                  | -                                               | 14.39 (10.561)                                  | 218082.70 (191731.884)                          | 1178.87 (991.607)                               | 7256.68 (5455.184)                              | 1096.40 (658.832)                               | 82.74 (53.548)                                  |
| Median                                          | 54.78                                           | --                                              | 12.85                                           | 166586.37                                       | 794.12                                          | 5696.43                                         | 942.15                                          | 72.39                                           |

| Parameter                                 | T-DXd (N =371)                            | Overall TPC (N = 172)                     | Eribulin (N = 89)                         | Capecitabine (N =36)                      | Nab- paclitaxel (N = 17)                  | Gemcitabine (N =16)                       | Paclitaxel (N = 14)                       | All BC T-DXd 5.4 mg/kg Pool (N=883)       |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Minimum, Maximum                          | 5.3, 219.8                                |                                           | 1.2, 54.2                                 | 6930.4, 772970.1                          | 260, 4334.9                               | 1986.8, 25000                             | 163.2, 2369.4                             | 5.3, 239.0                                |
| Numberofcycles                            | Numberofcycles                            | Numberofcycles                            | Numberofcycles                            | Numberofcycles                            | Numberofcycles                            | Numberofcycles                            | Numberofcycles                            | Numberofcycles                            |
| Mean (Std Dev)                            | 12.6 (8.75)                               | 6.2 (5.00)                                | 6.2 (4.61)                                | 7.9 (6.64)                                | 5.3 (5.10)                                | 3.9 (2.55)                                | 5.9 (3.25)                                | 16.0 (10.38)                              |
| Median                                    | 11.0                                      | 5.0                                       | 6.0                                       | 6.0                                       | 4.0                                       | 3.0                                       | 6.0                                       | 14.0                                      |
| Minimum, Maximum                          | 1, 47                                     | 1, 25                                     | 1, 25                                     | 1, 23                                     | 1, 23                                     | 2,10                                      | 1, 13                                     | 1, 47                                     |
| Dose intensity d                          | Dose intensity d                          | Dose intensity d                          | Dose intensity d                          | Dose intensity d                          | Dose intensity d                          | Dose intensity d                          | Dose intensity d                          | Dose intensity d                          |
| Mean (Std Dev)                            | 5.13 (1.165)                              | -                                         | 2.33 (0.421)                              | 26953.47 (5656.888)                       | 232.98 (34.103)                           | 2016.24 (544.569)                         | 182.58 (46.284)                           | 5.03 (0.883)                              |
| Median                                    | 5.24                                      |                                           | 2.34                                      | 26922.86                                  | 241.20                                    | 2140.46                                   | 180.80                                    | 5.21                                      |
| Minimum, Maximum                          | 2.6, 22.7                                 | --                                        | 1.3, 3.3                                  | 14553.8, 35965.5                          | 152.6, 282.2                              | 1192.1, 2678.6                            | 85.8, 263.6                               | 2.5, 22.7                                 |
| Relative dose intensity e(%)              | Relative dose intensity e(%)              | Relative dose intensity e(%)              | Relative dose intensity e(%)              | Relative dose intensity e(%)              | Relative dose intensity e(%)              | Relative dose intensity e(%)              | Relative dose intensity e(%)              | Relative dose intensity e(%)              |
| Mean (Std Dev)                            | 99.78 (1.796)                             | 102.65 (20.083)                           | 99.22 (4.555)                             | 114.10 f (41.730)                         | 100.35 (1.096)                            | 100.16 (2.392)                            | 100.65 (2.443)                            | 97.56 (7.196)                             |
| Median                                    | 99.97                                     | 100.00                                    | 99.92                                     | 99.71                                     | 100.05                                    | 100.18                                    | 100.23                                    | 99.81                                     |
| Minimum, Maximum                          | 91.5, 107.9                               | 59.0, 198.5                               | 78.5, 113.0                               | 59.0, 198.5                               | 98.5, 103.4                               | 94.6, 104.4                               | 97.6, 108.1                               | 46.1, 107.9                               |
| Relative dose intensity categories, n (%) | Relative dose intensity categories, n (%) | Relative dose intensity categories, n (%) | Relative dose intensity categories, n (%) | Relative dose intensity categories, n (%) | Relative dose intensity categories, n (%) | Relative dose intensity categories, n (%) | Relative dose intensity categories, n (%) | Relative dose intensity categories, n (%) |
| ≥90%                                      | 371 (100.0)                               | 157 (91.3)                                | 84 (94.4)                                 | 26 (72.2)                                 | 17 (100.0)                                | 16 (100.0)                                | 14 (100.0)                                | 813 (92.1)                                |
| <90% to≥80%                               | 0                                         | 9 (5.2)                                   | 4 (4.5)                                   | 5 (13.9)                                  | 0                                         | 0                                         | 0                                         | 34 (3.9)                                  |
| <80% to ≥60%                              | 0                                         | 5 (2.9)                                   | 1 (1.1)                                   | 4 (11.1)                                  | 0                                         | 0                                         | 0                                         | 29 (3.3)                                  |
| <60%                                      | 0                                         | 1 (0.6)                                   | 0                                         | 1 (2.8)                                   | 0                                         | 0                                         | 0                                         | 7 (0.8)                                   |

<div style=\"page-break-after: always\"></div>

BC =breast cancer; CSR = clinical study report;N = total number of treated subjects; RDI =relative dose intensity; SAP =Statistical Analysis Plan;

StdDev=standarddeviation;T-DXd=trastuzumabderuxtecan;TPC=treatmentofphysician'schoice

PercentageswerecalculatedusingthenumberofsubjectsintheSafetyAnalysisSetasthedenominator.

Units: T-DXd = mg/kg; capecitabine, gemcitabine, paclitaxel, nab-paclitaxel = mg/m2; eribulin = mg*/m2, where * refers to eribulin mesylate. 1.23 mg eribulin base=1.4mgeribulinmesylate

1month=365.25/12=30.44days

- a Treatment duration (months) =(date of last dose - date of first dose) + a cycle length [days]/30.44
- b Total patient-years ofexposure= sum of treatment duration (months) of all subjects/12
- c Cumulative doselevel(units)= sum of the actual dose levels received (units given above).Due to different dosing schedules and units among theindividual TPCtreatments,cumulativedoselevelisnotpresentedfortheoverallTPCarm.
- d Dose intensity (units/cycle length in weeks) = cumulative dose level (units given above) /(duration of treatment [days]/cycle length [days]).
- eRelativedoseintensity(%)derivation/definitionforeachstudyfollowedthestudyconventionspecifiedinthespecificCSRSAP.
- fFor capecitabine,the planned dose was derived based on the total daily dose on thefirst day of dosing/body surface area,and RDI was calculated as the planned dose onthefirst dosing day×the durationofexposure(days).For11 subjects,thedosereceived on thefirst dayof dosingwaslower than any subsequent doseforthat subject;therefore,theRDIfor these subjectsexceeded100%,and resulted in themeanRDI&gt;100%for thesubjects treatedwith capecitabine.

Source:Module5.3.5.3SCSTable1.1.3;Module5.3.5.1DS8201-A-U303CSR Table 14.1.5.1.1.

## Adverse events

Table 51: Summary of Subject Disposition (Safety Analysis Set)

| Parameter                                           | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|-----------------------------------------------------|--------------------------|--------------------------|---------------------------------------|
|                                                     | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Subjects who were ongoing study drug as of the DCO  | 58 (15.6)                | 3 (1.7)                  | 223 (25.3)                            |
| Subjects who discontinued study drug for any reason | 313 (84.4)               | 169 (98.3)               | 660 (74.7)                            |
| Progressive disease a                               | 220 (59.3)               | 130 (75.6)               | 395 (44.7)                            |
| Adverse event                                       | 60 (16.2)                | 14 (8.1)                 | 146 (16.5)                            |
| Withdrawal by subject                               | 12 (3.2)                 | 11 (6.4)                 | 41 (4.6)                              |
| Clinical progression b                              | 10 (2.7)                 | 8 (4.7)                  | 33 (3.7)                              |
| Death                                               | 5 (1.3)                  | 2 (1.2)                  | 16 (1.8)                              |
| Physician decision                                  | 4 (1.1)                  | 3 (1.7)                  | 14 (1.6)                              |
| Lost to follow-up                                   | 0                        | 1 (0.6)                  | 0                                     |
| Other                                               | 2 (0.5) c                | 0                        | 15 (1.7)                              |

BC = breast cancer; DCO = data cut-off; N = total number of treated subjects; RECIST v1.1 = Response Evaluation Criteria in Solid Tumors version 1.1; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

a Based on RECIST v1.1

b Per investigator assessment

c Subject No. xxxxxxxx (dose delay of longer than 28 days); Subject No. xxxxxxxx (physician decision entered as Other in electronic data capture) (Module 5.3.5.1 DS8201-A-U303 CSR Listing 16.2.1.1). Source:  Module 5.3.5.3 SCS Table 1.1.1

Table 52:  Overview of Treatment-emergent Adverse Events (Safety Analysis Set)

| Parameter                                        | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|--------------------------------------------------|--------------------------|--------------------------|---------------------------------------|
|                                                  | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Subjects with any TEAE                           | 369 (99.5)               | 169 (98.3)               | 878 (99.4)                            |
| TEAEs with worst CTCAE ≥Grade 3 a                | 195 (52.6)               | 116 (67.4)               | 479 (54.2)                            |
| Serious TEAEs                                    | 103 (27.8)               | 43 (25.0)                | 222 (25.1)                            |
| TEAEs associated with study drug discontinuation | 60 (16.2)                | 14 (8.1)                 | 143 (16.2)                            |

<div style=\"page-break-after: always\"></div>

| Parameter                                                     | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|---------------------------------------------------------------|--------------------------|--------------------------|---------------------------------------|
|                                                               | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| TEAEs associated with dose reduction                          | 84 (22.6)                | 66 (38.4)                | 195 (22.1)                            |
| TEAEs associated with study drug interruption                 | 143 (38.5)               | 72 (41.9)                | 369 (41.8)                            |
| TEAEs associated with an outcome of death b                   | 14 (3.8)                 | 5 (2.9)                  | 32 (3.6)                              |
| Subjects with any drug-related TEAE c                         | 357 (96.2)               | 162 (94.2)               | 862 (97.6)                            |
| Drug-related TEAEs with worst CTCAE ≥Grade 3 a                | 154 (41.5)               | 99 (57.6)                | 397 (45.0)                            |
| Drug-related serious TEAEs                                    | 48 (12.9)                | 19 (11.0)                | 112 (12.7)                            |
| Drug-related TEAEs associated with study drug discontinuation | 56 (15.1)                | 12 (7.0)                 | 133 (15.1)                            |
| Drug-related TEAEs associated with dose reduction             | 77 (20.8)                | 64 (37.2)                | 181 (20.5)                            |
| Drug-related TEAEs associated with study drug interruption    | 106 (28.6)               | 62 (36.0)                | 286 (32.4)                            |
| Drug-related TEAEs associated with an outcome of death b      | 7 (1.9)                  | 0                        | 11 (1.2)                              |

BC = breast cancer; CTCAE = Common Terminology Criteria for Adverse Events, Version 5.0; N = total number of treated subjects; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

a A subject was counted once at the maximum severity.

- b For specific TEAEs associated with an outcome of death, refer to Table 2.10.

c If relationship was missing, the TEAE was considered to be related to the drug. Source:  Module 5.3.5.3 SCS Table 1.2.1.1.1

Table 53: Treatmentemergent Adverse Events Reported in ≥10% of Subjects in Either Treatment Arm in Study U303, by Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRA Preferred Term/ Grouped Term a   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|-----------------------------------------|--------------------------|--------------------------|---------------------------------------|
| MedDRA Preferred Term/ Grouped Term a   | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Subjects with any TEAE                  | 369 (99.5)               | 169 (98.3)               | 878 (99.4)                            |
| Nausea                                  | 282 (76.0)               | 52 (30.2)                | 682 (77.2)                            |
| Fatigue a                               | 199 (53.6)               | 83 (48.3)                | 496 (56.2)                            |
| Vomiting                                | 150 (40.4)               | 23 (13.4)                | 406 (46.0)                            |
| Alopecia                                | 147 (39.6)               | 57 (33.1)                | 360 (40.8)                            |
| Anemia a                                | 143 (38.5)               | 47 (27.3)                | 317 (35.9)                            |
| Constipation                            | 126 (34.0)               | 38 (22.1)                | 308 (34.9)                            |
| Neutropenia a                           | 126 (34.0)               | 90 (52.3)                | 318 (36.0)                            |
| Transaminases increased a               | 120 (32.3)               | 54 (31.4)                | 254 (28.8)                            |
| Decreased appetite                      | 118 (31.8)               | 33 (19.2)                | 285 (32.3)                            |
| Diarrhoea                               | 100 (27.0)               | 38 (22.1)                | 260 (29.4)                            |
| Musculoskeletal pain a                  | 99 (26.7)                | 45 (26.2)                | 238 (27.0)                            |
| Thrombocytopenia a                      | 95 (25.6)                | 16 (9.3)                 | 220 (24.9)                            |
| Leukopenia a                            | 89 (24.0)                | 56 (32.6)                | 223 (25.3)                            |

<div style=\"page-break-after: always\"></div>

| MedDRA Preferred Term/ Grouped Term a       | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|---------------------------------------------|--------------------------|--------------------------|---------------------------------------|
| MedDRA Preferred Term/ Grouped Term a       | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Abdominal pain a                            | 65 (17.5)                | 23 (13.4)                | 173 (19.6)                            |
| Weight decreased                            | 60 (16.2)                | 14 (8.1)                 | 129 (14.6)                            |
| Headache a                                  | 55 (14.8)                | 11 (6.4)                 | 164 (18.6)                            |
| Upper respiratory tract infection a         | 51 (13.7)                | 9 (5.2)                  | 176 (19.9)                            |
| Stomatitis a                                | 49 (13.2)                | 19 (11.0)                | 142 (16.1)                            |
| Pyrexia                                     | 46 (12.4)                | 22 (12.8)                | 107 (12.1)                            |
| Interstitial lung disease b                 | 45 (12.1)                | 1 (0.6)                  | 112 (12.7)                            |
| Arthralgia                                  | 43 (11.6)                | 20 (11.6)                | 107 (12.1)                            |
| Blood potassium decreased a                 | 41 (11.1)                | 13 (7.6)                 | 108 (12.2)                            |
| Epistaxis                                   | 39 (10.5)                | 2 (1.2)                  | 105 (11.9)                            |
| Dyspnoea                                    | 38 (10.2)                | 16 (9.3)                 | 99 (11.2)                             |
| Peripheral sensory neuropathy               | 18 (4.9)                 | 19 (11.0)                | 55 (6.2)                              |
| Palmar-plantar erythrodysaesthesia syndrome | 5 (1.3)                  | 24 (14.0)                | 14 (1.6)                              |

BC = breast cancer; ILD = interstitial lung disease; MedDRA = Medical Dictionary for Regulatory Activities, Version 24.0; N = total number of treated subjects; PT = preferred term; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice

If a subject had multiple occurrences of the same PT/grouped term, the subject was counted once for that PT/grouped term.  If a subject had multiple PTs/grouped terms, the subject was counted in each of the different PTs/grouped terms.

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

TEAEs are sorted by descending frequency in the T-DXd arm.

a The PTs included in each grouped term are listed in Table 2.1.

b Interstitial lung disease includes events that were adjudicated as ILD and related to use of T-DXd or TPC.

Source:  Module 5.3.5.3 SCS Tables 1.2.1.3.1, 1.2.2.1, 1.2.4.1

## Treatment-related AEs

Table 54: Drug-related Treatmentemergent Adverse Events Reported in ≥10% of Subjects in Either Treatment Arm in Study U303, by Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRA Preferred Term/ Grouped Term a   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|-----------------------------------------|--------------------------|--------------------------|---------------------------------------|
| MedDRA Preferred Term/ Grouped Term a   | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Subjects with any drug-related TEAE     | 357 (96.2)               | 162 (94.2)               | 862 (97.6)                            |
| Nausea                                  | 271 (73.0)               | 41 (23.8)                | 657 (74.4)                            |
| Fatigue a                               | 177 (47.7)               | 73 (42.4)                | 447 (50.6)                            |
| Alopecia                                | 140 (37.7)               | 56 (32.6)                | 347 (39.3)                            |
| Vomiting                                | 126 (34.0)               | 17 (9.9)                 | 349 (39.5)                            |
| Anemia a                                | 123 (33.2)               | 39 (22.7)                | 279 (31.6)                            |
| Neutropenia a                           | 123 (33.2)               | 88 (51.2)                | 311 (35.2)                            |
| Decreased appetite                      | 106 (28.6)               | 28 (16.3)                | 258 (29.2)                            |
| Thrombocytopenia a                      | 88 (23.7)                | 16 (9.3)                 | 209 (23.7)                            |
| Transaminases increased a               | 87 (23.5)                | 39 (22.7)                | 200 (22.7)                            |

<div style=\"page-break-after: always\"></div>

| MedDRA Preferred Term/ Grouped Term a       | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|---------------------------------------------|--------------------------|--------------------------|---------------------------------------|
| MedDRA Preferred Term/ Grouped Term a       | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Leukopenia a                                | 86 (23.2)                | 54 (31.4)                | 217 (24.6)                            |
| Diarrhoea                                   | 83 (22.4)                | 31 (18.0)                | 209 (23.7)                            |
| Constipation                                | 79 (21.3)                | 22 (12.8)                | 191 (21.6)                            |
| Weight decreased                            | 46 (12.4)                | 8 (4.7)                  | 95 (10.8)                             |
| Abdominal pain a                            | 45 (12.1)                | 4 (2.3)                  | 108 (12.2)                            |
| Interstitial lung disease b                 | 45 (12.1)                | 1 (0.6)                  | 112 (12.7)                            |
| Stomatitis a                                | 42 (11.3)                | 18 (10.5)                | 126 (14.3)                            |
| Musculoskeletal pain a                      | 34 (9.2)                 | 20 (11.6)                | 92 (10.4)                             |
| Palmar-plantar erythrodysaesthesia syndrome | 4 (1.1)                  | 24 (14.0)                | 11 (1.2)                              |

BC = breast cancer; ILD = interstitial lung disease; MedDRA = Medical Dictionary for Regulatory Activities, Version 24.0; N = total number of treated subjects; PT = preferred term; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

If a subject had multiple occurrences of the same PT/grouped term, the subject was counted once for that PT/grouped term.  If a subject had multiple PTs/grouped terms, the subject was counted in each of the different PTs/grouped terms.

If relationship was missing, the event was considered to be related to the drug.

TEAEs are sorted by descending frequency in the T-DXd arm.

a The PTs included in each grouped term are listed in 2.1.

b Interstitial lung disease includes events that were adjudicated as ILD and related to use of T-DXd or TPC.

Source:  Module 5.3.5.3 SCS Tables 1.2.1.4, 1.2.2.2, 1.2.4.1

Table 55:  Treatment-emergent Adverse Events of CTCAE Grade 3 or Higher Reported in ≥5% of Subjects in Either Treatment Arm in Study U303, by Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRA Preferred Term/ Grouped Term a   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|-----------------------------------------|--------------------------|--------------------------|---------------------------------------|
| MedDRA Preferred Term/ Grouped Term a   | T-DXd (N = 371)          | TPC (N = 272)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Subjects with any TEAE ≥Grade 3 b       | 195 (52.6)               | 116 (67.4)               | 479 (54.2)                            |
| Neutropenia a                           | 52 (14.0)                | 71 (41.3)                | 152 (17.2)                            |
| Anemia a                                | 38 (10.2)                | 9 (5.2)                  | 81 (9.2)                              |
| Fatigue a                               | 32 (8.6)                 | 8 (4.7)                  | 68 (7.7)                              |
| Leukopenia a                            | 25 (6.7)                 | 33 (19.2)                | 59 (6.7)                              |
| Thrombocytopenia a                      | 22 (5.9)                 | 1 (0.6)                  | 53 (6.0)                              |
| Transaminases increased a               | 21 (5.7)                 | 17 (9.9)                 | 37 (4.2)                              |
| Lymphopenia a                           | 20 (5.4)                 | 6 (3.5)                  | 44 (5.0)                              |

BC = breast cancer; CTCAE = Common Terminology Criteria for Adverse Events, Version 5.0; MedDRA = Medical Dictionary for Regulatory Activities, Version 24.0; N = total number of treated subjects; PT = preferred term; T-DXd = trastuzumab deruxtecan; TEAE = treatmentemergent adverse event; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

If a subject had multiple occurrences of the same PT/grouped term, the subject was counted once for that PT/grouped term.  If a subject had multiple PTs/grouped terms, the subject was counted in each of the different PTs/grouped terms.

TEAEs are sorted by descending frequency in the T-DXd arm.

a The PTs included in each grouped term are listed in Table 2.1.

b For each PT/grouped term, a subject was counted once at the maximum severity.

Source:  Module 5.3.5.3 SCS Tables 1.2.1.5, 1.2.2.1

<div style=\"page-break-after: always\"></div>

Table 56

Table 10.7: Drug-related Treatment-emergent Adverse Events of CTCAE ≥Grade 3 Reported in ≥2% of Subjects in Either Treatment Arm, by Preferred Term or Grouped Term (Safety Analysis Set)

| MedDRA Preferred Term or Grouped Term a   | Number (%) of Subjects   | Number (%) of Subjects   |
|-------------------------------------------|--------------------------|--------------------------|
| MedDRA Preferred Term or Grouped Term a   | T-DXd (N = 371)          | TPC (N =172)             |
| Any drug-related TEAE ≥Grade 3            | 154 (41.5)               | 99 (57.6)                |
| Neutropenia a                             | 51 (13.7)                | 70 (40.7)                |
| Anemia a                                  | 30 (8.1)                 | 8 (4.7)                  |
| Fatigue a                                 | 28 (7.5)                 | 8 (4.7)                  |
| Leukopenia a                              | 24 (6.5)                 | 33 (19.2)                |
| Thrombocytopenia a                        | 19 (5.1)                 | 1 (0.6)                  |
| Nausea                                    | 17 (4.6)                 | 0                        |
| Lymphopenia a                             | 16 (4.3)                 | 6 (3.5)                  |
| Transaminases increased a                 | 12 (3.2)                 | 14 (8.1)                 |
| Decreased appetite                        | 9 (2.4)                  | 2 (1.2)                  |
| Interstitial lung disease b               | 8 (2.2)                  | 0                        |

| MedDRA Preferred Term or Grouped Term a     | Number (%) of Subjects   | Number (%) of Subjects   |
|---------------------------------------------|--------------------------|--------------------------|
|                                             | T-DXd (N =371)           | TPC (N = 172)            |
| Febrile neutropenia                         | 1 (0.3)                  | 5 (2.9)                  |
| Palmar-plantar erythrodysaesthesia syndrome | 0                        | 7 (4.1)                  |
| Neuropathy peripheral                       | 0                        | 4 (2.3)                  |

CTCAE = Common Terminology Criteria for Adverse Events v5.0; MedDRA = MedicalDictionary for Regulatory Activities v24.0; T-DXd =tra stuzumab deruxtecan; TEAE =treatment-emergent adverse event; TPC =trea tment of physician's choice

Percentages were calculatedusing the numberof subjects in the Safety Analysis Set as the denominator.

a The preferred terms included in each of the grouped terms in this table are listed in Table 6.5. b Interstitial lung disea se includes events that were a djudicated as ILD and related to use of T-DXd or TPC.

If the rela tionship wa s missing, the TEAE was consideredto be relatedto the drug.

Data cut-off: 11 Jan 2022

Source: Tables 14.3.1.6.3,14.3.1.7.7,14.3.1.8.1

## Adverse events of special interest

Table 57: Selected Preferred Terms in Adverse Events of Special Interest in Study U303

| Category                     | Selected Preferred Terms for Review                                                                                                                                                                                               |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ILD/pneumonitis              | Events of ILD/pneumonitis from PTs triggering adjudication, based on the current study MedDRA version for the narrow ILD SMQ, selected terms from the broad ILD SMQ, and PTs of respiratory failure and acute respiratory failure |
| Left ventricular dysfunction | Acute left ventricular failure Acute right ventricular failure Cardiac failure Cardiac failure acute Cardiac failure chronic Cardiac failure congestive Chronic left ventricular failure Chronic right ventricular failure        |

<div style=\"page-break-after: always\"></div>

| Category   | Selected Preferred Terms for Review                                                                                             |
|------------|---------------------------------------------------------------------------------------------------------------------------------|
|            | Ejection fraction decreased Left ventricular dysfunction Left ventricular failure Right ventricular failure Ventricular failure |

ILD = interstitial lung disease; MedDRA = Medical Dictionary for Regulatory Activities, Version 24.0; PT = preferred term; SMQ = Standardised MedDRA Query

## ILD/pneumonitis

Table 58: ILD Events by Adjudicated Outcome and Adjudicated Grade in Study U303 (Safety Analysis Set)

| Adjudicated Outcome / CTCAE Grade Reported by Adjudication Committee a     | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|----------------------------------------------------------------------------|--------------------------|--------------------------|---------------------------------------|
| Adjudicated Outcome / CTCAE Grade Reported by Adjudication Committee a     | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Subjects with any event of potential ILD (ie, event sent for adjudication) | 56 (15.1)                | 2 (1.2)                  | 147 (16.6)                            |
| Subjects with any event adjudicated as ILD                                 | 46 (12.4)                | 1 (0.6)                  | 117 (13.3)                            |
| Grade 1                                                                    | 13 (3.5)                 | 1 (0.6)                  | 28 (3.2)                              |
| Grade 2                                                                    | 25 (6.7)                 | 0                        | 67 (7.6)                              |
| Grade 3                                                                    | 5 (1.3)                  | 0                        | 9 (1.0)                               |
| Grade 4                                                                    | 0                        | 0                        | 1 (0.1)                               |
| Grade 5                                                                    | 3 (0.8)                  | 0                        | 12 (1.4)                              |
| ≥Grade 3                                                                   | 8 (2.2)                  | 0                        | 22 (2.5)                              |
| Subjects with any event adjudicated as drug-related ILD                    | 45 (12.1)                | 1 (0.6)                  | 112 (12.7)                            |
| Grade 1                                                                    | 13 (3.5)                 | 1 (0.6)                  | 28 (3.2)                              |
| Grade 2                                                                    | 24 (6.5)                 | 0                        | 65 (7.4)                              |
| Grade 3                                                                    | 5 (1.3)                  | 0                        | 9 (1.0)                               |
| Grade 4                                                                    | 0                        | 0                        | 0                                     |
| Grade 5                                                                    | 3 (0.8)                  | 0                        | 10 (1.1)                              |
| ≥Grade 3                                                                   | 8 (2.2)                  | 0                        | 19 (2.2)                              |

AC = Adjudication Committee; BC = breast cancer; CTCAE = Common Terminology Criteria for Adverse Events, Version 5.0; ILD = interstitial lung disease; N = total number of treated subjects; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event;

TPC = treatment of physician's choice

Table includes all events that were submitted to the ILD AC.

If a subject had multiple ILD events, the CTCAE grade is shown for the event with the worst grade.

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

a The ILD AC assigned grades to those events that were determined to be ILD.

Source:  Module 5.3.5.3 SCS Table 1.2.5.1

Table 59: Overview of Adjudicated Drug-related ILD Events (Safety Analysis Set)

| Adjudicated Outcome / CTCAE Grade Reported by Adjudication Committee   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|------------------------------------------------------------------------|--------------------------|--------------------------|---------------------------------------|
| Adjudicated Outcome / CTCAE Grade Reported by Adjudication Committee   | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Subjects with any event adjudicated as drug-related ILD                | 45 (12.1)                | 1 (0.6)                  | 112 (12.7)                            |
| ILD CTCAE ≥Grade 3 a                                                   | 8 (2.2)                  | 0                        | 19 (2.2)                              |

<div style=\"page-break-after: always\"></div>

| Adjudicated Outcome / CTCAE Grade Reported by Adjudication Committee   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|------------------------------------------------------------------------|--------------------------|--------------------------|---------------------------------------|
| Adjudicated Outcome / CTCAE Grade Reported by Adjudication Committee   | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Serious ILD                                                            | 16 (4.3)                 | 1 (0.6)                  | 36 (4.1)                              |
| ILD associated with study drug discontinuation b                       | 31 (8.4)                 | 0                        | 78 (8.8)                              |
| ILD associated with dose reduction b                                   | 2 (0.5)                  | 0                        | 8 (0.9)                               |
| ILD associated with study drug interruption b                          | 11 (3.0)                 | 0                        | 26 (2.9)                              |
| ILD associated with an outcome of death c                              | 3 (0.8)                  | 0                        | 10 (1.1)                              |

AC = Adjudication Committee; BC = breast cancer; CTCAE = Common Terminology Criteria for Adverse Events, Version 5.0; ILD = interstitial lung disease; N = total number of treated subjects; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

a The ILD AC assigned grades to those events that were determined to be ILD.  A subject was counted once at the maximum severity.

b Based on investigator assessment

c Adjudicated drug-related ILD associated with death was derived based on adjudicated CTCAE Grade 5 events.

Source:  Module 5.3.5.3 SCS Tables 1.2.4.1, 1.2.4.2, 1.2.4.3, 1.2.4.4, 1.2.4.5, 1.2.4.6

Table 60: Outcome of Events Adjudicated as Drug-related ILD (Safety Analysis Set)

| Outcome of Event                                        | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|---------------------------------------------------------|--------------------------|--------------------------|---------------------------------------|
|                                                         | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Subjects with any event adjudicated as drug-related ILD | 45 (12.1)                | 1 (0.6)                  | 112 (12.7)                            |
| Recovered/resolved                                      | 25 (55.6)                | 0                        | 59 (52.7)                             |
| Not recovered/not resolved                              | 10 (22.2)                | 1 (100.0)                | 29 (25.9)                             |
| Ongoing                                                 | 0                        | 0                        | 1 (0.9)                               |
| Recovering/resolving                                    | 4 (8.9)                  | 0                        | 7 (6.3)                               |
| Recovered/resolved with sequelae                        | 2 (4.4)                  | 0                        | 5 (4.5)                               |
| Death a                                                 | 2 (4.4)                  | 0                        | 8 (7.1)                               |
| Missing/unknown                                         | 2 (4.4)                  | 0                        | 3 (2.7)                               |

BC = breast cancer; ILD = interstitial lung disease; N = total number of treated subjects; T-DXd = trastuzumab deruxtecan; TEAE = treatmentemergent adverse event; TPC = treatment of physician's choice

For the 3 subjects who had more than 1 event of adjudicated drug-related ILD, the worst-grade event is included.

Percentage for adjudicated drug-related ILD (first row of results) was calculated using the number of subjects in the Safety Analysis Set as the denominator.

Percentage for each outcome was calculated using the number of subjects with adjudicated drug-related ILD as the denominator.

a Based on investigator assessment.  One of the 3 events adjudicated as Grade 5 ILD is not included in ILD associated with an outcome of death as assessed by the investigator.  One subject who experienced an investigator-assessed Grade 3 ILD event died due to disease progression (&gt;47 days after last study drug administration); the ILD Adjudication Committee adjudicated the event as Grade 5.

Source:  Module 5.3.5.3 SCS Table 1.2.5.4, Module 5.3.5.1 DS8201-A-U303 CSR Table 10.25

## LVEF decrease/Left ventricular dysfunction

Table 61: Summary of LVEF Values, Based on ECHO/MUGA Scan Data (Safety Analysis Set)

| Parameter                                                 | Number (%) of Subjects                                    | Number (%) of Subjects                                    | Number (%) of Subjects                                    |
|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
|                                                           | T-DXd (N = 371)                                           | TPC (N = 172)                                             | All BC T-DXd 5.4 mg/kg Pool (N = 883)                     |
| Subjects with worst LVEF CTCAE grade post-baseline, n (%) | Subjects with worst LVEF CTCAE grade post-baseline, n (%) | Subjects with worst LVEF CTCAE grade post-baseline, n (%) | Subjects with worst LVEF CTCAE grade post-baseline, n (%) |
| Non-missing n a                                           | 335                                                       | 142                                                       | 827                                                       |
| Grade 2                                                   | 50 (14.9)                                                 | 11 (7.7)                                                  | 131 (15.8)                                                |

<div style=\"page-break-after: always\"></div>

| Parameter                                                 | Number (%) of Subjects                                    | Number (%) of Subjects   | Number (%) of Subjects                |
|-----------------------------------------------------------|-----------------------------------------------------------|--------------------------|---------------------------------------|
| Parameter                                                 | T-DXd (N = 371)                                           | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Subjects with LVEF measurement after worst grade          | 36                                                        | 5                        | 100                                   |
| Recovered from worst grade to ≥90% of baseline, b n (%) c | 26 (72.2)                                                 | 3 (60.0)                 | 78 (78.0)                             |
| Grade 3                                                   | 5 (1.5)                                                   | 0                        | 7 (0.8)                               |
| Subjects with LVEF measurement after worst grade          | 4                                                         | 0                        | 6                                     |
| Recovered from worst grade to ≥90% of baseline, b n (%) c | 3 (75.0)                                                  | 0                        | 5 (83.3)                              |
| LVEF measurements at baseline                             |                                                           |                          |                                       |
| n                                                         | 370                                                       | 171                      | 882                                   |
| Mean (Std Dev)                                            | 64.1 (6.10)                                               | 63.8 (6.12)              | 64.2 (6.31)                           |
| Median                                                    | 64.0                                                      | 64.0                     | 64.0                                  |
| Minimum, Maximum                                          | 50, 83                                                    | 50, 87                   | 50, 86                                |
| 40% to 49%                                                | 0                                                         | 0                        | 0                                     |
| 20% to 39%                                                | 0                                                         | 0                        | 0                                     |
| <20%                                                      | 0                                                         | 0                        | 0                                     |
| Lowest LVEF measurement post-baseline                     |                                                           |                          |                                       |
| n                                                         | 335                                                       | 142                      | 827                                   |
| Mean (Std Dev)                                            | 60.4 (6.29)                                               | 62.6 (6.23)              | 60.3 (5.87)                           |
| Median                                                    | 61.0                                                      | 63.0                     | 60.0                                  |
| Minimum, Maximum                                          | 37, 79                                                    | 42, 79                   | 37, 79                                |
| 40% to 49%                                                | 13 (3.5)                                                  | 2 (1.2)                  | 23 (2.6)                              |
| 20% to 39%                                                | 2 (0.5)                                                   | 0                        | 2 (0.2)                               |
| <20%                                                      | 0                                                         | 0                        | 0                                     |
| Change from baseline to lowest post-baseline measurement  |                                                           |                          |                                       |
| n                                                         | 335                                                       | 142                      | 827                                   |
| Mean (Std Dev)                                            | -3.9 (5.70)                                               | -1.6 (5.32)              | -3.9 (5.35)                           |
| Median                                                    | -3.0                                                      | -1.0                     | -3.0                                  |
| Minimum, Maximum                                          | -36, 13                                                   | -17, 14                  | -36, 13                               |
| 10% to 19% decrease in absolute value                     | 44 (11.9)                                                 | 10 (5.8)                 | 120 (13.6)                            |
| ≥20% decrease in absolute value                           | 4 (1.1)                                                   | 0                        | 6 (0.7)                               |
| Highest LVEF measurement post-baseline                    |                                                           |                          |                                       |
| n                                                         | 335                                                       | 142                      | 827                                   |
| Mean (Std Dev)                                            | 65.8 (6.93)                                               | 64.6 (5.97)              | 67.0 (6.60)                           |
| Median                                                    | 66.0                                                      | 65.0                     | 67.0                                  |
| Minimum, Maximum                                          | 43, 90                                                    | 46, 80                   | 43, 90                                |
| Change from baseline to highest post-baseline measurement | Change from baseline to highest post-baseline measurement |                          |                                       |
| n                                                         | 335                                                       | 142                      | 827                                   |

<div style=\"page-break-after: always\"></div>

| Parameter                             | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|---------------------------------------|--------------------------|--------------------------|---------------------------------------|
|                                       | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Mean (Std Dev)                        | 1.5 (5.65)               | 0.4 (5.15)               | 2.7 (5.78)                            |
| Median                                | 1.0                      | 0                        | 2.0                                   |
| Minimum, Maximum                      | -20, 21                  | -17, 14                  | -20, 22                               |
| 10% to 19% increase in absolute value | 23 (6.2)                 | 7 (4.1)                  | 97 (11.0)                             |
| ≥20% increase in absolute value       | 1 (0.3)                  | 0                        | 3 (0.3)                               |

BC = breast cancer; CTCAE = Common Terminology Criteria for Adverse Events, Version 5.0; ECHO = echocardiogram; LVEF = left ventricular ejection fraction; MUGA = multigated acquisition; N = total number of subjects treated; Std Dev = standard deviation; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

Per CTCAE, LVEF decrease was defined as follows:  Grade 2 = resting LVEF ≥ 40% to &lt;50% or a 10% to &lt;20% decrease from baseline; Grade 3 = resting LVEF ≥20% to &lt;40% or a ≥20 % decrease from baseline; Grade 4 = resting LVEF &lt;20%.

a Non-missing n was the number of subjects with both baseline and post-baseline data.  Percentages were calculated using the non-missing n as the denominator.

b ≥90% baseline since worst grade was defined as the highest postbaseline LVEF after the measurement with worst grade that was ≥90% of the baseline LVEF value.

c Percentages were calculated using the number of subjects having worst post-baseline LVEF at the specific grade.  If there was no LVEF measurement after the worst grade of LVEF, the subject was not included in the denominator.

Source:  Module 5.3.5.3 SCS Table 1.2.6.8

## Serious adverse event/deaths/other significant events

Table 62:  Serious Treatment-emergent Adverse Events Reported in ≥1% of Subjects in Either Treatment Arm in Study U303, by Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRA Preferred Term/Grouped Term a   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|----------------------------------------|--------------------------|--------------------------|---------------------------------------|
| MedDRA Preferred Term/Grouped Term a   | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Any subject with a serious TEAE        | 103 (27.8)               | 43 (25.0)                | 222 (25.1)                            |
| Interstitial lung disease b,c          | 16 (4.3)                 | 1 (0.6)                  | 36 (4.1)                              |
| Pneumonia c                            | 7 (1.9)                  | 1 (0.6)                  | 17 (1.9)                              |
| Dyspnoea                               | 5 (1.3)                  | 2 (1.2)                  | 7 (0.8)                               |
| Musculoskeletal pain a                 | 5 (1.3)                  | 0                        | 8 (0.9)                               |
| Sepsis                                 | 5 (1.3)                  | 0                        | 7 (0.8)                               |
| Febrile neutropenia                    | 4 (1.1)                  | 4 (2.3)                  | 8 (0.9)                               |
| Anemia a                               | 4 (1.1)                  | 1 (0.6)                  | 10 (1.1)                              |
| Hypercalcaemia                         | 4 (1.1)                  | 0                        | 4 (0.5)                               |
| Nausea                                 | 4 (1.1)                  | 0                        | 9 (1.0)                               |
| Pyrexia                                | 4 (1.1)                  | 0                        | 8 (0.9)                               |
| Vomiting                               | 4 (1.1)                  | 0                        | 13 (1.5)                              |
| Fatigue a                              | 3 (0.8)                  | 2 (1.2)                  | 4 (0.5)                               |
| Pleural effusion                       | 3 (0.8)                  | 2 (1.2)                  | 6 (0.7)                               |
| Neutropenia a                          | 2 (0.5)                  | 4 (2.3)                  | 3 (0.3)                               |
| Disease progression                    | 2 (0.5)                  | 2 (1.2)                  | 7 (0.8)                               |
| Hepatic failure                        | 1 (0.3)                  | 2 (1.2)                  | 1 (0.1)                               |
| Hyponatraemia                          | 1 (0.3)                  | 2 (1.2)                  | 1 (0.1)                               |
| Colitis                                | 0                        | 2 (1.2)                  | 1 (0.1)                               |
| Femur fracture                         | 0                        | 2 (1.2)                  | 1 (0.1)                               |

<div style=\"page-break-after: always\"></div>

| MedDRA Preferred Term/Grouped Term a   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|----------------------------------------|--------------------------|--------------------------|---------------------------------------|
|                                        | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Medication error                       | 0                        | 3 (1.7)                  | 0                                     |
| Overdose                               | 0                        | 5 (2.9) d                | 0                                     |

BC = breast cancer; ILD = interstitial lung disease; MedDRA = Medical Dictionary for Regulatory Activities, Version 24.0; N = total number of treated subjects; PT = preferred term; TEAE = treatment-emergent adverse event; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

If a subject had multiple occurrences of the same serious PT/grouped term, the subject was counted once for that serious PT/grouped term.  If a subject had multiple serious PTs/grouped terms, the subject was counted once for each of the different PTs/grouped terms.

TEAEs are sorted by descending frequency in the T-DXd arm.

a The PTs included in each grouped term are listed in Table 2.1.

b Interstitial lung disease includes events that were adjudicated as ILD and related to use of T-DXd or TPC.

c Includes 2 subjects in the T-DXd arm with a PT of pneumonia that was adjudicated as drug-related ILD.  These subjects are counted under both adjudicated drug-related ILD and pneumonia.

d For more information on subjects with a TEAE of overdose, refer to Section 5.5

Source:  Module 5.3.5.3 SCS Tables 1.2.1.8, 1.2.2.3, 1.2.4.2

## Deaths

Table 63: Primary Cause of Any Deaths and On-treatment Deaths (Safety Analysis Set)

| Primary Cause of Death   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|--------------------------|--------------------------|--------------------------|---------------------------------------|
|                          | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Any death                | 148 (39.9)               | 88 (51.2)                | 280 (31.7)                            |
| Disease progression      | 122 (32.9)               | 79 (45.9)                | 217 (24.6)                            |
| Adverse event            | 10 (2.7) a               | 0                        | 20 (2.3)                              |
| Other                    | 3 (0.8) b                | 3 (1.7) c                | 13 (1.5)                              |
| Unknown                  | 13 (3.5)                 | 6 (3.5)                  | 30 (3.4)                              |
| On-treatment death d     | 14 (3.8)                 | 8 (4.7)                  | 30 (3.4)                              |
| Disease progression      | 4 (1.1)                  | 7 (4.1)                  | 12 (1.4)                              |
| Adverse event            | 8 (2.2) a                | 0                        | 14 (1.6)                              |
| Other                    | 1 (0.3)                  | 1 (0.6)                  | 2 (0.2)                               |
| Unknown                  | 1 (0.3)                  | 0                        | 2 (0.2)                               |

BC = breast cancer; N = total number of treated subjects; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

a Adverse events with outcome of death in the T-DXd arm were pneumonitis for Subject Nos. xxxxxxxxxxxxxxxxxxxx (on-treatment death for the latter subject), respiratory failure for Subject No. xxxxxxxx (on-treatment death), general physical health deterioration for Subject No. xxxxxx, colitis ischaemic for Subject No. xxxxxxxx (on-treatment death), dyspnoea for Subject No. xxxxxxxx (on-treatment death), sepsis for Subject Nos. xxxxxxxxxxxxxxxxxxx (both were on-treatment deaths), disseminated intravascular coagulation for Subject No. xxxxxxxx(ontreatment death), and febrile neutropenia for Subject No. xxxxxxxx (on-treatment death).

b The investigator recorded a primary cause of death as 'Other: disease worsening under study' for Subject No. xxxxxxxx, 'Other: clinical progression' for Subject No. xxxxxxxx, and 'Other: cachexia due to cancer' for Subject No. xxxxxxxx (on-treatment death).

c The investigator recorded a primary cause of death as 'Other: respiratory arrest' for Subject No. xxxxxxxx, 'Other: respiratory failure due to pneumonitis, pulmonary embolus' for Subject No. xxxxxxxx, and 'Other: disease progression (liver dysfunction)' for Subject No. xxxxxxxx (on-treatment death).

d On-treatment death was defined as any death that occurred from the date of the first dose to 28 days after the last dose of study drug for Study J101 and to 47 days after the last dose of study drug for other studies in the All BC T-DXd 5.4 mg/kg Pool.

Source:  Module 5.3.5.3 SCS Table 1.2.7, Listings 1.1, 1.2

<div style=\"page-break-after: always\"></div>

Table 64: Treatment-emergent Adverse Events Associated with an Outcome of Death, by Preferred Term (Safety Analysis Set)

| MedDRA Preferred Term                                       | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|-------------------------------------------------------------|--------------------------|--------------------------|---------------------------------------|
| MedDRA Preferred Term                                       | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Any subject with a TEAE associated with an outcome of death | 14 (3.8)                 | 5 (2.9)                  | 32 (3.6)                              |
| Disease progression                                         | 2 (0.5)                  | 2 (1.2)                  | 7 (0.8)                               |
| Pneumonitis                                                 | 2 (0.5)                  | 0                        | 4 (0.5)                               |
| Sepsis                                                      | 2 (0.5)                  | 0                        | 2 (0.2)                               |
| Colitis ischaemic                                           | 1 (0.3)                  | 0                        | 1 (0.1)                               |
| Death                                                       | 1 (0.3)                  | 0                        | 1 (0.1)                               |
| Disseminated intravascular coagulation                      | 1 (0.3)                  | 0                        | 1 (0.1)                               |
| Dyspnoea                                                    | 1 (0.3)                  | 1 (0.6)                  | 1 (0.1)                               |
| Febrile neutropenia                                         | 1 (0.3)                  | 0                        | 1 (0.1)                               |
| General physical health deterioration                       | 1 (0.3)                  | 0                        | 2 (0.2)                               |
| Pleural effusion                                            | 1 (0.3)                  | 0                        | 1 (0.1)                               |
| Respiratory failure                                         | 1 (0.3)                  | 0                        | 4 (0.5)                               |
| Acute hepatic failure                                       | 0                        | 0                        | 1 (0.1)                               |
| Acute kidney injury                                         | 0                        | 0                        | 1 (0.1)                               |
| Acute respiratory failure                                   | 0                        | 0                        | 1 (0.1)                               |
| COVID-19                                                    | 0                        | 0                        | 1 (0.1)                               |
| Hepatic failure                                             | 0                        | 2 (1.2)                  | 0                                     |
| Lymphangitis                                                | 0                        | 0                        | 1 (0.1)                               |
| Pneumonia                                                   | 0                        | 0                        | 1 (0.1)                               |
| Shock haemorrhagic                                          | 0                        | 0                        | 1 (0.1)                               |
| Sudden death                                                | 0                        | 0                        | 1 (0.1)                               |

BC = breast cancer; MedDRA = Medical Dictionary for Regulatory Activities, Version 24.0; N = total number of treated subjects; PT = preferred term; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

A death could be associated with multiple preferred terms.

If a subject had multiple occurrences of the same PT, the subject was counted once for the specific PT.  If a subject had multiple PTs, the subject was counted in each of the different PTs.

TEAEs are sorted by descending frequency in the T-DXd arm.

Source:  Module 5.3.5.3 SCS Table 1.2.1.16

<div style=\"page-break-after: always\"></div>

## Laboratory findings

Table 65:  Laboratory Abnormality Adverse Drug Reactions in Study U303 (Safety Analysis Set)

| Laboratory Abnormality               | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects   |
|--------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                      | T-DXd (N = 371)          | T-DXd (N = 371)          | TPC (N = 172)            | TPC (N = 172)            |
|                                      | All Grades               | Grade 3 or 4             | All Grades               | Grade 3 or 4             |
| Hematology                           |                          |                          |                          |                          |
| White blood cell count decreased     | 255 (69.7)               | 33 (9.0)                 | 132 (78.1)               | 42 (24.9)                |
| Hemoglobin decreased                 | 234 (63.9)               | 28 (7.7)                 | 90 (53.3)                | 10 (5.9)                 |
| Neutrophil count decreased           | 233 (64.0)               | 52 (14.3)                | 123 (72.8)               | 64 (37.9)                |
| Lymphocyte count decreased           | 202 (55.5)               | 65 (17.9)                | 67 (39.6)                | 19 (11.2)                |
| Platelet count decreased             | 162 (44.3)               | 21 (5.7)                 | 36 (21.3)                | 1 (0.6)                  |
| Chemistry                            |                          |                          |                          |                          |
| Aspartate aminotransferase increased | 140 (38.4)               | 8 (2.2)                  | 64 (37.9)                | 7 (4.1)                  |
| Alanine aminotransferase increased   | 132 (36.2)               | 3 (0.8)                  | 65 (38.5)                | 7 (4.1)                  |
| Blood alkaline phosphatase increased | 123 (33.7)               | 1 (0.3)                  | 41 (24.3)                | 0                        |
| Blood potassium decreased            | 92 (25.2)                | 12 (3.3)                 | 28 (16.7)                | 2 (1.2)                  |
| Blood bilirubin increased            | 59 (16.2)                | 10 (2.7)                 | 25 (14.8)                | 1 (0.6)                  |
| Blood creatinine increased           | 53 (14.5)                | 4 (1.1)                  | 16 (9.5)                 | 1 (0.6)                  |

CTCAE = Common Terminology Criteria for Adverse Events, Version 5.0; N = total number of treated subjects; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects with both baseline and post-treatment measurements as the denominator, based on

CTCAE grade-derived laboratory abnormalities.

Baseline was defined as the last non-missing value recorded before the first dose of study drug.

Parameters are presented in descending order of incidence in the All Grades column of the T-DXd arm.

Source:  Module 5.3.5.3 ADR Table 10.20

Table 66: Hepatic Function Abnormalities (Safety Analysis Set)

| Hepatic Parameter                | Number (%) of Subjects           | Number (%) of Subjects           | Number (%) of Subjects                |
|----------------------------------|----------------------------------|----------------------------------|---------------------------------------|
|                                  | Study U303                       | Study U303                       | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
|                                  | T-DXd (N = 371)                  | TPC (N = 172)                    | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Alanine aminotransferase (ALT)   |                                  |                                  |                                       |
| Non-missing n a                  | 365                              | 169                              | 875                                   |
| Baseline ≥ULN                    | 122 (33.4)                       | 59 (34.9)                        | 205 (23.4)                            |
| Maximum post-baseline value      |                                  |                                  |                                       |
| ≥3 × ULN                         | 43 (11.8)                        | 29 (17.2)                        | 75 (8.6)                              |
| ≥5 × ULN                         | 6 (1.6)                          | 12 (7.1)                         | 12 (1.4)                              |
| ≥8 × ULN                         | 2 (0.5)                          | 4 (2.4)                          | 3 (0.3)                               |
| ≥10 × ULN                        | 1 (0.3)                          | 3 (1.8)                          | 2 (0.2)                               |
| ≥20 × ULN                        | 0                                | 1 (0.6)                          | 0                                     |
| Aspartate aminotransferase (AST) | Aspartate aminotransferase (AST) | Aspartate aminotransferase (AST) | Aspartate aminotransferase (AST)      |

<div style=\"page-break-after: always\"></div>

| Hepatic Parameter                                    | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|------------------------------------------------------|--------------------------|--------------------------|---------------------------------------|
| Hepatic Parameter                                    | Study U303               | Study U303               | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Hepatic Parameter                                    | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Non-missing n a                                      | 365                      | 169                      | 875                                   |
| Baseline ≥ULN                                        | 199 (54.5)               | 81 (47.9)                | 366 (41.8)                            |
| Maximum post-baseline value                          |                          |                          |                                       |
| ≥3 × ULN                                             | 72 (19.7)                | 40 (23.7)                | 107 (12.2)                            |
| ≥5 × ULN                                             | 20 (5.5)                 | 17 (10.1)                | 31 (3.5)                              |
| ≥8 × ULN                                             | 8 (2.2)                  | 6 (3.6)                  | 11 (1.3)                              |
| ≥10 × ULN                                            | 5 (1.4)                  | 4 (2.4)                  | 7 (0.8)                               |
| ≥20 × ULN                                            | 2 (0.5)                  | 0                        | 3 (0.3)                               |
| ALT or AST                                           |                          |                          |                                       |
| Non-missing n a                                      | 365                      | 169                      | 875                                   |
| Baseline ≥ULN                                        | 208 (57.0)               | 89 (52.7)                | 386 (44.1)                            |
| Maximum post-baseline value                          |                          |                          |                                       |
| ≥3 × ULN                                             | 85 (23.3)                | 51 (30.2)                | 138 (15.8)                            |
| ≥5 × ULN                                             | 24 (6.6)                 | 21 (12.4)                | 39 (4.5)                              |
| ≥8 × ULN                                             | 8 (2.2)                  | 7 (4.1)                  | 11 (1.3)                              |
| ≥10 × ULN                                            | 5 (1.4)                  | 6 (3.6)                  | 7 (0.8)                               |
| ≥20 × ULN                                            | 2 (0.5)                  | 1 (0.6)                  | 3 (0.3)                               |
| Total bilirubin (TBL)                                |                          |                          |                                       |
| Non-missing n a                                      | 365                      | 169                      | 877                                   |
| Baseline ≥ULN                                        | 14 (3.8)                 | 5 (3.0)                  | 25 (2.9)                              |
| Maximum post-baseline value                          |                          |                          |                                       |
| ≥1.5 × ULN                                           | 31 (8.5)                 | 7 (4.1)                  | 62 (7.1)                              |
| ≥2 × ULN                                             | 19 (5.2)                 | 6 (3.6)                  | 30 (3.4)                              |
| ≥3 × ULN                                             | 11 (3.0)                 | 1 (0.6)                  | 13 (1.5)                              |
| Alkaline phosphatase (ALP)                           |                          |                          |                                       |
| Non-missing n a                                      | 365                      | 169                      | 877                                   |
| Baseline ≥ULN                                        | 152 (41.6)               | 64 (37.9)                | 291 (33.2)                            |
| Maximum post-baseline value                          |                          |                          |                                       |
| ≥1.5 × ULN                                           | 170 (46.6)               | 62 (36.7)                | 362 (41.3)                            |
| ≥2 × ULN                                             | 120 (32.9)               | 42 (24.9)                | 219 (25.0)                            |
| Concurrent TBL elevation with ALT or AST elevation b |                          |                          |                                       |
| Non-missing n a                                      | 365                      | 169                      | 875                                   |

<div style=\"page-break-after: always\"></div>

| Hepatic Parameter                                                     | Number (%) of Subjects                                                | Number (%) of Subjects                                                | Number (%) of Subjects                                                |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                       | Study U303                                                            | Study U303                                                            | All BC T-DXd 5.4 mg/kg Pool (N = 883)                                 |
|                                                                       | T-DXd (N = 371)                                                       | TPC (N = 172)                                                         |                                                                       |
| ALT or AST ≥3 × ULN and TBL ≥2 × ULN                                  | 13 (3.6)                                                              | 5 (3.0)                                                               | 17 (1.9)                                                              |
| Concurrent TBL elevation with ALT or AST elevation and ALP <2 × ULN b | Concurrent TBL elevation with ALT or AST elevation and ALP <2 × ULN b | Concurrent TBL elevation with ALT or AST elevation and ALP <2 × ULN b | Concurrent TBL elevation with ALT or AST elevation and ALP <2 × ULN b |
| Non-missing n a                                                       | 365                                                                   | 169                                                                   | 875                                                                   |
| ALT or AST ≥3 × ULN and TBL ≥2 × ULN and ALP <2 × ULN                 | 5 (1.4)                                                               | 2 (1.2)                                                               | 9 (1.0)                                                               |

BC = breast cancer; N = total number of treated subjects; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice; ULN = upper limit of normal Percentages were calculated using the non-missing n as the denominator.

Each subject was counted for only the worst case observed post-baseline.

a Non-missing n is the number of subjects with both baseline and post-baseline data.

b Concurrent was defined as abnormalities that occurred within a 28-day window.

Source:  Module 5.3.5.3 SCS Table 1.3.1.3

## Safety in special populations

## Intrinsic factors

Table 67: Overall Summary of Treatment-emergent Adverse Events, by Age Group (Safety Analysis Set)

| Parameter                                        | Age Group <65 years            | Age Group <65 years            | Age Group <65 years                   | Age Group ≥65 years            | Age Group ≥65 years            | Age Group ≥65 years                   |
|--------------------------------------------------|--------------------------------|--------------------------------|---------------------------------------|--------------------------------|--------------------------------|---------------------------------------|
| Parameter                                        | T-DXd (N = 289)                | TPC (N = 126)                  | All BC T-DXd 5.4 mg/kg Pool (N = 686) | T-DXd (N = 82)                 | TPC (N = 46)                   | All BC T-DXd 5.4 mg/kg Pool (N = 197) |
| Duration of treatment (months)                   | Duration of treatment (months) | Duration of treatment (months) | Duration of treatment (months)        | Duration of treatment (months) | Duration of treatment (months) | Duration of treatment (months)        |
| Median                                           | 8.25                           | 3.12                           | 10.00                                 | 6.98                           | 4.14                           | 9.43                                  |
| Minimum, Maximum                                 | 0.2, 28.1                      | 0.3, 17.6                      | 0.2, 37.1                             | 0.6, 33.3                      | 0.4, 15.8                      | 0.6, 33.3                             |
| Subjects with any TEAE                           | 287 (99.3)                     | 123 (97.6)                     | 681 (99.3)                            | 82 (100.0)                     | 46 (100.0)                     | 197 (100.0)                           |
| TEAEs with worst CTCAE ≥Grade 3 a                | 143 (49.5)                     | 83 (65.9)                      | 352 (51.3)                            | 52 (63.4)                      | 33 (71.7)                      | 127 (64.5)                            |
| Serious TEAEs                                    | 74 (25.6)                      | 31 (24.6)                      | 155 (22.6)                            | 29 (35.4)                      | 12 (26.1)                      | 67 (34.0)                             |
| TEAEs associated with study drug discontinuation | 40 (13.8)                      | 12 (9.5)                       | 99 (14.4)                             | 20 (24.4)                      | 2 (4.3)                        | 44 (22.3)                             |
| TEAEs associated with dose reduction             | 60 (20.8)                      | 45 (35.7)                      | 145 (21.1)                            | 24 (29.3)                      | 21 (45.7)                      | 50 (25.4)                             |
| TEAEs associated with study drug interruption    | 106 (36.7)                     | 48 (38.1)                      | 274 (39.9)                            | 37 (45.1)                      | 24 (52.2)                      | 95 (48.2)                             |
| TEAEs associated with an outcome of death b      | 12 (4.2)                       | 3 (2.4)                        | 23 (3.4)                              | 2 (2.4)                        | 2 (4.3)                        | 9 (4.6)                               |
| Subjects with any drug-related TEAE c            | 278 (96.2)                     | 118 (93.7)                     | 669 (97.5)                            | 79 (96.3)                      | 44 (95.7)                      | 193 (98.0)                            |
| Drug-related TEAEs with worst CTCAE ≥Grade 3 a   | 115 (39.8)                     | 71 (56.3)                      | 295 (43.0)                            | 39 (47.6)                      | 28 (60.9)                      | 102 (51.8)                            |
| Drug-related serious TEAEs                       | 35 (12.1)                      | 14 (11.1)                      | 80 (11.7)                             | 13 (15.9)                      | 5 (10.9)                       | 32 (16.2)                             |

<div style=\"page-break-after: always\"></div>

| Parameter                                                     | Age Group <65 years   | Age Group <65 years   | Age Group <65 years                   | Age Group ≥65 years   | Age Group ≥65 years   | Age Group ≥65 years                   |
|---------------------------------------------------------------|-----------------------|-----------------------|---------------------------------------|-----------------------|-----------------------|---------------------------------------|
| Parameter                                                     | T-DXd (N = 289)       | TPC (N = 126)         | All BC T-DXd 5.4 mg/kg Pool (N = 686) | T-DXd (N = 82)        | TPC (N = 46)          | All BC T-DXd 5.4 mg/kg Pool (N = 197) |
| Drug-related TEAEs associated with study drug discontinuation | 36 (12.5)             | 10 (7.9)              | 91 (13.3)                             | 20 (24.4)             | 2 (4.3)               | 42 (21.3)                             |
| Drug-related TEAEs associated with dose reduction             | 57 (19.7)             | 45 (35.7)             | 140 (20.4)                            | 20 (24.4)             | 19 (41.3)             | 41 (20.8)                             |
| Drug-related TEAEs associated with study drug interruption    | 79 (27.3)             | 42 (33.3)             | 211 (30.8)                            | 27 (32.9)             | 20 (43.5)             | 75 (38.1)                             |
| Drug-related TEAEs associated with an outcome of death b      | 6 (2.1)               | 0                     | 9 (1.3)                               | 1 (1.2)               | 0                     | 2 (1.0)                               |

BC = breast cancer; CTCAE = Common Terminology Criteria for Adverse Events, Version 5.0; N = total number of treated subjects; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the category as the denominator. Age in years was calculated using the date of birth and the date of informed consent. a A subject was counted once at the maximum severity. b For specific TEAEs associated with an outcome of death, refer to Table 2.10. c If relationship was missing, the TEAE was considered to be related to the drug. Source:  Module 5.3.5.3 SCS Tables 1.4.2, 1.4.3

Table 68: Treatment-emergent Adverse Events with a 10-percentage-point Difference Between Age Categories in Either Treatment Arm in Study U303, by Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRA Preferred Term/Grouped Term a        | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects   |
|---------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| MedDRA Preferred Term/Grouped Term a        | T-DXd                    | T-DXd                    | TPC                      | TPC                      |
| MedDRA Preferred Term/Grouped Term a        | Age <65 years (N = 289)  | Age ≥65 years (N = 82)   | Age <65 years (N = 126)  | Age ≥65 years (N = 46)   |
| Subjects with any TEAE                      | 287 (99.3)               | 82 (100.0)               | 123 (97.6)               | 46 (100.0)               |
| Nausea                                      | 221 (76.5)               | 61 (74.4)                | 33 (26.2)                | 19 (41.3)                |
| Diarrhoea                                   | 76 (26.3)                | 24 (29.3)                | 24 (19.0)                | 14 (30.4)                |
| Headache a                                  | 50 (17.3)                | 5 (6.1)                  | 8 (6.3)                  | 3 (6.5)                  |
| Palmar-plantar erythrodysaesthesia syndrome | 5 (1.7)                  | 0                        | 13 (10.3)                | 11 (23.9)                |

MedDRA = Medical Dictionary for Regulatory Activities, Version 24.0; N = total number of treated subjects; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the category as the denominator.

TEAEs are presented in descending order of incidence within the T-DXd age &lt;65 years column.

a The preferred terms included in each grouped term are listed in Table 2.1.

Source:  Module 5.3.5.1 DS8201-A-U303 CSR Table 10.10

<div style=\"page-break-after: always\"></div>

Table 69: Overall Summary of Treatment-emergent Adverse Events by Race (Safety Analysis Set)

| Parameter                                                     | White                       | White                       | White                               | Asian                       | Asian                       | Asian                                | Other                       | Other                       | Other                             |
|---------------------------------------------------------------|-----------------------------|-----------------------------|-------------------------------------|-----------------------------|-----------------------------|--------------------------------------|-----------------------------|-----------------------------|-----------------------------------|
| Parameter                                                     | T-DXd (N =175)              | TPC (N=85)                  | AIlBC T-DXd 5.4 mg/kg Pool (N =377) | T-DXd (N = 151)             | TPC (N = 69)                | AllBC T-DXd 5.4 mg/kg Pool (N = 404) | T-DXd (N = 45)              | TPC (N =17)                 | AIlBC T-DXd 5.4 mg/kg Pool (N=98) |
| Durationoftreatment(months)                                   | Durationoftreatment(months) | Durationoftreatment(months) | Durationoftreatment(months)         | Durationoftreatment(months) | Durationoftreatment(months) | Durationoftreatment(months)          | Durationoftreatment(months) | Durationoftreatment(months) | Durationoftreatment(months)       |
| Median                                                        | 8.21                        | 3.19                        | 9.63                                | 8.41                        | 3.52                        | 10.99                                | 6.21                        | 4.34                        | 9.64                              |
| Minimum, Maximum                                              | 0.2,28.1                    | 0.3,17.6                    | 0.2,31.7                            | 0.7,33.3                    | 0.5, 17.5                   | 0.7, 37.1                            | 0.6,22.0                    | 1.4, 10.3                   | 0.6,28.5                          |
| Subjects with any TEAE                                        | 173 (98.9)                  | 82 (96.5)                   | 374 (99.2)                          | 151 (100.0)                 | 69 (100.0)                  | 403 (99.8)                           | 45 (100.0)                  | 17 (100.0)                  | 97 (99.0)                         |
| TEAEs with worst CTCAE ≥Grade 3 a                             | 83 (47.4)                   | 53 (62.4)                   | 200 (53.1)                          | 90 (59.6)                   | 52 (75.4)                   | 226 (55.9)                           | 22 (48.9)                   | 11 (64.7)                   | 50 (51.0)                         |
| Serious TEAEs                                                 | 50 (28.6)                   | 21 (24.7)                   | 107 (28.4)                          | 41 (27.2)                   | 16 (23.2)                   | 90 (22.3)                            | 12 (26.7)                   | 6 (35.3)                    | 23 (23.5)                         |
| TEAEsassociatedwithstudy drug discontinuation                 | 30 (17.1)                   | 7 (8.2)                     | 55 (14.6)                           | 27 (17.9)                   | 4 (5.8)                     | 72 (17.8)                            | 3 (6.7)                     | 3 (17.6)                    | 16 (16.3)                         |
| TEAEs associatedwithdose reduction                            | 33 (18.9)                   | 27 (31.8)                   | 74 (19.6)                           | 42 (27.8)                   | 35 (50.7)                   | 99 (24.5)                            | 9 (20.0)                    | 4 (23.5)                    | 20 (20.4)                         |
| TEAEsassociatedwithstudy drug interruption                    | 62 (35.4)                   | 35 (41.2)                   | 145 (38.5)                          | 63 (41.7)                   | 30 (43.5)                   | 180 (44.6)                           | 18 (40.0)                   | 7 (41.2)                    | 41 (41.8)                         |
| TEAEs associated with an outcome of deathb                    | 10 (5.7)                    | 4 (4.7)                     | 24 (6.4)                            | 2 (1.3)                     | 1 (1.4)                     | 6 (1.5)                              | 2 (4.4)                     | 0                           | 2 (2.0)                           |
| Subjects with any drug-related TEAE c                         | 164 (93.7)                  | 77 (90.6)                   | 363 (96.3)                          | 150 (99.3)                  | 67 (97.1)                   | 400 (99.0)                           | 43 (95.6)                   | 17 (100.0)                  | 95 (96.9)                         |
| Drug-related TEAEs with worst CTCAE ≥Grade 3 a                | 61 (34.9)                   | 40 (47.1)                   | 155 (41.1)                          | 78 (51.7)                   | 49 (71.0)                   | 200 (49.5)                           | 15 (33.3)                   | 10 (58.8)                   | 40 (40.8)                         |
| Drug-related serious TEAEs                                    | 22 (12.6)                   | 7 (8.2)                     | 48 (12.7)                           | 22 (14.6)                   | 10 (14.5)                   | 50 (12.4)                            | 4 (8.9)                     | 2 (11.8)                    | 13 (13.3)                         |
| Drug-related TEAEs associated with study drug discontinuation | 27 (15.4)                   | 6 (7.1)                     | 49 (13.0)                           | 26 (17.2)                   | 4 (5.8)                     | 68 (16.8)                            | 3 (6.7)                     | 2 (11.8)                    | 16 (16.3)                         |

| Parameter                                                  | White           | White        | White                                | Asian          | Asian        | Asian                               | Other          | Other        | Other                               |
|------------------------------------------------------------|-----------------|--------------|--------------------------------------|----------------|--------------|-------------------------------------|----------------|--------------|-------------------------------------|
| Parameter                                                  | T-DXd (N = 175) | TPC (N = 85) | AllBC T-DXd 5.4 mg/kg Pool (N = 377) | T-DXd (N =151) | TPC (N = 69) | AIlBC T-DXd 5.4 mg/kg Pool (N =404) | T-DXd (N = 45) | TPC (N = 17) | AllBC T-DXd 5.4 mg/kg Pool (N = 98) |
| Drug-related TEAEs associatedwithdose reduction            | 28 (16.0)       | 26 (30.6)    | 62 (16.4)                            | 41 (27.2)      | 34 (49.3)    | 98 (24.3)                           | 8 (17.8)       | 4 (23.5)     | 19 (19.4)                           |
| Drug-related TEAEs associated with study drug interruption | 39 (22.3)       | 29 (34.1)    | 97 (25.7)                            | 53 (35.1)      | 27 (39.1)    | 152 (37.6)                          | 14 (31.1)      | 6 (35.3)     | 34 (34.7)                           |
| Drug-related TEAEs associatedwith anoutcome of deathb      | 7 (4.0)         | 0            | 10 (2.7)                             | 0              | 0            | 1 (0.2)                             | 0              | 0            | 0                                   |

Percentageswerecalculated usingthenumber ofsubjectsinthecategoryasthedenominator.

BC =breast cancer; CTCAE=Common Terminology Criteria for Adverse Events,Version 5.0; N=total number of treated subjects;T-DXd =trastuzumab deruxtecan;TEAE=treatment-emergent adverse event;TPC=treatment of physician'schoice

A subject was counted once at the maximum severity.

cIf relationshipwasmissing,theTEAEwas considered tobe related to the drug.

bFor specific TEAEs associated with outcome of death,refer toTable 2.10.

Source:Module 5.3.5.3 SCS Tables 1.4.2,1.4.3

<div style=\"page-break-after: always\"></div>

Table 70: Overall Summary of Treatment-emergent Adverse Events by ECOG Performance Status (Safety Analysis Set)

| Parameter                                                     | ECOGPerformanceStatus 0   | ECOGPerformanceStatus 0   | ECOGPerformanceStatus 0             | ECOGPerformanceStatus1   | ECOGPerformanceStatus1   | ECOGPerformanceStatus1              |
|---------------------------------------------------------------|---------------------------|---------------------------|-------------------------------------|--------------------------|--------------------------|-------------------------------------|
| Parameter                                                     | T-DXd (N =199)            | TPC (N = 95)              | AllBC T-DXd 5.4 mg/kg Pool (N =502) | T-DXd (N = 172)          | TPC (N = 77)             | AllBC T-DXd 5.4 mg/kg Pool (N =380) |
| Duration of treatment (months)                                |                           |                           |                                     |                          |                          |                                     |
| Median                                                        | 8.67                      | 3.48                      | 11.35                               | 6.90                     | 3.35                     | 8.36                                |
| Minimum, Maximum                                              | 0.4, 33.3                 | 0.3, 17.6                 | 0.4, 33.3                           | 0.2, 24.8                | 0.4, 17.4                | 0.2, 37.1                           |
| Subjects with any TEAE                                        | 197 (99.0)                | 92 (96.8)                 | 497 (99.0)                          | 172 (100.0)              | 77 (100.0)               | 380 (100.0)                         |
| TEAEs with worst CTCAE>Grade 3 a                              | 93 (46.7)                 | 58 (61.1)                 | 253 (50.4)                          | 102 (59.3)               | 58 (75.3)                | 225 (59.2)                          |
| Serious TEAEs                                                 | 37 (18.6)                 | 21 (22.1)                 | 96 (19.1)                           | 66 (38.4)                | 22 (28.6)                | 125 (32.9)                          |
| TEAEs associatedwithstudydrugdiscontinuation                  | 30 (15.1)                 | 8 (8.4)                   | 80 (15.9)                           | 30 (17.4)                | 6 (7.8)                  | 63 (16.6)                           |
| TEAEs associatedwithdosereduction                             | 37 (18.6)                 | 39 (41.1)                 | 92 (18.3)                           | 47 (27.3)                | 27 (35.1)                | 103 (27.1)                          |
| TEAEs associated with study drug interruption                 | 74 (37.2)                 | 39 (41.1)                 | 205 (40.8)                          | 69 (40.1)                | 33 (42.9)                | 164 (43.2)                          |
| TEAEs associatedwith an outcome of deathb                     | 3 (1.5)                   | 1 (1.1)                   | 10 (2.0)                            | 11 (6.4)                 | 4 (5.2)                  | 21 (5.5)                            |
| Subjects with any drug-related TEAE c                         | 194 (97.5)                | 86 (90.5)                 | 494 (98.4)                          | 163 (94.8)               | 76 (98.7)                | 367 (96.6)                          |
| Drug-related TEAEs withworst CTCAE>Grade3a                    | 78 (39.2)                 | 50 (52.6)                 | 219 (43.6)                          | 76 (44.2)                | 49 (63.6)                | 177 (46.6)                          |
| Drug-related serious TEAEs                                    | 20 (10.1)                 | 10 (10.5)                 | 56 (11.2)                           | 28 (16.3)                | 9 (11.7)                 | 56 (14.7)                           |
| Drug-related TEAEs associated with study drug discontinuation | 28 (14.1)                 | 8 (8.4)                   | 76 (15.1)                           | 28 (16.3)                | 4 (5.2)                  | 57 (15.0)                           |
| Drug-related TEAEs associatedwith dose reduction              | 36 (18.1)                 | 38 (40.0)                 | 88 (17.5)                           | 41 (23.8)                | 26 (33.8)                | 93 (24.5)                           |
| Drug-related TEAEs associated with study drug interruption    | 61 (30.7)                 | 36 (37.9)                 | 170 (33.9)                          | 45 (26.2)                | 26 (33.8)                | 116 (30.5)                          |
| Drug-related TEAEs associated with an outcome of death b      | 3 (1.5)                   | 0                         | 6 (1.2)                             | 4 (2.3)                  | 0                        | 5 (1.3)                             |

Percentageswerecalculatedusingthenumberofsubjectsinthecategoryasthedenominator.

BC =breast cancer; CTCAE = Common Terminology Criteria for Adverse Events,Version 5.0; ECOG=Eastern Cooperative Oncology Group; N= total number of treated subjects;T-DXd=trastuzumab deruxtecan;TEAE=treatment-emergent adverse event;TPC=treatment of physician'schoice

aA subject was counted once at themaximum severity.

cIf relationship was missing, the TEAE was considered to be related to the drug.

For specific TEAEs associated with an outcome of death, refer toTable 2.10.

Source: Module 5.3.5.3 SCS Tables 1.4.2,1.4.3

Table 71: Overall Summary of Treatment-emergent Adverse Events by Baseline Renal Function (Safety Analysis Set)

<div style=\"page-break-after: always\"></div>

| Parameter                                                     | Normal Renal Function       | Normal Renal Function       | Normal Renal Function                | Mild Renal Impairment       | Mild Renal Impairment       | Mild Renal Impairment               | ModerateRenalImpairment     | ModerateRenalImpairment     | ModerateRenalImpairment             |
|---------------------------------------------------------------|-----------------------------|-----------------------------|--------------------------------------|-----------------------------|-----------------------------|-------------------------------------|-----------------------------|-----------------------------|-------------------------------------|
| Parameter                                                     | T-DXd (N =201)              | TPC (N = 80)                | AIlBC T-DXd 5.4 mg/kg Pool (N = 456) | T-DXd (N =123)              | TPC (N = 65)                | AIlBC T-DXd 5.4 mg/kg Pool (N =319) | T-DXd (N = 41)              | TPC (N = 23)                | AllBC T-DXd 5.4 mg/kg Pool (N =101) |
| Durationoftreatment(months)                                   | Durationoftreatment(months) | Durationoftreatment(months) | Durationoftreatment(months)          | Durationoftreatment(months) | Durationoftreatment(months) | Durationoftreatment(months)         | Durationoftreatment(months) | Durationoftreatment(months) | Durationoftreatment(months)         |
| Median                                                        | 8.21                        | 3.42                        | 10.58                                | 7.59                        | 2.99                        | 9.89                                | 7.62                        | 4.63                        | 8.21                                |
| Minimum,Maximum                                               | 0.4, 33.3                   | 0.3, 17.5                   | 0.4, 33.3                            | 0.2, 25.5                   | 0.3, 17.6                   | 0.2,37.1                            | 0.7, 22.1                   | 0.4, 17.4                   | 0.7, 28.3                           |
| Subjects with any TEAE                                        | 200 (99.5)                  | 79 (98.8)                   | 453 (99.3)                           | 122 (99.2)                  | 63 (96.9)                   | 318 (99.7)                          | 41 (100.0)                  | 23 (100.0)                  | 100 (99.0)                          |
| TEAEs with worst CTCAE ≥Grade 3 a                             | 101 (50.2)                  | 53 (66.3)                   | 240 (52.6)                           | 63 (51.2)                   | 45 (69.2)                   | 176 (55.2)                          | 26 (63.4)                   | 16 (69.6)                   | 57 (56.4)                           |
| Serious TEAEs                                                 | 51 (25.4)                   | 19 (23.8)                   | 111 (24.3)                           | 36 (29.3)                   | 18 (27.7)                   | 76 (23.8)                           | 15 (36.6)                   | 6 (26.1)                    | 34 (33.7)                           |
| TEAEs associated with study drug discontinuation              | 26 (12.9)                   | 7 (8.8)                     | 64 (14.0)                            | 20 (16.3)                   | 5 (7.7)                     | 46 (14.4)                           | 12 (29.3)                   | 1 (4.3)                     | 30 (29.7)                           |
| TEAEsassociatedwith dose reduction                            | 41 (20.4)                   | 29 (36.3)                   | 97 (21.3)                            | 31 (25.2)                   | 23 (35.4)                   | 71 (22.3)                           | 9 (22.0)                    | 13 (56.5)                   | 24 (23.8)                           |
| TEAEsassociatedwithstudy drug interruption                    | 71 (35.3)                   | 33 (41.3)                   | 181 (39.7)                           | 50 (40.7)                   | 25 (38.5)                   | 139 (43.6)                          | 19 (46.3)                   | 14 (60.9)                   | 45 (44.6)                           |
| TEAEs associated with an outcome of deathb                    | 5 (2.5)                     | 2 (2.5)                     | 14 (3.1)                             | 5 (4.1)                     | 3 (4.6)                     | 12 (3.8)                            | 4 (9.8)                     | 0                           | 6 (5.9)                             |
| Subjects with any drug-related TEAE c                         | 194 (96.5)                  | 76 (95.0)                   | 445 (97.6)                           | 118 (95.9)                  | 60 (92.3)                   | 313 (98.1)                          | 39 (95.1)                   | 22 (95.7)                   | 97 (96.0)                           |
| Drug-related TEAEs with worst CTCAE ≥Grade 3a                 | 78 (38.8)                   | 43 (53.8)                   | 196 (43.0)                           | 52 (42.3)                   | 40 (61.5)                   | 148 (46.4)                          | 20 (48.8)                   | 14 (60.9)                   | 48 (47.5)                           |
| Drug-related serious TEAEs                                    | 25 (12.4)                   | 9 (11.3)                    | 63 (13.8)                            | 16 (13.0)                   | 7 (10.8)                    | 31 (9.7)                            | 7 (17.1)                    | 3 (13.0)                    | 18 (17.8)                           |
| Drug-related TEAEs associated with study drug discontinuation | 24 (11.9)                   | 6 (7.5)                     | 59 (12.9)                            | 18 (14.6)                   | 4 (6.2)                     | 43 (13.5)                           | 12 (29.3)                   | 1 (4.3)                     | 28 (27.7)                           |

| Parameter                                                  | Normal Renal Function   | Normal Renal Function   | Normal Renal Function                | Mild Renal Impairment   | Mild Renal Impairment   | Mild Renal Impairment               | Moderate Renal Impairment   | Moderate Renal Impairment   | Moderate Renal Impairment           |
|------------------------------------------------------------|-------------------------|-------------------------|--------------------------------------|-------------------------|-------------------------|-------------------------------------|-----------------------------|-----------------------------|-------------------------------------|
| Parameter                                                  | T-DXd (N=201)           | TPC (N =80)             | AllBC T-DXd 5.4 mg/kg Pool (N = 456) | T-DXd (N =123)          | TPC (N =65)             | AIlBC T-DXd 5.4 mg/kg Pool (N =319) | T-DXd (N = 41)              | TPC (N =23)                 | AllBC T-DXd 5.4 mg/kg Pool (N =101) |
| Drug-related TEAEs associated with dose reduction          | 39 (19.4)               | 29 (36.3)               | 93 (20.4)                            | 27 (22.0)               | 23 (35.4)               | 64 (20.1)                           | 8 (19.5)                    | 11 (47.8)                   | 21 (20.8)                           |
| Drug-related TEAEs associated with study drug interruption | 52 (25.9)               | 29 (36.3)               | 142 (31.1)                           | 39 (31.7)               | 23 (35.4)               | 106 (33.2)                          | 12 (29.3)                   | 10 (43.5)                   | 34 (33.7)                           |
| Drug-related TEAEs associatedwith an outcome of deathb     | 3 (1.5)                 | 0                       | 6 (1.3)                              | 2 (1.6)                 | 0                       | 2 (0.6)                             | 2 (4.9)                     | 0                           | 3 (3.0)                             |

BC =breast cancer; CTCAE =Common Terminology Criteria for Adverse Events,Version 5.0; N=total number of treated subjects; T-DXd = trastuzumab deruxtecan;TEAE=treatment-emergent adverse event;TPC=treatment of physician's choice Percentageswerecalculatedusingthenumberofsubjectsinthecategory asthedenominator.

aA subject was counted once at the maximum severity.

cIf relationshipwasmissing,theTEAEwas considered tobe related to the drug.

bFor specific TEAEs associated with an outcome of death,refer toTable 2.10.

Source:Module 5.3.5.3 SCS Tables 1.4.2,1.4.3

Table 72: Overall Summary of Treatment-emergent Adverse Events by Baseline Hepatic Function (Safety Analysis Set)

<div style=\"page-break-after: always\"></div>

| Parameter                                                     | Normal Hepatic Function   | Normal Hepatic Function   | Normal Hepatic Function              | Mild HepaticImpairment   | Mild HepaticImpairment   | Mild HepaticImpairment               |
|---------------------------------------------------------------|---------------------------|---------------------------|--------------------------------------|--------------------------|--------------------------|--------------------------------------|
|                                                               | T-DXd (N =170)            | TPC (N = 88)              | All BC T-DXd 5.4 mg/kg Pool (N =520) | T-DXd (N = 194)          | TPC (N =82)              | All BC T-DXd 5.4 mg/kg Pool (N =353) |
| Durationoftreatment(months)                                   |                           |                           |                                      |                          |                          |                                      |
| Median                                                        | 9.61                      | 4.11                      | 12.27                                | 6.85                     | 2.94                     | 8.21                                 |
| Minimum,Maximum                                               | 0.4, 33.3                 | 0.3, 17.5                 | 0.4, 37.1                            | 0.2, 25.5                | 0.3, 17.6                | 0.2,29.0                             |
| Subjects with any TEAE                                        | 168 (98.8)                | 88 (100.0)                | 515 (99.0)                           | 194 (100.0)              | 79 (96.3)                | 353 (100.0)                          |
| TEAEswithworst CTCAE>Grade 3a                                 | 86 (50.6)                 | 58 (65.9)                 | 274 (52.7)                           | 104 (53.6)               | 57 (69.5)                | 197 (55.8)                           |
| Serious TEAEs                                                 | 51 (30.0)                 | 17 (19.3)                 | 128 (24.6)                           | 49 (25.3)                | 26 (31.7)                | 90 (25.5)                            |
| TEAEsassociatedwithstudydrugdiscontinuation                   | 23 (13.5)                 | 9 (10.2)                  | 82 (15.8)                            | 36 (18.6)                | 5 (6.1)                  | 59 (16.7)                            |
| TEAEs associatedwithdosereduction                             | 40 (23.5)                 | 33 (37.5)                 | 117 (22.5)                           | 43 (22.2)                | 32 (39.0)                | 75 (21.2)                            |
| TEAEs associated with study drug interruption                 | 69 (40.6)                 | 42 (47.7)                 | 224 (43.1)                           | 70 (36.1)                | 30 (36.6)                | 140 (39.7)                           |
| TEAEs associated with an outcome of deathb                    | 4 (2.4)                   | 0                         | 15 (2.9)                             | 9 (4.6)                  | 5 (6.1)                  | 16 (4.5)                             |
| Subjects with any drug-related TEAE c                         | 164 (96.5)                | 86 (97.7)                 | 508 (97.7)                           | 187 (96.4)               | 74 (90.2)                | 345 (97.7)                           |
| Drug-related TEAEs with worst CTCAE>Grade 3 a                 | 67 (39.4)                 | 54 (61.4)                 | 227 (43.7)                           | 84 (43.3)                | 44 (53.7)                | 164 (46.5)                           |
| Drug-related serious TEAEs                                    | 24 (14.1)                 | 9 (10.2)                  | 66 (12.7)                            | 24 (12.4)                | 10 (12.2)                | 46 (13.0)                            |
| Drug-related TEAEs associated with study drug discontinuation | 22 (12.9)                 | 8 (9.1)                   | 76 (14.6)                            | 34 (17.5)                | 4 (4.9)                  | 56 (15.9)                            |
| Drug-related TEAEs associated with dose reduction             | 37 (21.8)                 | 31 (35.2)                 | 108 (20.8)                           | 39 (20.1)                | 32 (39.0)                | 70 (19.8)                            |
| Drug-related TEAEs associated with study drug interruption    | 51 (30.0)                 | 38 (43.2)                 | 170 (32.7)                           | 53 (27.3)                | 24 (29.3)                | 113 (32.0)                           |
| Drug-relatedTEAEs associatedwith an outcomeofdeathb           | 3 (1.8)                   | 0                         | 7 (1.3)                              | 4 (2.1)                  | 0                        | 4 (1.1)                              |

BC=breast cancer; CTCAE=Common Terminology Criteria for Adverse Events,Version 5.0;N=total number of treated subjects;T-DXd=trastuzumab deruxtecan;TEAE= treatment-emergent adverse event;TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the category as the denominator.

A subject was counted once at the maximum severity.

c If relationship was missing, the TEAE was considered to be related to the drug.

bFor specific TEAEs associated with an outcome of death, refer to Table 2.10.

Source:Module 5.3.5.3 SCS Tables 1.4.2,1.4.3

## Extrinsic factors

Table 73: Overall Summary of Treatment-emergent Adverse Events in Study U303 by Country (Safety Analysis Set)

<div style=\"page-break-after: always\"></div>

| Parameter                                                     | Japan          | Japan        | Japan                               | Non-Japan      | Non-Japan    | Non-Japan                            |
|---------------------------------------------------------------|----------------|--------------|-------------------------------------|----------------|--------------|--------------------------------------|
|                                                               | T-DXd (N = 56) | TPC (N = 29) | AllBCT-DXd 5.4 mg/kg Pool (N = 148) | T-DXd (N =315) | TPC (N =143) | AllBC T-DXd 5.4 mg/kg Pool (N = 735) |
| Duration of treatment(months)                                 |                |              |                                     |                |              |                                      |
| Median                                                        | 6.08           | 2.76         | 9.66                                | 8.25           | 3.52         | 9.99                                 |
| Minimum,Maximum                                               | 0.7, 33.3      | 0.5, 17.5    | 0.7, 37.1                           | 0.2, 28.1      | 0.3, 17.6    | 0.2, 31.7                            |
| Subjectswith any TEAE                                         | 56 (100.0)     | 29 (100.0)   | 148 (100.0)                         | 313 (99.4)     | 140 (97.9)   | 730 (99.3)                           |
| TEAEswithworst CTCAE>Grade3a                                  | 33 (58.9)      | 22 (75.9)    | 83 (56.1)                           | 162 (51.4)     | 94 (65.7)    | 396 (53.9)                           |
| Serious TEAEs                                                 | 10 (17.9)      | 5 (17.2)     | 26 (17.6)                           | 93 (29.5)      | 38 (26.6)    | 196 (26.7)                           |
| TEAEs associated with study drug discontinuation              | 16 (28.6)      | 2 (6.9)      | 41 (27.7)                           | 44 (14.0)      | 12 (8.4)     | 102 (13.9)                           |
| TEAEsassociatedwithdosereduction                              | 13 (23.2)      | 13 (44.8)    | 30 (20.3)                           | 71 (22.5)      | 53 (37.1)    | 165 (22.4)                           |
| TEAEsassociatedwithstudydruginterruption                      | 23 (41.1)      | 16 (55.2)    | 75 (50.7)                           | 120 (38.1)     | 56 (39.2)    | 294 (40.0)                           |
| TEAEs associated with an outcome of deathb                    | 0              | 1 (3.4)      | 1 (0.7)                             | 14 (4.4)       | 4 (2.8)      | 31 (4.2)                             |
| Subjects with any drug-related TEAE c                         | 55 (98.2)      | 29 (100.0)   | 147 (99.3)                          | 302 (95.9)     | 133 (93.0)   | 715 (97.3)                           |
| Drug-related TEAEs with worst CTCAE >Grade 3 a                | 30 (53.6)      | 21 (72.4)    | 77 (52.0)                           | 124 (39.4)     | 78 (54.5)    | 320 (43.5)                           |
| Drug-related serious TEAEs                                    | 6 (10.7)       | 3 (10.3)     | 16 (10.8)                           | 42 (13.3)      | 16 (11.2)    | 96 (13.1)                            |
| Drug-related TEAEs associated with study drug discontinuation | 16 (28.6)      | 2 (6.9)      | 39 (26.4)                           | 40 (12.7)      | 10 (7.0)     | 94 (12.8)                            |
| Drug-related TEAEs associated with dose reduction             | 12 (21.4)      | 13 (44.8)    | 29 (19.6)                           | 65 (20.6)      | 51 (35.7)    | 152 (20.7)                           |
| Drug-related TEAEs associated with study drug interruption    | 21 (37.5)      | 15 (51.7)    | 65 (43.9)                           | 85 (27.0)      | 47 (32.9)    | 221 (30.1)                           |
| Drug-related TEAEs associated with an outcome of death b      | 0              | 0            | 0                                   | 7 (2.2)        | 0            | 11 (1.5)                             |

BC =breast cancer; CTCAE= Common Terminology Criteria for Adverse Events,Version 5.0; N= total number of treated subjects; T-DXd = trastuzumab

deruxtecan;TEAE=treatment-emergentadverseevent;TPC=treatmentofphysician’schoice

Percentageswere calculated using thenumberof subjectsin theSafetyAnalysisSet as thedenominator.

aA subject was counted once at themaximum severity.

cIf relationship was missing, the TEAE was considered to be related to the drug.

bFor specificTEAEs associatedwithanoutcomeof death,refertoTable2.10

Source:Module 5.3.5.3 SCS Tables 1.4.2,1.4.3

Table 74: Overall Summary of Treatment-emergent Adverse Events by Geographic Region (Safety Analysis Set)

<div style=\"page-break-after: always\"></div>

| Parameter                                                  | Asia a                        | Asia a                        | Asia a                             | North Americab                | North Americab                | North Americab                     | Europe c                      | Europe c                      | Europe c                           | Rest of Worldd                | Rest of Worldd                | Rest of Worldd                      |
|------------------------------------------------------------|-------------------------------|-------------------------------|------------------------------------|-------------------------------|-------------------------------|------------------------------------|-------------------------------|-------------------------------|------------------------------------|-------------------------------|-------------------------------|-------------------------------------|
| Parameter                                                  | PXI-L (N = 147)               | TPC (N =63)                   | AIlBC T-DXd 5.4 mg/kg Pool (N=383) | T-DXd (N=58)                  | TPC (N =28)                   | AlBC T-DXd 5.4 mg/kg Pool (N =173) | PXI-L (N =154)                | TPC (N =73)                   | AllBC T-DXd 5.4 mg/kg Pool (N=274) | T-DXd (N =12)                 | TPC (N=8)                     | AllBC T-DXd 5.4 mg/kg Pool (N = 53) |
| Duration of treatment(months)                              | Duration of treatment(months) | Duration of treatment(months) | Duration of treatment(months)      | Duration of treatment(months) | Duration of treatment(months) | Duration of treatment(months)      | Duration of treatment(months) | Duration of treatment(months) | Duration of treatment(months)      | Duration of treatment(months) | Duration of treatment(months) | Duration of treatment(months)       |
| Median                                                     | 8.41                          | 3.52                          | 11.01                              | 6.96                          | 2.81                          | 8.57                               | 7.79                          | 3.35                          | 9.46                               | 8.44                          | 3.75                          | 14.45                               |
| Minimum,Maximum                                            | 0.7, 33.3                     | 0.5, 17.5                     | 0.7, 37.1                          | 0.7, 24.3                     | 0.4, 9.8                      | 0.7, 31.7                          | 0.2, 28.1                     | 0.3, 17.6                     | 0.2, 28.5                          | 0.7,20.9                      | 1.8,17.4                      | 0.7, 28.5                           |
| Subjects with any TEAE                                     | 147 (100.0)                   | 63 (100.0)                    | 382 (99.7)                         | 58 (100.0)                    | 27 (96.4)                     | 172 (99.4)                         | 152(98.7)                     | 71(97.3)                      | 271 (98.9)                         | 12 (100.0)                    | 8 (100.0)                     | 53 (100.0)                          |
| TEAEs with worst CTCAE ≥Grade 3 e                          | 87 (59.2)                     | 48 (76.2)                     | 217 (56.7)                         | 29 (50.0)                     | 20 (71.4)                     | 94 (54.3)                          | 73 (47.4)                     | 43(58.9)                      | 141 (51.5)                         | 6 (50.0)                      | 5 (62.5)                      | 27 (50.9)                           |
| SeriousTEAEs                                               | 38 (25.9)                     | 15 (23.8)                     | 83 (21.7)                          | 24 (41.4)                     | 6 (21.4)                      | 49 (28.3)                          | 36 (23.4)                     | 20(27.4)                      | 74 (27.0)                          | 5 (41.7)                      | 2 (25.0)                      | 16 (30.2)                           |
| TEAEs associated with study drug discontinuation           | 26 (17.7)                     | 4 (6.3)                       | 71 (18.5)                          | 8 (13.8)                      | 2 (7.1)                       | 22 (12.7)                          | 23 (14.9)                     | 8 (11.0)                      | 40 (14.6)                          | 3 (25.0)                      | 0                             | 10 (18.9)                           |
| TEAEs associated with dose reduction                       | 42 (28.6)                     | 30 (47.6)                     | 96 (25.1)                          | 7 (12.1)                      | 12 (42.9)                     | 33 (19.1)                          | 32 (20.8)                     | 21 (28.8)                     | 56 (20.4)                          | 3 (25.0)                      | 3 (37.5)                      | 10 (18.9)                           |
| TEAEs associated with study drug interruption              | 60 (40.8)                     | 28 (44.4)                     | 172 (44.9)                         | 23 (39.7)                     | 13 (46.4)                     | 65 (37.6)                          | 53 (34.4)                     | 27 (37.0)                     | 109 (39.8)                         | 7 (58.3)                      | 4 (50.0)                      | 23 (43.4)                           |
| TEAEs associated with an outcome of deathf                 | 2 (1.4)                       | 1 (1.6)                       | 5 (1.3)                            | 3 (5.2)                       | 0                             | 9 (5.2)                            | 8 (5.2)                       | 4 (5.5)                       | 15 (5.5)                           | 1 (8.3)                       | 0                             | 3 (5.7)                             |
| Subjects with any drug- related TEAE                       | 146 (99.3)                    | 63 (100.0)                    | 379 (99.0)                         | 57 (98.3)                     | 25 (89.3)                     | 170 (98.3)                         | 144 (93.5)                    | 66 (90.4)                     | 263 (96.0)                         | 10 (83.3)                     | 8 (100.0)                     | 50 (94.3)                           |
| Drug-related TEAEs with worst CTCAE ≥Grade3 e              | 77 (52.4)                     | 46 (73.0)                     | 193 (50.4)                         | 18 (31.0)                     | 14 (50.0)                     | 73 (42.2)                          | 55 (35.7)                     | 34 (46.6)                     | 112 (40.9)                         | 4 (33.3)                      | 5 (62.5)                      | 19 (35.8)                           |
| Drug-related serious TEAEs                                 | 21 (14.3)                     | 10 (15.9)                     | 47 (12.3)                          | 9 (15.5)                      | 0                             | 22 (12.7)                          | 17 (11.0)                     | 7 (9.6)                       | 39 (14.2)                          | 1 (8.3)                       | 2 (25.0)                      | 4 (7.5)                             |
| Drug-related TEAEs associatedwithstudy drugdiscontinuation | 25 (17.0)                     | 4 (6.3)                       | 67 (17.5)                          | 6 (10.3)                      | 1 (3.6)                       | 18 (10.4)                          | 22 (14.3)                     | 7 (9.6)                       | 38 (13.9)                          | 3 (25.0)                      | 0                             | 10 (18.9)                           |

| Parameter                                                  | Asia a          | Asia a      | Asia a                             | North Americab   | North Americab   | North Americab                      | Europec        | Europec     | Europec                             | Rest of Worldd   | Rest of Worldd   | Rest of Worldd                    |
|------------------------------------------------------------|-----------------|-------------|------------------------------------|------------------|------------------|-------------------------------------|----------------|-------------|-------------------------------------|------------------|------------------|-----------------------------------|
| Parameter                                                  | T-DXd (N = 147) | TPC (N =63) | AllBC T-DXd 5.4 mg/kg Pool (N=383) | T-DXd (N =58)    | TPC (N =28)      | AllBC T-DXd 5.4 mg/kg Pool (N =173) | T-DXd (N =154) | TPC (N =73) | AllBC T-DXd 5.4 mg/kg Pool (N =274) | T-DXd (N =12)    | TPC (N=8)        | AIlBC T-DXd 5.4 mg/kg Pool (N=53) |
| Drug-related TEAEs associated with dose reduction          | 41 (27.9)       | 30 (47.6)   | 95 (24.8)                          | 6 (10.3)         | 11 (39.3)        | 27 (15.6)                           | 27 (17.5)      | 20 (27.4)   | 49 (17.9)                           | 3 (25.0)         | 3 (37.5)         | 10 (18.9)                         |
| Drug-related TEAEs associated with study drug interruption | 51 (34.7)       | 25 (39.7)   | 147 (38.4)                         | 13 (22.4)        | 10 (35.7)        | 44 (25.4)                           | 38 (24.7)      | 23 (31.5)   | 80 (29.2)                           | 4 (33.3)         | 4 (50.0)         | 15 (28.3)                         |
| Drug-related TEAEs associated with an outcome of death f   | 0               | 0           | 0                                  | 2 (3.4)          | 0                | 4 (2.3)                             | 4 (2.6)        | 0           | 6 (2.2)                             | 1 (8.3)          | 0                | 1 (1.9)                           |

Percentageswerecalculated using thenumberofsubjectsin theSafetyAnalysisSet asthedenominator.

BC=breast cancer;CTCAE=Common Terminology Criteria forAdverse Events,Version 5.0;N= total number oftreated subjects;T-DXd= trastuzumab deruxtecan;TEAE=treatment-emergent adverseevent;TPC=treatment ofphysician'schoice

Asia included thefollowing countries:Japan,China,Republic ofKorea,Taiwan,and Hong Kong

For Study U303,Europe included the following countries:AustriaBelgium,France,Greece,Hungary,Italy,Portugal,Russia,Spain,Sweden,Switzerland,and United Kingdom;for the All BC T-DXd 5.4 mg/kgPool,Europe also included Netherlands.

bNorth America included the following countries:United States (n =55 T-DXd and 27 TPC) and Canada(n =3 T-DXd and1 TPC)

dFor Study U303,Rest of World included only Israel;for the All BCT-DXd5.4mg/kgPool,Rest of World includedAustralia,Brazil, andIsrael

fFor specific TEAEs associated with an outcome of death, refer toTable 2.10.

A subject was counted once at the maximum severity.

Ifrelationship was missing.the TEAE was considered to be related to the drug.

Source:Module5.3.5.3SCS Tab1es 1.4.2,1.4.3

## Safety related to drug-drug interactions and other interactions

No clinically meaningful changes in T-DXd or DXd steady state area under the plasma/serum concentration time curve from time 0 to 17 days (AUC0-17) days were observed after coadministration of itraconazole or ritonavir (study A104).

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

Table 75: Treatment-emergent Adverse Events Associated with Study Drug Discontinuation in at Least 2 Subjects in Either Treatment Arm of Study U303, by Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRA Preferred Term/ Grouped Term a                            | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|------------------------------------------------------------------|--------------------------|--------------------------|---------------------------------------|
| MedDRA Preferred Term/ Grouped Term a                            | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Any subject with TEAE associated with study drug discontinuation | 60 (16.2)                | 14 (8.1)                 | 143 (16.2)                            |
| Interstitial lung disease b                                      | 31 (8.4)                 | 0                        | 78 (8.8)                              |
| Left ventricular dysfunction c                                   | 3 (0.8)                  | 0                        | 4 (0.5)                               |
| Blood bilirubin increased a                                      | 2 (0.5)                  | 0                        | 2 (0.2)                               |
| Dyspnoea                                                         | 2 (0.5)                  | 0                        | 3 (0.3)                               |
| Pleural effusion                                                 | 2 (0.5)                  | 0                        | 3 (0.3)                               |
| Peripheral sensory neuropathy                                    | 0                        | 4 (2.3)                  | 0                                     |

AESI = adverse event of special interest; BC = breast cancer; ILD = interstitial lung disease; MedDRA = Medical Dictionary for Regulatory Activities, Version 24.0; N = total number of treated subjects; PT = preferred term; T-DXd = trastuzumab deruxtecan; TEAE = treatmentemergent adverse event; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

If a subject had multiple occurrences of the same PT/grouped term, the subject was counted once for that PT/grouped term.  If a subject had multiple PTs/grouped terms, the subject was counted in each of the different PTs/grouped terms.

a The PTs included in each grouped term are listed in Table 2.1.

b ILD includes events that were adjudicated as ILD and related to use of T-DXd or TPC.  Note that, per protocol, discontinuation was required for any subject with ≥Grade 2 ILD in the studies in the All BC T-DXd 5.4 mg/kg Pool except for Study J101 and Study U201, which used a different criterion for discontinuation due to ILD when the studies started:  prior to Study J101 protocol v11.0 (effective 25 Jan 2018) and prior to Study U201 v3.0 (effective 22 Jan 2018).

c The PTs included in the AESI of left ventricular dysfunction are listed in Table 2.22.

Source:  Module 5.3.5.3 SCS Tables 1.2.1.10, 1.2.2.4, 1.2.4.3, 1.2.6.3

Table 76: Treatment-emergent Adverse Events Associated with Dose Reduction Reported in ≥1% of Subjects in Either Treatment Arm in Study U303, by Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRA Preferred Term/Grouped Term a                 | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|------------------------------------------------------|--------------------------|--------------------------|---------------------------------------|
| MedDRA Preferred Term/Grouped Term a                 | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Any subject with TEAE associated with dose reduction | 84 (22.6)                | 66 (38.4)                | 195 (22.1)                            |
| Fatigue a                                            | 17 (4.6)                 | 8 (4.7)                  | 34 (3.9)                              |
| Nausea                                               | 17 (4.6)                 | 4 (2.3)                  | 43 (4.9)                              |
| Thrombocytopenia a                                   | 13 (3.5)                 | 0                        | 21 (2.4)                              |
| Neutropenia a                                        | 11 (3.0)                 | 24 (14.0)                | 28 (3.2)                              |
| Anemia a                                             | 7 (1.9)                  | 3 (1.7)                  | 9 (1.0)                               |
| Decreased appetite                                   | 7 (1.9)                  | 2 (1.2)                  | 11 (1.2)                              |
| Diarrhoea                                            | 5 (1.3)                  | 2 (1.2)                  | 9 (1.0)                               |
| Leukopenia a                                         | 3 (0.8)                  | 7 (4.1)                  | 5 (0.6)                               |
| Transaminases increased a                            | 3 (0.8)                  | 6 (3.5)                  | 7 (0.8)                               |
| Electrocardiogram QT prolonged                       | 2 (0.5)                  | 2 (1.2)                  | 3 (0.3)                               |
| Febrile neutropenia                                  | 1 (0.3)                  | 3 (1.7)                  | 4 (0.5)                               |

<div style=\"page-break-after: always\"></div>

| MedDRA Preferred Term/Grouped Term a        | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|---------------------------------------------|--------------------------|--------------------------|---------------------------------------|
|                                             | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Neuropathy peripheral                       | 0                        | 3 (1.7)                  | 2 (0.2)                               |
| Neurotoxicity                               | 0                        | 2 (1.2)                  | 0                                     |
| Overdose                                    | 0                        | 2 (1.2)                  | 0                                     |
| Palmar-plantar erythrodysaesthesia syndrome | 0                        | 9 (5.2)                  | 0                                     |
| Peripheral sensory neuropathy               | 0                        | 4 (2.3)                  | 1 (0.1)                               |

BC = breast cancer; MedDRA = Medical Dictionary for Regulatory Activities, Version 24.0; N = total number of treated subjects; PT = preferred term; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

If a subject had multiple occurrences of the same PT/grouped term, the subject was counted once for that PT/grouped term.  If a subject had multiple PTs/grouped terms, the subject was counted in each of the different PTs/grouped terms.

TEAEs are sorted by descending frequency in the T-DXd arm.

a The PTs included in each grouped term are listed in Table 2.1.

Source:  Module 5.3.5.3 SCS Tables 1.2.1.14, 1.2.2.5

Table 77:  Treatment-emergent Adverse Events Associated with Study Drug Interruption Reported in ≥1% of Subjects in Either Treatment Arm in Study U303, by Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRA Preferred Term/ Grouped Term a                         | Number (%) of Subjects   | Number (%) of Subjects   | Number (%) of Subjects                |
|---------------------------------------------------------------|--------------------------|--------------------------|---------------------------------------|
| MedDRA Preferred Term/ Grouped Term a                         | T-DXd (N = 371)          | TPC (N = 172)            | All BC T-DXd 5.4 mg/kg Pool (N = 883) |
| Any subject with TEAE associated with study drug interruption | 143 (38.5)               | 72 (41.9)                | 369 (41.8)                            |
| Neutropenia a                                                 | 34 (9.2)                 | 39 (22.7)                | 114 (12.9)                            |
| Fatigue a                                                     | 19 (5.1)                 | 4 (2.3)                  | 41 (4.6)                              |
| Anemia a                                                      | 17 (4.6)                 | 4 (2.3)                  | 35 (4.0)                              |
| Leukopenia a                                                  | 13 (3.5)                 | 10 (5.8)                 | 34 (3.9)                              |
| COVID-19 b                                                    | 11 (3.0)                 | 2 (1.2)                  | 18 (2.0)                              |
| Interstitial lung disease c                                   | 11 (3.0)                 | 0                        | 26 (2.9)                              |
| Transaminases increased a                                     | 11 (3.0)                 | 6 (3.5)                  | 16 (1.8)                              |
| Blood bilirubin increased a                                   | 8 (2.2)                  | 0                        | 15 (1.7)                              |
| Pneumonia                                                     | 7 (1.9)                  | 0                        | 18 (2.0)                              |
| Thrombocytopenia a                                            | 7 (1.9)                  | 2 (1.2)                  | 25 (2.8)                              |
| Left ventricular dysfunction d                                | 5 (1.3)                  | 0                        | 10 (1.1)                              |
| Nausea                                                        | 5 (1.3)                  | 4 (2.3)                  | 18 (2.0)                              |
| Pyrexia                                                       | 5 (1.3)                  | 1 (0.6)                  | 15 (1.7)                              |
| Upper respiratory tract infection a                           | 5 (1.3)                  | 0                        | 21 (2.4)                              |
| Decreased appetite                                            | 2 (0.5)                  | 3 (1.7)                  | 6 (0.7)                               |
| Diarrhoea                                                     | 2 (0.5)                  | 4 (2.3)                  | 6 (0.7)                               |
| Dyspnoea                                                      | 2 (0.5)                  | 2 (1.2)                  | 12 (1.4)                              |
| Abdominal pain a                                              | 1 (0.3)                  | 2 (1.2)                  | 4 (0.5)                               |
| Palmar-plantar erythrodysaesthesia syndrome                   | 0                        | 6 (3.5)                  | 0                                     |
| Peripheral sensory neuropathy                                 | 0                        | 4 (2.3)                  | 0                                     |
| Febrile neutropenia                                           | 0                        | 2 (1.2)                  | 2 (0.2)                               |

<div style=\"page-break-after: always\"></div>

AESI = adverse event of special interest; BC = breast cancer; COVID-19 = coronavirus disease 2019; ILD = interstitial lung disease;

MedDRA = Medical Dictionary for Regulatory Activities, Version 24.0; N = total number of treated subjects; PT = preferred term;

T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

If a subject had multiple occurrences of the same PT/grouped term, the subject was counted once for that PT/grouped term.  If a subject had multiple PTs/grouped terms, the subject was counted in each of the different PTs/grouped terms.

TEAEs are sorted by descending frequency in the T-DXd arm.

a The PTs included in each grouped term are listed in Table 2.1.

b The PTs included in the TEAE of COVID-19 are listed in Section 5.10.

c Interstitial lung disease includes events that were adjudicated as ILD and related to use of T-DXd or TPC.

d The PTs included in the AESI of left ventricular dysfunction are listed in Table 2.22.

Source:  Module 5.3.5.3 SCS Tables 1.2.1.12, 1.2.2.6, 1.2.4.5, 1.2.6.5; Module 5.3.5.1 DS8201-A-U303 CSR Listing 16.2.7.8.1

## Post marketing experience

Cumulatively, since the first approval of T-DXd in the US on 20 December 2019 through 01 March 2022, 480,209 vials of T-DXd were distributed to hospitals/clinics worldwide (Austria, Brazil, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Israel, Japan, Norway, Poland, Portugal, Puerto Rico, Slovenia, Sweden, Switzerland, United Kingdom, and US).

For the period from 20 December 2021 through 01 March 2022, a total of 840 new AEs meeting PBRER reporting criteria were reported; the majority (670) of those events were non-serious. Reported events were generally consistent with the established safety profile of T-DXd. There were no new safety findings during this period.

## 2.5.1. Discussion on clinical safety

Safety data has been provided for 883 patients that received trastuzumab deruxtecan (T-DXd) 5.4 mg/kg in the breast cancer pool (BC pool). The other safety population of interest are patients from the pivotal study Destiny Breast04 or U303 (n=371 who received T-DXd). The size of the safety data available on patients who have received T-DXd at the proposed dose of 5.4 mg/kg Q3W is considered acceptable. The median treatment duration of T-DXd for in study U303 and the BC pool were 8.21 months and 9.9 months, respectively. A total of 70% of the patients in the BC pool, which includes the T-DXd-treated patients from study U303, had an exposure of T-DXd for more than 6 months and 43% were exposed for more than 12 months, which is acceptable and considered a relevant exposure for the safety assessment.

Almost all patients experienced at least one adverse event (AE) in the pivotal study U303 and the most frequently observed adverse events in the T-DXd arm vs the TPC arm were nausea (76% vs 30.2%), fatigue (53.6% vs 48.3%), vomiting (40.4% vs 13.4%), anaemia (38.5% vs 27.3%), and neutropenia (34.0% vs 52.3%). Alopecia was almost similar in both arms with T-DXd compared to TPC (39.6% vs 33.1%). GI toxicity of T-DXd was more frequent for most AEs such as constipation (34.0% vs 22.1%), decreased appetite (31.8% vs 19.2%) and diarrhoea (27.0% vs 22.1%).

Thrombocytopenia and epistaxis were reported at a much higher incidence for T-DXd compared to TPC (25.6% vs 9.3% and 10.5% vs 1.2%, respectively). These incidences are in line with those reported in the BC pool and the SmPC.

Treatment-related AEs with T-DXd vs TPC were also nausea (73% vs 23.8%), fatigue (47.7% vs 42.4%), vomiting (34% vs 9.9%), anaemia (33.2% vs 22.7%) and neutropenia (33.2% vs 51.2%) of almost the same incidences as for the AEs. Gastrointestinal toxicity was markedly increased with TDXd vs TPC, and besides vomiting, AEs of decreased appetite (28.6% vs 16.3%), constipation (21.3% vs 12.8%) and decreased weight (12.4% vs 4.7%) were clinically significantly more commonly observed.

Interstitial lung disease (ILD) was very commonly observed with T-DXd versus TPC (12.1% vs 0.6%), and this high risk of ILD/pneumonitis with T-DXd is important information for the prescriber

<div style=\"page-break-after: always\"></div>

and should be considered if the patients had prior clinical lung problems (see SmPC section 4.2 and 4.4). It should be noted that patients with a history of (non-infectious) ILD/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that could not be ruled out by imaging at screening were excluded from the pivotal Study U303, and this is adequately reflected in section 5.1 of the SmPC.

Grade ≥ 3 AEs in the T-DXd arm vs the TPC arm were: neutropenia (14% and 41.3%), anaemia (10.2% and 5.2%) and fatigue (8.6% vs 4.7%). Hence, more high-grade neutropenia was observed with TPC while anaemia was more frequent with T-DXd. The incidences of the treatment-related grade ≥ 3 adverse events were much in line with this. No major bleedings were seen within 14 days of any grade thrombocytopaenia among the patients from the T-DXd arm of Study U303 and the 'All BC TDXd 5.4 mg/kg Pool' (see SmPC section 4.8).

Adverse events of special interest include ILD/pneumonitis and Left ventricular dysfunction, which are important identified risks of treatment with trastuzumab deruxtecan (see RMP section). ILD was as expected commonly observed in both the pivotal study U303 (12.4%) and in the BC pool (13.3%), and these events were most often of grade 2 (6.7% vs 7.6%). The majority of these events were assessed to be treatment-related (12.1% vs 12.7%) and often led to discontinuations (8.4% vs 8.8%). Approximately half (55.6%) of the patients had recovered/resolved events of ILD, while 22.2% had not recovered/not resolved events. 2 patients (4.4%) died of ILD in study U303. This is not totally in line with what was reported for the BC pool, where deaths due to treatment-related ILD were even more frequent (7.1%), which is probably more in line with the true incidence. Lower frequencies of high-grade ILD compared to earlier studies are likely related to enhanced awareness and risk minimisation measures. However, it remains an important safety issue and the occurrence of drugrelated fatal cases stresses the importance of continuous monitoring of this AESI.

Left ventricular dysfunction was observed as grade 2 decreased LVEF in 13.5% and 16.1%, or as grade 3 decrease of LVEF (0.4% and 0.2%), and the incidences were similar in the T-DXd arm and the BC pool, respectively. In the BC pool, 14.5% of the patients had a 10%-19% decrease in absolute value of LVEF, and only one patient had ≥20% increase in absolute value. It is noted that pat ients in the All BC T-DXd 5.4 mg/kg Pool the majority of discontinuations due to LV dysfunction were from Study U303 (3 out of 4). Also, the Grade 3 LVEF decreases in the All BC T-DXd 5.4 mg/kg Pool were mainly caused by patients from Study 303 (5 out of 7). In 12 of the 17 patients experiencing an event of LV dysfunction in the T-DXd arm of Study U303, there was a concurrent or underlying cardiovascular condition and/or other medical condition associated with increased cardiovascular risk. All 17 patients had previous exposure to at least one potentially cardiotoxic agents and 13 of the 17 patients (76%) had previous lines of treatment with anthracyclines. Two events were Grade 3 and no Grade 4 or 5 events were reported. Regarding prior treatment with anthracyclines, in the All BC T-DXd 5.4 mg/kg Pool 20 out of 34 patients (59%) with an event of LV dysfunction had prior anthracycline exposure. Prior treatment with anthracyclines could play a role in the development of LV dysfunction events, although the causality is likely multifactorial including comorbidity, prior and concurrent comedication, and T-DXd treatment. LVEF decrease is already an important identified risk for T-DXd and there were no new safety signals. No further additional measures are required at this point.

Serious adverse events (SAEs) were observed in 25.1% of the patients in the BC pool, which is similar to the incidences observed in the T-DXd arm (27.8%) and the TPC arm (25%). The most commonly observed SAEs in the BC pool and the T-DXd arm were interstitial lung disease (ILD) in 4.19% vs 4.3% of the patients, respectively, and pneumonia (1.9% in both arms). The pattern was different for the TPC arm, where the most common SAEs were overdose (2.9%, febrile neutropenia and neutropenia (2.3% each), which is in line with the known toxicities of single-agent chemotherapy.

<div style=\"page-break-after: always\"></div>

In the BC pool, 31.7% of the patients had died, most commonly due to disease progression (24.6%) and rarely due to an AE (2.3%) or other/unknown reasons (1.5%/3.4%). In the T-DXd arm of Study U303, 39.9% had died, 32.9% of disease progression and 2.7% of an adverse event. In comparison, more patients had died in the TPC arm, 45.9% of disease progression and no patients died from an adverse event. AEs associated with an outcome of death were reported in 3.8% of patients in the TDXd arm and 2.9% of patients in the TPC arm. Among these patients, the following AEs in the T-DXd arm were considered to be treatment-related by the investigator: pneumonitis in 2 patients, and colitis ischaemic, disseminated intravascular coagulation, dyspnea, febrile neutropenia, and sepsis in 1 patient each. None of the deaths in the TPC arm were considered to be treatment-related. It is noted that 7 out of the 11 treatment-related AEs associated with an outcome of death in the All BC T-DXd 5.4 mg/kg Pool were observed in Study U303. In addition, new treatment-related AEs leading to death were reported in Study U303, such as colitis ischaemic, disseminated intravascular coagulation, dyspnoea/pneumonia, febrile neutropenia, and sepsis. SmPC 4.4 and 4.8 has been updated to include the fatal cases of febrile neutropenia that were observed.

Hence, treatment with T-DXd carries more severe toxicity. The narratives for the patients who died from other causes in the pivotal study were provided. The overall incidence of deaths due to adverse events could be considered acceptable for this non-curative treatment setting and considering the underlying metastatic breast cancer.

The overall discontinuation rate due to AEs in the BC pool was 16.2%, which is double as many compared to the TPC arm (8.2%), but in line with the rate for the T-DXd arm (16.2%). Most often, patients discontinued treatment due to ILD/pneumonitis in both the BC pool (8.8%) and the T-DXd arm (8.4%), which is in line with the known safety profile of trastuzumab deruxtecan and the incidence of ILD in other studies using the dosing of 5.4 mg/kg Q3W. Other reasons were left ventricular dysfunction, bilirubin increased, dyspnoea, and pleural effusion. In the TPC arm, the most common AE leading to discontinuations was peripheral neuropathy (2.3%). Overall, the rate of discontinuations is considered acceptable for the proposed extension of indication and targeted patient population.

Laboratory findings were in line with the reported AEs and may also reflect that liver metastases are very common in the targeted patient population. Increasing toxicity of T-DXd was observed with increasing age regarding grade ≥3 AEs and serious adv erse events (SAEs) both in the pivotal study and the BC pool. However, the increased toxicity with age is considered acceptable. The higher incidence of Grade 3-4 adverse reactions observed in patients aged 65 years or older was already reflected in section 4.8 of the SmPC.

It is noted that significantly more patients had an ADR of ≥grade 3 in the Asian population both for the T-DXd arms (51.7% vs 34.9%) and the BC pool. This may be explained by the known ethnic differences in drug toxicity, which is documented in the scientific literature where higher haematologic toxicity have been described for Asian vs. Non-Asian cancer patients. This was already reflected in section 4.8 of the SmPC.

Hence, the overall toxicity observed with T-DXd 5.4 mg/kg is, in general, considered manageable and in line with what has previously been observed in other clinical trials and the incidences reflected in the BC pool. No new toxicities were observed in the pivotal study. The occurrence of fatal ILD/pneumonitis remains a major safety issue as reflected in the SmPC and RMP. Additional risk minimisation measures are in place to manage this risk.

## 2.5.2. Conclusions on clinical safety

Based on safety data from ~880 patients with breast cancer who have had relevant exposure to the approved dose of trastuzumab deruxtecan (5.4 mg/kg Q3W) no clinically significant changes of the

<div style=\"page-break-after: always\"></div>

known  safety  profile  nor  any  new  safety  findings  were  detected.  The  safety  profile  of  T-DXd  was compared  head-to-head  with  treatment  per  Physicians'  choice  of  single-agent  chemotherapy  in  the metastatic treatment setting, and the toxicities observed with TPC are considered clinically significantly different from those observed with T-DXd. Although tolerability of T-DXd appears lower compared to single-agent chemotherapy, it remains mostly manageable. ILD/pneumonitis is still the greatest risk in the treatment with trastuzumab deruxtecan and the occurrence of drug-related fatal cases stresses the importance of continuous monitoring of this AESI, as reflected in the SmPC and the RMP.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 4.0 is acceptable.

The CHMP endorsed the Risk Management Plan version 4.0 with the following content:

## Safety concerns

Table 78: Summary of Safety Concerns

| Summary of safety concerns   | Summary of safety concerns                                                      |
|------------------------------|---------------------------------------------------------------------------------|
| Important identified risks   | • Interstitial lung disease/Pneumonitis • Left ventricular dysfunction          |
| Important potential risks    | • Embryo-foetal toxicity • Product confusion-related medication errors          |
| Missing information          | • Use in patients with moderate or severe hepatic impairment • Long-term safety |

## Pharmacovigilance plan

Table 79 : Ongoing and Planned Additional Pharmacovigilance Activities

| Study: Status                                                                                                                                                                                                                    | Summary of objectives                                                                                                                                                                                                            | Safety concerns addressed                                                                                                                                                                                                        | Milestones                                                                                                                                                                                                                       | Due dates                                                                                                                                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation: None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation: None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation: None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation: None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation: None                                                                                                 |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None |

<div style=\"page-break-after: always\"></div>

| Study: Status                                                 | Summary of objectives                                                                                                                | Safety concerns addressed                                     | Milestones                                                    | Due dates                                                     |
|---------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities                                                                        | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| Prescriber Survey preparations ongoing                        | EU survey of relevant healthcare professionals on understanding of key risk minimization measures pertaining to ILD/pneumonitis      | ILD                                                           | Final Report                                                  | Q2 2024                                                       |
| Phase 2 or 3 studies preparations ongoing                     | Collection of PK and safety data in at least 10 subjects with moderate hepatic impairment from ongoing Phase 2 or 3 clinical studies | Use in patients with moderate or severe hepatic impairment    | Final report (for 10 subjects)                                | Q4 2023                                                       |

EU = European Union; ILD = interstitial lung disease

Risk minimisation measures

Table 80 : Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety concern                        | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Pharmacovigilance activities                                                                                                                                                    |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks            | Important Identified Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Important Identified Risks                                                                                                                                                      |
| Interstitial Lung Disease/Pneumonitis | Routine risk minimisation measures: SmPC Section 4.2 SmPC Section 4.4 SmPC Section 4.8 Patient Information Leaflet Section 2 Patient Information Leaflet Section 4 Recommendations for ILD/pneumonitis monitoring and detecting early signs and symptoms of ILD/pneumonitis are included in SmPC Section 4.4. Dose modification guidance and recommendation for corticosteroid treatment for managing the risk of ILD/pneumonitis are included in SmPC Section 4.2. Recommendation for careful monitoring of patients with moderate or severe renal impairment is included in SmPC Section 4.2. Additional risk minimisation activities: HCP Guide and Patient Card | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted questionnaire Additional pharmacovigilance activities: Prescriber survey |
| Left ventricular dysfunction          | Routine risk minimisation measures: SmPC Section 4.2 SmPC Section 4.4 SmPC Section 4.8 Patient Information Leaflet Section 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted questionnaire Additional pharmacovigilance activities: None              |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk minimisation measures                                                                                                                                                                                                                                       | Pharmacovigilance activities   |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
|                  | Recommendations for monitoring of left ventricular dysfunction are included in SmPC Section 4.4. Dose modification guidance for managing the risk of left ventricular dysfunction is included in SmPC Section 4.2. Additional risk minimisation activities: None |                                |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

The posology, administration and method of reconstitution for the extension of the indication is unchanged. The updates to the PL, including the safety sections, are not significant and utilise well recognised lay terms. Furthermore, the PL will be kept in an identical format size, colours and layout/design.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

## 3.1.2. Available therapies and unmet medical need

Metastatic breast cancer remains an incurable disease. Although treatment has improved disease outcomes over the years, the disease will invariably progress. The aim of therapy is to prolong progression-free survival (PFS) and overall survival (OS).

Treatment outcomes with currently approved therapies in patients with metastatic HER2 negative breast cancer who progressed on at least 1 line of chemotherapy illustrate the high unmet medical need for new treatment options. No targeted therapy is specifically approved for patients with HER2low breast cancer (BC). The most recently approved single agents for patients with metastatic hormone receptor-positive HER2-low/negative BC, are abemaciclib and eribulin. Abemaciclib has since been approved in earlier lines of therapy and is rarely used in the proposed setting where the cornerstone of treatment remains conventional chemotherapy (Gennari et al. ESMO. 2021). For

<div style=\"page-break-after: always\"></div>

patients with TNBC who have received at least 2 previous regimens, with at least one of them in the metastatic setting, the antibody-drug conjugate (ADC) sacituzumab govitecan is also approved.

Despite available therapies,   the high unmet medical need for new therapeutic options that would provide a clinically meaningful delay in time to progression and improved survival remains.

## 3.1.3. Main clinical studies

The single pivotal study Destiny breast04 (Study U303) is a phase 3 randomised open-label two-arm study comparing trastuzumab deruxtecan (T-DXd) head-to-head with the current SOC in patients with HER2-low, unresectable and/or metastatic breast cancer.

Patients were randomised 2:1 to receive T-DXd or single-agent chemotherapy by Physician's choice (TPC; capecitabine, eribulin, gemcitabine, paclitaxel, nab-paclitaxel). 557 patients were recruited from 19 countries. Randomisation was stratified by HER2 IHC status (ICH 1+ vs ICH2+/ISH negative), number prior lines of chemotherapy (1 vs 2), and HR/CDK4/6 status (HR+ with CDK4/6 (min 240) vs HR+ without CDK4/6 (max 240) vs HR- (max 60)).

The primary endpoint of the pivotal trial was PFS by BIRC in the hormone receptor-positive cohort (HR+) and the key secondary endpoints were PFS by BIRC in all randomised patients (FAS) and OS of both populations.

## 3.2. Favourable effects

The presented data are from the primary analysis of the primary efficacy endpoint of blinded independent central review (BICR)-assessed progression-free survival (PFS) at DCO 11 January 2022. The median duration of follow-up was 16.1 months in the T-DXd arm vs 13.5 months in the TPC arm at the DCO. The primary endpoint was met and the primary analysis of PFS by BIRC in the HR+ population (n=494) showed a statistically significant improvement from 5.4 months (95%CI: 4.4; 7.1) with TPC to 10.1 months (95%CI: 9.5; 11.5) with T-DXd, HR 0.51 (95%CI: 0.40; 0.64). The data were mature with 63.7% events in the active T-DXd arm and 67.5% events in the control arm. The KM curves for PFS by BIRC separated early and remained separated.

The key secondary endpoint of PFS by BIRC in the FAS (n=557) was improved from 5.1 months (95%CI: 4.2; 6.8) with TPC to 9.9 months (95%CI: 9.0; 11.3) with T-DXd, HR 0.50 (95%CI: 0.40, 0.63). The data from the FAS were also mature with 65.1% events in the active T-DXd arm and 69% events in the control arm and the KM curves also separated early and stayed separated.

The key secondary endpoint of overall survival in the HR+ population and the FAS was statistically significantly improved at the time of the first IA with 38.1% events with T-DXd and 44.8% events in the control arm after 18.4 months of follow up and the efficacy stopping boundary of 0.00748 was crossed. The median OS for the HR+ population was 23.9 months (95%CI: 20.8, 24.8) in the T-DXd arm vs 17.5 months (95%CI: 15.2, 22.4) in the TPC arm, HR 0.64 (95%CI: 0.48, 0.86), while the median OS for the FAS was 23.4 months (95%CI: 20.0, 24.8) in the T DXd arm vs 16.8 months (95%CI: 14.5, 20.0) in the TPC arm.

Confirmed ORR by IRC was improved from 16.3% in the control arm to 52.3% with T-DXd in the FAS and the median DoR was 10.7 months in the T DXd arm vs 6.8 months in the TPC arm after ~57% and ~67 events in each arm, respectively.

In the HR- population (n=58), PFS was 6.6 months (95%CI: 4.1, 11.7) in the T DXd arm vs 2.9 months (95% CI: 1.4, 4.0) in the TPC arm, HR 0.45 (95% CI: 0.23, 0.87). Median OS was 16.6

<div style=\"page-break-after: always\"></div>

months (95% CI: 11.3, NE) in the T-DXd arm vs 10.3 months (95% CI: 6.1, 15.2) in the TPC arm (HR: 0.63, 95% CI: 0.32, 1.23). Confirmed ORR by ICR was improved from 14.3% in the control arm to 47.6% in the T-DXd arm and median DoR was 8.6 months in the T-DXd arm vs 4.9 months in the TPC arm.

Subgroup analyses of PFS and OS by BIRC in the FAS supported a benefit of T-DXd compared with TPC for important pre-specified subgroups including HR status, prior CDK4/6i treatment, number of prior chemotherapies, and IHC 1+ and IHC 2+/ISH- status.

## 3.3. Uncertainties and limitations about favourable effects

There was a limited number of patients in the HR- cohort (n=40 T-DXd arm and n=18 TPC arm), leaving some uncertainty in the true effect size in this subpopulation. Sensitivity analysis based on electronic data capture data showed a beneficial effect. In addition, the Applicant plans additional observational studies which most likely will provide additional data in the HR- subgroup.

A difference in OS of more than 6 months between the treatment arms is considered clinically meaningful. Based on the available data, a later detriment in OS is considered unlikely. Results from the final OS analysis are projected to occur in Q4 2024 and will be provided post-authorisation when available (PAM-REC).

## 3.4. Unfavourable effects

In the pivotal Study U303, median treatment duration in Study U303 was 8.2 months for T-DXd and 3.5 months in the TPC arm.

Almost all the patients experienced at least one adverse event (AE) in the pivotal study U303 and the most frequently observed adverse events in the T-DXd arm vs the TPC arm were nausea (76% vs 30.2%), fatigue (53.6% vs 48.3%), vomiting (40.4% vs 13.4%), anaemia (38.5% vs 27.3%), and neutropenia (34.0% vs 52.3). Alopecia was almost similar in both arms (39.6% vs 33.1%). Gastrointestinal toxicity of T-DXd was more frequent for most AEs such as constipation (34.0% vs 22.1%), decreased appetite (31.8% vs 19.2%) and diarrhoea (27.0% vs 22.1%). Thrombocytopenia and epistaxis were reported at a much higher incidence for T-DXd compared to TPC (25.6% vs 9.3% and 10.5% vs 1.2%, respectively). These incidences are in line with those reported in the BC pool and the SmPC.

Treatment-related AEs with T-DXd vs TPC were also nausea (73% vs 23.8%), fatigue (47.7% vs 42.4%), vomiting (34% vs 9.9%), anaemia (33.2% vs 22.7%) and neutropenia (33.2% vs 51.2%) of almost the same incidences. Gastrointestinal toxicity was as mentioned markedly increased with T-DXd vs TPC, and besides vomiting, ADR of decreased appetite (28.6% vs 16.3%), constipation (21.3% vs 12.8%) and decreased weight (12.4% vs 4.7%) were clinically significantly more commonly observed.

Grade ≥ 3 AEs in the T-DXd arm vs the TPC arm were neutropenia (14% and 41.3%), anaemia (10.2% and 5.2%) and fatigue (8.6% vs 4.7%) which were consistent with. treatment related grade ≥ 3 adverse events reported.

Adverse events of special interest include ILD/pneumonitis and left ventricular dysfunction. ILD was commonly observed in both the pivotal study U303 (12.4%) and in the BC pool (13.3%), most often of grade 2 (6.7% vs 7.6%). Approximately half (55.6%) of the patients had recovered/resolved at DCO, while 22.2% had not recovered/not resolved events. 2 patients (4.4%) died of ILD. In the BC pool, deaths due to treatment-related ILD were even more frequent (7.1%). LVEF dysfunction was observed of grade 2 in 13.5% and 16.1%, or grade 3 decrease of LVEF (0.4% and 0.2%) and the incidences

<div style=\"page-break-after: always\"></div>

were similar in the T-DXd arm and the BC pool, respectively. All events except one with T-DXd were resolved at DCO.

Serious adverse events (SAEs) were observed in 25.1% of the patients in the BC pool, which is similar to the SAEs observed in the T-DXd arm (27.8%) and the TPC arm (25%). The most common SAE observed were interstitial lung disease (ILD) and pneumonia. In the TPC arm, the most common SAEs were overdose, febrile neutropenia and neutropenia, which is in line with the known toxicities of singleagent chemotherapy.

In the BC pool, 31.7% of the patients had died, most commonly due to disease progression (24.6%) and rarely due to an AE (2.3%) or other/unknown reasons (1.5%/3.4%). In the T-DXd arm, 39.9% had died, 32.9% of disease progression and 2.7% of an adverse event. In comparison, more patients had died in the TPC arm, 45.9% of disease progression and no patients died from an adverse event. Regarding fatal AEs, 7 out of the 11 treatment-related AEs association with an outcome of death in the All BC T-DXd 5.4 mg/kg Pool were observed in Study U303. In addition, new treatment-related AEs leading to death were reported in Study U303, such as colitis ischaemic, disseminated intravascular coagulation, dyspnoea, febrile neutropenia, and sepsis.

The overall discontinuation rate due to AEs in the BC pool was 16.2%, which is double as many compared to the TPC arm (8.2%), but in line with the rate for the T-DXd arm (16.2%) and was most commonly due to ILD/pneumonitis.

Laboratory findings were in line with the reported AEs and may also reflect that liver metastases are very common in the targeted patient population. Increasing toxicity of T-DXd was observed with increasing age regarding grade ≥ 3 AEs and serious adverse events (SAEs) both in the pivotal study and the BC pool.

## 3.5. Uncertainties and limitations about unfavourable effects

Safety data in patients &gt;75 years, patients with severe renal impairment, and patients with moderate/severe hepatic impairment remain limited. These uncertainties have been reflected in the SmPC (see SmPC section 4.2 and 4.4).

## 3.6. Effects Table

Table 81 Effects Table for Enhertu (T-DXd) for unresectable or metastatic HER2-low BC (data cut-off: 11 January 2022)

| Effect             | Short description         | Unit               | Treatment T-DXd N=373   | Control TPC N=184   | Uncertainties / Strength of evidence              | Ref                |
|--------------------|---------------------------|--------------------|-------------------------|---------------------|---------------------------------------------------|--------------------|
| Favourable Effects | Favourable Effects        | Favourable Effects | Favourable Effects      | Favourable Effects  | Favourable Effects                                | Favourable Effects |
| PFS by BIRC HR+    | Progression-free survival | Months (95%CI)     | 10.1 9.5; 11.5          | 5.4 4.4; 7.1        | HR 0.51 0.40; 0.64 Strengths: RCT, blinded review |                    |
| PFS by BIRC FAS    | Progression-free survival | Months (95%CI)     | 9.9 9.0; 11.3           | 5.1 4.2; 6.8        | HR 0.50 0.40; 0.63 Strengths: RCT, blinded review |                    |

<div style=\"page-break-after: always\"></div>

| Effect                         | Short description              | Unit                         | Treatment T-DXd N=373        | Control TPC N=184            | Uncertainties / Strength of evidence                                | Ref                          |
|--------------------------------|--------------------------------|------------------------------|------------------------------|------------------------------|---------------------------------------------------------------------|------------------------------|
| OS HR+                         | Overall survival               | Months (95%CI)               | 23.9 20.8; 24.8              | 17.5 15.2; 22.4              | HR 0.64 0.48; 0.86 Strengths: RCT Uncertainties: Immaturity         |                              |
| OS FAS                         | Overall survival               | Months (95%CI)               | 23.4 20.0; 24.8              | 16.8 14.5; 20.0              | HR 0.64 0.49; 0.84 Strengths: RCT Uncertainties: Immaturity         |                              |
| Unfavourable Effects (N=543)   | Unfavourable Effects (N=543)   | Unfavourable Effects (N=543) | Unfavourable Effects (N=543) | Unfavourable Effects (N=543) | Unfavourable Effects (N=543)                                        | Unfavourable Effects (N=543) |
| Grade ≥3 AEs                   | Grade ≥3 AEs                   | %                            | 52.6                         | 67.4                         |                                                                     |                              |
| SAEs                           | SAEs                           | %                            | 27.8                         | 25.0                         |                                                                     |                              |
| AEs leading to discontinuation | AEs leading to discontinuation | %                            | 16.2                         | 8.1                          |                                                                     |                              |
| AEs associated with death      | AEs associated with death      | %                            | 3.8                          | 2.9                          |                                                                     |                              |
| ILD/pneumonitis                | ILD/pneumonitis                | %                            | 12.1                         | 0.6                          | 8.4% discontinue treatment and 0.8% with outcome of death T-DXd arm |                              |
| LV dysfunction                 | LV dysfunction                 | LV dysfunction               | LV dysfunction               | LV dysfunction               | LV dysfunction                                                      | LV dysfunction               |
| - AE LV dysfunction            | - AE LV dysfunction            | %                            | 4.6                          | 0.0                          |                                                                     |                              |
| - Grade 2 LVEF decrease        | - Grade 2 LVEF decrease        | %                            | 14.9                         | 7.7                          |                                                                     |                              |

Abbreviations: HR+: Hormone-receptor positive cohort; FAS: Full Analysis Set; SAE: Serious Adverse event.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The efficacy of trastuzumab deruxtecan (T-DXd) compared to single-agent chemotherapy per Physicians' choice (TPC) in the proposed setting after a prior systemic chemotherapy in the metastatic setting is considered clinically meaningful, since the primary endpoint of PFS by BIRC for the hormonereceptor positive cohort was prolonged from 5.4 months to 10.1 months, HR 0.51. Similar results were observed for the FAS, as expected given that the HR+ cohort constituted about 90% of the FAS.

OS was also clinically significantly improved for both the HR+ and the FAS populations (HR 0.64) and although data are only partly mature, a detriment in OS at a later time point is considered unlikely. The MAH is recommended to provide final efficacy data from the pivotal U303 study post-authorisation.

PFS and OS results support a beneficial effect of T-DXd in the hormone-receptor negative cohort as well, although some uncertainty exists on the true effect size in the HR- cohort due to the small sample size. However, given the magnitude of the effect size (increase of 3.7 months in median PFS and 6 months in median OS) it is reasonable to exclude a detrimental effect compared to TPC. Further,

<div style=\"page-break-after: always\"></div>

although the prognosis is worse in the HR- cohort, it is unlikely that T-DXd would act differently in the HR- cohort compared to the HR+ cohort given the mechanism of action. Furthermore, post hoc sensitivity analyses showed a beneficial effect. The Applicant plans additional observational studies which most likely will provide additional data in the HR- subgroup.

Overall, treatment options in HR- population are limited in this patient population. T-DXd could offer an alternative to existing therapies with a different safety profile.

The safety profile of T-DXd was not significantly changed with added safety data from the pivotal study U303 and the most frequently reported adverse events of trastuzumab deruxtecan are haematological and gastrointestinal nature. The major safety concern continues to be the risk of ILD/pneumonitis (12.1%), which frequently led to drug discontinuation and was fatal in 4 cases. The current guidance for the handling of ILD/pneumonitis is considered adequately reflected in the SmPC. Also, a higher rate of LV dysfunction events was observed in the T-DXd arm compared to the TPC arm. This was already reflected in 4.4 and 4.8 of the SmPC.

Overall, the toxicity of T-DXd is not negligible and the risk of fatal ILD/pneumonitis stresses the importance of continuous monitoring of this AESI. Most AEs are manageable and, overall, the safety is considered outweighed by the benefits associated with T-DXd in terms of PFS and OS improvement.

## 3.7.2. Balance of benefits and risks

The shown improvement of PFS and OS are considered clinically relevant and outweigh the risks of treatment with T-DXd in the target population, including both HR+ and HR- patients. Though some uncertainty remains on the true effect size in the HR- subgroup due to the small sample size, given the magnitude of efficacy observed, the poor prognosis of the HR- patients and the mechanism of action of T-DXd, it is reasonable to assume that HR- patients will benefit from treatment and inclusion in the indication is sufficiently supported. Treatment with T-DXd carries more severe toxicity, which is considered to be outweighed by a lower risk of disease progression and death compared to standard of care (TPC).

## 3.7.3. Additional considerations on the benefit-risk balance

Low HER2 expression was defined as IHC2+/ISH- or ICH1+ (ISH- or not tested) according to ASCO/CAP guidelines per central assessment using the most recent tumour tissue sample available, which is endorsed. Although there was a slight difference in the wording of the HER2 1+ definition between the ASCO/CAP guidelines, the protocol for the pivotal study, and the pathologist training material used to train DB-04 central pathologist, it is considered that the definitions are similar. This is agreed since the slight difference is only in the wording, not in the interpretation of the staining. In both definitions, the % of cells presenting such staining intensity needs to be &gt;10%. This has been reflected in SmPC 5.1.

## 3.8. Conclusions

The overall B/R of Enhertu in the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy is positive.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy; for ENHERTU, based on final results from study DS8201-A-U303 (DESTINY-Breast04). This is a Phase III, multicentre, randomised, open-label, active-controlled trial of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2antibody Drug Conjugate (ADC), versus treatment of physician's choice for HER2-low, unresectable and/or metastatic breast cancer subjects.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP is approved.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

<div style=\"page-break-after: always\"></div>

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Enhertu-005124-II-22'